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1 INTRODUCTION AND AIMS OF THE PROJECT 
1.1 RELEVANCE OF INDOLES AND THEIR SYNTHESIS 
Tryptamines are involved in various different biological processes. Serotonin for example, 
is a neurotransmitter and influences the human nervous system. It controls the state of mind, 
affects the circadian rhythm, sexual urge and body temperature and seems to play a key role 
in neurological disorders like migraines. Tailored serotonin type tryptamines are 
therapeutically used to influence these systems by addressing the responsible receptors 
selectively. Recent contributions in migraine drug development clearly demonstrate that not 
only extended substituents in 5-position are required to achieve high selectivities towards 
subtypes of the serotonin receptor family, but also sophisticated amine moieties in the 
3-position as well as a defined distance by which this amine is attached to the indole core 
(Scheme 1)1. 
Scheme 1: Recent developments in migraine therapy2. 
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From a synthetic chemist’s point of view these and additional features of indole type 
pharmaceuticals are interesting, such as the occurrence of branching in the a- and b-positions 
with respect to the indole core, or stereochemical issues as well as the fact that the side chain 
nitrogen might be embedded in a cyclic system such as piperidines, pyrrolidines or 
                                               
1 For reviews on migraine therapy see: a) Schaible, H.-G.; Ebersberger, A.; PharmIUZ 2002, 31, 452-457. b) 
Limmroth, V.; PharmIUZ 2002, 31, 458-461. c) Gurrath, M.; PharmIUZ 2002, 31, 470-478. Link, A.; Link, B.; 
PharmIUZ 2002, 31, 486-493. 
2 a) Johnson, K.W.; Schaus, J.M.; Durkin, M.M.; Audia, J.E.; Kaldor, S.W.; Flaugh, M.E.; Adham, N.; 
Zgombick, J.M.; Cohen, M.L.; Branchek, T.A.; Phebus, L.A.; NeuroReport 1997, 8, 2237-2240. b) Harding, V. 
D.; Macrae, R.J.; Ogilvie, R.J.; PCT Int. Appl. 1996, WO9606842A1. c) MacLeod, A.M.; Street, L. J.; Reeve, 
A.J.; Jelley, R.A.; Sternfeld, F.; Beer, M.S.; Stanton, J.A.; Watt, A.P.; Rathbone, D.; Matassa, V.G.; J. Med. 
Chem. 1997, 22, 3501-3503. 
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piperazines. All these features demand synthetic strategies which give convenient and fast 
access to highly diverse libraries of tryptamines and their homologues. Therefore, it would be 
preferable to have a general protocol allowing the synthesis of these compounds with 
simultaneous variations in all important positions. A modular approach with high diversity 
desires fusion of all building blocks in a late synthetic step with flexible determination of the 
chain length and the substitution pattern in the side chain. Such a convergent strategy should 
preferably include the construction of the indole core, with all necessary building blocks 
(amine moiety, side chain fragment, properly substituted aromatic indole precursor) being 
easily available in large amounts in prior synthetic steps (Scheme 2). 
Scheme 2: Modular approach to 
tryptamines. 
NH
R R
R2N amine moiety
side chain
fragment
aromatic indole
precursor
n
R
 
FISCHER’s and the LAROCK’s method are the most common for the preparation of indoles. In 
LAROCK’s indole synthesis o-halo anilines are connected with a functionalized alkyne under 
palladium catalysis3 (Scheme 3). 
Scheme 3: Basic principle of the Larock indole 
synthesis. 
NH2
I
R
R
N
H
R
R
[Pd0]
R
R
 
Synthesis of additionally substituted o-halo anilines, however, requires further steps and is 
not always easily achieved. Similarly the alkyne unit may require laborious synthetic 
procedures. If the final product bears additional substituents on the six-membered ring of the 
indole core, the substituted o-halo anilines subjected to the LAROCK synthesis can cause steric 
hindrance. Similarly, obtaining the starting materials for FISCHER’s indole synthesis can be 
                                               
3 a) Larock, R.C.; Yum, E.K. J. Am. Chem. Soc. 1991, 113, 6689. b) Larock, R.C.; Yum, E.K.; Refvik, M.D. J. 
Org. Chem. 1998, 63, 7652. 
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laborious. Here, carbonyl compounds are reacted with aryl hydrazines under acid catalysis4 
(Scheme 4). 
Scheme 4: Basic principle of The Fischer indole 
synthesis. 
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H
NH2R O
R
N
HR
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While a number of different approaches have been reported for the synthesis of substituted 
aryl hydrazines (the degree of substitution is reduced by one as compared to the aryl halide 
required for a LAROCK synthesis of the same compound), synthesis of the carbonyl compound 
very often requires a large number of simple functional group transformations (e.g. 
homologization of the carbon chain, reduction, oxidation). If aldehydes are needed for the 
indolization step, these have to be protected as acetals, aminals, enol ethers or bisulfite 
adducts in order to prevent aldol condensation and oligomerization under the harsh conditions 
of the FISCHER indole synthesis. In some cases the use of masked carbonyl compounds like in 
the JAPP-KLINGEMANN modification is useful. Here b-ketoesters are reacted with aryl 
diazonium salts to give aryl hydrazones after cleavage of acetic acid. The same hydrazone can 
be obtained upon condensation of the corresponding a-keto ester with aromatic hydrazines. 
Scheme 5: Use of Ketoesters as masked aldehydes in indole syntheses. 
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N
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4 a) Robinson, B.; Chem. Rev. 1963, 3, 373. b) Ishii, H.; Acc. Chem. Res. 1981, 14, 233-247. c) Robinson, B.; 
“The Fischer Indole Synthesis”; Wiley, New York, 1982. d) Hughes, D. L.; Org. Prep. Proced. Int. 1993, 25, 
607-632. e) Gribble, G. W.; J. Chem. Soc., Perkin Trans. 1 2000, 1045. 
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FISCHER indolization of this hydrazone gives the indole-2-carboxylic acid ester which 
decarboxylates after hydrolysis, giving indoles without a substituent at the 2-position5. In 
summary, both, the a-keto ester as well as the b-ketoester, serve as masked aldehydes 
(Scheme 5). These methodologies require additional steps and reagents and may hamper a 
general application with broad diversity as demanded for an ideal synthesis6 and the 
medicinal chemist’s needs. 
1.2 HYDROFORMYLATION 
A chain elongating in situ synthesis of aldehydes might be an alternative to the above 
described methods. The hydroformylation of olefins is a well known and reliable method for 
the synthesis of aldehydes and has been used in industrial processes7. But although the 
aldehyde functionality offers a wide range of further transformations, only a few examples are 
reported in which hydroformylation is used in a multi-step synthesis of fine chemicals. 
Obviously the homologization of the carbon skeleton by one carbon atom is not efficient 
enough and is only useful for simple steps at the very beginning of a synthesis. If the 
hydroformylation could be combined with methodologies for the derivatization of the 
aldehyde group to one step, the hydroformylation may become an even more attractive tool in 
the synthesis of fine chemicals. 
In the past few decades, a number of so called tandem reactions or reaction sequences under 
hydroformylation conditions have been reported8. The hydroformylation of terminal 
diarylethenes in the presence of primary and secondary amines affords direct access to 
pharmacologically active 3,3-diarylpropylamines. This tandem reaction consists of 
hydroformylation and reductive amination. Rhodium catalyzes the hydroformylation of the 
olefin as well as the hydrogenation of the enamine which results from the condensation of the 
aldehyde with the secondary amine (Scheme 6)9. 
 
 
                                               
5 For recent examples see: Heinrich, T.; Böttcher, H.; Gericke, R.; Bartoszyk, G.D.; Anzali, S.; Seyfried, C.A.; 
Greiner, H.E.; van Amsterdam, C.; J. Med. Chem. 2004, 47, 4684-4692. 
6 Wender, P.A.; Handy, S.T.; Wright, D.L.; Chemistry & Industry 1997, 765-769. 
7 Beller, M.; Cornils, B.; Frohning, C. D.; Kohlpaintner, C. W.; J. Mol. Catal. A 1995, 104, 17. 
8 a) Eilbracht, P; Bärfacker, L.; Buss, C.; Hollmann, C.; Kitsos-Rzychon, B. E.; Kranemann, C. L.; Rische, T.; 
Roggenbuck, R.; Schmidt, A.; Chem. Rev. 1999, 99, 3329-3366. b) Schmidt, A.M.; Eilbracht, P; in Transition 
Metals for Organic Synthesis: Building Blocks and Fine Chemicals; (Beller, M.; Bolm, C.), 2nd ed., Wiley-VCH, 
Weinheim, 2004, 57-111. c) Schmidt, A.M.; Eilbracht, P.; in Topics in Organometallic Chemistry; (Beller, M.), 
Springer Verlag, New York, 2005, in preparation.  
9 Rische, T.; Eilbracht, P.; Tetrahedron 1999, 55, 1915-1920. 
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Scheme 6: Hydroaminomethylation in the synthesis of 
pharmaceuticals. 
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Among all tandem hydroformylation sequences, methods in which the aldehyde 
functionality is used for the formation of additional C-C-bonds seem to be the most attractive. 
The tandem enolboration / hydroformylation / aldol addition may act as a good example. 
Here, hydroformylation of an unsaturated carbonyl compound is combined with an aldol 
reaction. The boron enolate is generated in a previous step from the unsaturated carbonyl, a 
boron halide and triethylamine. This boron enolate is hydroformylated selectively at the 
terminal double bond. The resulting aldehyde undergoes an aldol reaction with the boron 
enolate in situ with transfer of the boron enolate’s configuration to the aldol product, resulting 
in good to excellent diastereoselectivities (Scheme 7).  
Scheme 7: Tandem enolboration/hydroformylation/aldol 
reaction. 
O O
OH
COOEt
COOEt
OH
86%, dr 20:1
82%, only cis
tandem enolboration/
hydroformylation/ aldol reaction
tandem hydroformylation/
enolboration/ aldol reaction
 
Very recently this methodology has been used for a diastereoselective synthesis of the 
A-ring of forskolin (Scheme 8)10. 
                                               
10 Keränen M.D.; Eilbracht P.; Org. Biomol. Chem. 2004, 2, 1688-1690. 
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Scheme 8: Synthesis of the A-ring of forskolin via tandem 
enolboration/hydroformylation/aldol reaction. 
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1.3 HYDROFORMYLATION AND INDOLE SYNTHESIS 
Surprisingly, only few examples are described in which the hydroformylation has been used 
to generate aldehydes required for indole syntheses. Thus, hydroformylation of styrene type 
anilines, derived from a HECK reaction of o-halo anilines, gives tryptamines in fair yields. 
Here, the olefinic bond is regioselectively hydroformylated, and the resulting aldehyde 
condenses intramolecularly with the amine to give 3-substituted indoles (Scheme 9)11.  
Scheme 9: Tandem hydroformylation/enamine formation in the synthesis of tryptamines 
CO/H2 (1:1), 21 bar
HRh(CO)(PPh3)3/PPh3
toluene, 70h, 70°C
32-73%
X
NH2R NH2R
R'
N
H
R'
R
[Pd]
X = Br, I
R = Hal, OMe, CH3, CF3 R' = N(Boc)2, OH, NHTs  
o-Nitrostyrenes can also be converted with this method, as the nitro group is reduced under 
hydroformylation conditions12. This approach is then comparable with the indole syntheses of 
REISSERT13, SUGASAWA14 and BATCHO and LEIMGRUBER15. 
More recently SELWOOD et al. have used the hydroformylation for the synthesis of migraine 
drug 4991W93 to control the relative configuration of the final product, albeit with poor 
regioselectivity (Scheme 10)16.  
 
                                               
11 Dong, Y.; Busacca, C. A.; J. Org. Chem. 1997, 62, 6464-6465. 
12 Ucciani, E.; Bonfand, A.; Chem. Commun. 1981, 82. 
13 Cannon, J. G.; J. Med. Chem., 1981, 24, 238. 
14 Douglas, A.W.; Tetrahedron Letters 1994, 35, 6807. 
15 Siu, J.; Baxendale, I.R.; Ley, S.V.; Org. Biomol. Chem. 2004, 2, 160-167. 
16 Jandu, K.S; Barrett, V.; Brockwell, M.; Cambridge, D.; Farrant, D.R.; Foster, C.; Giles, H.; Glen, R.C.; Hill, 
A.P.; Hobbs, H.; Honey, A.; Martin, G.R.; Salmon, J.; Smith, D.; Wollard, P.; Selwood, D.L.; J. Med. Chem. 
2001, 44, 681-693. 
INTRODUCTION AND AIMS OF THE PROJECT 
 
- 23 - 
Scheme 10: Hydroformylation in indole syntheses: Control of relative configuration. 
CN CN
O N
H
N
N
N
N
hydroformylation
4991W93  
SHELDON et al. have published the synthesis of melatonin via regioselective 
hydroformylation of N-allyl acetamide followed by FISCHER indole synthesis (Scheme 11)17.  
Scheme 11: Synthesis of melatonin via hydroformylation followed by Fischer indole synthesis. 
NHAc
NHAc
O
N
H
NHAc
MeO
MeO
NHNH3Cl
CO/H2(1:1), 10bar
[Rh] /xanthphos
toluene/H2O
70°C, 10h acetic acid
96 %
44 %  
In 2001, KÖHLING was able to demonstrate that, both, the hydroformylation and the FISCHER 
indolization can be combined to a new tandem reaction18. While the chain elongating 
hydroformylation is used to synthesize the aldehyde in situ from an olefin, reducing 
functional group transformations to a minimum, the presence of an aryl hydrazine and a 
BRØNSTED acid allows direct conversion to the indole.  
Scheme 12: Basic principle of the tandem 
hydroformylation / Fischer indole synthesis. 
N
H
R
R
R
R
R
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O
R R
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phenylhydrazine
- H2O / - NH3
[H+]   - NH3
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- H2O
101
102 103
104
 
                                               
17 Verspui, G.; Elbertse, G.; Sheldon, F. A.; Hacking, M. A. P. J.; Sheldon, R. A.; Chem. Commun. 2000, 1363. 
18 Köhling, P.; Diploma Thesis 2001, University of Dortmund.  
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Thus, this tandem reaction includes three steps: hydroformylation of an olefin 101, 
condensation of aldehyde 102 with an aryl hydrazine to an aryl hydrazone 103 and finally 
BRØNSTED acid mediated [3,3]-sigmatropic Diaza-COPE rearrangement and cyclization to 
indole 104 (Scheme 12). The fact that aldehydes as well as hydrazones are intermediates in 
this tandem reaction and do not have to be isolated clearly saves time and resources. A series 
of simple indole derivatives, including tryptophols and tryptamines, have been synthesized 
with this innovative methodology, starting from easily available olefins and phenylhydrazine 
(Scheme 13). However, yields need to be improved for more complex structures. 
Scheme 13: First examples of tandem hydroformylation / Fischer indole 
synthesis. 
N
H
N
H
Ph
Ph
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OEt
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H
NPht6
25% 50%18% 55%  
1.4 AIM OF THE PROJECT 
Encouraged by these initial results the scope and limitations of this new tandem reaction 
should be clarified. While tryptophols, 2,3-disubstituted indoles and bisindoles will be 
discussed in a parallel work19, this work shall concentrate on the following topics: 
Ø Improvement of the existing protocol in order to 
Ø develop a modular approach towards biologically and pharmaceutically relevant 
tryptamines and homologues under 
Ø consideration of all necessary biological valances (i.e. substitution pattern at the indole 
core, type of amine moiety, length of side chain in 3-position, substituents in the side 
chain). 
Ø Application towards recent drug candidates and 
Ø synthesis of substance libraries for biological evaluations. 
In this context 
Ø the tandem reaction and its singular steps shall be investigated intensively starting 
with basic model aminoolefins with respect to 
· stability of nitrogen protecting groups and 
                                               
19 Köhling, P.; Dissertation 2005, University of Dortmund.  
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· different sources of aryl hydrazines. 
Ø Furthermore, the tandem reaction shall be optimized with respect to 
· chemoselectivity of the tandem reaction, 
· regioselectivity of the hydroformylation and of the indolization and 
· stereoselectivity of the hydroformylation. 
Ø These optimized conditions shall be applied towards more complex substrates such as 
highly functionalized tryptamine derivatives of pharmacological relevance. 
Ø The tandem reaction shall be transferred from solution to solid phase to allow 
automated, combinatorial access to substance libraries. 
 - 26 - 
2 SYNTHESIS OF PRIMARY AND SECONDARY TRYPTAMINES 
To achieve high chemoselectivities for the overall tandem process, it is important that all 
individual steps work as selectively as possible and all reagents and reactants required as well 
as all intermediates are compatible and do not affect each other. To ensure this, investigations 
are started with optimizations of each step, i.e. hydroformylation of aminoolefins, 
hydroformylation in the presence of hydrazines, FISCHER indolization of aryl hydrazones and 
finally the complete tandem hydroformylation / FISCHER indole synthesis. 
2.1 HYDROFORMYLATION IN THE PRESENCE OF HYDRAZINES 
It is well known that hydroformylations can be conducted in the presence of amines. While 
tertiary amines increase the hydrogenation activity of rhodium based hydroformylation 
catalysts giving alcohols exclusively20, primary and secondary amines condense with the 
aldehyde followed by hydrogenation of the resulting imines or enamines to amines in an 
overall hydroaminomethylation21. In 1999, RISCHE conducted hydroformylations in the 
presence of aliphatic hydrazines in order to show whether hydrazines behave similarly. In 
fact, the hydroformylation of styrene (201) in the presence of N,N-disubstituted hydrazines 
(202) gave the hydrazones (203) in excellent yields. No hydrogenation product of the 
aldehyde or the hydrazone was observed whereas imines are usually reduced under harsh 
hydroformylation conditions. Obviously, the hydrazine does not enhance the hydrogenation 
activity of the catalyst and, on the other hand, protects the aldehyde against reduction. Only 
after prolonged reaction times, could the hydrogenated product 204 be selectively obtained as 
a result of a hydroaminomethylation. If the styrene (201b) was used in a two-fold excess, 
unsymmetrically substituted alkyl hydrazine 205 was obtained as a 2:1 adduct (Scheme 14).21 
If this hydroformylation / hydrazone formation shall be applied to the synthesis of 
tryptamine derivatives, allylic amines have to be used. Since hydroformylation of terminal 
olefins typically results in a mixture of linear and branched aldehydes, disubstituted terminal 
olefins like N-ethyl-N-methallylic amine (206) are preferably investigated. Such olefins 
undergo regioselective hydroformylation to form linear aldehydes and make use of 
n-directing ligands obsolete. To prevent hydrogenation of the starting olefin, high carbon 
monoxide partial pressures are chosen in order to support the rate determining carbon 
monoxide insertion.  
                                               
20 a) Kaneda, K.; Yasumura, M.; Hiraki, M.; Imanaka, T.; Teransihi, S. Chem. Lett. 1981, 1763. b) Kaneda, K.; 
Imanaka, T.; Teranishi, S. Chem. Lett. 1983, 1465. 
21Rische, T.; Dissertation 1999, University of Dortmund. 
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Scheme 14: Hydroformylation in the presence of alkyl hydrazines. 
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cond.21: i) 1equiv. 201, 1equiv. 202, 1mol% [Rh(cod)Cl]2, dioxane, 90bar 
CO, 20bar H2, 18h, 110°C ii) like i) but 3d; iii) like i) but 5d. 
 
Hydroformylation of 206 indeed gives the desired aryl hydrazone 207, but neither are inter- 
nor intramolecular reductive amination products of the aldehyde observed (Scheme 15). 
However, approximately 10% of lactam 208 is obtained as a byproduct.  
Scheme 15: Hydroformylation of secondary 
aminoolefins. 
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cond.: 1equiv. 206, 1equiv. phenylhydrazine, 0.3mol% 
Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 68h, 100°C. 
 
Obviously, the rhodium acyl species partially tends toward intramolecular nucleophilic 
addition of the secondary amine and the formation of lactam 208, instead of hydrogenolysis to 
SYNTHESIS OF PRIMARY AND SECONDARY TRYPTAMINES 
- 28 - 
form the aldehyde. This behavior has previously been reported for allylic amines and could be 
suppressed with the use of supercritical carbon dioxide (scCO2) as a solvent and as an 
intermediate protecting group22. 
In order to avoid formation of the lactam as a side product, protection of the allylic amine is 
necessary. In fact methallylic phthalimide (211a) is regioselectively hydroformylated in 
quantitative yields to give aldehyde 212 and its hydroformylation in the presence of 
phenylhydrazine yields the corresponding hydrazone 213 as a mixture of E/Z-isomers in 
excellent yields (Scheme 16).  
Scheme 16: Hydroformylation and 
hydroformylation/hydrazone formation of 
methallyic phthalimide. 
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cond.: i) 1eq 211a, 0.3mol% Rh(acac)(CO)2, THF, 
50bar CO, 10bar H2, 20h, 100°C; ii) like a) but with 
phenylhydrazine 68h. 
 
After three days reaction time23 at higher temperatures no hydrogenation of the hydrazone 
bond can be observed, so that aryl hydrazones seem to be of higher stability against 
hydrogenation than their alkyl analogues. Thus, the hydrazones obtained from 
                                               
22 Wittmann, K.; Wisniewski, W.; Mynott, R.; Leitner, W.; Kranemann, C.L.; Rische, T.; Eilbracht, P.; Kluwer, 
S.; Ernsting, J.M.; Elsevier, C.J.; Chem. Eur. J. 2001, 7, 4584-4589. 
23 It turned out, that the hydroformylation of olefins in the presence of aromatic hydrazines is 2 times slower than 
in their absence. Turn-Over-Frequency (TOF) for the single hydroformylation was calculated as TOF»5.4 h-1 
(determined from a linear fit of a concentration-time plot for the hydroformylation of 114a). Turn-Over-
Frequency (TOF) for the hydroformylation in the presence of phenylhydrazine was calculated as TOF»2.6 h-1 
(determined from a linear fit of a concentration-time plot for the hydroformylation of 211a in the presence of 
phenylhydrazine). These low TOFs result from the use of magnetically stirred pressure vessels. In a pressure 
vessel with a motor stirrer hydroformylation is up to ten times faster. 
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hydroformylation reactions are of high purity24. Apparently, hydrazines do not alter the 
chemoselectivity of the hydroformylation catalysts [Rh(cod)Cl]2 and Rh(acac)(CO)2.  
2.2 INDOLIZATION OF ARYL HYDRAZONES  
After having found conditions for a highly selective synthesis of hydrazones under 
hydroformylation conditions, the conditions for the FISCHER indolization are optimized. These 
must be compatible with the hydroformylation step which, therefore, has to be conducted in 
the same solvent as used for indolization. Furthermore, it is important, that the 
hydroformylation is not hampered by the addition of acids. The latter can only be tested in a 
tandem reaction, since olefins can oligomerize and aldehydes can undergo aldol reactions in 
the presence of acids. Therefore, the FISCHER indolization is optimized by testing different 
solvents and acids25. Most common systems for FISCHER indole synthesis are H2SO4 in 
alcohols such as methanol or ethanol. Indeed, there are examples, where hydroformylation of 
alkenes has also been carried out in alcoholic solution. However, using these solvents, 
depending on the reaction conditions, the intermediate rhodium acyl species can be trapped by 
the alcohol to give esters26, or the aldehyde suffers nucleophilic attack by the alcohols to yield 
acetals27. Since acetals are used as protected aldehydes in FISCHER indole synthesis, the use of 
alcoholic solvents in the hydroformylation step is an option and would support the principle 
of low stationary aldehyde concentrations. Surprisingly, hydrazone 213 does not lead to 
indolization in the presence of 4 wt% H2SO4, neither in methanol nor in ethanol. Only less 
polar solvents like refluxing THF or toluene, which are also very common in 
hydroformylation chemistry, allow satisfying conversions. 
In a next step, different acids are tested, concentrating on commercially available and 
inexpensive acids. In order to find even minor differences in the acids activity, only one 
equivalent of each acid is used, the reaction is stopped after two hours and the conversion is 
estimated by NMR. In this screening, acids from pKa = 5 to pKa = -8, i.e. acetic acid, formic 
                                               
24 Beller et al. have simultaneously found that hydrazones can be obtained upon hydroformylation of olefins in 
the presence of hydrazines. For further details see a) Ahmed, M.; Jackstell, R.; Seayad, A.M.; Klein, H.; Beller, 
M.; Tetrahedron Lett. 2004, 45, 869-873. 
25 Beller et al. have simultaneously found that a tandem hydroformylation / indolization can be performed with 
Lewis acids such as ZnCl2 instead of Brønsted acids. For further details see Ahmed, M.; Jackstell, R.; Seayad, 
A.M.; Klein, H.; Beller, M.; Tetrahedron Lett. 2004, 45, 869-873. 
26 Hakkaku, K.; Sakakibara, Y.; Jap. Pat. Appl. 2000, JP2000143587. 
27 a) Bohnen, H. W.; Cornils, B.; Adv. Catal. 2002, 47, 1-64. b) Cornils, B.: J. Mol. Catal. A-Chem. 1999, 143, 
1-10. c) Beller, M.; Cornils, B.; Frohning, C. D.; Kohlpaintner, C. W.; J. Mol. Catal. A-Chem. 1995, 104, 17-85. 
d) Cornils, B.; Herrmann, W. A.; Kohlpaintner, C. W. Angew. Chem. 1994, 106, 2219, Angew. Chem. Int. Ed. 
Engl. 1994, 33, 2144. e) Cornils, B.; Herrmann, W. A. Applied Homogeneous Catalysis with Organometallic 
Compounds, VCH: Weinheim 1996. (f) van Leeuwen, P. W. N. M.; Claver, C. (Eds.) Rhodium Catalyzed 
Hydroformylation Kluwer Academic Publishers, Dordrecht, 2000. 
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acid, phosphorous acid, trichloroacetic acid, trifluoroacetic acid, nitric acid, p-toluene sulfonic 
acid (PTSA), H2SO4 and hydrochloric acid, are used. A good indication for the starting 
reaction is the precipitation of ammonium salts from the non-polar solvent. Among all acids, 
H2SO4 as well as PTSA show the best results, leading to full conversion. Obviously the 
combination of a less polar solvent with at least one equivalent of a strong acid provides a fast 
and selective conversion of the aryl hydrazones to the desired tryptamines. The high 
conversions observed within the two hours reaction time are especially encouraging. A slow 
hydroformylation step, together with a fast condensation and a fast indolization help to keep 
concentrations of aldehyde and hydrazone low, so that both do not undergo intermolecular 
acid mediated side reactions.  
2.3 DIFFERENT SOURCES OF ARYL HYDRAZINES 
In the next step the optimized conditions for each step are combined into a tandem reaction 
and different sources of aromatic hydrazines are tested. 
2.3.1 COMMERCIALLY AVAILABLE ARYL HYDRAZINES 
Tandem hydroformylation / FISCHER indolization of methallylic phthalimide (211a) with 
phenylhydrazine (214a) in the presence of one equivalent of PTSA give the desired 
tryptamine in 60% isolated yield (Table 1). Here the tosylation of the indole nitrogen helps to 
separate the product from impurities. Obviously, the tandem reaction does not proceed with a 
selectivity as high as for the single steps. Nevertheless, simple substituents are tolerated, e.g. 
the tert.-butyl group which can be found in a number of in vitro serotonin receptor 
antagonists. 
Table 1: Use of commercially available aryl hydrazines in 
the tandem hydroformylation / Fischer indolization with 
subsequent tosylation of the indole nitrogen. 
N
NPhtRNPht
211a
215
NHNH2
R
214
Ts  
entry hydrazine 214 yield 215 
1 214a (R=H) 60% (215a; R=H) 
2 214b (R=Cl) 53% (215b; R=Cl) 
3 214c (R=tert.-butyl) 48% (215c; R=tert.-butyl) 
cond.: 1equiv. 211a, 1equiv. 214, 1mol% [Rh(cod)Cl]2, 50bar 
CO, 10bar H2, 1equiv. PTSA, 3d, 100°C; then 1equiv. 
tosylchloride, 50wt% NaOH in H2O, toluene, 20h, rt. 
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2.3.2 BENZHYDRYLIDENE PROTECTED ARYL HYDRAZINES 
In mixing all reagents in non-polar solvents like toluene or THF, a precipitation is observed 
due to protonation of the aryl hydrazine. Therefore solubility problems might be responsible 
for the decrease in selectivity. An appropriate protection of the basic hydrazine on the other 
hand, must allow the conversion of the aldehyde, thus only acid sensitive protecting groups 
are of interest. BUCHWALD et al. have demonstrated that benzhydrylidene protected aryl 
hydrazines undergo high yielding FISCHER indolization in the presence of carbonyl 
compounds under acidic conditions28. The benzophenone hydrazone itself cannot cyclize to 
form an indole, it can only transcondense with a second carbonyl compound allowing 
FISCHER indolization. Benzhydrylidene protected aryl hydrazines are either obtained from 
commercially available aryl hydrazines or by palladium catalyzed amination of aryl halides 
with benzophenone hydrazone (Scheme 17).  
Scheme 17: Different access to benzhydrylidene protected aromatic hydrazines. 
N
H
N Ph
Ph
X
H2N
N Ph
Ph
[Pd]
N
H
NH2
PhO
PhR R R
X=Br, I  
Indeed, the use of protected hydrazines increases the selectivity as well as the yield of the 
tandem reaction making a consecutive tosylation of the indole nitrogen obsolete. In using this 
methodology, substituted tryptamines are isolated with up to 83% yield (Table 2). 
Remarkably, aryl bromides are tolerable although they are known to undergo oxidative 
addition with rhodium (I) complexes29 leading to defunctionalization of the aryl bromides. In 
some cases bromo substituents are even cleaved without a transition metal catalyst under the 
conditions of FISCHER indolization. On the other hand, bromo substituted indoles are valuable 
starting materials for further derivatization (e.g. palladium catalyzed cross coupling 
methodologies of 5-bromo-indole30). Therefore, tandem hydroformylation / FISCHER indole 
synthesis offers a convenient pathway to bromo substituted tryptamine derivatives from easily 
available starting material. 
 
 
                                               
28 a) Wagaw, S.; Yang, B. H.; Buchwald, S. L.; J. Am. Chem. Soc. 1998, 120, 6621-6622. b) Wagaw, S.; Yang, 
B. H.; Buchwald, S. L. J. Am. Chem. Soc. 1998, 121, 10251-10263. 
29 Ishiyama, T.; Hartwig, J. Am. Chem. Soc. 2000, 122, 12043-12044. 
30 Blatcher, P.; Carter, M.; Hornby, R.; Owen, M.R.; PCT Int. Appl. 1995, WO9509166. 
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Table 2: Tandem hydroformylation / Fischer 
indolization of benzhydrylidene protected aryl 
hydrazines. 
NPht
N
H
NPht
NH
R
214 215
R
N CPh2
211a
 
entry hydrazine 214 yield 215 
1 214d (R=H) 83% (215d; R=H) 
2 214e (R=4-F) 47% (215e; R=5-F) 
3 214f (R=4-Cl) 78% (215f; R=5-Cl) 
4 214g (R=4-Br) 50% (215g; R=5-Br) 
5 214h (R=2-CH3) 48% (215h; R=7-CH3) 
6 214i (R=2-Cl) 42% (215i; R=7-Cl) 
cond.: 1equiv. 211a, 1equiv. 214, 1mol% 
[Rh(cod)Cl]2, 50bar CO, 10bar H2, 1equiv. PTSA, 
3d, 100°C. 
2.3.3 a-BOC PROTECTED ARYL HYDRAZINES 
In 2004, CHO et al. have successfully applied a-Boc aryl hydrazines in FISCHER indolization 
and obtained indoles with very high purity31. Therefore, 214j is tested as a substrate for the 
tandem hydroformylation / FISCHER indole synthesis. Here, the reaction has to be conducted 
in a stepwise manner with subsequent addition of acid. Since the Boc group is stable under 
hydroformylation conditions, a-Boc protected aryl hydrazones can be obtained in quantitative 
yields. Tandem hydroformylation / FISCHER indolization of 214j gives the protected serotonin 
analogue 215j32 in nearly quantitative yields without the need for further purification. A 
number of different aryl hydrazines, synthesized using BUCHWALD’s optimized conditions of 
the copper(I) catalyzed N-arylation of amides (GOLDBERG reaction, Scheme 18)33 and their 
non-protected analogues are compared with respect to their reactivity towards tandem 
hydroformylation / FISCHER indole synthesis.  
Scheme 18: Principle of the Goldberg reaction. 
IR
NR
NH2
Boc
HN
NH2
Boc
[CuI]
 
                                               
31 Lim, Y.-K.; Cho, C.-G.; Tetrahedron Lett. 2004, 45, 1857-1859. 
32 Kenton, R.E; Dudlettes, S.D.; Shulgin, A.T.; Biological Psychiatry 1980, 15, 349-352. 
33 Wolter, M.; Klapars, A.; Buchwald, S.; Org. Lett. 2001, 3 , 3803-3805. 
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Only the p-methoxy phenylhydrazine 214j gives a clearly increased yield (Scheme 19) 
whereas a-Boc protected phenylhydrazine 214k gives only 38% of indole 215d. 4-Bromo 
substituted a-Boc protected phenylhydrazine 214l gives 50% of indole 215g. 
Scheme 19: Tandem hydroformylation / Fischer indole synthesis 
of a-Boc protected aromatic hydrazines. 
NPht
N
H
NPht
N
214j: R=OMe
214k: R=H
214l: R=Br
215j: R=OMe (95%)
215d: R=H (38%)
215g: R=Br (50%)
Boc
NH2
R R
211a
 
cond.: 1eq 211a, 1eq 214, 1mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, 
THF, 68h; 120°C, then 4wt% H2SO4/THF, 2h, 80°C. 
2.4 STABILITY OF NITROGEN PROTECTING GROUPS 
In order to compare the stability of different protecting groups under tandem 
hydroformylation / FISCHER indole synthesis various methallylic amines are N-protected with 
phthalimide, acetyl, benzoyl, tosyl and ethyloxycarbonyl groups and converted in a stepwise 
manner. While the hydrazone formation under hydroformylation conditions in all cases gives 
excellent yields, the FISCHER indolization disclosed differences: The phthalimide has already 
been proven to be stable under the selected conditions. Also the tosylate and the benzamide 
give good yields of the desired tryptamides. The acetyl group, however, gives a slightly 
decreased yield.  
Table 3: Nitrogen protecting groups in the 
tandem hydroformylation / Fischer indolization. 
NHNH2
N
H
N
R1
R2 N R2
R1
211
215
214a
 
entry olefin 211 yield 215 
1 211b (R1=Et, R2=Ts) 94% (215k) 
2 211c (R1=Et, R2=Bz) 85% (215l) 
3 211d (R1=Et, R2=Ac) 61% (215m) 
4 211e (R1=Et, R2=Eoc) 58% (215n) 
cond.: 1equiv. 211, 1equiv. 215a, 1mol% 
Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 68h, 
120°C, then 4wt% H2SO4/THF, 2h, 80°C. 
 
Not surprisingly, the Boc group is cleaved under FISCHER indolization conditions, but with a 
simple switch from tert.-butyloxycarbonyl to an ethyloxycarbonyl group the protected 
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tryptamine is obtained in 58% yield. Thus, all protecting groups chosen are tolerated under 
the reaction conditions (Table 3). 
2.5 APPLICATIONS OF THE HYDROFORMYLATION / FISCHER INDOLIZATION 
Having a reliable protocol in hand, the hydroformylation / indolization sequence was 
applied in the synthesis of pharmacologically active compounds. Scheme 20 illustrates the 
importance of a-branched tryptamides which become more and more interesting for 
pharmaceutical applications. LY 156735, for example, has recently been discovered as a drug 
against sleeping disorders34. As shown above, this substitution pattern of the side chain can be 
obtained by the use of disubstituted terminal olefins in the tandem 
hydroformylation / FISCHER indole synthesis. 
Scheme 20: a-branched 
tryptamines as pharmaceuticals. 
N
H
NHAc
MeO
Cl
LY 156735  
Besides compounds with linear or branched aliphatic side chains, tryptamine analogues with 
additional cyclic units, such as 3-piperidyl indoles, have been recognized as important 
pharmacophores in the last decade. The most prominent example is the N-phenylindole 
sertindole. 
Scheme 21: Sertindole and its optimized lead structure. 
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O
 
                                               
34 Flaugh, M.E.; Eur. Pat. Appl. 1995, EP 655243 A2. 
SYNTHESIS OF PRIMARY AND SECONDARY TRYPTAMINES 
- 35 - 
Sertindole blocks diverse dopamine and serotonin receptors, predominantly inhibiting the 
a1-adrenoceptor. It is used for the treatment of schizophrenia, helping to reduce typical side 
effects of classical neuroleptica like clozapin, risperidon or olanzapin (attention deficit 
disorder, apathy or social withdrawal)35. In 2002, ANDERSEN et al. optimized the structure of 
sertindole and increased the selectivity towards the a1-adrenoceptor by variation of the 
substituents in 5-position of the indole and of the piperidyl nitrogen. The replacement of the 
chloro substituent by heterocyclic substituents in 216 especially helps to increase this 
selectivity36. In most cases, these substituents can be introduced via palladium catalysis 
starting from intermediate 5-bromo-indole 218. Tandem hydroformylation / FISCHER indole 
synthesis is a useful method for the synthesis of 218 starting from easily available olefin 217 
via conversion with commercially available 4-bromo-phenylhydrazine 214m to give indole 
218 in 39% yield. Copper catalyzed N-arylation with 4-iodo-fluoro-benzene leads to the 
intermediate 219, which is thus conveniently obtainable in only two steps, increasing the 
earlier reported yield (11%) of a 4-step synthesis that started with 5-bromo indole (Scheme 
22)36. 
Scheme 22: Synthesis of the intermediate for sertindole analogues. 
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cond.: a) 1equiv. 217, 1equiv. 214m, 0.3mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 68h, 120°C then 
4wt% H2SO4/THF, 2h, 80°C, 39%. b) 1.2equiv. 4-fluoro-iodobenzene, 2.1equiv. K3PO4*7H2O, 5mol% 
CuI, 20mol% N,N’-dimethylethylendiamine, toluene, 24h, 110°C, 100%. 
2.6 N-SELECTIVE TANDEM HYDROFORMYLATION / FISCHER INDOLIZATION 
2.6.1 N-SELECTIVE HYDROFORMYLATION OF ALLYLIC AMIDES 
So far the use of disubstituted terminal olefins leads to indoles with branched chains in a 
3-position. Most of the biologically active tryptamines however, are tryptamines with a 
non-branched side chain. Here, the hydroformylation / indolization sequence requires 
                                               
35 Arnt, J.; Skarsfeldt, T.; Neuropsychopharmacology 1998, 18, 2539-2544. 
36 Balle, T.; Perregaard, J.; Ramirez, M.T.; Larsen, A.K.; Søby, K.K.; Liljefors, T.; Andersen, K.; J. Med. Chem. 
2003, 46, 265-283. 
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monosubstituted olefins. While ligand free hydroformylation of terminal disubstituted olefins 
regioselectively gives n-aldehydes, ligand free hydroformylation of monosubstituted olefins 
leads to a mixture of n- and iso-aldehydes. n-Selectivity is increased by the use of bidentate 
ligands such as the biphosphite BIPHEPHOS or the biphosphane XANTPHOS. Both ligands 
lead to high n-selectivities if simple olefins like 1-hexene or 1-octene are used. With 
functionalized olefins however, the n-selectivity decreases dramatically. In tandem 
hydroformylation / FISCHER indole synthesis protected amino olefins have to be used. The 
nature of the protecting group strongly affects the n/iso-selectivity. Not only may donor 
groups attached to the olefin compete with the catalyst ligand, but also aryl hydrazines may 
act as ligands since amines in general coordinate to the metal center and influence the 
performance of the hydroformylation. For an investigation of the n/iso-selectivity, allylic 
phthalimide (220a) is hydroformylated with use of Rh(acac)(CO)2/biphephos in a 1:4 ratio. 
Here, only a 2:1 mixture of n/iso-aldehydes is obtained. As an alternative XANTPHOS is 
tested, giving higher n/iso-ratios in hydroformylation of functionalized olefins. Indeed, the 
use of Rh/xantphos (1:5) gives the n-aldehyde with 81% selectivity. Increasing the 
catalyst/ligand ratio to 1:10 results only in a marginal enhancement of the n-selectivity (85%) 
(Table 4). To test the influence of the protecting group towards n/iso-selectivity, several 
protected allylic amines are hydroformylated with a Rh(acac)(CO)2/xantphos system (1:5) at 
70°C. In contrast to the hydroformylation of disubstituted terminal olefins, a lower carbon 
monoxide partial pressure is chosen to ensure that carbon monoxide does not displace 
XANTPHOS from the catalytically active rhodium complex. Although under these conditions 
all hydroformylation experiments proceed with complete olefin conversion, aldehydes can 
only be detected as the minor product. Instead, 2-hydroxy pyrrolidines (223) are formed in 
nearly quantitative yield via intramolecular attack of the carbonyl group by the protected 
primary amine. JACKSON et al. found a similar behavior37. Since only the n-aldehydes can 
cyclize, this isomer is removed from the hydroformylation equilibrium, shifting the product 
distribution towards the n-aldehyde selectively (Scheme 23). 
Consequently, by use of protected secondary allylic amines, this consecutive reaction can be 
suppressed and the n-aldehydes are obtained with high yields and selectivities. Among the 
amides tested, three different types can be recognized. 
                                               
37 a) Teoh, E.; Campi, E. M.;, Jackson, W. R.; Chem. Commun. 2002, 978-979. b) Teoh, E.; Campi, E. M.; 
Jackson, W. R. N.; Robinson, A. J. New J. Chem. 2003, 27, 387-394. 
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Scheme 23: Hydroformylation of protected primary amines and 
consecutive cyclization. 
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n-aldehyde 221a-c iso-aldehyde 222a-c220b-d
b = Ac
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d = Ts
223a-c
quant.
+
a = Ac
b = Boc
c = Ts
 
cond.: 1equiv. 220, 0.3mol% Rh(acac)(CO)2, 1.5mol% XANTPHOS, 
10bar CO, 10bar H2, THF, 20h, 70°C. 
 
Those containing two carbonyl groups give the lowest n/iso-ratios. Here a precoordination 
of the catalyst is more probable than in substrates with only one carbonyl group. The allylic 
acetamide 220f for example gives an n/iso-ratio of 12:1. Ethyloxycarbonyl protected N-ethyl 
allyl amine 220g gives the highest n/iso-selectivity of approximately 14:1, with an optimum 
of the catalyst ligand ratio at 1:10. Higher catalyst ligand ratios give no further enhancement 
of the n-selectivity in the case of allylic phthalimide. 
Table 4: Regioselectivity of the hydroformylation of allylic amines in 
dependence from the protecting group. 
N
R2
R1
N
R2
R1
O
N
R2
R1
O
+
220 221 222  
entry olefin 220 XANTPHOS : [Rh] 221/222a),b) 
1 220a (R1=R2=Pht) 
5 : 1 
10 : 1 
4:1 
6:1 
221a/222a 
2 220e (R1=Et, R2=Ts) 
5 : 1 
10 : 1 
6:1 
6:1 
221e/222e 
3 220f (R1=Et, R2=Ac) 
5 : 1 
10 : 1 
11:1 
12:1 
221f/222f 
4 220g (R1=Et, R2=Eoc) 
5 : 1 
10 : 1 
13:1 
14:1 
221g/222g 
cond.: 1equiv. 220, 0.3mol% Rh(acac)(CO)2, XANTPHOS (see table), 10bar 
CO, 10bar H2, THF, 20h, 70°C. a) determined by 1H-NMR of the crude reaction 
mixture. b) full conversion. 
2.6.2 INFLUENCE OF ARYL HYDRAZINES ON N-SELECTIVE HYDROFORMYLATION 
In order to study the influence of hydrazines on the n/iso-selectivity of the 
rhodium/xantphos catalyst, hydroformylation of protected allylic amines is conducted in the 
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presence of phenylhydrazine. From the results compiled in Table 5 it can be concluded that 
aromatic hydrazines are not competing with the n-directing XANTPHOS. Therefore aryl 
hydrazones are obtained with a high degree of n-selectivity starting from protected allylic 
amines. 
Table 5: Tandem hydroformylation / hydrazone formation of allylic 
amines in dependence from the protecting group. 
N
R2
R1
N
R2
R1
N
N
R2
R1
+
220 224 225
HN
Ph N
HN
Ph
 
entry olefin 220 XANTPHOS : [Rh] 224/225a),b) 
1 220a (R1=R2=Pht) 
5 : 1 
10 : 1 
1:1 
6:1 
224a/225a 
2 220e (R1=Et, R2=Ts) 
5 : 1 
10 : 1 
3:1 
6:1 
224b/225b 
3 220f (R1=Et, R2=Ac) 
5 : 1 
10 : 1 
11:1 
12:1 
224c/225c 
cond.: 1equiv. 220, 1equiv. 214a, 0.3mol% Rh(acac)(CO)2, XANTPHOS (see 
table), 10bar CO, 10bar H2, THF, 68h, 70°C. a)determined by 1H-NMR of the 
crude reaction mixture. b)full conversion. 
2.6.3 APPLICATION OF N-SELECTIVE HYDROFORMYLATION / INDOLIZATION 
In using the optimized conditions of the tandem hydroformylation / indolization procedure, 
olefin 220j gives the methyl ester of the plant growth regulator 3-indole butanoic acid (IBA, 
226) in 91% isolated yield (Scheme 24). Hydrazone formation and indolization proceed 
smoothly after addition of dilute H2SO4. 
Scheme 24: Synthesis of the plant growth regulator 
IBA. 
NHNH2
N
H
O
O
O
O
91%
226
220j
214a
 
cond.: a) 1equiv. 220j, 1equiv. 214a, 0.3mol% 
Rh(acac)(CO)2, 3mol% XANTPHOS, 10bar CO, 10bar H2, 
68h, 70°C b) 4wt% H2SO4/THF, 2h, 80°C. 
 
If allylic amides and homoallylic amides are subjected to the same conditions, tryptamines 
and homotryptamines are obtained in good yields. All protecting groups are tolerated and as 
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expected from the results described above, strong electron withdrawing protecting groups 
give the best yields (Table 6).  
Table 6: Tandem hydroformylation / Fischer indole synthesis of non-
branched tryptamines and homologues. 
NHNH2
N R2
R1
n
N
H
N
R2
R1
n
R3
220
227
R3
214
 
entry olefin 220 hydrazine 214 yield 227 
1 220c (n=1, R1=H, R2=Ts) 214a 
N
H
227a, 59%
NHTs
 
2 220a (n=1, R1=R2=Pht) 214a 
N
H
227b, 51%
NPht
 
3 220a (n=1, R1=R2=Pht) 214j 
N
H
227c, 80%
NPhtO
 
4 220e (n=1, R1=Et, R2=Ts) 214a 
N
H 227d, 81%
N Ts
 
5 220f (n=1, R1=Et, R2=Ac) 214a 
N
H 227e, 59%
N Ac
 
6 220h (n=2, R1=Et, R2=Ts) 214a 
N
H
227f, 58%
N
Ts
 
7 220g (n=1, R1=Et, R2=Eoc) 214a 
N
H 227g, 51%
N Eoc
 
8 220j (n=1, R1=Et, R2=Bz) 214a 
N
H 227h, 32%
N Bz
 
cond.: a) 1equiv. 214, 1equiv. 220, 0.3mol% Rh(acac)(CO)2, 3mol% 
XANTPHOS, 10bar CO, 10bar H2, 68h, 70°C b) 4wt% H2SO4/THF, 2h, 80°C. 
 
It is noteworthy that tandem hydroformylation / FISCHER indole synthesis of 220h gives 
tosylated homotryptamine 227f in good yields. Application of a-Boc protected p-methoxy 
phenylhydrazine 214j yields the 5-methoxy-tryptamine 227c in excellent yields. Here, no 
further purification is required.  
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2.7 INTERIM CONCLUSION 
In this chapter the optimization towards the synthesis of protected primary and secondary 
tryptamines starting from allylic amides is described.  
Ø Two different protocols have been developed: 
· First generation protocol. The hydroformylation of allylic amides is conducted in 
the presence of an appropriate aromatic hydrazine in unpolar solvents such as 
THF. Commercially available aryl hydrazines as well as a-Boc protected aryl 
hydrazines can be used. Indolization is started by subsequent addition of acid to 
this reaction mixture. Here H2SO4 turned out to be the acid of choice. 
· Second generation protocol. The hydroformylation of allylic amides is conducted 
in the presence of an appropriate aromatic hydrazine and PTSA. If commercially 
available hydrazines are used, subsequent tosylation helps to purify the indole 
from by-products. The selectivity of this tandem reaction can be increased by the 
use of benzhydrylidene protected aryl hydrazines. 
Ø Aryl hydrazones can be obtained from a hydroformylation of olefins in the presence of 
aryl hydrazines in almost quantitative yields. These hydrazones might be useful 
intermediates for other applications, such as [2+3]-cycloadditions. 
Ø n-selective hydroformylation can be achieved with the use of XANTPHOS. Aromatic 
hydrazines do not compete with the ligand for the catalyst and do not hamper the 
n-selectivity. 
Ø Several basic applications have been presented, such as the synthesis of the serotonin 
analogues 215j and 227c, the methyl ester of the plant growth regulator IBA (226) and 
of 219, a valuable intermediate in the synthesis of sertindole analogues. 
 - 41 - 
3 SYNTHESIS OF TERTIARY TRYPTAMINES 
Many therapeutically relevant tryptamines contain tertiary amine moieties. In the preceding 
chapter the application of the tandem hydroformylation / indolization towards primary and 
secondary tryptamines is described. Here, the tandem reaction of protected primary and 
secondary allylic and homoallylic amines was preferably conducted in non-polar solvents 
such as toluene or THF. In order to obtain tryptamines with tertiary amine moieties, tertiary 
aminoolefins have to be used. Surprisingly, the previously developed protocols fail with this 
type of substrates. Several reasons might be responsible: 
Ø More nucleophilic tertiary amines might be protonated in the presence of acid and 
precipitate from the non-polar reaction mixture. Precipitation of aryl hydrazine salts is 
responsible for a lower selectivity earlier. Therefore, benzhydrylidene protected 
hydrazines are used. The same enrichment of salts might hamper the tandem protocol 
applied to tertiary amines.  
Ø Rhodium catalysts exhibit double bond isomerization activity. It has been reported, 
that allylic amines isomerize to enamines under rhodium catalysis at mild 
temperatures38. It is also well known, that enamines are easily hydrogenated under 
hydroformylation conditions in an overall hydroaminomethylation8. Such 
isomerization / hydrogenation processes would lead to a loss of olefin. 
Ø It is well documented that the hydrogenation activity of rhodium catalysts is increased 
in the presence of catalytic amounts of tertiary amines39. In using amino olefins, the 
tertiary amines, as part of the substrate, are present in high excess relative to the 
catalyst. Therefore, hydrogenation of the olefin can result in loss of starting material 
while consecutive hydrogenation of the hydroformylation product leads to the 
corresponding alcohol or hydrazine. 
Ø Furthermore, tertiary amines acting as bases can induce aldol condensation reactions 
of the aldehydes as a side-reaction. 
Therefore, a new set of conditions has to be developed for tertiary aminoolefins by 
conducting the tandem reaction stepwise, and optimization of each single step. 
                                               
38 Tani, K.; Yamagata, T.; Akutagawa, S.; Kumobayashi, H.; Taketomi, T.; J. Am. Chem. Soc. 1984, 106, 5208-
5217. 
39 a) Kaneda, K.; Yasumura, M.; Hiraki, M.; Imanaka, T.; Teransihi, S. Chem. Lett. 1981, 1763. b) Kaneda, K.; 
Imanaka, T.; Teranishi, S. Chem. Lett. 1983, 1465. 
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3.1 HYDROFORMYLATION IN THE PRESENCE OF ARYL HYDRAZINES 
As expected, hydroformylation of N-allylic, N,N-dimethyl amine (301a) and of 
4-methylene, N-methyl piperidine (301l) does not give any aminoaldehyde even if 
XANTPHOS is added. If, however, hydroformylation of the same allylic amines is conducted 
in the presence of phenylhydrazine (302a), the expected aryl hydrazones 303 can be isolated 
in almost quantitative yields (Table 7). No purification is needed, so the products can be used 
for indolization directly. Under the chosen conditions, electron withdrawing as well as 
electron donating substituents at the aryl hydrazine are tolerated. Even nitro groups that are 
prone to catalytic hydrogenation are stable under the selected conditions40. It is also important 
to mention that the use of Rh/xantphos grants high n-selectivity in the hydroformylation of 
terminal monosubstituted amino olefins. 
Table 7: Tandem hydroformylation / hydrazone formation of 
tertiary allylic amines. 
N
R1
R1
N
R1
R1
N
301
H
N
303
R2C6H4NHNH2
R2
+
302  
entry olefin 301 hydrazine 302 yield 303 
1 301a (R1=CH3) 302a (R2=H) quant. (303a) 
2 301b (R1=(CH2)5) 302a (R2=H) 97% (303b) 
3 301b (R1=(CH2)5) 302b (R2=OMe) 93% (303c) 
4 301a (R1=CH3) 302c (R2=CN) 90% (303d) 
5 301b (R1=(CH2)5) 302d (R2=NO2) 80% (303e) 
cond.: 1equiv. 301, 1equiv. 302, 0.3mol% Rh(acac)(CO)2, 
1.5mol% XANTPHOS, 10bar CO, 10bar H2, THF, 3d, 70°C. 
 
In all cases, hydrogenation products are not observed neither of the olefin nor the aldehyde 
which is immediately trapped by the hydrazine. Also the aryl hydrazone double bond is not 
hydrogenated, presumably due to higher stability of aryl hydrazones towards hydrogenation 
as compared to the aldehyde precursors. In summary, the hydrazone group acts as an efficient 
protecting group for aldehydes against hydrogenation and aldol reactions. In contrast to other 
protecting groups, the phenylhydrazone is a building block for the final indole product at the 
same time. 
                                               
40 Nitro groups can be reduced under harsh hydroformylation conditions allowing to be used as aniline 
precursors in hydroaminomethylations. Rische, T.; Dissertation 1999, University of Dortmund. 
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3.2 FISCHER INDOLIZATION 
3.2.1 TRYPTAMINES WITH LINEAR SIDE CHAINS 
While the hydroformylation described above is performed in THF, FISCHER indolization 
requires a more polar solvent in order to prevent precipitation of salts formed by protonation 
of the amino and/or hydrazine/hydrazone groups. Alcohols are common solvents in FISCHER 
indole syntheses. However, indolization of 303a in ethanol gives tryptamine 304a only in an 
unselective conversion with poor yields. Reaction in methanol does not lead to any 
improvements, while in aqueous H2SO4, fast and highly selective conversion towards indole 
304a is found with quantitative yields. Surprisingly this method proceeds with such a high 
degree of selectivity that a purification of the reaction product is obsolete. If after a 
hydroformylation of the amino olefin in the presence of an aryl hydrazine the solvent is 
removed and the remaining aryl hydrazone is taken up in aqueous H2SO4 for the final 
indolization, a combination of these two steps seems to be a suitable protocol for the synthesis 
of tryptamines directly from olefins. The reliability of this first generation protocol is tested 
with a number of different allylic and homoallylic amines and the results are compiled in 
Table 8.  
Table 8:Tandem hydroformylation / Fischer indole synthesis of tertiary allylic amines. 
N
R1
R1
301
n
N
H
N R1
R1
n
304
NHNH2
+
302a
 
entry olefin 301 yield 304 entry olefin 301 yield 304 
1 N
301a  304aquant.NH
N
 
2 N
301b  NH
N
304b
97%  
3 N
N
Ph
301c
 
N
H
N
N
Ph304c
a)
96%  
4 
N
N O
O
301d  
N
H
N
N
O
O304d
94%
 
5 N
301e  N
H
N
304e
91%  
6 N
N O
O
301f
 
N
H
N N O
O
304f
91%
 
cond.: i) 1equiv. 301, 1equiv. 302a, 0.3mol% Rh(acac)(CO)2, 1.5mol% XANTPHOS, 10bar CO, 10bar H2, 
THF, 3d, 70°C. ii) 4wt% H2SO4, 2h, 100°C. Yield is given for the tandem reaction starting with the olefin. 
a)precipitated as hydrochloride salt. 
 
SYNTHESIS OF TERTIARY TRYPTAMINES 
- 44 - 
Without exception, all indoles are obtained in excellent yields and no products stemming 
from iso-aldehydes are detected. Thus, Rh/xantphos is a powerful hydroformylation catalyst 
for the regioselective conversion of amino olefins and, in contrast to other observations41, the 
positive effect of the ligand is not suppressed in the presence of the amine and hydrazine 
units. The stability of the carbamate protecting group in 304d and 304f is also surprising. 
After removal of this group the nitrogen can be activated for further derivatization as required 
for target molecules such as pharmaceutical compound L 775 606. While tryptamine 304a is 
known as a prominent structural element in many biologically active indole derivatives, 
tryptamines with the nitrogen as part of a cyclic moiety are garnering more and more interest. 
The piperazin moiety especially seems to be very attractive for pharmaceutical use. The 
structural element of 304c for example, is found in the antipsychotic oxypertine (Scheme 25). 
For targets of this type, it is important to prove that both, allylic piperazines as well as 
homoallylic piperazines, are tolerated under the used conditions, allowing the attachment of 
amines at varying distances to different indole cores. In general, allylation and homoallylation 
of amines proceed with excellent yields, thus allowing a modular approach using the method 
described above. 
Scheme 25: Piperazine units 
in pharmaceutically relevant 
tryptamines. 
N
H
N
MeO
MeO
N
Ph
Oxypertine  
3.2.2 TRYPTAMINES WITH BRANCHED SIDE CHAINS 
Apart from tryptamine analogues with linear side chains as prepared above, derivatives with 
branched side chains have also come into the focus of medicinal chemistry. In the past few 
years, the first examples of such branched tryptamines possessing pharmacologically 
interesting properties have been developed. The a-branched tryptamine LY 156735 for 
                                               
41 Angelovski, G.; Eilbracht, P.; Tetrahedron 2003, 41, 8265-8274. 
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example, is a melatonin agonist, which helps to alleviate the symptoms of jet lag and which 
enhances readaptation of desynchronized circadian rhythms to a new time zone42.  
Scheme 26: Pharmaceutically relevant tryptamines 
with branches in the side chain. 
N
H
NHAc
MeO
Cl
LY 156735
N
H
NH
N
HN
R
R
R
R
R
b-carboline derivatives  
Tryptamines with branches at the b-carbon as found in various b-carboline derivatives 
(Scheme 26) act as potential drugs against depression anxiety. Most of the known b-branched 
tryptamines are tryptophan derivatives and can be synthesized starting from this essential 
amino acid. Therefore, not surprisingly, only a few examples of b-branched tryptamines are 
reported with substituents not possessing the oxidation level of carboxylic groups or with 
substituents not obtainable from carboxylic groups. Obviously there is a need for a method 
that allows fast access to branched tryptamines as well. The tandem 
hydroformylation / FISCHER indolization can be such a method. If branched olefins are used 
instead of linear olefins, tryptamines and homotryptamines with branches in the side chain 
can be obtained.  
In chapter 2, it has already been demonstrated that a-branched tryptamines can be obtained 
by using terminally disubstituted olefins like methallyic amines which can easily be prepared 
by simple allylation with methallyic chloride. The allylic amines required for the synthesis of 
b-branched tryptamines are obviously less conveniently obtained and in addition, they bear a 
stereogenic center. Simple allylation of amines may fail due to poor regioselectivity and 
problems to control the configuration of the newly formed stereocenter, if it is required. A 
well-described method to synthesize chiral allylic amines is the OVERMAN rearrangement of 
allylic trihaloacetimidates, giving protected primary amines43. After deprotection and 
alkylation the tertiary chiral amine 301g can be obtained as a racemate. An alternative method 
to obtain chiral allylic amines has been published in 2001 by TAKEUCHI et al.44. Here 
regioselective allylic amination of allylic carbonates and acetates has been achieved with a 
Ir/P(OPh)3 catalyst. In 2002, HARTWIG published the first regio- and enantioselective allylic 
                                               
42 Nickelsen, T.; Samel, A.; Vejvoda, M.; Wenzel, J.; Smith, B.; Gerzer, R.; Chronobiol Int.,2002, 5, 915-936. 
43 Overman, L.E.; J. Am. Chem. Soc. 1974, 96, 597. 
44 Takeuchi, R.; Ue, N.; Tanabe, K.; Yamashita, K.; Shiga, N.; J. Am. Chem. Soc. 2001, 123, 9525-9534. 
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amination45. With this methodology, a large number of different allylic amines is accessible, 
such as 301h, with varying amine functionalities as well as alkyl, homoaryl and heteroaryl 
substituents tolerable at the stereocenter. Using these methods (OVERMAN rearrangement, 
allylic amination) for selected examples followed by the tandem hydroformylation / FISCHER 
indole procedure b-branched indoles are obtained in good to excellent yields (Table 9).While 
the allylic amination proceeds with high enantiomeric excesses, the stereocenter may 
epimerize during a tandem hydroformylation / FISCHER indolization via reversible double 
bond isomerization either by the transition metal catalyst or the acid. The tryptamines 
obtained from enantiomerically pure allylic amines however, reveal complete retention of 
chirality under hydroformylation conditions.  
Table 9: Tandem hydroformylation / Fischer 
indolization of branched allylic amines. 
N
R1
R1
301 NH
N R1
R1
304
R2
R2
NHNH2
+
302a  
entry olefin 301 yield 304 
1 
N
301g
Ph
 304g85%
N
H
N
Ph
 
2 
N
rac-301h
Ph
 rac-304h54%a
N
H
N
Ph
 
3 
N
(+)-301h (96%ee)
Ph
 (+)-304h54%a, 95%eea,b
N
H
N
Ph
 
4 
N
(-)-301h (96%ee)
Ph
 (-)-304h54%a, 95%eea,b
N
H
N
Ph
 
cond.: i) 1equiv. 301, 1equiv. 302a, 1mol% 
Rh(acac)(CO)2, 5mol% XANTPHOS , 10bar CO, 
10bar H2, THF, 3d, 80°C. ii) 4wt% H2SO4, 2h, 
100°C. Yield is given for the tandem reaction starting 
with the olefin. a) average of all reactions with 201h, 
b) Determined by HPLC with a Daicel Chiracel OJ. 
 
                                               
45 Ohmura, T.; Hartwig, J.F.; J. Am. Chem. Soc. 2002, 124, 15164-15165. 
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This combination of iridium catalyzed enantioselective allylic amination and tandem 
hydroformylation / FISCHER indole synthesis, in contrast to other methods reported, gives fast 
access to b-branched tryptamines which can not be derived from tryptophan and therefore 
allows access to a new class of tryptamine derivatives for biological screenings. 
3.2.3 INDOLIZATION UNDER REARRANGEMENT 
In contrast to the use of branched olefins the use of internal olefins is another option to place 
substituents on the olefin. If, for example, cinnamyl piperidine (301i) as a styrene type olefin 
is used, hydroformylation takes place preferably in benzyl position. Regioselectivity can be 
improved by the additional use of the biphosphite ligand BIPHEPHOS. Hydroformylation of 
301i and condensation leads to hydrazone 306. After a [3,3]-sigmatropic rearrangement and 
cyclization, intermediate 308 is formed which rearranges to gain aromaticity. In this case, the 
aromatic ring migrates into the 2-position exclusively, forming the selective 5-HT2A 
antagonist 2-phenyl-trpytamine 304i in 60% yield (Scheme 27). 
Scheme 27: Hydroformylation / Fischer indolization of 
internal olefins – Synthesis of 2-aryl tryptamines. 
Ph
NH
NH2
N
Ph
Ph N
N
H
Ph
N
Ph N
OH
Ph N
NH
H
N
Ph
N
N
hydroformylation
hydrazone 
formation
[3,3]~
cyclization
rearrangement
301i
305
306
307
308
304i, 60%
 
cond.: i) 1equiv. 301i, 1equiv. 302a, 0.5mol% Rh(acac)(CO)2, 
10mol% XANTPHOS , 10bar CO, 10bar H2, THF, 3d, 100°C. ii) 
4wt% H2SO4, 2h, 100°C. Yield is given for the tandem reaction 
starting with the olefin. 
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This combination of aryl migration and tandem hydroformylation / FISCHER indole reaction 
is not limited to allylic amines and might therefore be a valuable tool for the synthesis of drug 
candidates possessing an aryl moiety in the 2-position like the examples in Scheme 28 46. 
Scheme 28: Pharmaceutically relevant 2-aryl tryptamines. 
N
H
HN
Et2N
O
N
N
N
O
O
N
H
NH
Ph
Br
GnRH-antagonist 5-HT6-modulator  
3.2.4 HOMOTRYPTAMINES WITH BRANCHED SIDE CHAINS 
In using the same protocol with branched homoallylic amines, branched homotryptamines 
are achieved. The required amines are easily obtained via a combination of MANNICH reaction 
and WITTIG olefination, by carbomagnezation or by simple BARBIER type reactions.  
Scheme 29: Pharmaceutically 
relevant branched homotryptamine. 
N
H
N
O2
S
MeHN
Naratriptan  
A number of different methods have been published to control absolute configuration of the 
stereocenters in BARBIER type reactions. The homoallylic moiety can also be embedded in an 
exocyclic olefin. If 4-methylene-piperidines are used, 3-(N-methyl piperdiyl)-indoles are 
obtained containing an important structural element for active agents like anti-migraine drug 
L 775 606 or naratriptan (Scheme 29). As it can be seen from Table 10 most 
homotryptamines can be obtained in good to excellent yields. Halide substituents are tolerated 
allowing further derivatization with common cross coupling methodologies. With this respect, 
substrate 204o may act as a valuable intermediate for the synthesis of naratriptan.  
 
                                               
46 Köhling, P.; Schmidt, A.M.; Eilbracht, P.; Org. Biomol. Chem. 2005, in preparation. 
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Table 10: Tandem hydroformylation / Fischer indolization towards branched homotryptamines. 
N
H
N
R
304
R
R
N
R
R
301
R
RR NH
H2N
R
302
+ R
R
R
 
Entry olefin 301 
hydrazine 
302 
yield 304 Entry olefin 301 
hydrazine 
302 
yield 304 
1 301j
NPh
 
302a 
(R=H) 
304j
41%a
N
H
N
Ph
 
2 
301k
N
Ph
 
302a 
(R=H) 304k
51%a
N
H
N
Ph
 
3 
301l
N
Ph
 
302a 
(R=H) 304l
81%b
N
H
N
Ph
 
4 
N
301m  
302a 
(R=H) 304m
78%cN
H
N
 
5 
N
301m  
302e 
(R=F) 304n
65%cN
H
N
F
 
6 
N
301m  
302f 
(R=Cl) 304o
85%cN
H
N
Cl
 
7 
N
301m  
302g 
(R=Br) 304p
quant.cN
H
N
Br
 
8 
N
301m  
302h 
(R=CH3) 304q
66%cN
H
N
 
9 
N
301m  
302b 
(R=OCH3) 304r
85%cN
H
N
O
 
 
cond.: a) i) 1equiv. 301, 1equiv. 302, 1mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 3d, 120°C. ii) 4wt% 
H2SO4, 2h, 100°C. Yield is given for the tandem reaction starting with the olefin; b) i) 1equiv. 301, 1equiv. 
302, 0.3mol% Rh(acac)(CO)2, 1.5mol% XANTPHOS, 10bar CO, 10bar H2, THF, 3d, 70°C. ii) 4wt% H2SO4, 
2h, 100°C. Yield is given for the tandem reaction starting with the olefin; c) i) 1equiv. 301, 1equiv. 302, 
0.3mol% Rh(acac)(CO)2, 50 bar CO, 10 bar H2, THF, 3d, 100°C. ii) 4wt% H2SO4, 2h, 100°C. Yield is given 
for the tandem reaction starting with the olefin. 
 
3.3 TANDEM REACTION IN WATER 
In conclusion, this first generation protocol for tandem hydroformylation / FISCHER indole 
synthesis gives fast and convenient access to a large number of differently substituted 
tryptamines with tertiary amine moieties. However, this protocol requires a change of solvent 
to complete the procedure, although there is no need for a purification of the aryl hydrazones. 
Therefore, it is desirable to develop an advanced protocol that allows direct access to 
tryptamine derivatives from amino olefins. This requires a solvent with good solubility for all 
reagents and reactants. While alcoholic solvents have failed in test reactions, it turned out that 
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water is the solvent of choice, since H2SO4 in water allows a smooth conversion of the aryl 
hydrazones to tryptamines. Solubility of the rhodium based hydroformylation catalyst in 
water and even in aqueous H2SO4 can be achieved in using sulfonated ligands such as TPPTS 
or the analogous derivative 309 of XANTPHOS (Scheme 30).  
Scheme 30: Water soluble ligands for the second generation 
protocol in water. 
P
NaO3S SO3Na
SO3Na
O
PPh2PPh2
SO3HHO3S
309TPPTS  
With respect to the pharmacological relevance of 3-piperidyl indoles this modification was 
tested with allylic and homoallylic substrates mostly containing the piperidyl or the 
piperazinyl moiety with rhodium/TPPTS or rrhodium/309 in aqueous H2SO4. As shown in 
Table 11, tandem hydroformylation / FISCHER indole synthesis in water gives, in all cases, 
excellent results. For 3-piperidyl-indoles (entries 1-4) no further purification is required. It is 
worth to mention that sensitive bromo substituents are maintained, even at prolonged reaction 
times, during which the aryl halide is treated with mineral acid under harsh conditions. 
Clearly, regioselective tandem hydroformylation / FISCHER indole synthesis in water is not 
limited to disubstituted terminal olefins as the substrate. Conversion of allylic and 
homoallylic amines also gives good to excellent yields of the desired tryptamine analogues. 
High regioselectivities can also be achieved with sulfonated xantphos 309.  
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Table 11: Tandem hydroformylation / Fischer indolization in water. 
N
H
N R
R
304
R
R
N
R
R
301
R
RR NH
H2N
302
+
R
R  
entry olefin 301 hydrazine 302 yield 304 
1 
N
301m  
302a (R=4-H) 
304m
80%bN
H
N
 
2 
N
301m  
302e (R=4-F)a 
304n
95%bN
H
N
F
 
3 
N
301m  
302f (R=4-Cl)a 
304o
quant.bN
H
N
Cl
 
4 
N
301m  
302g (R=4-Br)a 
304p
96%bN
H
N
Br
 
5 
N
301m  
302h (R=2-Cl)a 
304s
96%bN
H
N
Cl  
6 
N
N O
O
301d  
302a (R=4-H) 
N
H 304dquant.c
N
N
O
O
 
7 N
301e  
302a (R=4-H) 
N
H
N
304e
50%c  
8 
301l
N
Ph
 
302a (R=4-H) 
304l
quant.c
N
H
N
Ph
 
cond.: a) hydrochlorides were used directly; b) 1equiv. 301, 1equiv. 302, 
0.3mol% Rh(acac)(CO)2, 1.5mol% TPPTS, 50bar CO, 10bar H2, 4wt% 
H2SO4, 3d, 100°C; c) 2equiv. 301, 1equiv. 302, 0.3mol% Rh(acac)(CO)2, 
3mol% 305, 10bar CO, 10bar H2, 4wt% H2SO4, 3d, 100°C. 
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3.4 APPLICATION – SYNTHESIS OF MIGRAINE DRUGS 
In further experiments, both protocols for tandem hydroformylation / FISCHER indole were 
tested in the synthesis of the three anti-migraine drugs LY 334 370, L 775 606 and 
LY 349 950. The results are given in Table 12. While for entry 1&3 the second generation 
protocol gives no significant improvement, the tandem reaction in water gives LY 334 370 
(entry 2) in almost quantitative yield, making further purifications not necessary. In all cases, 
overall yields improved, and the number of required steps is reduced compared to already 
described syntheses. 
Table 12: Synthesis of migraine drugs via tandem hydroformylation / Fischer indolization. 
N
H
N
304
R
R
N
R
301
R
RR
N
H2N
R
302
+
Boc
n
R
R
n
 
entry olefin 301 hydrazine 302 yield 304 
1 N
301a  
H
N
O
F
N
Boc
NH2
302i  
LY 349 950
44%a
N
H
N
H
N
O
F
 
2 
N
301m  
H
N
O
F
N
Boc
NH2
302i  
LY 334 370
95%b
N
H
N
H
N
O
F
 
3 N
N
F301n  
N
N
Boc
NH2
302j
N
N
 
L 775 606
51%aN
H
N
N
N N
N
F
 
cond.: a) i) 1equiv. 301, 1equiv. 302, 1mol% Rh(acac)(CO)2, 5mol% XANTPHOS, 10bar CO, 10bar 
H2, THF, 3d, 70°C. ii) 4wt% H2SO4, 2h, 100°C. Yield is given for the tandem reaction starting with 
the olefin; b) 1equiv. 301, 1equiv. 302, 0.3mol% Rh(acac)(CO)2, 1.5mol% TPPTS, 50 bar CO, 10 bar 
H2, 4wt% H2SO4, 3d, 100°C. 
 
Although syntheses of the required aryl hydrazines have been reported47,48, it turned out to 
be hard to obtain the products with sufficient purity. Obviously the classical approach of 
aniline diazotation and reduction of the resulting diazonium salts with bisulfites or tin 
dichloride, suffers from low selectivity. Furthermore, purification of aryl hydrazines is hard to 
manage. Therefore, the GOLDBERG reaction was used to synthesize the required hydrazines 
                                               
47 Xu, Y.-C.; Johnson, K.W.; Phebus, L.A.; Cohen, M.; Nelson, D.L.; Schenck, K.; Walker, C.D.; Fritz, J.E.; 
Kaldor, S.W.; LeTourneau, M.E.; Murff, R.E.; Zgombick, J.M.; Calligaro, D.O.; Audia, J.E.; Schaus, J.M.; J. 
Med. Chem. 2001, 24, 4031-4034. 
48 Sternfeld, F.; Guiblin, A.R.; Jelley, R.A.; Matassa, V.G.; Reeve, A.J.; Hunt, P.A.; Beer, M.S.; Heald, A.; 
Stanton, J.A.; Sohal, B.; Watt, A.P.; Street, L.J; J. Med. Chem. 1999, 4, 677-690. 
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starting from the corresponding aryl iodides under copper catalysis in good yields. The a-Boc 
protected aryl hydrazines are not prone to oxidation and can be easily purified by LC. Under 
FISCHER indolization conditions, the Boc group is removed to give the desired products in 
medium to excellent yields. Neither hydrolysis of the amide bonds in LY 334 950 and 
LY 334 370 nor hydrogenation of the imine-enamine pattern in L 775 606 is observed. 
3.5 INTERIM CONCLUSION 
Ø In almost every case, aryl hydrazones can be obtained in quantitative yields with high 
purity upon hydroformylation of aminoolefins in the presence of aromatic hydrazines. 
Ø The hydrazone group protects the aminoaldehyde from undesired consecutive 
reactions such as hydrogenation or aldol reaction. Therefore the hydrazone acts as an 
efficient and productive protecting group at the same time being part of the final 
indole product.  
Ø Stereogenic centers within the olefin are configuratively stable. Thus, no double bond 
migration is involved which might lead to thermodynamically more stable enamines. 
Ø Two different protocols for the tandem hydroformylation / FISCHER indolization 
towards tryptamines with tertiary amine moieties have been developed: 
· First generation protocol. The hydroformylation of aminoolefins is conducted in 
the presence of aryl hydrazines or a-Boc aryl hydrazines in THF. After 
evaporation of the solvent the remaining hydrazone is indolized in aqueous H2SO4.  
· Second generation protocol. The hydroformylation of aminoolefins is conducted 
in the presence of aryl hydrazines, hydrazine hydrochlorides or a-Boc protected 
hydrazines in aqueous H2SO4 giving tryptamines directly. Water solubility of the 
catalyst can be achieved by the use of water soluble ligands such as TPPTS or 
SulfoXANTPHOS. Water is benign and therefore environmentally friendly. 
Ø With both protocols, tryptamines and homotryptamines with linear and branched side 
chains can be obtained in excellent yields and in many cases without further 
purification. 
Ø The combination of modern olefin and hydrazine syntheses with the tandem 
hydroformylation / FISCHER indolization is a modular approach that allows fast and 
convenient access towards tryptamines and analogues with high diversity in all 
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important positions (i.e. substituents on the indole ring, type of amine moiety, length 
of the side chain, substituents in the side chain). 
Ø Even under harsh conditions, useful substituents, such as bromine, are tolerated, 
offering fast access to valuable intermediates for the synthesis of pharmaceuticals. 
Ø Both protocols can be used for the total synthesis of migraine drugs. Here yields of up 
to 95% are observed. 
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4 FUNCTIONALIZATION OF TRYPTAMINES UNDER 
HYDROFORMYLATION CONDITIONS 
In the past few years a number of tryptamines and homotryptamines bearing more 
sophisticated substituents at the amine moiety have been patented as potential drugs for the 
treatment of completely different medical conditions. Here especially, the substituents on the 
amine moiety seem to play a key role for the selectivity towards these different receptor 
families. A selection of such compounds is compiled in Scheme 31.  
Scheme 31: Selected examples for recent pharmaceutically active tryptamines. 
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All these compounds can be obtained from simple tryptamines and homologues by 
alkylation or reductive amination with an aldehyde. In using the hydroaminomethylation, the 
synthesis of the required aldehyde via hydroformylation can be combined with the reductive 
amination to a one step procedure. Thus, starting with appropriate olefins (blue), tryptamines 
(green) and CO/H2 (red), the pharmaceuticals in Scheme 31 may be accessible in only one 
step. The required tryptamines can also be synthesized efficiently under hydroformylation 
conditions as described in the previous chapters. In summary, a total synthesis of such 
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sophisticated tryptamine drugs might be achieved in a few steps using two different tandem 
hydroformylation sequences. Although primary or secondary tryptamines with aliphatic side 
chains in the 3-position derived from tandem hydroformylation / FISCHER indolization can be 
used in hydroaminomethylations in order to attach further substituents on the amine moieties, 
in this chapter 3-piperidyl indole drugs 401-404 (Scheme 31) are synthesized exclusively, 
representing pharmaceuticals for the treatment of important medical conditions. The 
compounds with the general structure 401 for example are LDL-receptor regulators and can 
be used for the treatment of an imbalance of low density lipoprotein cholesterol (LDL), which 
is responsible for a number of cardiovascular diseases, such as atherosclerosis, pancreatitis or 
non-insulin dependent diabetes mellitus (NIDDM)49. Substance 402 has a strong affinity 
towards the dopamine 4 (D4) receptor. This antagonist can be used for the treatment of certain 
psychiatric and neurological disorders, in particular psychoses50. Compound 403 is a ligand 
that binds to the chemokine receptor 5 (CCR5). This receptor is involved in many medical 
conditions such as asthma or atopic disorders (e.g. atopic dermatitis or allergies). Therefore, 
substances that modulate this receptor might be used for the prevention or treatment of such 
diseases51. Compound 404 is a member of a class of MCP-1 (CCR2b) receptor antagonists. 
They inhibit MCP-1 stimulated chemotaxis in monocytes and can be used in the treatment of 
diseases with a clear inflammatory component, such as atherosclerosis, multiple sclerosis and 
AIDS49a. 
Furthermore, in the synthesis of the selected drugs 401-404 different types of olefins have to 
be used for the hydroaminomethylation step. Therefore different reaction conditions are 
presented and will be discussed in detail within this chapter. 
4.1 SYNTHESIS OF THE 3-PIPERIDYL INDOLES 
Syntheses of the required 3-piperidyl indoles have already been published. In many cases, 
this core is built up by electrophilic substitution of appropriately substituted indoles (407) 
which have to be synthesized previously (Scheme 32). After elimination of water, the 
resulting double bond is hydrogenated. This hydrogenation seems to be problematic since a 
selective differentiation of the conjugated double bonds is hard to manage. Poor yields 
(around 50%) are obtained for this ostensibly simple transformation reducing the overall 
                                               
49 a) Bouillot, A.M.J.; Bombrun, A.; Dumaitre, B.A.; Gosmini, R.L.M.; PCT. Int. Appl. 2002, WO2002055496. 
b) Bouillot, A.M.J.; Dumaitre, B.A.; PCT. Int. Appl. 2004, WO2004006923. c) Bouillot, A.M.J.; Dumaitre, B.A., 
PCT. Int. Appl. 2004, WO2004006922. 
50 Bang-Andersen, B.; Felding, J.; Kehler, J.; Andersen, K.; PCT. Int. Appl. 2001, WO2001096328. 
51 Bondell, W.E.; Chan, J.; Porter, R.A. PCT. Int. Appl. 1999, WO1999017773. 
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yield. Tandem hydroformylation / FISCHER indolization can be an attractive alternative since 
simple functional group transformations are replaced by skeleton building steps. 
Scheme 32: Comparison of syntheses towards 3-piperidyl indoles. 
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Since for further derivatization a secondary piperidyl indole is required, it would be 
desirable to subject secondary aminoolefins to the hydroformylation / FISCHER indole 
sequence directly.  
Scheme 33: Attempts to synthesize 
secondary tryptamines under 
hydroformylation conditions. 
NH
NH
N
H
N
Ph
N
H
NH
up to 90%
206
207
411
i)
ii)
iii)
 
cond.: i) 1equiv. 206, 1equiv. 302a, 0.3mol% 
Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 
100°C, 3d, 90%. ii) 1equiv. 207, 4wt% 
H2SO4/THF, 80°C, 2h, 0%. iii) 1equiv. 206, 
1equiv. 302a, 0.3mol% Rh(acac)(CO)2, 
1.5mol% TPPTS, 50bar CO, 10bar H2, 4wt% 
H2SO4, 68h, 60%. 
 
Although the secondary aminoolefin 206 gives the corresponding hydrazone 207 with up to 
90% selectivity upon hydroformylation in the presence of phenylhydrazine, indolization of 
207 in aqueous H2SO4 as well as 4wt% H2SO4 in DMF fails (Scheme 33). Even the second 
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generation protocol (tandem hydroformylation / FISCHER indole synthesis in water) gives 
hydrazone 207 in 60% yield. No indole formation is observed. 
Therefore, protected primary and secondary aminoolefins, as described in chapter 2, have to 
be used. The ethyl carbamate group is stable under the conditions of this protocol and can be 
cleaved off under basic conditions very easily. 412a can be obtained from ethyl 
4-methylenepiperidine-1-carboxylate via simple WITTIG olefination in 81% yield. In order to 
find the ideal hydrazine source, both protocols for the tandem hydroformylation / FISCHER 
indolization are tested in the synthesis of the intermediate 3-piperidyl indoles. If 
benzhydrylidene protected aryl hydrazine 413a is used with 412a in the second generation 
protocol only 20% of the desired indole 414a is obtained. If in contrast, the free 
phenylhydrazine is subjected to the first generation protocol, 414a is isolated in 56% yield. 
The use of a-Boc phenylhydrazine (413c) gives only a small improvement of the yield 
allowing 61% of 414a to be isolated (Table 13). 
Table 13: Different hydrazines sources 
for the synthesis of 3-piperidyl indoles. 
N
H
414a
N
O
O
N O
O
412a
 
entry hydrazine 413 yield 414a 
1 N
H
N Ph
Ph 413a 
20%a 
2 N
H
NH2
413b 
56%b 
3 N NH2
Boc 413c 
61%b 
cond.: a)1equiv. 412a, 1equiv. 413, 1equiv. 
PTSA, 0.3mol% Rh(acac)(CO)2, 50bar CO, 
10bar H2, THF, 100°C, 3d; b)1equiv. 412a, 
1equiv. 413, 0.3mol% Rh(acac)(CO)2, 50bar 
CO, 10bar H2, THF, 68h, then 4wt% 
H2SO4/THF, 80°C, 2h. 
 
In the same manner, tandem hydroformylation / FISCHER indole synthesis of 412a with 
4-fluoro phenylhydrazine carbamic acid tert-butyl ester (413d) gives indole 414b in 38%. It 
seems that the fluoro substituent reduces electron density in the aromatic system and that the 
FUNCTIONALIZATION OF TRYPTAMINES UNDER HYDROFORMYLATION CONDITIONS 
 
- 59 - 
key step of the FISCHER indolization, the [3,3]-sigmatropic Diaza-Cope rearrangement, is 
therefore hampered. In contrast, the use of 413e, bearing an electron pushing substituent, in 
the tandem hydroformylation / FISCHER indolization with 412a gives the desired indole 414c 
in 70% isolated yield (Table 14). 
Table 14: Synthesis of 3-piperidyl indoles. 
N
H
414
N
O
O
N O
O
412a
R
R
NHNH2
413
 
entry hydrazine 413 yield 414 
1 413d (R=F) 38% (414b; R=F) 
2 413e (R=OCH3) 70% (414c; R=OCH3) 
cond.: 1equiv. 412a, 1equiv. 413, 0.3mol% 
Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 68h, then 
4wt% H2SO4/THF, 80°C, 2h. 
 
Deprotection of 414a-d was in all cases conducted with 20wt% NaOH-solution in ethanol, 
giving the deprotected products 415 in almost quantitative yields without further purification 
needed.  
Table 15: Deprotection of 3-piperdiyl indoles. 
N
H
414
N
R
O
O
N
H
415
H
N
R
 
entry indole 414 yield 415 
1 414a (R=H) 96% (415a; R=H) 
2 414b (R=F) 100% (415b; R=F) 
3 414c (R=OCH3) 100% (415c; R=OCH3) 
cond.: 1equiv. 414, 20wt% NaOH, EtOH, 20h 100°C. 
4.2 FUNCTIONALIZATION OF 3-PIPERIDYL INDOLES VIA 
HYDROAMINOMETHYLATION 
For the synthesis of compounds 401-404 different types of olefins have to be used in the 
hydroaminomethylation step. Hydroformylation of allylic amides as required for 401 and 402 
usually gives mixtures of n- and iso-aldehydes. Therefore the use of n-directing ligands like 
BIPHEPHOS or XANTPHOS is necessary. In 2003, BELLER et al. developed a protocol for 
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an n-selective hydroaminomethylation of simple olefins52, but if functionalized olefins are 
used, the n-selectivity is reduced in many cases due to precoordination of the catalyst to the 
functional groups within the olefin. In the case of allylic amides, the catalyst may 
precoordinate to the amide oxygen and one edge of the double bond simultaneously giving a 
favored six membered cyclic transition state in a 6-exo-trig fashion (Scheme 34).  
Scheme 34: Mechanisms for the control of the regioselectivity of the 
hydroformylation. 
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This results in an increased amount of iso-product. To suppress this substrate control, the 
ligand to catalyst ratio has to be increased compared to the original BELLER conditions. 
Hydroaminomethylation of allylic benzamide 412b gives the formal analogue 401b of 
LDL-receptor regulators 401 in 57% isolated yield. NMR of the crude product indicates 
n-selective hydroaminomethylation. It is also important to mention that only the piperidyl 
nitrogen is functionalized, no hydroaminomethylation of the indole nitrogen can be observed. 
Thus, a protection of this nitrogen prior to the conversion is not necessary. In Scheme 35 the 
total synthesis of 401’s analogue 401b is presented. 
 
 
                                               
52 Ahmed, M.; Seayad, A.M.; Jackstell, R.; Beller, M.; J. Am. Chem. Soc. 2003, 125, 10311-10318. 
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Scheme 35: Synthesis of the analogue of the LDL-receptor regulator 401. 
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cond.: i) 1equiv. 412a, 1equiv. 413c, 0.3mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 120°C, 68h; 
then 4wt%H2SO4 / THF, 80°C, 2h, 61%; ii) 20wt% NaOH / EtOH, 100°C, 18h, 96%; iii) 1equiv. allylic 
benzamide (412b), 1mol% [Rh(cod)BF4]2, 10mol% XANTPHOS, 10bar CO, 50bar H2, MeOH/toluene 
(1:1), 125°C, 3d, 57%. 
 
In a comparable experiment functionalization of 415b with 1-allyl-3,4-dihydroquinolin-
2(1H)-one (412c) in a regioselective hydroaminomethylation gives D4-receptor antagonist 
402 in 49% isolated yield. As well as in the synthesis of 401b the optimized 
hydroaminomethylation conditions lead to an n-selective reaction (Scheme 36). 
Scheme 36: Synthesis of a D4-antagonist. 
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cond.: i) 1equiv. 412a, 1equiv. 409d, 0.3mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 120°C, 68h; then 
4wt% H2SO4 / THF, 80°C, 2h, 38%; ii) 20wt% NaOH / EtOH, 100°C, 18h, 100%; iii) 1equiv. 412c, 1mol% 
[Rh(cod)BF4]2, 1mol% XANTPHOS, 10bar CO, 50bar H2, MeOH/toluene (1:1), 125°C, 3d, 49%. 
 
The CCR5 modulator 403 has the same 3-piperidyl indole core as LDL-receptor antagonist 
401, but in contrast 403 contains a 3,3-diaryl propyl amine unit. Such units can be synthesized 
by hydroaminomethylation of 1,1-diarylethenes. Due to steric and electronic reasons, such 
olefins require harsh conditions for hydroformylation. However, under these harsh conditions 
the oxidative addition of hydrogen to the intermediate rhodium alkyl species and reductive 
elimination of the hydrogenated olefin is faster than the rate determining CO-insertion. In 
1999, RISCHE developed a protocol that allows chemoselective hydroaminomethylation of 
1,1-diarylethenes 53. Here the addition of PBu3 is crucial, since this phosphane ligand reduces 
the catalyst’s hydrogenation activity. At high temperature and with a high carbon monoxide 
partial pressure, pharmacologically active 3,3-diarylethenes can be obtained in excellent 
                                               
53 Rische, T.; Eilbracht, P.; Tetrahedron 1999, 55, 1915-1920. 
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yields. The same protocol can be applied in the synthesis of 403 giving a 57% of this CCR5 
receptor antagonist (Scheme 37). 
Scheme 37: Synthesis of a CCR5-modulator. 
N
H
N
N O
O
N
H
N
O
O
N
H
H
N
i) ii) iii)
Ph
Ph
412a
414a 415a 403  
cond.: i) 1equiv. 412a, 1equiv. 413c, 0.3mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 120°C, 68h; 
then 4wt% H2SO4 / THF, 80°C, 2h, 61%; ii) 20wt% NaOH / EtOH, 100°C, 18h, 100%; iii) 1equiv. 1,1-
diphenylethane (412d), 5mol% [Rh(cod)Cl]2, 15mol% PBu3, 90bar CO, 10bar H2, dioxane, 130°C, 3d, 
57%. 
 
In the synthesis of 404 olefin 412a is used twice. It is used for the initial tandem 
hydroformylation / FISCHER indolization and it is used to attach the second piperidyl ring to 
the first via hydroaminomethylation to give 416 in 55% yield.  
Scheme 38: Synthesis of a CCR2b-modulator. 
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cond.: i) 1equiv 412a, 1equiv. 413e, 0.3mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 120°C, 68h; then 4wt% 
H2SO4 / THF, 80°C, 2h, 70%; ii) 20wt% NaOH / EtOH, 100°C, 18h, 100%; iii) 1equiv. 412a, 1mol% 
[Rh(cod)Cl]2, 50bar CO, 10bar H2, dioxane, 130°C, 3d, 55% iv) 20wt% NaOH, EtOH, 100°C, 20h, 98% v) 
3,4-dichlorocinnamylacid, DCC, DMAP, THF, 24h, 62%. 
 
The additional use of ligands is not necessary since hydroformylation of terminal 
disubstituted olefins proceeds with a high degree of regioselectivity. Further quantitative 
deprotection (417) allows the 3,4-dichlorocinnamyl acid moiety to be attached under 
carbodiimide mediation in 62% yield giving the anti-HIV drug 404 (Scheme 38). 
FUNCTIONALIZATION OF TRYPTAMINES UNDER HYDROFORMYLATION CONDITIONS 
 
- 63 - 
4.3 INTERIM CONCLUSION 
In this chapter a new synthetic approach towards highly functionalized tryptamines and 
homologues is developed and is applied towards the synthesis of four 3-piperidyl indole drugs 
(401-404). 
Ø This innovative and efficient approach consists of 3 steps: 
· The tandem hydroformylation / FISCHER indolization is used to synthesize the 
required indole amines. In contrast to published syntheses 3-piperidyl indoles are 
obtained in one step with up to 70% yield. Simple functional group 
transformations are replaced by skeleton building steps. 
· Deprotection of the resulting indoles and activation for the final step in all cases 
gives almost quantitative yields. 
· The hydroaminomethylation allows a highly selective and salt free attachment of 
required substituents on the amine moiety. Adjustment of the 
hydroaminomethylation conditions allows the use of different types of olefins. A 
previous protection of the indole nitrogen is not required. 
Ø This modular approach is characterized by a high degree of diversity since substituents 
in all relevant positions can be varied. 
Ø All building blocks are commercially available or can be obtained in a few steps. 
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5 INTRAMOLECULAR TANDEM HYDROFORMYLATION / FISCHER 
INDOLIZATION 
The tandem hydroformylation / FISCHER indole synthesis has so far been applied to the 
synthesis of 5- or 7-substituted tryptamines and analogues due to their biological relevance. 
But many naturally occurring indole derivatives and indole drugs possess additional 
substituents in the 4-position including 3,4-ring annelations. The structures in Scheme 39 may 
act as representative examples. Psilocybin is reported to enter the central nervous system and 
causes powerful psychotomimetic effects54 and (-)-indolactam V is a protein kinase C 
modulator55. 
Scheme 39: Examples of biologically relevant 
4-substituted indoles. 
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Synthesis of 4-substituted indoles either starts with a simple indole bearing appropriate 
substituents in the required positions, or the indole core is built up selectively. To achieve a 
regioselective indole formation, appropriately substituted precursors defining the substitution 
pattern within the final product are often used.  
Scheme 40: Synthesis of psilocin via Larock indole synthesis. 
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In the LAROCK indole synthesis, for example, o-halo-anilines are reacted with alkynes under 
palladium catalysis. SCAMMELLS et al. have used this method to obtain psilocin, which is a 
                                               
54 a) Stoll, A.; Troxler, F.; Peyer, J.; Hofmann, A. Helv. Chim. Acta 1955, 38, 1452. b) Hofmann, A. Experientia 
1958, 14, 107. c) Hofmann,A.; Heim, R.; Brack, A.; Kobel, H.; Frey, A.; Ott, H.; Petrzilka, T.; Troxler,F. Helv. 
Chim. Acta 1959, 42, 1557. d) Troxler, F.; Seemann, F.; Hofmann,A. Helv. Chim. Acta 1959, 42, 2073. 
e) Downing, D. F. Quart. Rev.(London) 1962, 16, 133. f) Hofmann, A. Bull. Narc. 1971, 23, 3. 
g) Brimblecombe, R. W.; Pinder, R. M. Hallucinogenic Agents; Wright-Scientechnica: Bristol, UK, 1975; pp 
106-108. 
55 Kazanietz, M. G.; Areces, L. B.; Bahador, A.; Mischak, H.; Goodnight, J.; Mushinski, J. F.; Blumberg, P. M. 
Mol. Pharmacol. 1993, 44, 298. 
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metabolite of psilocybin, in 69% isolated yield starting from a 1,2,3-trisubstituted aryl iodide 
(Scheme 40)56. But even the synthesis of such starting compounds is sometimes problematic 
since the bulky iodide has to be placed in between two substituents.  
4-Substituted indoles are also synthesized via the FISCHER indole reaction, although the key 
step, the [3,3]-sigmatropic rearrangement proceeds with poor regioselectivity. While 
involvement of the ortho-carbon in the cyclic transition state leads to the desired product, a 
transition state that contains the ortho’-carbon gives the undesired 6-substituted indole. If a 
1:1 mixture of both regioisomers is not obtained, the indole with substitution in the 6-position 
is favored due to steric reasons (Scheme 41).  
Scheme 41: Regioselectivity in the Fischer indole synthesis. 
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If 3,4-annelated indoles have to be synthesized, such as indolactams (Scheme 39), the 
additional ring can be closed in an appropriately substituted indole, or the indole may be 
formed through intramolecular and regioselective indolization from the appropriate 
macrocyclic hydrazone.  
Scheme 42: Retro synthetic analysis of indolactam-V. 
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56 Gathergood, N.; Scammells, P.J.; Org. Lett. 2003, 5, 921-923. 
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In both cases ultra high dilution techniques, which are generally limited to small scale 
reactions, will be required to avoid intermolecular reactions in the ring closing step. This ring 
closing step is in the first case an intramolecular peptide bond formation, while in the second 
case an intermolecular condensation of the aldehyde with the hydrazine group has to take 
place (Scheme 42). An in situ formation of the aldehyde via hydroformylation might ensure 
low concentrations of the intermediate aldehyde as an alternative to high dilution techniques. 
As long as the hydroformylation is slower than the consecutive reaction (intramolecular 
condensation and indolization) the aldehyde is not enriched in the reaction mixture, and 
intermolecular reactions might be suppressed without using ultra high dilution techniques. 
Apart from the synthesis of 3,4-annelated indoles, this method might also be useful for the 
synthesis of 4-substituted tryptamines, such as psilocin, if the additional ring contains a 
cleavable tether (Scheme 43).  
Scheme 43: Concept for an intramolecular tandem hydroformylation / Fischer indole synthesis. 
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In this chapter preliminary investigations on an intramolecular tandem 
hydroformylation / FISCHER indolization are presented.  
5.1 INTRAMOLECULAR CONDENSATION AND INDOLIZATION 
Since the classical synthesis of functionalized aryl hydrazines is in many cases problematic, 
it is advantageous to start with a commercially available hydrazine and attach the olefinic 
moiety to the aromatic ring. To achieve high selectivities, the hydrazine group has to be 
protected first. The benzhydrylidene group turned out to be very effective since the protected 
hydrazines are stable against oxidation and can be purified by flash chromatography. In 
addition, benzhydrylidene protected aryl hydrazines can be subjected to a FISCHER indole 
reaction without previous deprotection as demonstrated earlier. While benzophenone can not 
undergo tautomerization, transcondensation with an aldehyde proceeds under the acidic 
FISCHER conditions followed by indolization. Furthermore, the use of protected aryl 
hydrazines seems to improve the selectivity of the tandem reaction (see above). Condensation 
of commercially available 3-hydrazino-benzoic acid (501) with benzophenone gives the 
protected hydrazine 502 in 54% yield. The olefin moiety can be introduced under 
carbodiimide mediation giving the desired test substrate 503 in 76% yield. This substrate is 
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then subjected to the tandem hydroformylation / FISCHER indole synthesis using the standard 
protocol with 10 wt% concentration and 0.5 wt% concentration of the substrate to simulate 
high dilution. In both cases NMR does not show any indole product. Instead, benzophenone 
was detected as the major compound of a mixture of products. This indicates that the 
hydroformylation leads to an aldehyde which then transcondenses intermolecularly and sets 
the benzophenone free (Scheme 44).  
Scheme 44: Synthesis of a benzhydrylidene protected test substrate. 
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cond.: i) 1equiv. 501, 1equiv. benzophenone, EtOH/H2O, 20h, 80°C, 54%. ii) 1equiv. N-ethyl-N-methallylic 
amine, 1.1equiv. DCC, 5mol% DMAP, CH2Cl2, 20h, rt, 76%. iiia) 1equiv. PTSA, 1mol% [Rh(cod)Cl]2, 20bar 
CO, 20bar H2, THF (10wt% olefin), 120°C, 39h. iiib) 1equiv. PTSA, 1mol% [Rh(cod)Cl]2, 10bar CO, 10bar H2, 
THF (0.5wt% olefin), 100°C, 68h. 
 
To give evidence to this assumption and to exclude the problems of single steps of the 
tandem reaction, the sequence is conducted stepwise. Hydroformylation of 503 in the absence 
of acid gave the desired aldehyde 504 in 83% isolated yield (Scheme 45).  
Scheme 45: Hydroformylation of 402. 
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402 40383%  
cond.: 1equiv. 402, 1mol% [Rh(cod)Cl]2, 50bar CO, 
10bar H2, THF (1wt% olefin), 120°C, 7h, 83%. 
 
This aldehyde is then subjected to an indolization in high dilution and the reaction is 
monitored with TLC. With one equivalent of PTSA, no reaction is observed. The reaction is 
conducted with 5 and 10 equivalents of acid to increase acid concentration. In both cases, the 
formation of benzophenone is observed, but neither condensation nor indolization are 
witnessed (Table 16). 
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Table 16: Intramolecular Fischer indole synthesis. 
O N
N
H
N Ph
Ph
O
N
H
N
O Ph
Ph
O
504 505
expected  
entry equiv of PTSA result 
1 1 no conversion 
2 5 
formation of benzophenone, 
no hydrazone formation 
3 10 
formation of benzophenone, 
no hydrazone formation 
cond.: 1equiv. 504, PTSA (see table), dioxane (0.5wt% 
olefin), 100°C. 
 
The disfavored ring size of the desired 11-membered cyclic hydrazone might be an 
explanation. Elongation of the olefinic side chain is achieved by the STEGLICH esterification 
of 502 with w-pentenol (506a) and w-undecenol (506b). Hydroformylation gives aldehydes 
508a and 508b in 32% and 87% yield. Intramolecular condensation might lead to cyclic 
hydrazones with a ring size of 13 and 19, but again no intramolecular hydrazone formation 
can be observed. Only cleavage of the benzophenone hydrazone is detected (Scheme 46). 
Scheme 46: Synthesis of a benzhydrylidene protected test substrate with prolonged olefinic side chain. 
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502 506a, n=4506b, n=9  
cond.: i) 1equiv. 502, 1equiv. 506, 1.1equiv. DCC, 5mol% DMAP, CH2Cl2, rt, 18h. ii) 1equiv. 507, 1mol% 
Rh(acac)(CO)2, 10mol% BIPHEPHOS 10bar CO, 10bar H2, THF (10wt% olefin), 60°C, 5h. iii) 1equiv. 508, 
10equiv. H2SO4, dioxane (20mmol/ml), 100°C. 
 
Although the hydrazone formation is catalyzed by acids, the presence of PTSA may hamper 
the hydrazone formation since protonated hydrazines possess a lower nucleophilicity. 
Therefore, it would be desirable to allow condensation under neutral or less acidic conditions. 
Two options might be viable: (1) The simplest way is to condense 3-hydrazino-benzoic acid 
(501) with the oxo-aldehyde of w-undecenol (509). Ring closure might then be achieved with 
established methods of macrolactonization. While the condensation gives the hydrazone 510 
in 58% yield, macrolactonization failed. Different sets of reaction conditions are tested, such 
as the STEGLICH esterification or the MITSUNOBU reaction. In both cases no product could be 
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isolated. It could not be clarified, if the reaction fails, or if the enolizable hydrazone 
decomposes during flash chromatography (Scheme 47).  
Scheme 47: Synthesis of a meta-cyclophaneic hydrazone via macrolactonization. 
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cond.: i) 1equiv. 501, 1equiv. 509, THF, rt, 18h, 97%. iia) 1equiv. 510, 10equiv. DCC, 50mol% 
DMAP, THF (<1mmol/l). iib) 1equiv. 511, 2equiv. PPh3, 1.5equiv. DEAD, toluene (2mmol/l). 
 
(2) Since the presence of acid is crucial for the transcondensation step, the benzophenone 
group has to be cleaved off in a prior step. Deprotection of benzhydrylidene protected amines 
is achieved by palladium catalyzed hydrogenolysis57 or by acidic hydrolysis58. Both 
conditions may lead to undesired side reactions such as hydrogenation of the olefinic bond, 
cleavage of the N-N-bond or hydrolysis of the ester group. Therefore, other methods for the 
introduction of the hydrazine group have to be used. The GOLDBERG reaction offers an 
alternative. Alkylation of m-iodo-phenol (512) with undecenyl iodide (513) followed by 
copper(I) mediated N-arylation gives the a-Boc-protected hydrazine 515 in fair yields. The 
b-nitrogen is now available for an electrophilic attack by the aldehyde. No acid is needed for a 
cleavage of a protecting group or for the condensation. Indeed, hydroformylation of 515 
results in the desired condensation product with excellent yield. This hydrazone is then 
subjected to the standard indolization conditions with a substrate concentration of 5mmol/l to 
suppress intermolecular reactions (Scheme 48). Surprisingly, 20% of indolization product 517 
was obtained as an approx. 1:1 mixture of n/iso-regioisomers and as the only indole product. 
Obviously, the intramolecular indolization gives regioselective indolization, but with 
unexpected regioselectivity. Nevertheless, conversion was unselective. Although a long 
alkenyl chain has been selected, 516 might not easily reach a conformation which is required 
for the transition state of the indolization. This transition state can either be planar, if a pseudo 
aromatic transition state is assumed, or can be of chair-type conformation, if the 
rearrangement is interpreted as an electrophilic aromatic substitution.  
                                               
57 Barrett, A.G.M.; Seefeld, M.A.; White, A.J.P.; Williams, D.J.; J. Org. Chem. 1996, 61, 2677-2685. 
58 a) Kaepplinger, C.; Beckert, R.; Syn. Lett. 2001, 7, 1188-1190. b) Hicks, F.; Gou, D.M.; Marchese, S.; Martel, 
L.J.; Necula, A.; Bennetti, R.; Silva, R.A.; PCT Int. Appl. 2004, WO2004000218. 
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Scheme 48: First intramolecular tandem hydroformylation / Fischer indolization. 
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cond.: i) 1.05equiv. 512, 1equiv. 513, 1.1equiv. K2CO3, 10mol% 18-crown[6], THF, reflux, 18h, 
92%. ii) 1equiv. 514, 1.2equiv. tert.-butylcarbazate, 1.4equiv. Cs2CO3, 5mol% CuI, 20mol% 1,10-
phenantroline, DMF, 21h, 80°C, 68%. iii) 1equiv. 515, 4mol% Rh(acac)(CO)2, 20mol% 
XANTPHOS, THF (5mmol/l), 10bar CO, 10bar H2, 18h, 100°C, 100%. iv) 1eq 516, 4wt% 
H2SO4/THF (5mmol/l), 18h, 80°C. 
 
A higher flexibility of the intermediate hydrazone 516 can be achieved by enlarging the ring 
size. One option is to elongate the alkenyl chain which is attached to the aryl halide.  
Scheme 49: Use of spacers in the intramolecular indolization. 
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For the synthesis of the 4-substituted tryptamine derivative for example, this means that a 
spacer has to be introduced between the amine moiety and the substituent in the 4-position. 
This spacer is either part of the desired structure or acts as an auxiliary group that must be 
cleaved off after synthesis.  
5.2 INTERMOLECULAR CONDENSATION AND INTRAMOLECULAR INDOLIZATION 
The most atom economic spacer might be the hydrazone itself in a macrocyclic 
bishydrazone as illustrated in Scheme 50.  
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Scheme 50: Hydrazones as spacers. 
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Here two different orientations are possible:  
Ø Each amine moiety is linked with the substituent in the 4-position of the aromatic ring 
or  
Ø both amine moieties and both aryl hydrazine moieties are connected with appropriate 
linkers.  
Since the hydrazone bond is formed during hydroformylation, 522 may be synthesized from 
one single olefin (523), which has to give a 1:1 adduct selectively. But compound 523 
contains both functionalities and, as demonstrated above, such a hydrazinoolefin undergoes 
selective intramolecular condensation.  
Scheme 51: Synthesis of a symmetric bishydrazine via Goldberg reaction. 
OH
Br Br
O O O O
n
n n
527 528a: n=4528b: n=10
529a: n=4 (97%)
529b: n=10 (87%)
530a: n=4 (84%)
530b: n=10 (77%)
i) ii)I I I N N
NH2
Boc
NH2
Boc
 
cond.: i) 2.2equiv. 527, 1equiv. 528, 2.5equiv. K2CO3, 10mol% 18-crown[6], THF, reflux, 20h. ii) 1equiv. 529, 
2.4equiv. tert.-butyl carbazate, 2mol% CuI, 22mol% 1,10-phenantroline, 2.8equiv. Cs2CO3, DMF, 80°C, 21h. 
 
INTRAMOLECULAR TANDEM HYDROFORMYLATION / FISCHER INDOLIZATION 
- 72 - 
In contrast, macrocycle 524 may be synthesized from bishydrazine 525 and bisolefin 526. 
As mentioned previously, hydroformylation is an excellent tool to convert bisolefins and 
bisamines to macrocyclic amines in an overall hydroaminomethylation. This methodology 
might also be helpful for the synthesis of macrocyclic bishydrazones. The required 
bishydrazines can be synthesized via copper (I) mediated N-Arylation exclusively. The 
classical approach of diazotation and reduction of the resulting diazonium salt fails due to the 
formation of azo-compounds. The previously used BUCHWALD-HARTWIG amination with 
benzophenone hydrazone does not give a selective product. Here oligomerization or 
intramolecular N-arylation occurs. Only the GOLDBERG reaction gives the desired product 
selectively since mono-N-arylation occurs only on the more acidic carbamate nitrogen.  
To prove whether macrocyclic bishydrazones can be obtained upon 
hydroformylation / hydrazone formation and whether these macrocycles can be indolized, 
p-substituted hydrazines are synthesized. Indolization of the resulting hydrazone would then 
lead to one single regioisomer in contrast to the use of the m-substituted hydrazines. Thus, 
two different bishydrazines are synthesized in two steps and in good yields (Scheme 51). 
Scheme 52: Configuratively consistent formation of (E)-hydrazones. 
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Similar to the synthesis of 215j the Boc group will stay on the hydrazine during the 
hydroformylation and will be cleaved off in the indolization step. This is advantageous since 
a-Boc protected hydrazines as well as their hydrazones are stable against oxidation and can 
be chromatographed. In addition, the a-Boc protected hydrazines give (E)-configured 
hydrazones exclusively, as the hydrazone required for the synthesis of 215j clearly 
demonstrates (Scheme 52). Thus the use of a-Boc protected hydrazines allows a 
stereospecific formation of the macrocycles and simplifies characterization.  
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The bisolefin is obtained in two steps starting with ethyl 4-methylenepiperidine-
1-carboxylate (412a). Deprotection followed by conversion with oxalyl chloride gives a 
symmetric olefin which can be hydroformylated regioselectively. The symmetry of the 
resulting aldehydes is important to prevent formation of different regioisomeric macrocycles. 
Scheme 53: Synthesis of a symmetric bisolefin. 
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cond.: i) 1equiv. 412a, glycol/NaOH (50wt% in H2O), 80°C, 18h, 44%. ii) 
2.1equiv. 532, 1equiv. oxalyl chloride, 2.1equiv. NEt3, 5mol% DMAP, THF, rt, 
1h, 68%. 
 
Both, bisolefin 533 and bishydrazines 530a,b, have been subjected to the hydroformylation 
with a concentration of 5mmol/l of each starting compound. This concentration is much 
higher than typically used for high dilution techniques. The reason is the in situ formation of 
the reactive aldehyde compound which is trapped by the hydrazone instantly.  
Scheme 54: Synthesis of macrocyclic bishydrazones via hydroformylation / hydrazone 
formation. 
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cond.: 1equiv. 530, 1equiv. 533, 4mol% Rh(acac)(CO)2, THF (5mmol/l), 50bar CO, 10bar 
H2, 110°C, 20h. 
 
Therefore the concentration of the bisaldehyde is much lower than 5mmol/l, and at no time 
are concentrations reached which are high enough for side reactions, such as oligomerization, 
to occur. This allows the conduction of reactions in a 500mg scale in a 250ml PARR pressure 
vessel. In both cases, the macrocycles can be obtained with excellent yields. These high yields 
have been explained with a template effect of the rhodium catalyst41. These macrocycles are 
subjected to the same indolization conditions as 516 was subjected to. Although the 
macrocycles should be flexible enough to reach the required transition states, only traces of 
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indolization product are determined by HPLC/MS. A successful intramolecular indolization 
may need a different set of conditions as developed for tryptamines and tryptamides. 
Therefore an intense and laborious screening of conditions, including solvents and acids, 
seems to be reasonable and may be part of further investigations. An alternative application of 
macrocyclic bishydrazones is described in the following chapter. 
5.3 INTERIM CONCLUSION 
In this chapter preliminary results towards the first successful intramolecular Fischer indole 
synthesis are presented.  
Ø Two different strategies have been investigated: 
· An intramolecular condensation under hydroformylation conditions of an olefin 
bearing a hydrazine group followed by subsequent indolization under pseudo high 
dilution conditions. This strategy results in a 20% yield of the 6-substituted indole 
as the only regioisomer. 
· Intermolecular condensation under hydroformylation conditions of symmetric 
bisolefins with symmetric bishydrazines gives macrocyclic bishydrazones in 
excellent yields. Subsequent indolization gives a very unselective conversion 
where no indole products were isolated. 
Ø In both cases, the intermediate hydrazines are synthesized via the GOLDBERG reaction 
giving a-Boc protected hydrazines as stable hydrazine compounds. The classical 
approach of diazotation and reduction as well as the synthesis of benzhydrylidene 
protected hydrazines via BUCHWALD-HARTWIG amination fail. 
Ø The Boc group is crucial for the isolation of the macrocycles since the macrocyclic 
bishydrazones are stable against oxidation and can easily be purified with 
chromatographic methods.  
Ø The presence of the Boc-group also leads to the configuratively consistent formation 
of the stereogenic hydrazone double bond. Due to hydrogen bonding between the Boc-
carbonyl and the hydrazone CH-group, only the (E)-isomers are formed.  
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6 SYNTHESIS OF MACROCYCLIC BISHYDRAZONES AND THEIR 
APPLICATION AS METAL SENSORS 
In this chapter an alternative application for the previously described macrocycles 534a and 
534b will be presented. ANGELOVSKI demonstrated in 2004 that azamacrocycles derived from 
tandem hydroformylation sequences are valuable substrates for the recognition of metals and 
chiral material via fluorescence spectroscopy. In this manner, 601 was used for the detection 
of zinc and cobalt ions while 602 was used for the differentiation of enantiomeric pairs of 
chiral amines, such as a-phenyl ethylamine (Scheme 55)59. 
Scheme 55: Macrocycles for fluorescence sensing derived from 
hydroaminomethylations. 
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Fluorescence spectroscopy is based on the fact that UV active molecules, such as aromatic 
compounds, absorb light of a defined wavelength. Absorbance of energy results in an 
excitation of the molecule which relaxes via different mechanisms such as vibration, emission 
of sound, solvent interactions, internal conversion or emission of light. The emission of light 
from electronically excited molecules is called luminescence. Depending on the type of 
excited state the light is emitted from, it can be differentiated between phosphorescence (from 
triplet excited states) and fluorescence (from singlet excited states). The latter can be observed 
as a bathochromic shifted and inverted absorption spectrum with a fluorometer (Scheme 
56)60. In contrast to UV spectroscopy, fluorescence spectroscopy is a direct measurement of 
the emitted light and is therefore more sensitive than the measurement of absorbance (usually 
measured as difference spectra between the light, which is sent to the sample and the emitted 
light). Thus fluorescence spectroscopy is attractive for the examination of sample material 
with nano-molar to micro-molar concentrations. In addition, fluorescence spectroscopy gives 
access to additional valuable data such as quantum yield and fluorescence lifetime. 
                                               
59 Angelovski, G.; Dissertation 2004, University of Dortmund 
60 Lakowicz, J.R.; Principles of Fluorescence Spectroscopy, 2nd ed., Kluwer Academic/Plenum Publishers, New 
York, 1999. 
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Scheme 56: Principle of fluorescence.60 
 
The intensity of a fluorescence spectrum is strongly depending on the presence of other 
compounds, such as solvents or metals. Interactions between such compounds and the 
fluorophore can either enhance fluorescence intensity or decrease its intensity (quenching). In 
the latter case, the excited molecule relaxes faster since the energy is transferred to the 
additional compound due to collision or complexation. This change of fluorescence intensity 
can be used analytically for the detection of certain compounds with fluorescence sensors. 
Scheme 57: Setup of ideal fluorescence sensors. 60 
 
A selective fluorescence sensor consists of two essential parts: 
Ø Preferably large aromatic systems are used as signaling units that emit light after 
excitation.  
Ø Recognition units should interact with the analyte (e.g. a metal) selectively and 
intensely to observe a strong and specific enhancement or quenching of fluorescence.  
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Both units can either be integrated or can be linked via a spacer (Scheme 57). It is well 
documented that hydrazones can complex metal ions such as vanadium61, iron62, palladium63, 
copper64 or lithium65. The hydrazone moiety can either be embedded in a cyclic system or can 
be part of an acyclic ligand, but only in a few cases have hydrazones been used as a 
recognition unit for fluorophores66. Macrocycle 534 may act as a metal sensing fluorophore. 
While the hydrazone moieties are possible coordination sides, the aromatic systems may only 
be poor signaling units due to their small size. Large aromatic systems such as binaphthyl 
systems are even better signaling units. Therefore an additional macrocycle is synthesized. 
Starting with bishydrazine 530a and bisolefin 603 macrocycle 604 can be obtained with 
almost quantitative yield (Scheme 58).  
Scheme 58: Synthesis of 503 via tandem hydroformylation / hydrazone formation. 
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cond.: 1equiv. 530a, 1equiv. 603, 4mol% Rh(acac)(CO)2, 20mol% XANTPHOS, THF (5mmol/l), 
10bar CO, 10bar H2, 100°C, 20h. 
 
Fluorescence spectra are recorded with 308nm as the excitation wavelength. The obtained 
spectra are compared with those upon addition of one and two equivalents of different metal 
salts. After addition of one equivalent of V(II) salt, the fluorescence of 604 for example, is 
quenched to 50% of the original intensity. The addition of a second equivalent gives 
additional quenching of 46% (Scheme 59). A similar behavior can be observed after addition 
of Fe(III) salt (37% quenching with 1eq. and 33% after 2equiv.).  
                                               
61 Aggerwall, R.C.; Singh, B.; Transition Met. Chem. 1976, 1, 275. 
62 Rastogi, D.K.; Dua, S.K.; Rana, V.B.; Sahni, S.K.; J. Inorg. Nucl. Chem. 1978, 40, 1323-1326. 
63 Natile, G.; Cattalini, L.; Gasparrini, F.; J. Chem. Soc., Chem. Commun. 1977, 89. 
64 Iskander, M.F.; El-Sayed, L.; Saddeck, S.; Transition Met. Chem. 1981, 6, 27. 
65 Ahlbrecht, H.; Dueber, E.O.; Enders, D.; Eichenauer, H.; Weuster, P.; Tetrahedron Lett. 1978, 3691. 
66 Taniguchi, H.; Tsuge, K.; Nakano, S.;J. Pharm. Soc. Jpn 1974, 94, 759-765. 
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Scheme 59: Quenching of fluorescence intensity upon addition of vanadium(II) and iron(III) salts. 
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cond.: 1equiv. 604 (30µmol/l in acetonitrile)lex=305nm, 25°C. a) 1-2equiv. V(acac)2 b) 1-2equiv. FeCl3. 
 
The results of an intense metal screening are compiled in Scheme 60 using the STERN-
VOLMER equation [1].  
quencherckI
I
×+= 10
 
[1] 
In Scheme 60 a selectivity towards vandium(II), chromium(III), iron(III) and rhodium(I) is 
disclosed. All four metals are known to prefer octahedral complexes. The quenching in the 
presence of rhodium(I) might support the hypothesis that the hydroformylation catalyst acts as 
a template in the synthesis of the macrocycles. 
Scheme 60: Screening of different metal salts in fluorescence measurements. 
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cond.: 1equiv. 604 (30µmol/l in acetonitrile), 1-2equiv. metal salts, lex=305nm, 25°C. 
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In contrast, metals that usually give distorted octahedral complexes show weaker quenching, 
and metals with different complex geometry show no effect at all. 
A comparison of the three macrocycles (534a, 534b and 604) shows a clear dependency of 
fluorescence quenching from the ring size (Scheme 61). While quenching is the weakest with 
the biggest ring (534b), quenching can be increased by a reduction of ring size. This result 
suggests that the ring of 534b is probably too big for a strong complexation or chelation of the 
metal ions. Although 604 has the same ring size as 534a, quenching of 604 is in between 
quenching of 534a and 534b. But in contrast to the latter, 604 contains a binaphthyl unit 
which may spread the macrocycle’s conformation and its bite angle, allowing improved 
chelation of metal ions. Only in the case of vanadium(II) does the behavior of 604 differ from 
534. Here, the quenching of fluorescence is much higher compared to the quenching of 
fluorescence of 534. This may be explained by the additional coordination to the extra 
oxygens. 
Although the macrocycles seem to be good ligands for vanadium(II) and chromium(III), the 
interaction with iron(III) is deemed to be the most promising for further applications.  
Scheme 61: Comparison of different macrocycles. 
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The determination of iron in blood serum and other body fluid samples is important for the 
study, diagnosis, and treatment of nutritional and metabolic diseases that cause low or high 
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iron levels. Iron metabolism disorders have been found to cause iron-deficiency anemia and 
hemochromatosis, which might ultimately result in liver cancer, liver cirrhosis, arthritis, 
diabetes, or heart failure67. Recent studies have linked late-onset neurodegenerative disorders 
such as Parkinson´s disease to elevated iron levels68. The analysis of iron levels in blood 
serum and cell extracts is crucial for the diagnosis and treatment of cancer because high 
amounts of iron are found during tumor cell proliferation. Iron also plays a role in important 
infectious diseases such as malaria69. Since iron is involved in biological redox processes, 
cycling between the most stable oxidation states of iron (iron(II) and iron(III) ) it might be 
desirable to differentiate between these two oxidation states. A comparison of fluorescence 
quenching of 604 in the presence of iron(II) and iron(III) clearly demonstrates a selectivity of 
604 towards iron(III). The STERN-VOLMER plot in Scheme 62 shows that fluorescence 
intensity of 604 is almost stable upon addition of 2 equivalents of iron(II), while addition of 
iron(III) leads to quenching. 
Scheme 62: Comparison of fluorescence 
quenching upon addition of iron(II) and iron(III). 
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cond.: 1equiv. 604, (30µmol/l in acetonitrile), 
1-2equiv. metal salts, lex=305nm, 25°C. 
 
The intensity of fluorescence and the rate of relaxation processes, such as quenching, are 
strongly depending on the solvent which is used. Polar solvents undergo stronger interactions 
with the fluorophore, depopulating its excitation state faster60. So far fluorescence 
experiments are performed in acetonitrile, but since most biological samples are dissolved in 
                                               
67 a) Trinder, D.; Macey, D. J.; Olynyk, J. K.; Int. J. Mol. Med. 2000, 6, 607–612. b) Burkitt, M. J.; Milne, L.; 
Raafat, A.; Clin. Sci. 2001, 100, 239–247. c) Brugnara, C.; Clin. Chem. 2003, 49, 1573–1578. d) Leong, W.; 
Loennerdal, B.; J. Nutr. 2004, 134, 1–4. 
68 a) Bharath, S.; Hsu, M.; Kaur, D.; Rajagopalan, S.;Andersen, J. K.; Biochem. Pharmacol.; 2002, 64, 1037–
1048. b) Beard, J.; J. Nutr. 2003, 133, 1468S–1472S. 
69 a) ONeill, P. M.; Bray, P. G.; Hawley, S. R.; Ward, S. A.;Park, B. K.; Pharmacol. Ther. 1998, 77, 29–58. b) 
Blauer,G.; Akkawi, M.; Fleischhacker, W.; Hiessboeck, R.; Chirality 1998, 10, 556–563. c) Egan, T. J.; Hunter, 
R.; Kaschula, C. H.; Marques, H. M.; Misplon, A.; Walden, J.; J. Med. Chem. 2000, 43, 283–291. 
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water, fluorescence quenching of 604 upon addition of iron(III) is also tested in a 1:1 mixture 
of water/acetonitrile. Although changes in this solvent mixture are less drastic, fluorescence 
quenching to 10% of the original fluorescence intensity can be achieved by addition of 
20 equivalents of iron(III) (Scheme 63). 
Scheme 63: Obliteration of fluorescence activity upon addition of iron(III). 
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cond.: 1equiv. 503 (30µmol/l in acetonitrile/H2O (1:1)), 1-20equiv metal salts, lex=305nm, 25°C. 
 
At higher concentrations of iron(III), a deviation of fluorescence quenching from the linear 
dependency can be observed. This can be explained with a shifted equilibrium between free 
ligand 604 and an iron/604 complex towards the complex. While at low concentrations the 
complex has such a short lifetime, that quenching can be referred to a collision of metal and 
ligand (collisional or dynamic quenching), the higher concentrations result in more stable 
complexes (static quenching) and therefore in increased quenching.  
Scheme 64: Fluorescence quenching with iron(III) 
and additional electrolytes. 
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cond.: 1equiv. 604 (30µmol/l in acetonitrile/H2O 
(1:1)), 1-2equiv. metal salts, lex=305nm, 25°C. 
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A similar result is illustrated in Scheme 64. Body fluids usually contain other salts, such as 
sodium, potassium and calcium salts. Therefore fluorescence measurements have also been 
conducted in the presence of one equivalent of each salt in water/acetonitrile (1:1). Although 
all used salts show no quenching at all upon addition to the fluorophore 604, fluorescence 
quenching in the presence of iron(III), sodium, potassium, calcium and iron(II) is higher than 
in the absence of these additional salts. This can also be explained with a higher part of static 
quenching since the salts increase the complex’s lifetime.  
6.1 INTERIM CONCLUSION 
The synthesis of macrocyclic bishydrazones via tandem hydroformylation of bisolefins in 
the presence of bishydrazones is described.  
Ø The rhodium catalyst acts as a template for the condensation giving excellent yields 
under pseudo high dilution conditions. 
Ø Different metals salts are screened for their interaction with the macrocycles via 
fluorescence spectroscopy. Although none of the investigated macrocycles is designed 
for metal detection or for fluorescence spectroscopy, the screening disclosed a good 
fluorescence activity and a remarkable selectivity of the macrocycles towards 
vanadium, chromium and iron.  
Ø The determination of iron levels might be interesting for medicinal applications since 
iron(II) is differentiated from iron(III) which is involved in many biological processes. 
Quenching of fluorescence to 10% of its original intensity can be achieved upon 
addition of only 20 equivalents. Even in water, the fluorescence is quenched in the 
presence of iron(III). In the presence of other salts, contained in biological samples, 
fluorescence quenching is enhanced. 
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7 INITIAL INVESTIGATIONS TOWARDS ASYMMETRIC TANDEM 
HYDROFORMYLATION / FISCHER INDOLE SYNTHESIS 
In the previous chapters, many examples are presented in which disubstituted terminal 
olefins have been used to achieve a high regioselectivity in the hydroformylation step without 
the use of n-directing ligands. On the other hand, tryptamines with branched side chains have 
become interesting substrates for medicinal purposes, as LY 156 735 demonstrates (Scheme 
65)34.  
Scheme 65: Example of a pharmaceutically 
relevant chiral a-branched tryptamine 
N
H
NHAc
MeO
Cl
LY 156735  
The use of such prochiral olefins in the tandem hydroformylation / FISCHER indolization 
results in chiral tryptamines (Scheme 66).  
Scheme 66: Use of prochiral olefins in the tandem hydroformylation / Fischer indole 
synthesis. 
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A control of the configuration of this new stereogenic center during the tandem reaction 
would be desirable. In general, there exist two different strategies for asymmetric 
hydroformylations: 
(1) Reagent controlled asymmetric hydroformylation. Here, hydroformylation catalysts are 
modified with chiral ligands. Hydroformylation of 2-methoxy-6-vinylnaphthalene, for 
example, with a Pt/(-)-bppm system gives the diethyl acetal of the corresponding aldehyde 
required for the analgesic naproxen (Scheme 67)70. The in situ protection is required to 
conserve the enantiomeric excess since the aldehyde undergoes tautomeric epimerization.  
                                               
70 a) Gladiali, S.; Bayon, J. C.; Claver, C. Tetrahedron: Asymmetry, 1995, 6, 1453-1474. b) Eilbracht, P. in 
Methoden der Organischen Chemie (Houben-Weyl) Vol. E 21c: Stereoselective Synthesis (Helmchen, G.; 
Hoffmann, R. W.; Mulzer, J.; Schaumann, Eds.), Thieme: Stuttgart, 1995, 2488-2733. c) Agbossou, F.; 
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Scheme 67: Enantioselective hydroformylation with a-induction. 
MeO MeO
(EtO)2HC H
MeO
HOOC H
CO/H2 (1:1), HC(OEt)3
[(-)-BPPM]Pt(SnCl3)Cl
180bar, 200h, 60°C
55% (iso/n=0.7)
>96% ee naproxen  
In contrast to asymmetric hydroformylation with induction of stereocenters in a-position to 
the aldehyde, the hydroformylation of disubstituted terminal olefins gives stereocenters in 
b-position ( b-induction). The best enantiomeric excess so far, can be observed in the 
asymmetric hydroformylation of dimethyl itaconate, albeit with poor chemoselectivity 
(Scheme 68)71.  
Scheme 68: Enantioselective hydroformylation with b-induction. 
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--
51.4% ee
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[Rh] rac6% yield
9.1% ee
80% yield
rac
11% yield  
Apart from this special case, hydroformylation of other disubstituted terminal olefins gives 
lower enantioselectivity. In 2000, BUß conducted asymmetric hydroformylations in the 
presence of amines to establish an asymmetric hydroaminomethylation. Independent from the 
type of olefin and from the type of stereochemical induction, enantioselectivities of the 
hydroaminomethylation are much smaller compared to the enantioselectivities of the 
hydroformylation. Even if enantiomerically enriched aldehydes are subjected to a rhodium 
catalyzed reductive amination, epimerization can be observed (Scheme 69)72. As a 
conclusion, sufficient enantioselectivity in the hydroformylation of disubstituted terminal 
olefins with b-induction is still not achievable, especially in the presence of nitrogen 
nucleophiles. 
 
 
 
                                                                                                                                                   
Carpentier, J.-F.; Mortreux, A. Chem. Rev. 1995, 95, 2485-2506. d) Breit, B.; Seiche, W.; Synthesis 2001, 1-36. 
e) Breit, B.; Accounts Chem. Res. 2003, 36, 264-275. 
71 Gladiali, S.; Pinna, L.; Tetrahedron Asymmetry 1991, 2, 623. 
72 Buß, C.; Dissertation 1999, University Dortmund. 
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Scheme 69: Attempts towards enantioselective 
hydroaminomethylation. 
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(2) Substrate controlled asymmetric hydroformylation. An alternative to reagent controlled 
enantioselective hydroformylation is the substrate controlled diastereoselective 
hydroformylation. In 1997, BREIT published the first diastereoselective hydroformylation of 
chiral methallylic alcohol. 
Scheme 70: Diastereoselective hydroformylation using a catalyst directing auxiliary. 
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In this approach the auxiliary ortho-diphenylphosphino benzoic acid (o-dppb) is appended 
to the alcohol group helping the catalyst to differentiate between the two diastereotopic faces 
of the double bond. Hydroformylation gives then the corresponding aldehydes with good 
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diastereoselectivities (Scheme 70)73. Even in the presence of primary and secondary amines, 
good diastereoselectivities are obtained for the diastereomeric secondary and tertiary amines 
upon hydroaminomethylation (Scheme 70). BREIT’s strategy might also be useful for the 
stereoselective synthesis of branched tryptamines since the hydroformylation is the stereo 
discriminating step in the tandem reaction. Substrate controlled hydroformylation of a chiral 
methallylic amine bearing the o-DPPB-group might lead to the corresponding aldehyde with 
high diastereomeric excesses. This aldehyde should undergo condensation with the present 
aromatic hydrazine in situ. After addition of acid, this hydrazone should give the indole, 
conserving the diastereomeric ratio (Scheme 71).  
Scheme 71: Principle of a diastereoselective tandem hydroformylation / Fischer indole synthesis. 
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The fact that the aromatic hydrazine does not compete with the diphenylphosphino group is 
one condition for the high diastereoselectivities in the hydroformylation step. Another 
condition is that this protocol can be transferred from chiral allylic alcohols to chiral allylic 
amines. A change from an ester group to an amide group may result in the formation of 
rotamers, giving an additional stereogenic center which can affect the conformation of the two 
diastereomeric cyclic transition states dramatically.  
7.1 SYNTHESIS OF A TEST SUBSTRATE VIA OVERMAN REARRANGEMENT  
To investigate both aspects, chiral methallylic amine 701 is synthesized via OVERMAN 
rearrangement. Attachment of the auxiliary gives the test substrate 702 in quantitative yield. 
The hydroformylation is conducted in a non-polar, non-coordinating solvent such as benzene, 
without the addition of ligand to support the active direction of the catalyst by the auxiliary. 
Under these conditions low conversion of 702 towards the aldehyde 703 is observed. 
Conversion can be increased upon addition of P(OPh)3 according to BREIT’s conditions73. In 
this case, preferred formation of the aldehyde 703 can be observed accompanied with 
N,O-hemiacetal 704. This behavior has been observed previously37. Since the cyclization of 
the diastereomeric aldehydes may precede with different reaction rates, and since 
                                               
73 a) Breit, B.; Heckmann, G.; Zahn, S.K.; Chemistry 2003, 9, 425-434. b) Breit, B.; Dauber, M.; Harms, K.; 
Chemistry 1999, 5, 2819-2827. c) Breit, B.; Tetrahedron Lett. 1998, 39, 5163-5166. d) Breit, B.; Eur. J. Org. 
Chem. 1998, 6, 1123-1134. e) Breit, B.; Zahn, S.K.; Tetrahedron Lett. 1998, 39, 1901-1904. f) Breit, B.; Chem. 
Commun. 1997, 6, 591-592. g) Breit, B.; Angew. Chem. Int. Ed. 1996, 35, 2835-2837. 
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hydroformylation is reversible, the observed diastereomeric ratio of 92:8 may not be 
representative for the diastereoselectivity of the hydroformylation. The cyclization may be 
prevented by an in situ protection of the aldehyde or alkylation of the NH-group. Unlike the 
synthesis of naproxene, the addition of triethyl orthoformiate does not lead to the 
corresponding acetal 705 (Scheme 67). While subsequent alkylation of 702 turns out to be 
difficult, reductive amination of olefin 701 with acetaldehyde followed by attachment of the 
auxiliary is unselective (Scheme 72).  
Scheme 72: Diastereoselective hydroformylation of prochiral allylic amines. 
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cond.: i) 1equiv. 701, 1equiv. o-diphenylphosphino benzoic acid, 1.1equiv. DCC, 5mol% DMAP, CH2Cl2, rt, 
24h, 45%. ii) 1equiv. 702, 0.7mol% Rh(acac)(CO)2, 2.8mol% P(OPh3)3, 10bar H2, 10bar CO, benzene, 90°C, 
20h. iii) 1equiv. 702, 1equiv. HC(OEt)3, 0.7mol% Rh(acac)(CO)2, 2.8mol% P(OPh3)3, benzene, 80°C, 20h. 
iv) 1equiv. 702, 10equiv. bromoethane, 5mol% 18-crown[6], 2.5equiv. K2CO3, acetonitrile, 100°C, 12h. v) 
1equiv. 701, 1equiv. acetaldehyde, THF, rt, 20min, then 0.3equiv. LiAlH4, THF, 80°C, 2h. 
7.2 SYNTHESIS OF A TEST SUBSTRATE VIA ALLYLIC AMINATION  
Unfortunately, OVERMAN rearrangement gives access to only primary chiral allylic amines. 
Therefore, an alternative method has to be used to synthesize secondary chiral allylic amines.  
Scheme 73: Allylic amination. 
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cond.: i) 1equiv. 708, 3equiv. piperidine, 2mol% 
[Ir(cod)Cl]2, 8mol% P(OPh)3, EtOH, 80°C, 2h, 84%. 
ii) 1equiv. 709, 3equiv. hexylamine, 2mol% 
[Ir(cod)Cl]2, 8mol% P(OPh)3, EtOH, 80°C, 2h, 56%. 
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Iridium catalyzed allylic amination of cinnamyl carbonate 708 has already been used for the 
enantioselective synthesis of chiral allylic amine 301h in this thesis and might also work here. 
To synthesize a prochiral, olefin a-methyl cinnamyl carbonate (709) is subjected to the allylic 
amination. In contrast to previous experiments, this reaction results in cleavage of the 
carbonate as the major product (Scheme 73). Although the mechanism of the iridium 
catalyzed allylic amination is so far not completely investigated, the following mechanistic 
considerations are assumed in analogy to the palladium catalyzed allylic substitution as a 
working hypothesis74. 
Allylic substitutions usually proceed via an allyl metal complex formed by SN2’-anti- 
substitution of the leaving group by the catalyst. In the presence of electron withdrawing 
ligands, such as P(OPh)3, the resulting s-allyl complex 711a rearranges via the p-allyl 
complex 711b to the s'-allyl complex 711c which is attacked by the nucleophile anti to the 
catalyst giving the branched isomer preferably (Scheme 74). 
Scheme 74: Mechanism of the iridium catalyzed allylic amination of cinnamyl carbonates. 
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cond.: 1equiv. 631, 3equiv. piperidine, 2mol% [Ir(cod)Cl]2, 8mol% P(OPh)3, EtOH, 80°C, 2h, 84%. 
 
In the case of a-methyl cinnamyl carbonate (709), s-p-s-rearrangement of s-complex 
712a to p-complex 712c may be kinetically hindered by increased syn-periplanar repulsion of 
                                               
74 For a review on Palladium catalyzed allylation reactions see: Trost, B.M.; Lee, C.; in Catalytic Asymmetric 
Synthesis, 2nd ed. (Ojima, I. eds.), Wiley-VCH, New York, 2000, 593-650. 
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the methyl and the phenyl substituent. If an SN2’-anti substitution takes place, it may proceed 
from s-complex 712a to give 714a or from s-complex 713a to give 714b. Here however, the 
alcohol 634 is formed as the major product via base induced decomposition of the starting 
material. This suggests that SN2’ might, in this special case, be slower than the product 
decomposition. Steric repulsions within both s-complexes may not result in a conformation in 
which the iridium catalyst is anti-periplanar to the incoming nucleophile, reducing the SN2’ 
reaction rate by far (Scheme 75). 
Scheme 75: Mechanism of the iridium catalyzed allylic amination of cinnamyl carbonates. 
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cond.: 1equiv. 709, 3equiv. hexylamine, 2mol% [Ir(cod)Cl]2, 8mol% P(OPh)3, EtOH, 80°C, 2h, 56%. 
 
However, if carbonate 715 is subjected to the allylic amination, 717 can be isolated in 
quantitative yield as the only regioisomer.  
Scheme 76: Mechanism of the iridium catalyzed allylic amination of cyclic allylic carbonates. 
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cond.: 1equiv. 715, 3equiv. hexylamine, 2mol% [Ir(cod)Cl]2, 8mol% P(OPh)3, EtOH, 80°C, 2h, 100%. 
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The fact that the amine replaces the carbonate on the same carbon atom is known as the 
memory effect of iridium (Scheme 76)75. Here s-p-rearrangement may be hampered by an 
increased steric repulsion between the two ring-CH2-groups in p-complex 716b, therefore, 
SN2’ proceeds from the initially formed s-complex giving the linear amine. Consequently, 
regioisomeric carbonate 718 has been subjected to the allylic amination resulting in the 
desired regioisomeric allylic amine 719 in 92% yield (Scheme 77). 
Scheme 77: Synthesis of a chiral and 
prochiral allylic amine. 
OCOOEt NHC6H13
719
92%718  
cond.: 1equiv. 718, 3equiv. hexylamine, 
2mol% [Ir(cod)Cl]2, 8mol% P(OPh)3, 
EtOH, 80°C, 2h, 92%. 
 
Obviously iridium catalyzed allylic amination can proceed via two different ways. If a fast 
s-p-s-rearrangement is possible, nucleophilic attack takes place preferably at the higher 
substituted carbon atom. Although TAKEUCHI supposes that electronic reasons are 
responsible76 similar to palladium catalyzed allylations77, a preference of s-complex 711c 
appears to be reasonable due to steric pressure. SN2’-substitution gives then the branched 
product preferably. In contrast, if a fast s-p-s-rearrangement is hindered, either by the 
syn-periplanar interactions or interactions between the catalyst and bulky substituents in the 
anti-p-allyl-iridium complex, the s-complex undergoes SN2’-anti-substitution, giving a 
product in which the leaving group and the nucleophile are placed at the same carbon atom 
(memory effect).  
Upon having a secondary chiral allylic amine o-DPPB was attached to this substrate using 
the STEGLICH protocol giving substrate 720 together with an olefinic by-product. 
 
                                               
75 Faller, J.W.; Sarnatopoulos, N.; Organometallics 2004, 23, 2179-2185. 
76 a) Takeuchi, R.; Kashio, M.; J. Am. Chem. Soc. 1998, 120, 8647-8655. b) Takeuchi, R.; Ue, N.; Tanabe, K.; 
Yamashita, K.; Shiga, N.; J. Am. Chem. Soc. 2001, 123, 9525-9534. 
77 Åkermark, B.; Hansson, S.; Krakenberger, B.; Vitagliano, A.; Zetterberg, K.; Organometallics 1984, 3, 679-
682. 
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Scheme 78: Steglich amidation towards a test substrate. 
NHC6H13 NC6H13
o-dppb
inseparable olefinic by-product
719 720  
cond.: 1equiv. 719, 1equiv. o-diphenylphosphino benzoic acid, 1.1equiv. DCC, 5mol% 
DMAP, CH2Cl2, rt, 12h. 
7.3 STEREOSELECTIVE HYDROFORMYLATION / FISCHER INDOLIZATION 
Since this byproduct can not be separated from the desired olefin, the starting material for 
carbonate 718 is used for further studies on the influence of aromatic hydrazines on the 
diastereoselectivity. Hydroformylation of 721 has already been investigated by CRUDDEN in 
2002, and a basic diastereoselectivity was observed depending from the alcohol protecting 
group used. Nevertheless, in all cases the diastereoselectivity does not exceed a 6:1 ratio in 
favor of the trans product (Scheme 79)78. 
Scheme 79: Diastereoselective hydroformylation of 
protected 2-methylene cyclohexanols. 
Opg
Opg
CHO
OH
dr < 6:1721 722
723
 
Carbodiimide mediated attachment of o-DPPB to 721 gives substrate 724 in quantitative 
yields. Hydroformylation is conducted without addition of ligand in benzene at low 
temperature giving aldehyde 649 with excellent diastereoselectivity (dr > 95:5). The NMR 
shows a chemical shift of the aldehyde group that corresponds with that of the trans isomer 
(Scheme 80).  
Scheme 80: Diastereoselective hydroformylation using 
Breit’s protocol. 
OH O(o-dppb) O(o-dppb)
CHO
dr > 95:5721 724
725
i) ii)
 
cond.: i) 1equiv. 721, 1equiv. o-diphenylphosphino benzoic 
acid, 1.1equiv. DCC, 5mol% DMAP, CH2Cl2, rt, 48h, 100%. 
ii) 1equiv. 724, 3mol% Rh(acac)(CO)2, 30bar H2, 30bar CO, 
40°C, 20h. 
 
                                               
78 Ren, L.; Crudden, C.M.; J. Org. Chem. 2002, 67, 1746-1750. 
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To test the influence of hydrazines on the diastereoselectivity, hydroformylation is 
conducted in the presence of an aromatic hydrazine. Since the presence of an additional 
stereogenic center would hamper the determination of the diastereomeric ratio, a-Boc 
protected p-methoxy phenylhydrazine 214j is used. Hydrogen bonding between the 
Boc-carbonyl group and the hydrazone-CH group is responsible for the selective formation of 
the (E)-hydrazone. Tandem hydroformylation / hydrazone formation gives hydrazone 726 
with no loss of diastereoselectivity compared to the hydroformylation (Scheme 81).  
Scheme 81: Diastereoselective tandem hydroformylation / Fischer indole synthesis. 
O(o-dppb)
O(o-dppb)
dr > 95:5
N
N
O
OO
H
N
H
(o-dppb)O O
N
O
Boc
H2N
724 214j
726
727 44%  
cond.: i) 1equiv. 724, 1equiv. 214j, 3mol% Rh(acac)(CO)2, 30bar CO, 30bar H2, THF, 100°C, 20h, 76%. ii) 
1equiv. 650, 4wt% H2SO4 in THF, 80°C, 2h, 44%. 
 
Subsequent indolization of 726 gives the desired indole in 44% yield as a first example of a 
stereoselective tandem hydroformylation / FISCHER indole synthesis. During acid mediated 
indolization, the diphenyl phosphino group is partially oxidized to the phosphane oxide which 
could not be isolated, lowering the isolated yield of indole 727. Though comparable substrates 
may easily be achieved by electrophilic substitution of indole 728 with cyclohexene oxide 
729. If further substituents are present on the cyclohexane ring, as required for hapalindole Q, 
epoxide opening would not precede regioselectively. Here diastereoselective tandem 
hydroformylation / FISCHER indole synthesis of 731 might be an attractive alternative 
(Scheme 82).  
Scheme 82: Comparison with electrophilic substitution of indoles with epoxides. 
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7.4 INTERIM CONCLUSION 
In this chapter, the first asymmetric tandem hydroformylation / FISCHER indole synthesis 
has been described.  
Ø Due to a lack of enantioselective hydroformylation catalysts for b-induction of 
stereocenters, BREIT’s protocol for a diastereoselective hydroformylation of 
methallylic alcohols is used. Ortho-diphenylphosphino benzoic acid acts as an 
auxiliary that directs the hydroformylation catalyst to one diastereotopic faces of the 
double bond preferably.  
Ø Even in the presence of aromatic hydrazines high diastereoselectivities are obtained 
upon tandem hydroformylation / hydrazone formation.  
Ø It couldn’t be clarified completely if BREIT’s strategy can be transferred to chiral 
allylic amines, but initial results suggest that even here high diastereoselectivities can 
be expected. 
Ø This methodology might be synthetically valuable for the stereoselective approach 
towards an intermediate for the total synthesis of hapalindole Q. 
Ø Insight into the regioselectivity of the iridium catalyzed allylic amination is given in 
the context of the synthesis of chiral allylic amines.  
Ø If a p-allyl-iridium-complex can be formed, the catalyst evades steric hindrance, 
giving the branched amination product upon SN2’-anti-substitution.  
Ø If the formation of this p-allyl-complex is hindered by steric interaction of substituents 
amination does not precede formally as an allylic substitution giving linear or 
branched products depending on the starting material (memory effect). 
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8 TANDEM HYDROFORMYLATION / FISCHER INDOLE SYNTHESIS ON 
SOLID PHASE 
The discovery of new pharmaceuticals is one of the most challenging issues in medicinal 
chemistry. This search has been revolutionized in the early 1990’s by the introduction of 
automated, polymer supported, combinatorial chemistry. Nowadays, the search for new 
pharmacologically active compounds can be described as a two-step process in which a 
library of compounds with as much diversity as possible is synthesized, starting with a 
defined set of reactants (Scheme 83). The compounds in this library can differ in their 
substitution pattern, in their absolute or relative configuration or even in their scaffold. A 
primary screening on a special target discovers a possible lead structure, which is then 
optimized in a second combinatorial approach.79 In many cases, these compounds contain 
privileged structures, such as benzodiazepines, quinolones or indoles.  
Scheme 83. Solid phase supported two step process for the development of new lead structures. 
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In the previous chapters it has been demonstrated, that the tandem hydroformylation / 
FISCHER indole synthesis is a powerful synthetic tool for the synthesis of indoles with unusual 
substitution patterns as well as pharmaceuticals. Considering all experiments, including the 
work of KÖHLING18,19, the tandem hydroformylation / FISCHER indolization might also be a 
very attractive tool for the discovery of new pharmaceuticals. In using different olefins and 
aromatic hydrazines, not only the substitution pattern of the indole can be varied, but the 
diversity of the molecule’s scaffold can be achieved if the indolization incorporates an 
additional rearrangement as in the use of internal olefins. Here, the intermediate indolenine 
rearranges to give the aromatic indole. But with an appropriate set of reaction conditions, the 
                                               
79 Schreiber, S.L.; Burke, M.D.; Angew. Chem. 2004, 116, 48-60. 
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indolenine can either be isolated or hydrogenated to give spiro-indolines. Therefore, tandem 
hydroformylation / FISCHER indole synthesis can be used to create substrate controlled 
diversity as well as reagent controlled diversity of the molecule’s scaffold. Furthermore, the 
indoles derived from this tandem reaction are ideal intermediates for a WITCOP-
WINTERFELDT-oxidation80 which gives direct access to g-quinolones. This consecutive 
reaction together with a previous tandem hydroformylation / FISCHER indole synthesis in a 
split-pool approach may give convenient access to a highly diverse library of potentially 
pharmaceutically active compounds (Scheme 84). 
Scheme 84: Structural elements that can be accessed by tandem hydroformylation / Fischer indole 
synthesis. 
 
                                               
80 a) Jiang, W.; Zhang, X.; Sui, Z. Org. Lett. 2003, 5, 43. b) Zhang, X.; Jiang, W.; Sui, Z. Asymmetric total 
syntheses of quinolactacin A and B through an improved Winterfeldt Oxidation. Abstracts of Papers; 224th ACS 
National Meeting, Boston, MA, 18-22 Aug, 2002; American Chemical Society: Washington, DC, 2002. 
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A necessity for the use of this new tandem reaction for the identification of new leads is its 
transfer from solution to solid phase in order to allow automated combinatorial synthesis. In 
this chapter, initial investigations for the tandem hydroformylation / FISCHER indole synthesis 
on polymer support are compiled.  
In this context, it has to be focused on the hydroformylation process to allow 
Ø small scale parallel synthesis 
Ø on polymer support 
Ø under a pressurized atmosphere, 
as well as on the polymer’s design to ensure 
Ø a high yielding linkage of the substrate to the polymer, 
Ø stability of the linker under the reductive hydroformylation conditions and the harsh 
and acidic FISCHER indolization conditions, 
Ø orthogonal and selective cleavage of the indole product. 
8.1 HYDROFORMYLATION ON SOLID PHASE 
In the past decade several hydroformylations and tandem reactions under hydroformylation 
conditions have been transferred from solution to solid phase. Special attention must be paid 
to the apparatus in which the hydroformylation experiment is conducted in. High reaction 
rates can only be expected if the gas phase and solution phase are mixed intensively. For this 
purpose special stirrers were designed as shown in Figure 1.  
Figure 1: Parr autoclave with special stirrer for extensive mixing of liquid and gas phase. 
      
On the other hand, KOÇ experienced that polymer beads are destroyed by such stirrers due 
to shear stress. Therefore, magnetically stirred or shaken reaction vessels are preferred with 
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prolongation of the reaction time as a consequence. However, even magnetic stir bars can 
pulverize polymer beads if the resin gets between the stir bar and the bottom of the reaction 
vessel. In 1997, TAKAHASHI et al. used a Multipin™ system for the hydroformylation in a 
solid phase approach towards muscone. Hydroformylation was conducted on a polystyrene 
resin with a 4-hydroxy-phenyl-sulfonylchloride modified trityl linker.81 While the trityl group 
can easily be cleaved after hydroformylation, the 4-hydroxy-phenyl sulfonate acts as a leaving 
group for consecutive alkylations (Scheme 85). 
Scheme 85: Hydroformylation of unsaturated alcohols on a modified trityl linked 
resin. 
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In 2003, MARCHETTI has modified a glass vial for hydroformylation on solid phase. Here, 
the reaction area is separated from the stirring area with a sintered glass filter and a basket in 
which the resin is placed (Figure 1). With this method MARCHETTI conducted a series of 
hydroformylations and tandem reactions under hydroformylation conditions, such as a 
hydroaminomethylation and a hydroformylation / PICTET-SPENGLER reaction, of different 
trityl linked olefins.82  
Figure 2: Glass vial for solid phase 
synthesis in autoclaves. 
 
                                               
81 a) Takahashi, T.; Machida, K.; Kido, Y.; Nagashima, K.; Ebata, S.; Doi, T.; Chem. Lett. 1997, 1291-1292. b) 
Takahashi, T.; Ebata, S.; Doi, T.; Tetrahedron Lett. 1998, 1369-1372. 
82 a) Dessole, G.; Marchetti, M.; Taddei, M.; J. Comb. Chem. 2003, 5, 198-200. b) Marchetti, M.; Botteghi, C.; 
Paganelli, S.; Taddei, M.; Adv. Synth. Catal. 2003, 345, 1229-1236. 
TANDEM HYDROFORMYLATION / FISCHER INDOLE SYNTHESIS ON SOLID PHASE 
- 98 - 
Very recently KOÇ used an intermolecular hydroaminomethylation on Wang resin to build 
up dendrons for dendrimer synthesis in a slowly stirred Parr autoclave (Scheme 86).83 
Scheme 86: Dendrimer synthesis on solid phase. 
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8.2 FISCHER INDOLE SYNTHESES ON SOLID PHASE 
Due to the importance of the indole ring in biological and medicinal chemistry, many 
approaches towards a polymer supported FISCHER indole synthesis have been reported.  
Scheme 87: Chapman’s Fischer indole synthesis on solid phase. 
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In 1997, CHAPMAN et al. synthesized 2-aryl indoles from a HMBA linked 4-benzoylbutyric 
acid on a polyethyleneglycol modified polystyrene (PS) resin and various aromatic 
                                               
83 Koç, F.; Dissertation 2004, University of Dortmund. 
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hydrazines.84 The FISCHER indolization was mediated by ZnCl2 in glacial acetic acid (Scheme 
87). While the solid phase synthesis of similar compounds using a safety catch linker failed 
due to an intramolecular substitution of the sulfonamide by the hydrazone NH-group, the use 
of a carbamate linker on a hydroxymethylated polystyrene resin afforded the desired 2-aryl 
indoles (Scheme 88).85  
Scheme 88: Fischer indole synthesis on solid phase using a carbamate linker. 
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A traceless FISCHER indole synthesis has been developed by WALDMANN.86 Here, in contrast 
to previous examples, the aromatic hydrazine is linked to the resin. The hydrazine can be 
bound to an aldehyde functionalized resin as a hydrazone. In the presence of a carbonyl 
compound and an acid, this hydrazone is cleaved by transcondensation and the resulting 
hydrazone undergoes indolization in solution (Scheme 89). This approach can be compared to 
the BUCHWALD-HARTWIG modification of the FISCHER indole synthesis (see above).  
Scheme 89: Waldmann’ approach of traceless Fischer indole synthesis. 
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As an alternative, the aromatic hydrazine can be bound via an alkyl spacer. Condensation 
with a carbonyl gives an ene-hydrazine on solid phase, which is cleaved from the resin upon 
acid mediated indolization (Scheme 90).  
                                               
84 Hutchins, S.M.; Chapman, K.T.; Tetrahedron Lett. 1997, 37, 4869-4872. 
85 Yang, L.; Tetrahedron Lett. 2000, 6981-6984. 
86 a) Rosenbaum, C.; Baumhof, P.; Mazitschek, R.; Müller, O.; Giannis, A.; Waldmann, H.; Angew. Chem. Int. 
Ed. 2004, 43, 224-228. b) Rosenbaum, C.; Katzka, C.; Marzinik, A.; Waldmann, H.; Chem. Commun. 2003, 
1822-1823. 
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Scheme 90: Waldmann’ approach of traceless Fischer indole synthesis. 
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JEONG has used the traceless ELLMANN silicon linker to synthesize indoles and the required 
hydrazines on a Tentagel S NH2 resin.87 Indolization is mediated with ZnCl2 in acetic acid, 
while the silyl linker is cleaved with TFA (Scheme 91). 
Scheme 91: Ellmann silicon linker in Fischer indole synthesis. 
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Very recently BREINBAUER applied the sulfonamide linker on a polystyrene resin to the 
FISCHER indole synthesis of 2,3-anellated indoles as well as spiro-indolines starting with 
polymer bound 4-piperidone. Cleavage of this linker can be achieved with Li-biphenylide 
(Scheme 92).88  
Scheme 92: Acid stable sulfonyl chloride PS resin for Fischer indole synthesis on solid phase. 
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Except this last work and the initial work of CHAPMAN, all linkers, that have been used for 
FISCHER indole synthesis are acid labile. Here, milder acidic conditions are required for the 
indolization step to prevent the products or intermediates from being released too early. 
Therefore, low yields are observed in many cases. Since good results in the tandem 
hydroformylation / FISCHER indole synthesis with tosylated allylic amines have been observed 
in solution, the sulfonamide linker seems to be the most promising linker for the tandem 
hydroformylation / FISCHER indole synthesis on polymer support.  
The following results are collected in cooperation with MATTHIAS MENTEL and DR. ROLF 
BREINBAUER. 
                                               
87 Mun, H.S.; Ham, W.H.; Jeong, J.H.; J. Comb. Chem. 2005, 7, 130-135. 
88 Mentel, M,; Breinbauer, R.; in preparation. 
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8.3 HYDROFORMYLATION OF SULFONAMIDE LINKED AMINOOLEFINS 
Starting with simple aminoolefins linked to the sulfonamide resin, the single steps for the 
tandem reaction shall be optimized first. Three different aminoolefins are linked to the 
polystyrene sulfonylchloride resin (802) (Scheme 93). On the other hand, disubstituted, 
terminal olefins require harsher hydroformylation conditions. In contrast, N-methyl allylic 
amine can be hydroformylated under milder conditions with or without control of the 
regioselectivity. 4-Methylene piperidine and N-ethyl-methallylic-amine give linear aldehydes 
without addition of n-directing ligands. 802-804 are hydroformylated in a slowly stirred Parr 
autoclave applying the same conditions KOÇ has used for the hydroaminomethylation on solid 
phase. Since the resulting aldehydes do not tolerate the conditions required for the cleavage of 
the sulfonamide linker, aldehyde loadings are determined using the FmPh-method (Scheme 
94)89.  
Scheme 93: Hydroformylation of different olefins on solid phase. 
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cond.: i) 1equiv. 801, 5equiv. 4-methylene piperidine, THF/pyridine (1:1), rt, 
20h. ii) 1equiv. 801, 5equiv. N-ethyl methallylic amine, CH2Cl2/pyridine, rt, 
24h. iii) 1equiv. 801, 5equiv. N-methyl allylic amine, pyridine, 60°C, 2h. iv) 
1equiv olefin, 20mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 80°C, 2d. 
 
This method was developed by BARANY in 2004, and is a convenient tool for the on-bead 
analysis of aldehyde loadings. Here the fluorenylmethyl ester of 4-hydrazinobenzoic acid 
(FmPh, 808) is reacted with the aldehyde (805) to give aromatic hydrazone 809. 
                                               
89 Shannon, S.K.; Barany, G.; J. Org. Chem. 2004, 69, 4586-4594. 
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Scheme 94: On-bead analysis of aldehyde loadings – the FmPh-method. 
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cond.: i) 1equiv. 805, 3equiv. 808, 3equiv. DIPEA, DMF/trimethyl orthoformiate (1:1), 80°C, 30min; 
ii) DMF/piperidine (1:1), rt, 30min. 
 
After washing and upon addition of piperidine in DMF, the fluorenylmethylester is cleaved 
and the resin is washed properly. The washing solution is collected and the concentration of 
the fluorenylpiperidine (811), and therefore the aldehyde’s loading, is analyzed via 
UV-spectroscopy. The determined loadings, compiled in Scheme 93, are much smaller than 
the theoretical loadings of the starting olefin. Three reasons are imaginable: 
Ø Since there is no direct method to determine olefin loadings, the conversion of the 
sulfonamide formation is assumed to be quantitative. If attachment of the aminoolefin 
proceeds not in quantitative yields, the loading with olefin, and therefore, with the 
aldehyde is much smaller. 
Ø The conditions KOÇ has found might not be ideal for the hydroformylation of allylic 
and homoallylic sulfonamides, causing incomplete conversion. 
Ø The FmPh-method may fail with aldehydes derived upon olefin hydroformylation. 
In order to exclude problems with the linkage of the aminoolefin to solid phase, N-methyl 
allylic amine is reacted with a spacer to give sulfonamide 813 in solution. This spacer is then 
placed on aminomethylated polystyrene resin (812) under reliable carbodiimide mediation. 
The obtained olefin is hydroformylated under KOÇ’s conditions and the aldehyde loading is 
determined with the FmPh-method. Again the aldehyde loading is much smaller than the 
theoretical loading. For a comparison, olefin 814 was ozonolysized to give a-aminoaldehyde 
816 with slightly higher loadings than for the hydroformylation aldehyde. These loadings, 
however, are still smaller than the theory would let to expect (Scheme 95). To prove the 
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reliability of KOÇ’s conditions, undecenoic acid, attached to Wang resin (817), is 
hydroformylated. 
Scheme 95: Comparison of hydroformylation and ozonolysis. 
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cond.: i) 1equiv. 812, 5equiv. 813, 3equiv. DIC, 3equiv. HOBt, 3equiv. NEt3, CH2Cl2, rt, 12h. ii)1equiv. 
814, 20mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 80°C, 5d. iii) O3, CH2Cl2, -78°C, 10min, then 
5equiv. PPh3, rt, 12h. 
 
The aldehyde loading is determined with the FmPh-method on the one hand and on the 
other hand the resulting aldehyde 818 is cleaved off with TFA. While the aldehyde loading 
was 0.21mmol/g according to the FmPh-method the pure hydroformylation product could be 
isolated with 87% yield corresponding with an aldehyde loading of 0.84mmol/g (Scheme 96).  
Scheme 96: Reliability of the FmPh method. 
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cond.: i) 1equiv. 817, 20mol% Rh(acac)(CO)2, 10bar CO, 10bar H2, THF, 80°C, 20h. 
ii) TFA/CH2Cl2 (1:1), rt, 20min, (3x). 
 
Surprisingly, the FmPh-method does not seem to be a reliable method for the control of the 
hydroformylation’s conversion. However, it can be assumed, that the hydroformylation is 
reliable either on Wang resin or on PS sulfonylchloride resin. To give evidence to this 
assumption, olefin 820 is hydroformylated followed by cleavage of the Wang linker. 
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Scheme 97: Hydroformylation of 4-methylene piperidines on sulfonamide PS resin. 
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cond.: i) 1equiv. 820, 20mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 80°C, 44h. ii) TFA/CH2Cl2 (1:1), 
rt, 20min, (3x). 
 
Aldehyde 822 was isolated in quantitative yield and with high purity upon treatment of the 
resin with TFA (Scheme 97).  
8.4 TANDEM HYDROFORMYLATION / HYDRAZONE FORMATION OF SULFONAMIDE 
LINKED AMINOOLEFINS 
Upon having found conditions for a selective hydroformylation of sulfonamide linked 
aminoolefins, olefin 820 is subjected to a tandem hydroformylation / hydrazone formation. 
Based on KOÇ’s conditions, the hydroformylation is conducted in the presence of 
10 equivalents of phenylhydrazine. After cleavage of the product, a complex mixture is 
obtained. One can expect that the acidic cleavage conditions may initialize indolization of the 
hydrazone, but neither indoles nor hydrazones can be detected. If the hydrazone is formed, it 
might be hydrolyzed during release of the product or the hydrazone is oxidized.  
Figure 3: Conical glass vials for parallel synthesis on 
solid phase in autoclaves. 
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On the other hand, hydrazone formation might be hampered by the large amount of solvent 
needed in a Parr autoclave resulting in low hydrazine concentrations. In using magnetically 
stirred conical glass vials as illustrated in Figure 3 the amount of solvent can be reduced from 
80ml to 2ml. The fact that only the cone end of the magnetic stir bar touches the bottom of the 
flask is crucial to minimize mechanical stress to the polymer beads. Since several flasks can 
be placed in one autoclave, this method allows parallel synthesis.  
While the stability of the resulting hydrazones against oxidation can be improved by 
replacing unprotected aromatic hydrazines by a-Boc protected aromatic hydrazines, a partial 
indolization of the hydrazone is prevented by using a base labile linker such as the HMBA 
linker in olefin 823. Tandem hydroformylation / hydrazone formation followed by cleavage 
of the HMBA linker under mild basic conditions gives the desired hydrazone 825 in 23% 
yield but most importantly with high purity (Scheme 98). This high purity is deemed to 
indicate a selective hydrazone formation under hydroformylation conditions. Although the 
amount of rhodium catalyst was increased compared to the reactions in solution, neither side 
reactions such as aldehyde or olefin hydrogenation nor a consecutive hydrogenation of the 
hydrazone is observed. The low yield might be caused by an incomplete cleavage of the 
product but harsher conditions such as sodium methanolat in methanol may affect the 
hydrazone or Boc group. 
Scheme 98: Tandem hydroformylation / hydrazone formation on solid phase. 
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cond.: i) 1equiv. 823, 10equiv. 214j, 20mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 80°C, 44h. ii) 
1equiv. 824, dioxane/DIPEA/MeOH (5:4:1), 80°C, 12h. 
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8.5 TANDEM HYDROFORMYLATION / FISCHER INDOLIZATION OF SULFONAMIDE 
LINKED AMINOOLEFINS 
Two different options for the tandem hydroformylation / FISCHER indolization on polymer 
support exist: 
Ø First generation protocol for non-polar olefins. Here the hydroformylation of a 
polymer bound olefin is conducted in the presence of an aromatic hydrazine. After 
washing of the resin the hydrazone is indolized in a separate step. 
Ø Second generation protocol for unpolar olefins. The hydroformylation is conducted in 
the presence of benzhydrylidene protected hydrazines and PTSA. 
8.5.1 FIRST GENERATION PROTOCOL 
Since H2SO4 in THF turned out to be ideal for reactions in solution, substrate 825 is 
subjected to the same conditions. After a low yielding cleavage, however, no indole can be 
isolated. It seems that the indolization conditions are too harsh and induce early cleavage of 
the HMBA linker. 
Scheme 99: Stepwise hydroformylation / hydrazone formation / indolization. 
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cond.: i) 1equiv. 825, 4wt% H2SO4/THF, 80°C 2h. ii) 1eq 826, dioxane/TEA/MeOH (5:4:1), 80°C, 12h. 
 
Thus, WALDMANN’s conditions, TFA/DCE (1:9), are tested. Although the HMBA linker 
seems to be stable, no indole product is observed. With TFA/DCE (1:1) neither indole nor any 
other reasonable product can be isolated from solid phase. Instead, the washing solution 
contains at least four different products, including the desired indole as the free acid. 
Obviously the HMBA linker is cleaved during treatment with TFA at 100°C. This clearly 
demonstrates once more the necessity for an acid stable linker for FISCHER indole synthesis. 
Therefore, further investigations are made on PS sulfonylamide resin 803, which is 
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hydroformylated in the presence of phenylhydrazine (214a) and a-Boc protected p-methoxy-
phenylhydrazine (214j). 
Scheme 100: First generation protocol for the tandem hydroformylation / Fischer indolization on solid 
phase. 
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cond.: i) 1equiv. 803, 10equiv. 214a, 20mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 80°C, 44h. ii) 
1equiv. 803, 10equiv. 214j, 20mol% Rh(acac)(CO)2, 50bar CO, 10bar H2, THF, 80°C, 44h. iii) 1equiv. 
hydrazone, TFA/DCE (1:1), 10°C, 18h; iv) 1equiv. 831, 10equiv. ZnCl2, THF, 100°C, 17h or 1equiv. 831, 
10equiv. BF3*Et2O, CH2Cl2, AcOH (1:1), 65°C, 12h. v) 1equiv. indole, 10equiv. Li-biphenylide (1M in 
THF), 0°C, 2h. 
 
Both hydrazones are reacted with TFA/DCE (1:1), but under no circumstances can the 
desired indole be isolated upon cleavage with Li-biphenylide. An intensive screening of 
reaction conditions discloses that BF3*Et2O in CH2Cl2/AcOH (1:1) and ZnCl2 in THF give 
smooth indolization of 831, but further optimizations are needed to suppress the formation of 
an unidentified by-product 
8.5.2 SECOND GENERATION PROTOCOL 
An alternative and improvement of this stepwise approach is the second generation protocol. 
Here, olefins are hydroformylated in the presence of benzhydrylidene protected hydrazines 
and PTSA to allow direct access to tryptamines in high yields and with high selectivity. To 
test if this protocol can be transferred from solution to solid phase, olefin 803 is subjected to 
this tandem reaction using 10 equivalents of hydrazine and 5 equivalents of PTSA. 
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Scheme 101: Second generation protocol for the tandem 
hydroformylation / Fischer indolization on solid phase. 
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The desired indole can be isolated in 19% yield from a very selective reaction. This then, is 
the first example of a successful tandem hydroformylation / FISCHER indole synthesis on solid 
support. 
8.6 INTERIM CONCLUSION 
In this chapter the first tandem hydroformylation / FISCHER indole synthesis on solid phase 
is developed. In this context the following features were investigated: 
Ø Hydroformylation process. It turned out, that the use of conical glass vials is 
reasonable, in order to 
· combine a fast hydroformylation with a minimized mechanical stress to the 
polymer beads, 
· and to allow the simultaneous conduction of different reactions in one pressure 
vessel (parallel synthesis). 
Ø Tandem hydroformylation / hydrazone formation. The first hydrazone formation under 
hydroformylation conditions on solid phase is presented.  
· The use of PS HMBA resin is appropriate since the mild basic conditions for a 
product release do not affect the hydrazone’s stability.  
· a-Boc protected aromatic hydrazines derived via the GOLDBERG reaction are 
suitable hydrazine sources and do not undergo oxidation during the hydrazone 
formation or the cleavage of the HMBA linker. 
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Ø Tandem hydroformylation / Fischer indole synthesis. The basis for the synthesis of 
substance libraries via tandem hydroformylation / FISCHER indolization is established. 
Since the HMBA linker is not acid stable under harsh indolization conditions, the PS 
sulfonylchloride resin turned out to be appropriate for the synthesis of tryptamine 
derivatives. Two protocols have been developed: 
· First generation protocol. Here the hydroformylation of a polymer bound olefin is 
conducted in the presence of aromatic hydrazines, preferably an a-Boc protected 
hydrazine. Subsequent indolization is achieved upon treatment with ZnCl2 or 
BF3*Et2O in acetic acid/CH2Cl2.  
· Second generation protocol. Hydroformylation of a polymer bound olefin in the 
presence of benzhydrylidene protected hydrazines and PTSA results in selective 
indole formation.  
 - 110 - 
9 SUMMARY AND OUTLOOK 
9.1 SUMMARY 
Tandem hydroformylation / FISCHER indole synthesis has proved to be a diversity oriented 
synthetic tool for the fast and convenient synthesis of biologically relevant tryptamines and 
homologues. In this new tandem reaction, the hydroformylation of aminoolefins is conducted 
in the presence of aromatic hydrazines and BRØNSTEDT acids to give tryptamines in one pot 
(Scheme 102).  
Scheme 102: Principle of the tandem hydroformylation / 
Fischer indole synthesis. 
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In contrast to the classical protocol, this new approach makes a previous synthesis of 
aldehydes, followed by their protection as acetals, aminales, bisulfite adducts or enol ethers, 
obsolete. Instead olefins are converted to aldehydes in situ, trapped as aryl hydrazones in situ 
and are indolized to tryptamines instantly. Thus, simple functional group transformations are 
replaced by C-C-bond forming steps in a one pot procedure that saves time and resources. 
Therefore, this approach may be an attractive alternative production process, especially since 
olefins can be used as a different source of starting material, circumventing patented 
production processes. 
Starting with appropriate amines, aminoolefins can be synthesized with different state-of-
the-art methods (substitution, allylation, WITTIG olefination, BARBIER reaction, 
carbomagnezation, etc.), allowing high diversity in the chain length and the substitution 
pattern of the aminoolefins. Independently from these different types of olefins, tandem 
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hydroformylation / FISCHER indole synthesis is a reliable tool to yield the corresponding 
indoles (Scheme 103). 
 
Depending on the nature of the aminoolefin, different conditions have been developed. Non-
polar olefins, especially protected primary and secondary aminoolefins, require a non-polar 
reaction medium. Here the use of THF/H2SO4 turned out to be the best system.  
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Scheme 103: Combination of modern syntheses of aminoolefins with the tandem hydroformylation / 
Fischer indole synthesis as a highly diversity oriented approach towards tryptamines and homologues. 
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Scheme 104: Tandem hydroformylation / Fischer indole synthesis of non-polar olefins. 
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The highest selectivity can be observed, if benzhydrylidene protected aromatic hydrazines, 
derived from BUCHWALD-HARTWIG amination, are subjected to this tandem reaction. Other 
sources, such as non-protected hydrazines as well as a-Boc protected hydrazines derived from 
a GOLDBERG reaction, give satisfying yields too (Scheme 104). 
Polar aminoolefins, such as tertiary aminoolefins, require a very polar medium. Here 
aqueous H2SO4 is used. Solubility of the rhodium hydroformylation catalyst is achieved by 
addition of sulfonated phosphane ligands, such as trisulfonated triphenylphosphane (TPPTS) 
or disulfonated XANTPHOS (SulfoXANTPHOS), the latter giving high n-selectivities. 
Commercially available hydrazine hydrochlorides as well as synthesized a-Boc protected 
aromatic hydrazines can be used. the latter is the option of choice for the synthesis of 
migraine drugs (Scheme 105). 
Scheme 105: Tandem hydroformylation / Fischer indole synthesis of polar olefins. 
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Even stereochemical issues can be incorporated: Either the aminoolefins includes 
stereochemical information or prochiral olefins are used resulting in the formation of an 
additional stereocenter.  
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Scheme 106: Use of chiral allylic amines with transfer of the 
absolute configuration to the indole. 
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In using chiral allylic amines, no epimerization due to double bond migration either by the 
rhodium catalyst or by the acid is observed, giving full retention of absolute configuration 
(Scheme 106).  
If disubstituted terminal olefins are used, the relative configuration of the stereocenter in 
b-position in relation to the aldehyde group can be controlled applying BREIT’s protocol of 
substrate directed hydroformylation to this new tandem sequence (Scheme 107).  
Scheme 107: Diastereoselective tandem hydroformylation / Fischer 
indole synthesis. 
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Even regioselectivity problems in the classical indolization of the meta-substituted aromatic 
hydrazines can be overcome by the first intramolecular FISCHER indole synthesis yielding the 
6-substituted indole as the only regioisomer and being an illustrative example for the synergy 
of this tandem reaction (Scheme 108).  
Scheme 108: Regioselective tandem hydroformylation / Fischer 
indole synthesis. 
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After deprotection, primary and secondary tryptamines and homologues derived from a 
tandem hydroformylation / FISCHER indolization can be subjected to hydroaminomethylation. 
This rhodium catalyzed tandem reaction consists of hydroformylation and reductive 
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amination and allows further, highly selective functionalization towards tryptamines drugs. 
The combination of these two tandem reactions under hydroformylation conditions gives 
unusually convenient access to highly functionalized 3-piperidyl indole drugs (Scheme 109).  
 
 
 
Scheme 109: Combination of tandem hydroformylation / Fischer indole synthesis and 
hydroaminomethylation in a fast synthesis of highly functionalized tryptamines. 
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The automated combinatorial synthesis on solid support is a key technology for the 
development of new pharmaceuticals. The tandem hydroformylation / FISCHER indole 
synthesis can be an attractive tool for the combinatorial synthesis of highly diverse indole 
libraries, since this tandem reaction is successfully transferred from solution to solid phase, 
using a polystyrene sulfonylchloride resin (Scheme 110). 
Scheme 110: Tandem hydroformylation / Fischer indole synthesis on 
solid phase, 
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If the hydroformylation of olefins is conducted in the presence of aromatic hydrazines but in 
the absence of acid, aromatic hydrazones are obtained in almost quantitative yields and can be 
subjected to highly selective subsequent indolization. Side reactions or consecutive reactions 
such as hydrogenation could not be observed in any case. Substituents that are prone to 
catalytic hydrogenation turned out to be stable as well as the aromatic hydrazones group 
itself, quite in contrary to the analogue alkyl hydrazones or the corresponding aldehydes. In 
contrast to aminoaldehydes, aminohydrazones derived from aldehydes in situ do not undergo 
consecutive base induced aldol reactions. In conclusion the aromatic hydrazone can be 
interpreted as a productive protecting group unless it is to be part of the final product. This 
tandem hydroformylation / hydrazone formation can be used for the synthesis of macrocyclic 
bishydrazones in extraordinary high yields (Scheme 111).  
Scheme 111: Synthesis of macrocyclic bishydrazones under 
hydroformylation conditions. 
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Scheme 112: Metal screening of fluorescence quenching of macrocyclic bishydrazones. 
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Although these compounds do not undergo selective indolization upon acid addition, these 
macrocycles represent a new class of macrocycles that show some unexpected selectivity 
towards metals in the quenching of their fluorescence activity. Besides strong interactions 
with vanadium(II) and chromium(III), the interaction with iron(III) salts may be interesting 
for medicinal and environmental applications (Scheme 112). 
9.2 OUTLOOK 
With the optimized protocols that have been developed in this project, the tandem reaction 
is now ready for advanced applications: 
Ø Although there is still need for further optimizations to increase the yield of the 
polymer supported tandem hydroformylation / FISCHER indolization, it becomes 
apparent that this tandem reaction is an appropriate tool for the synthesis of substance 
libraries. In forthcoming investigations the following issues should be considered: 
· The synthesis of starting material should be incorporated. For example ring-
closing metathesis for the synthesis of dihydropyrroles, which are needed for 
b-carbolines, or allylic aminations for the synthesis of chiral allylic amines as 
needed for b-branched tryptamines (Scheme 113). 
· Tandem hydroformylation / FISCHER indole synthesis must not be the final step in 
a synthesis on solid phase. Consecutive reactions such as PICTET-SPENGLER 
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reactions especially of chiral tryptamines to b-carbolines and their WITKOP-
WINTERFELDT oxidation to g-quinolones increase the substance library’s diversity 
(Scheme 113). 
Scheme 113: Tandem hydroformylation / Fischer indole synthesis for the synthesis of b-carbolines and 
g-quinolones on solid phase. 
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· If the tandem hydroformylation / FISCHER indole synthesis is to be incorporated in 
a multi step synthesis of indole and quinolone derivatives, on-bead analysis of the 
tandem reaction’s conversion is crucial. Besides instrumental analysis such as 
magic angle spinning NMR, methods based on the derivatization are important, 
such as the FmPh-method for the determination of aldehyde loadings. The fact, 
that the b-nitrogen of the aromatic hydrazone is eliminated during indolization as 
ammonia might be of help if the b-nitrogen is labeled with an UV-active signaling 
unit. This signaling unit is not allowed to hamper the condensation with the 
carbonyl or the indolization of the resulting hydrazone (Scheme 114).  
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Scheme 114: On-bead analysis of the conversion of the Fischer indole synthesis. 
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· Thus, this signaling unit should be attached via an alkyl chain. Here the tandem 
hydroformylation / hydrazone formation might be of help if the reaction is 
conducted under more forcing conditions that allow consecutive hydrogenation of 
the hydrazone. However, other methods such as simple alkylation may also be 
appropriate. Condensation with a carbonyl on solid phase then gives an ene-
hydrazine, which undergoes sigmatropic rearrangement followed by elimination of 
labeled ammonia whose concentration, and therefore, the indolization’s conversion 
might be determined by UV-spectroscopy without need for cleavage of the indole 
or its derivatization (Scheme 115). 
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Scheme 115: Synthesis of labeled aromatic hydrazines under hydroformylation 
conditions for on-bead analysis of the Fischer indolization’s conversion. 
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· If the reduction of aromatic hydrazones derived upon tandem hydroformylation / 
hydrazone formation can undergo subsequent hydrogenation under forcing 
hydroformylation conditions, this might also be an interesting option to attach 
aromatic hydrazine to solid phase. This method would be an improvement of 
WALDMANN’s traceless FISCHER indole synthesis on solid phase. Here, the 
hydrazine was reacted with an aldehyde resin, followed by reduction of the 
hydrazone with BH3/THF, still being problematic but the only method for a 
selective reduction without cleavage of the N-N-bond.  
Scheme 116: Attachment of aromatic hydrazines to olefin functionalized resins 
under hydroformylation conditions. 
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Based on the positive experience with the PS sulfonylchloride resin, simple allylic 
alcohols of amines might be attached. Hydroformylation / hydrazone formation / 
hydrogenation might give a polymer bound hydrazine, which is ready for FISCHER 
indole synthesis (Scheme 116). 
Ø Many natural products contain the indole core as the privileged structure. 
Hapalindoles for example might be synthesized using the intermolecular & 
diastereoselective tandem hydroformylation / FISCHER indole synthesis. On the other 
hand, indolactams might be achieved from the intramolecular tandem reaction. 
Ø The patented production processes for tryptamine drugs contain, in many cases, 
necessary, but low yielding, functional group transformation or indolizations towards 
intermediate 3-alkyl indoles. The tandem hydroformylation / FISCHER indole synthesis 
might be an alternative since functional group transformations are reduced to a 
minimum and aminoolefins can be obtained in broad variety. On the other hand 
production costs will come into the focus. Here the rhodium catalyst will determine 
the large part of the production costs. Therefore, optimizations towards replacement of 
rhodium by cobalt, or towards a reduction of the amount of the catalyst seem to be 
important. Alternatively, 2-phase-techniques or immobilization of the rhodium 
catalyst might allow reusing this expensive catalyst several times without loss of 
activity. 
Ø The combination of other formylation reactions with the FISCHER indole synthesis 
might give interesting products: 
· Hydroformylation of epoxides. The hydroformylation of expoxides has been 
developed in 1978 and allows the stereoselective synthesis of aldols.  
Scheme 117: Tandem epoxides-hydroformylation / Fischer 
indole synthesis. 
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Implementation in a tandem reaction might give Tryptamines with hydroxyl 
functionality in the a-position relative to the indole core (Scheme 117).  
· Silylformylation of Olefines. The same product would be achieved in a tandem 
silylformylation / FISCHER indole synthesis of olefins, followed by TAMAO 
oxidation of the resulting a-silyl-tryptamine. In contrast, desilylation in the 
presence of electrophils or HIYAMA coupling reactions might give access to 
indoles with sophisticated branches (Scheme 118). 
Scheme 118: Tandem silylformylation / Fischer indole synthesis and synthetic options. 
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Ø Macrocyclic bisarylhydrazones are proven to be interesting fluorophores for metal 
sensing. Base on the results compiled in chapter 6, the structure of the presented 
macrocycles should be optimized with respect to their fluorescence activity and their 
absorption wavelength. This might be achieved by introducing larger aromatic 
systems close to the hydrazone group. Here, the GOLDBERG reaction seems to be 
appropriate for a broad variation of Ar2. 
Scheme 119: Synthesis of fluorescent active hydrazones. 
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10 EXPERIMENTAL SECTION 
10.1 MATERIALS 
All reagents and solvents were dried and purified before use by the usual procedures. 
Rh(acac)(CO)2, XANTPHOS and P(OPh)3 were purchased. Cinnamyl carbonat90, 
[Rh(cod)Cl]291, [Rh(cod)BF4]292, [Ir(cod)Cl]293, BIPHEPHOS94, TPPTS95, 9,9-dimethyl-4,5-
bis(diphenylphosphino)-9H-xanthene-2,7-disulfonic acid96, O,O'-(R)-(1,1'-Dinaphthyl-2,2'-
diyl)-N,N'-di-(R,R)-1-phenylethylphosphoramidite97 and O,O'-(S)-(1,1'-Dinaphthyl-2,2'-diyl)-
N,N'-di-(S,S)-1-phenylethylphosphoramidite97 were prepared according to the published 
method. All aromatic hydrazines and all olefins were purchased unless mentioned otherwise. 
N-Allyl, N-ethylamides (127e-127g) were synthesized by allylation of the corresponding 
secondary amides. All N-ethylamides required were prepared by the reaction of EtNH2 with 
the corresponding acid chloride in the presence of NEt3 and DMAP. All other protected 
allylic amines (114b-114e, 127b-127d) were synthesized by the reaction of the corresponding 
allylic amines with the corresponding acid chlorides in the presence of NEt3 and DMAP. 
2-(2-Methyl-allyl)-isoindole-1,3-dione (114a) and 2-allyl-isoindole-1,3-dione (127a) were 
synthesized according to published methods98. Allylic amines 301b-301d were synthesized by 
allylation of the corresponding amines. Homoallylic amines 310e and 301f were prepared by 
homoallylation of the corresponding amines with 4-bromobutene. Benzhydrylidene protected 
aryl hydrazines99,100 and N-Boc-arylhydrazines101 were prepared according to published 
methods. 2,2'-Bis(allyloxy)-1,1'-binaphthyl (502) was donated by GORAN ANGELOVSKI. 
Polystyrene resins 802, 803, 804, 820 and 823 were donated by MATTHIAS MENTEL. 
                                               
90 Wuts, P.G.M.; Ashford, S.W.; Anderson, A.M.; Atkins, J.R.; Org. Lett. 2003, 5, 9, 1483-1485. 
91 Giordano, G.; Crabtree, R.; Inorg. Chem. 1979, 19, 218-219. 
92 Giordano, G.; Crabtree, R.; Inorg. Chem. 1979, 19, 218-219. 
93 Herde, J.L.; Lambert, J.C.; Senoff, C.V.; Inorg. Synth. 1974, 15, 18. 
94 Cuny, G.D.; Buchwald, S.L.; J. Am. Chem. Soc. 1993, 115, 2066-2068. 
95 Herrmann, W.A.; Kulpe, J.A.; Konkol, W.; Bahrmann, H.; J. Organom. Chem. 1990, 389, 1, 85-101. 
96 Mul, W.P.; Ramkisoensing, K.; Kramer, P.C.J.; Reek, J.N.H.; Linden, A.J. van der; Marson, A.; Leeuwen, 
P.W.N.M. van; Adv. Synth. Catal.2002, 3, 293-298. 
97 Alexakis, A.; Rosset, S.; Allamand, J.; March, S.; Guillen, F.; Benhaim, C.; Synlett 2001, 1375. 
98 Delogu, G.; Faedda, G.; Gladiali, S.; J. Organomet. Chem. 1984, 268, 167-174. 
99 a) Wagaw, S.; Yang, B. H.; Buchwald, S. L.; J. Am. Chem. Soc. 1998, 120, 6621-6622. b) Wagaw, S.; Yang, 
B. H.; Buchwald, S. L.; J. Am. Chem. Soc. 1998, 121, 10251-10263. 
100 Köhling, P.; Schmidt, A.M.; Eilbracht, P.; Org. Lett. 2003, 5, 3213-3216. 
101 Wolter, M.; Klapars, A.; Buchwald, S.; Org. Lett. 2001, 3, 3803-3805. 
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10.2 GENERAL METHODS 
1H-NMR and 13C-NMR spectra were measured on a BRUKER Advance DRX 400 
spectrometer or a BRUKER Advance DRX 500 spectrometer using CHCl3 or CH2Cl2 as 
internal standard. All samples were dissolved in CDCl3. IR spectra were measured on a 
NICOLET Impact 400D FT-IR spectrometer. Column chromatography was carried out on 
70-230 mesh silica gel (MACHEREY-NAGEL;silicagel 60). Optical rotation was determined on 
a PERKIN Elmer 341. Elemental analyses were performed on a LECO CHNS-932. High 
resolution mass analyses were performed on a JEOL JMS-SX 102A. Fluorescence 
measurements were performed on a SPEX Fluoromax-3 spectrofluorometer (JOBINYVON, 
Edison, NJ, USA) in a 1ml quartz cuvette (HELLMA). Reaction under pressure were carried 
out in a magnetically stirred BERGHOF type A (250ml, 4 glass vials a 20ml) pressure vessel, a 
comparable house made autoclave (100ml) or in a PARR autoclave. 
10.3 EXPERIMENTS IN CHAPTER 2 
10.3.1 GENERAL PROCEDURE FOR THE HYDROFORMYLATION 
4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-butyraldehyde (221a/222a). A typical procedure 
is described. 2-Allyl-isoindole-1,3-dione (86 mg, 0.50 mmol), Rh(acac)(CO)2 (0.38 mg, 
0.30 mol%) and XANTPHOS (see table entries) were dissolved in anhydrous THF (0.78 g, 
10 wt% olefin), filled in an autoclave and pressurized with 10bar H2 and 10bar CO. After 
stirring for 20 hours at 70°C the solvent was removed and the crude product (containing n- 
and iso-regioisomers) was analyzed by NMR. n-regioisomer: 1H-NMR: (CDCl3, 500 MHz) 
d = 1.95 (t, 2H, J = 7.2 Hz, CH2); 2.48 (t, 2H, J = 7.2 Hz, CH2); 3.67 (t, 2H, J = 7.0 Hz, CH2); 
7.67 (d, 2H, J = 5.2 Hz, 2xCH); 7.77 (d, 2H, J = 5.2 Hz, 2xCH); 9.71 (bs, 1H, CH). 
13C-NMR: (CDCl3, 125 MHz) d = 21.0 (CH2); 37.0 (CH2); 40.9 (CH2); 123.1 (2xCH); 131.9 
(2xC); 133.9 (2xCH); 168.2 (2xC); 200.8 (CH). Characteristic data for the iso-regioisomer: 
1H-NMR: (CDCl3, 500 MHz) d = 1.11 (d, 3H, J = 7.2 Hz, CH3); 2.84 (sext*, 1H, J = 6.7 Hz, 
CH); 3.76 (dd, 1H, J = 6.5 Hz, J = 14.2 Hz, CHH); 3.97 (dd, 1H, J = 7.1Hz, J = 14.2 Hz, 
CHH); 9.68 (d, 1H, J = 1.0 Hz, CH). 13C-NMR: (CDCl3, 125 MHz) d = 11.5 (CH3); 38.0 
(CH2); 45.7 (CH); 123.3 (2xCH); 134.0 (2xCH); 202.1 (CH). Analytical data fits with 
literature102. 
3-Methyl-4-(1,3-dioxoisoindolin-2-yl)butanal (212). The general procedure was followed 
with 2-(2-methylallyl)isoindoline-1,3-dione (1.00 g, 5.00 mmol), Rh(acac)(CO)2 (4.0 mg, 
                                               
102 Delugo, G.; Faedda, G.; Gladiali, S.; J. Organomet. Chem.1984, 268, 167-174. 
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0.3 mol-%), 10bar H2 and 50bar CO. After stirring for 20 hours at 100°C the solvent is 
removed to give 3-methyl-4-(1,3-dioxoisoindolin-2-yl)butanal (1.16 g, 100 %) without further 
purification. Analytical data fits with literature103. 
N-Ethyl-4-methyl-N-(4-oxo-butyl)-benzenesulfonamide (221e/222e). The general 
procedure was followed with N-allyl-N-ethyl-4-methyl-benzenesulfonamide (222 mg, 
0.93 mmol), Rh(acac)(CO)2 (0.72 mg, 0.30 mol%) and XANTPHOS (see table entries) to 
give a mixture of n-aldehyde and iso-aldehyde, which was analyzed by NMR. n-regioisomer: 
1H-NMR: (CDCl3, 400 MHz) d = 1.06 (t, 3H, J = 7.3 Hz, CH3); 1.84 (p, 2H, J = 7.0 Hz, 
CH2); 2.38 (s, 3H, CH3); 2.55 (t, 2H, J = 7.3 Hz, CH2); 3.10 (t, 2H, J = 7.0 Hz, CH2); 3.17 (q, 
2H, J = 7.0 Hz, CH2); 7.25 (d, 2H, J = 8.3 Hz, 2xCH); 7.63 (d, 2H, J = 8.3 Hz, 2xCH); 9.76 
(bs, 1H, CH). 13C-NMR: (CDCl3, 100 MHz) d = 13.9 (CH3); 21.1 (CH2); 21.4 (CH3); 40.6 
(CH2); 43.0 (CH2); 46.6 (CH2); 127.0 (2xCH); 129.7 (2xCH); 136.8 (C); 143.2 (C); 201.5 
(CH). Characteristic data for the iso-regioisomer: 1H-NMR: (CDCl3, 400 MHz) d = 1.03 (t, 
3H, J = 7.3 Hz, CH3); 1.14 (d, 3H, J = 7.3 Hz, CH3); 2.37 (s, 3H, CH3); 2.78 (m, 1H, CH); 
3.10 (t, 2H, J = 7.0 Hz, CH2); 3.17 (q, 2H, J = 7.0 Hz, CH2); 7.19 (d, 2H, J = 8.3 Hz, 2xCH); 
7.77 (d, 2H, J = 8.3 Hz, 2xCH); 9.67 (d, 1H, J = 1.8 Hz, CH). 13C-NMR: (CDCl3, 100 MHz) 
d = 12.0 (CH3); 13.9 (CH3); 21.4 (CH3); 43.9 (CH2); 46.1 (CH); 48.1 (CH2); 127.2 (2xCH); 
129.7 (2xCH); 136.8 (C); 143.2 (C). (CH) not detectable. IR: n~  [cm-1] = 2935 (s); 2727 (m); 
1724 (vs); 1596 (s); 1336 (vs); 1157 (vs); 1089 (vs); 730 (vs); 549 (vs). HRMS found [M+H]+ 
270.1190, C13H19NO3S requires [M+H]+, 270.1164. 
N-Ethyl-N-(4-oxo-butyl)-acetamide (221f/222f). The general procedure was followed with 
N-allyl-N-ethyl-4-methyl-acetamide (162 mg, 1.27 mmol), Rh(acac)(CO)2 (0.98 mg, 
0.30 mol%) and XANTPHOS (see table entries) to give a mixture of n-aldehyde and iso-
aldehyde, which was analyzed by NMR. n-regioisomer: 1H-NMR: (CDCl3, 500 MHz) 
d = 1.03, 0.96 (2t, 3H, J = 7.2 Hz, CH3); 1.71 (m, 2H, CH2); 1.93, 1.94 (2s, 3H, CH3); 2.33, 
2.38 (2t, 2H, J = 7.0 Hz, CH2); 3.10-3.24 (4H, 2xCH2); 9.62, 9.65 (2bs, 1H, CH). 13C-NMR: 
(CDCl3, 125 MHz) d = 13.7, 12.7 (CH3); 20.1, 21.0 (CH2); 21.1, 21.2 (CH3); 43.0, 40.9 
(CH2); 44.0, 40.1 (CH2); 47.1 (CH2); 170.0 (C); 201.5, 200.6 (CH). Characteristic data for 
the iso-regioisomer: 1H-NMR: (CDCl3, 500 MHz) d = 2.59, 2.64 (2m, 1H, CH); 3.51, 3.54 
(2d, 2H, J = 8.5 Hz, CH2); 9.48, 9.59 (2d, 1H, J = 1.8 Hz, CH). 13C-NMR: (CDCl3, 125 MHz) 
d = 11.6 (CH3); 45.8 (CH); 46.1 (CH2); 202.9 (CH). IR: n
~
 [cm-1] = 2935 (s); 2726 (m); 1722 
                                               
103 Ahman, J.; Somfai, P.; Tetrahedron 1992, 48, 9537-9544. 
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(vs); 1644 (vs); 1459 (s); 1425 (vs); 1376 (s); 1278 (s); 1035 (m); 794 (m). HRMS found 
[M+H]+ 158.1210, C8H15NO2 requires [M+H]+, 158.1181.  
Ethyl-(4-oxo-butyl)-carbamic acid ethyl ester (221g/222g). The general procedure was 
followed with allyl-ethyl-carbamic acid ethyl ester (84 mg, 0.53 mmol), Rh(acac)(CO)2 
(0.41 mg, 0.30 mol%) and XANTPHOS (see table entries) to give a mixture of n-aldehyde 
and iso-aldehyde, which was analyzed by NMR. n-regioisomer: 1H-NMR: (CDCl3, 500 MHz) 
d = 1.04 (t, 3H, J = 7.0 Hz, CH3); 1.17 (t, 3H, J = 7.0 Hz, CH3); 1.78 (t, 2H, J = 7.1 Hz, CH2); 
2.40 (m, 2H, CH2); 3.19 (bs, 4H, 2xCH2); 4.05 (q, 2H, J = 7.0 Hz, CH2); 9.70 (bs, 1H, CH). 
13C-NMR: (CDCl3, 125 MHz) d = 13.9, 13.6 (CH3); 14.5 (CH3); 20.8 (CH2); 40.9 (CH2); 41.6 
(CH2); 45.9, 45.2 (CH2); 60.9 (CH2); 201.5 (CH). (C) not detectable. Characteristic data for 
the iso-regioisomer: 1H-NMR: (CDCl3, 500 MHz) d = 9.59 (d, 1H, J = 2.0 Hz, CH). 
13C-NMR: (CDCl3, 125 MHz) d = 11.6 (CH3). IR: n
~
 [cm-1] = 2977 (s); 2933 (m); 2722 (w); 
1697 (vs); 1479 (s); 1425 (s); 1276 (s); 1189 (s); 1147 (m); 1074 (m); 1025 (m); 771 (m). 
HRMS found [M+H]+ 188.1290, C9H18NO3 requires [M+H]+, 188.1287. 
10.3.2 GENERAL PROCEDURE FOR THE TANDEM HYDROFORMYLATION / HYDRAZONE 
FORMATION 
2-[4-(Phenyl-hydrazono)-butyl]-isoindole-1,3-dione (224a/225a). A typical procedure is 
described. 2-Allyl-isoindole-1,3-dione (967 mg, 5.17 mmol), phenylhydrazine (557 mg, 
5.17 mmol), Rh(acac)(CO)2 (0.38 mg, 0.30 mol%) and XANTPHOS (see table entries) were 
dissolved in anhydrous THF (8.70 g, 10 wt% olefin), filled in an autoclave and pressurized 
with 10bar H2 and 10bar CO. After stirring for 68 hours at 70°C the solvent was removed and 
the crude product (containing n- and iso-regioisomers) was analyzed by NMR. Analytical 
data was obtained from an inseparable mixture of E/Z & n/iso-isomers. n-regioisomer: 1H-
NMR: (CDCl3, 500 MHz) d = 1.96 (m, 2H, J = 7.2 Hz, CH2); 2.36, 2.27 (dt, 2H, J = 5.2 Hz, 
J = 7.5 Hz, CH2); 3.78 (t, 2H, J = 7.0 Hz, CH2); 6.77, 6.82 (dd, 1H, J = 7.2 Hz, J = 7.5 Hz, 
CH); 6.91, 7.01 (d, 2H, J = 7.5 Hz, 2xCH); 7.05, 6.45 (t, 1H, J = 5.2 Hz, CH); 7.18 (dd, 1H, 
J = 8.5 Hz, J = 8.5 Hz, 2xCH); 7.23 (s, 1H, NH); 7.65 (d, 2H, J = 5.3 Hz, 2xCH); 7.81 (d, 2H, 
J = 5.3 Hz, 2xCH). 13C-NMR: (CDCl3, 125 MHz) d = 25.6 (CH2); 29.5 (CH2); 37.4 (CH2); 
112.3 (2xCH); 119.4 (CH); 123.2 (2xCH); 129.0 (CH); 129.1 (CH); 132.0 (2xC); 133.9 
(2xCH); 139.2, 141.6 (CH); 144.9 (C); 168.4 (2xC). Characteristic data for the 
iso-regioisomer: 1H-NMR: (CDCl3, 500 MHz) d = 1.17 (d, 3H, J = 7.0 Hz, CH3); 2.96 (m, 
1H, J = 7.0 Hz, CH); 6.35 (d, 1H, J = 6.5 Hz, CH); 7.47 (s, 1H, NH); 7.71-7.73 (2H, 2xCH2); 
7.86-7.88 (2H, 2xCH). 13C-NMR: (CDCl3, 125 MHz) d = 16.0 (CH3); 36.2 (CH); 112.9 
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(2xCH); 120.1 (CH); 123.5 (2xCH). IR: n~  [cm-1] = 3315 (s); 2966 (s); 1770 (vs); 1722 (vs); 
1600 (s); 1398 (s); 1259 (s); 1066 (m); 750 (m); 723 (m). HRMS found [M]+ 307.1349, 
C18H17N3O2 requires [M]+, 307.1321. 
N-Ethyl-4-methyl-N-[4-(phenyl-hydrazono)-butyl]-benzenesulfonamide (224b/225b). 
The general procedure was followed with N-allyl-N-ethyl-4-methyl-benzenesulfonamide 
(349 mg, 1.46 mmol), phenylhydrazine (158 mg, 1.46 mmol), Rh(acac)(CO)2 (1.13 mg, 
0.30 mol%) and XANTPHOS (see table entries) to give an inseparable mixture of E/Z & 
n/iso-isomers, which was analyzed by NMR. n-regioisomer: 1H-NMR: (CDCl3, 400 MHz) 
d = 1.08 (t, 3H, J = 7.1 Hz, CH3); 2.29 (dt, 2H, J = 5.1 Hz, J = 7.3 Hz, CH2); 2.37 (s, 3H, 
CH3); 3.13-3.23 (4H, 2xCH2); 6.78 (dd, 1H, J = 7.3 Hz, J = 8.3 Hz, CH); 6.93 (d, 2H, 
J = 9.5 Hz, 2xCH); 7.17, 6.65 (t, 1H, J = 5.1 Hz, CH); 7.19 (dd, 2H, J = 7.3 Hz, J = 8.3 Hz, 
2xCH); 7.23 (s, 1H, NH); 7.24 (d, 2H, J = 8.2 Hz, 2xCH); 7.65 (d, 2H, J = 8.2 Hz, 2xCH). 
13C-NMR: (CDCl3, 100 MHz) d = 14.0 (CH3); 21.4 (CH3); 26.0 (CH2); 29.1 (CH2); 42.9 
(CH2); 47.0 (CH2); 112.4, 112.9 (2xCH); 119.4, 120.0 (CH); 127.0 (2xCH); 129.1 (2xCH); 
129.6 (2xCH); 136.9 (C); 139.6, 142.2 (CH); 143.0 (C); 145.3 (C). Characteristic data for the 
iso-regioisomer: 1H-NMR: (CDCl3, 400 MHz) d = 1.11 (d, 3H, J = 7.0 Hz, CH3); 2.76 (m, 
1H, J = 7.0 Hz, CH); 3.09 (dd, 1H, J = 6.8 Hz, J = 13.8 Hz, CHH); 3.30 (dd, 1H, J = 8.5 Hz, 
J = 13.8 Hz, CHH); 6.24 (d, 1H, J = 7.3 Hz, CH). 13C-NMR: (CDCl3, 100 MHz) d = 16.2 
(CH3); 35.6 (CH); 43.2 (CH2); 51.4 (CH2); 115.1 (2xCH); 136.5 (C); 139.1 (CH). IR: n
~
 [cm-
1] = 3399 (m); 2923 (m); 2856 (m); 1598 (m); 1455 (m); 1332 (m); 1153 (s); 1089 (m); 742 
(m). HRMS found [M]+ 359.1689, C19H25N3O2S requires [M]+ 359.1667. 
N-Ethyl-N-[4-(phenyl-hydrazono)-butyl]-acetamide (224c/225c). The general procedure 
was followed with N-allyl-N-ethyl-4-acetamide (276 mg, 2.17 mmol), phenylhydrazine 
(235 mg, 2.17 mmol), Rh(acac)(CO)2 (1.68 mg, 0.30 mol%) and XANTPHOS (see table 
entries) to give an inseparable mixture of E/Z & n/iso-isomers, which was analyzed by NMR. 
n-regioisomer: 1H-NMR: (CDCl3, 500 MHz) d = 1.15, 1.10 (t, 3H, J = 7.1 Hz, CH3); 1.79 (m, 
2H, J = 7.8 Hz, CH2); 2.07, 2.08 (s, 3H, CH3); 2.27 (dt, 2H, J = 5.2 Hz, J = 7.2 Hz, CH2); 3.29 
(t, 2H, J = 7.2 Hz, CH2); 3.36 (q, 2H, J = 7.2 Hz, CH2); 6.78 (dd, 1H, J = 7.5 Hz, J = 8.0 Hz, 
CH); 6.95 (d, 2H, J = 8.0 Hz, 2xCH); 7.05, 6.45 (t, 1H, J = 5.2 Hz, CH); 7.20 (dd, 2H, 
J = 7.2 Hz, J = 7.5 Hz, 2xCH); 7.53, 7.67 (s, 1H, NH). 13C-NMR: (CDCl3, 100 MHz) 
d = 13.9, 12.8 (CH3); 21.3 (CH3); 24.9, 25.6 (CH2); 29.4, 29.0 (CH2); 43.3, 40.3 (CH2); 44.6, 
47.6 (CH2); 112.3 (2xCH); 119.1, 119.4 (CH); 129.0, 129.1 (2xCH); 140.1, 138.9 (CH); 145.4 
(C); 170.0 (C). Characteristic data for the iso-regioisomer: 1H-NMR: (CDCl3, 500 MHz) 
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d = 2.77 (m, 1H, J = 6.7 Hz, CH); 3.16 (dd, 1H, J = 6.2 Hz, J = 13.7 Hz, CHH); 3.63 (dd, 1H, 
J = 9.3 Hz, J = 13.7 Hz, CHH); 6.19 (d, 1H, J = 6.7 Hz, CH). 13C-NMR: (CDCl3, 100 MHz) 
d = 16.1 (CH3); 35.8 (CH); 143.0 (CH). HRMS found [M]+ 247.1702, C14H21N3O requires 
[M]+ 247.1685. 
2-[2-Methyl-4-(phenyl-hydrazono)-butyl]-isoindole-1,3-dione (213). The general 
procedure was followed with 2-(2-methylallyl)-isoindoline-1,3-dione (3.131 mg, 
15.56 mmol), phenylhydrazine (1.682 mg, 15.56 mmol), Rh(acac)(CO)2 (40 mg, 1.0 mol%), 
10bar H2 and 50bar CO. After stirring for 68 hours at 100°C the solvent was removed and the 
crude product, containing an inseparable mixture of E/Z isomers, was analyzed by NMR. 
1H-NMR: (CDCl3, 500 MHz) d = 0.98, 1.05 (d, 3H, J = 6.6 Hz, CH3); 2.18-2.37 (3H, CH2, 
CH); 3.56 (dd, 1H, J = 7.0 Hz, J = 13.7 Hz, CHH); 3.63 (dd, 1H, J = 6.7 Hz, J = 13.7 Hz, 
CHH); 6.76, 6.82 (dd, 1H, J = 8.0 Hz, J = 8.0 Hz, CH); 6.90, 7.00 (d, 2H, J = 8.3 Hz, CH); 
7.02 (t, 1H, J = 5.0 Hz, CH); 7.16, 7.20 (dd, 2H, J = 8.0 Hz, J = 8.3 Hz, 2xCH); 7.32, 7.44 (s, 
1H, NH); 7.64, 7.67 (d, 2H, J = 5.5 Hz, 2xCH); 7.77, 7.80 (d, 2H, J = 5.5 Hz, 2xCH). 
13C-NMR: (CDCl3, 125 MHz) d = 17.8, 18.0 (CH3); 31.0, 31.1 (CH); 36.9 (CH2); 43.5 (CH2); 
112.3, 112.9 (2xCH); 119.3 (CH); 123.1 (2xCH); 129.0 (2xCH); 131.8 (2xC); 133.8, 134.0 
(2xCH); 138.6, 138.3 (CH); 145.1 (C); 168.5 (2xC). IR: n~  [cm-1] = 3315 (s); 2964 (vs); 2873 
(s); 1772 (vs); 1600 (s); 1497 (vs); 1257 (vs); 1058 (s); 912 (s). HRMS found [M]+ 321.1472, 
C19H19N3O2 requires [M]+ 321.1477. 
10.3.3 GENERAL PROCEDURE FOR THE TANDEM HYDROFORMYLATION / FISCHER 
INDOLE SYNTHESIS FOLLOWED BY TOSYLATION OF THE CRUDE PRODUCT 
2-{2-[1-(Toluene-4-sulfonyl)-1H-indol-3-yl]-propyl}-isoindole-1,3-dione (215a). A 
typical procedure is described. 2-(2-methylallyl)isoindoline-1,3-dione (0.66 g, 3.3 mmol), 
phenylhydrazine (0.36 g, 3.3 mmol), Rh(acac)(CO)2 (16 mg , 1 mol%) and PTSA (0.63 g, 
3.3 mmol) were dissolved in anhydrous toluene (12g), filled in an autoclave and pressurized 
with 10bar H2 and 10bar CO. After stirring for 2 days at 120°C the mixture was poured into a 
suspension of Bu4NHSO4 (0.1 g) in toluene (15 ml) and NaOH (10 g, 50wt% in water). 
Tosylchloride (0.69 g, 3.6 mmol) in toluene (15 ml) was dropped to the mixture within 
10 minutes. After stirring for 1 hour the layers were separated and the organic layer was 
extracted 3 times with EtOAc. The solvent was evaporated and the residue was purified by 
flash chromatography on silica to give 2-{2-[1-(toluene-4-sulfonyl)-1H-indol-3-yl]-propyl}-
isoindole-1,3-dione (0.91 g, 60%) 1H-NMR: (CDCl3, 400MHz) d = 1.24 (d, 3H, J = 7.0 Hz, 
CH3), 2.16 (s, 3H, CH3), 3.43 (m, 1H, CH), 3.64 (dd, 1H, J = 8.9 Hz, J = 13.8 Hz, CHH), 3.88 
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(dd, 1H, J = 6.1 Hz, J = 13.8 Hz, CHH), 7.03 (d, 1H, J = 8.3 Hz, CH), 7.09-7.22 (2H, 2xCH), 
7.38 (s, 1H, CH), 7.56 – 7.68 (8H, 8xCH), 7.84 (d, 1H, J = 8.3 Hz, CH). 13C-NMR: (CDCl3, 
100MHz) d = 17.7 (CH3), 21.3 (CH3), 29.9 (CH), 43.4 (CH2), 113.5 (CH), 119.7 (CH), 122.2 
(2xCH), 123.0 (2xCH), 124.6 (CH), 124.7 (C), 126.6 (2xCH), 127.7 (CH), 129.6 (2xCH), 
130.0 (C), 131.7 (C), 133.8 (2xCH), 135.0 (2xC), 144.6 (C), 168.2 (2xC, C not observed. IR: 
n~  [cm-1] = 2966 (s), 2933 (s), 1770 (vs), 1718 (vs), 1398 (vs), 1184 (vs), 1132 (vs), 717 (vs), 
671 (vs). MS (EI, 70eV): m/z (%) = 458 (M+, 22), 298 (100), 200 (25), 160 (51), 155 (60), 
106 (31), 91 (91). HRMS found M+ 458.1314, C26H22N2O4S requires M+, 458.1300. 
Elementary analysis found C 67.30%, H 4.60%, N 5.90%, C26H22N2O4S requires C 68.11%, 
H 4.84%, N 6.11%. 
2-{2-[5-Chloro-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-propyl}-isoindole-1,3-dione 
(215b). The general procedure was followed with 2-(2-methylallyl)isoindoline-1,3-dione 
(1.3 g, 6.5 mmol), 4-chloro-phenylhydrazine (0.92 g, 6.5 mmol), [Rh(cod)Cl]2 (32 mg, 
1 mol%) and PTSA (1.23 g, 6.5 mmol) to give 2-{2-[5-chloro-1-(toluene-4-sulfonyl)-1H-
indol-3-yl]-propyl}-isoindole-1,3-dione (0.82 g, 53 %). 1H-NMR: (CDCl3, 500MHz) d = 1.37 
(d, 3H, J = 7.0 Hz, CH3), 2.35 (s, 3H, CH3), 3.52 (m, 1H, CH), 3.78 (dd, 1H, J = 8.6 Hz, 
J = 13.6 Hz, CHH), 3.98 (dd, 1H, J = 6.4 Hz, J = 13.6 Hz, CHH), 7.21 (d, 1H, J = 8.2 Hz, 
CH), 7.26 (d, 1H, J = 8.7 Hz, CH), 7.52 (s, 1H, CH), 7.69 (s, 1H, CH), 7.73-7.75 (4H, 4xCH), 
7.83-7.88 (4H, 4xCH). 13C-NMR: (CDCl3, 125MHz) d = 17.9 (CH3), 21.5 (CH3), 29.9 (CH), 
43.5 (CH2), 114.7 (CH), 119.5 (CH), 123.3 (2xCH), 124.3 (C), 125.0 (CH), 126.7 (2xCH), 
129.0 (CH), 129.1 (C), 129.9 (2xCH), 131.4 (C), 131.8 (C), 133.5 (C), 134.0 (2xCH), 145.0 
(2xC), 168.3 (2xC), C not observed. 
2-{2-[5-t-Butyl-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-propyl}-isoindole-1,3-dione 
(215c). The general procedure was followed with 2-(2-methylallyl)isoindoline-1,3-dione 
(0.27 g, 1.3 mmol), 4-tert-butyl-phenylhydrazine (0.22 g, 1.3 mmol), Rh(acac)(CO)2 (14 mg, 
1 mol%) and PTSA (0.25 g, 1.3 mmol) to give of 2-{2-[5-t-butyl-1-(toluene-4-sulfonyl)-1H-
indol-3-yl]-propyl}-isoindole-1,3-dione (0.32 g, 48 %). 1H-NMR: (CDCl3, 400MHz) d = 1.20 
(s, 9H, 3xCH3), 1.26 (d, 3H, J = 6.8 Hz, CH3), 2.15 (s, 3H, CH3), 3.44 (m, 1H, CH3), 3.64 (dd, 
1H, J = 8.5 Hz, J = 13.5 Hz, CHH), 3.86 (dd, 1H, J = 6.2 Hz, J = 13.5 Hz, CHH), 7.03 (d, 2H, 
J = 8.6 Hz, 2xCH) 7.23 (d, 1H, J = 8.8 Hz, CH), 7.54 (s, 1H, CH), 7.53-7.55 (2H, 2xCH), 
7.62-7.67 (4H, CH), 7.66 (d, 2H, J = 8.6 Hz, 2xCH). 13C-NMR: (CDCl3, 100MHz) d = 17.7 
(CH3), 21.3 (CH3), 26.7 (C), 29.7 (CH), 31.5 (3xCH3), 43.6 (CH2), 112.9 (CH), 115.6 (CH), 
122.1 (CH), 122.6 (CH) 123.0 (2xCH), 124.9 (C), 126.6 (2xCH), 129.6 (2xCH), 129.9 (C), 
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131.7 (2xC), 133.0 (C), 133.8 (2xCH), 135.2 (C), 144.4 (C), 146.1 (C), 168.5 (2xC). IR: n~  
[cm-1] = 2962 (s), 2870 (m), 1772 (s), 1713 (vs), 1398 (vs), 1398 (vs), 1369 (vs), 1173 (vs). 
HRMS found M+, 514.1946, C30H30SN2O4 requires M+, 514.1926. Elementary analysis found 
C 69.10%, H 5.70%, N 5.40%, C30H30SN2O4 requires C 70.02%, H 5.88%, N 5.44%. 
10.3.4 GENERAL PROCEDURE FOR THE TANDEM HYDROFORMYLATION / FISCHER 
INDOLE SYNTHESIS USING BENZHYDRYLIDENE PROTECTED ARYL HYDRAZINES 
2-[2-(1H-Indol-3-yl)-propyl]-isoindole-1,3-dione (215d). A typical procedure is described. 
2-(2-methylallyl)isoindoline-1,3-dione (1.32 g, 6.60 mmol), N-benzhydrylidene-
N'-phenylhydrazine (1.79 g, 6.60 mmol), [Rh(cod)Cl]2 (32 mg, 1 mol% and PTSA (1.25 g, 
6.60 mmol) were dissolved in anhydrous THF (11 g, 10 wt% olefin), filled in an autoclave 
and pressurized with 10bar H2 and 10bar CO. After stirring for 3 days at 100°C the mixture 
was filtered through a pad of alumina and the solvent was evaporated to give the crude 
product (3.16g). 1.06g crude product were purified by flash chromatography on silica to give 
2-[2-(1H-indol-3-yl)-propyl]-isoindole-1,3-dione (0.56 g, 83%). 1H-NMR: (CDCl3, 400MHz) 
d = 1.44 (d, 3H, J = 7.0 Hz, CH3), 3.73 (m, 1H, CH), 3.87 (dd, 1H, J = 9.0 Hz, J = 13.3 Hz, 
CH2), 4.09 (dd, 1H, J = 6.3 Hz, J = 13.3 Hz, CH2), 7.13-7.24 (3H, 3xCH), 7.37 (d, 1H, J = 8.0 
Hz, CH), 7.70-7.87 (5H, 5xCH), 8.31 (s, 1H, NH). 13C-NMR: (CDCl3, 100MHz) d = 18.4 
(CH3), 30.0 (CH), 44,5 (CH2), 111.1 (CH), 118.3 (C), 119.1 (CH), 119.2 (CH), 120.6 (CH), 
121.9 (2xCH), 123.0 (2xCH), 126.7 (C), 131.9 (C), 133.8 (CH), 136.2 (2xC), 168.6 (2xC). IR: 
n~  [cm-1] = 3406 (s), 2962 (m), 2931 (m), 1770 (vs), 1712 (vs), 1398 (vs), 1034 (s), 714 (vs). 
HRMS found M+, 304.1219, C19H16N2O2 requires M+, 304.1212. 
2-(2-(5-fluoro-1H-indol-3-yl)propyl)isoindoline-1,3-dione (215e). The general procedure 
was followed with 2-(2-methylallyl)isoindoline-1,3-dione (0.62 g, 3.1 mmol), 
N-benzhydrylidene-N'-(4-fluoro-phenyl)-hydrazine (0.90 g, 3.1 mmol), Rh(acac)(CO)2 (8 mg, 
1 mol%) and PTSA (0.59 g, 3.1 mmol) to give 2-[2-(5-fluoro-1H-indol-3-yl)-propyl]-
isoindole-1,3-dione (0.47 g, 47 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.37 (d, 3H, J = 7.0 Hz, 
CH3); 3.59 (m, 1H, J = 7.0 Hz, CH); 3.79 (dd, 1H, J = 8.7 Hz, J = 13.5 Hz, CHH); 3.97 (dd, 
1H, J = 6.7 Hz, J = 13.5 Hz, CHH); 6.88 (dd, 1H, J = 9.0 Hz, J = 9.0 Hz, CH); 7.13 (s, 1H, 
CH); 7.23 (dd, 1H, J = 9.0 Hz, J = 9.0 Hz, CH); 7.41 (d, 1H, J = 9.7 Hz, CH); 7.67-7.69 (2H, 
2xCH); 7.78-7.80 (2H, 2xCH); 8.10 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 18.4 
(CH3); 30.0 (CH); 44.4 (CH2); 104.1 (d, 1C, JC-F = 23 Hz, CH); 110.3 (d, 1C, JC-F = 25 Hz, 
CH); 111.7 (d, 1C, JC-F = 10 Hz, CH); 116.2 (C); 118.7 (C); 122.3 (CH); 123.1 (2xCH); 132.0 
(2xC); 133.9 (2xCH); 157.7 (d, 1C, JC-F = 234 Hz, C); 168.6 (2xC). IR: n
~
 [cm-1] = 3392 (m); 
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2964 (w); 2933 (w); 1770 (w); 1708 (vs); 1486 (s); 1398 (vs); 1153 (m); 1033 (m). HRMS 
found M+, 323.1145, C19H15FN2O2 requires M+, 323.1118. Elementary analysis found 
C 70.38%, H 5.02%, N 8.30%, C19H15FN2O2 requires C 70.80%, H 4.69%, N 8.69%. 
2-[2-(5-Chloro-1H-indol-3-yl)-propyl]-isoindole-1,3-dione (215f). The general procedure 
was followed with 2-(2-methylallyl)isoindoline-1,3-dione (0.92 g, 4.6 mmol), 
N-benzhydrylidene-N'-(4-chloro-phenyl)-hydrazine (1.40 g, 4.6 mmol), [Rh(cod)Cl]2 (22 mg, 
1 mol%) and PTSA (0.87 g, 4.6 mmol) to give 2-[2-(5-chloro-1H-indol-3-yl)-propyl]-
isoindole-1,3-dione (0.58 g, 78 %). 1H-NMR: (CDCl3, 400MHz) d = 1.41 (d, 3H, J = 7.0 Hz, 
CH3), 3.63 (m, 1H, CH), 3.8 (dd, 1H, J = 8.3 Hz, J = 13.6 Hz, CHH), 4.00 (dd, 1H, 
J = 6.8 Hz, J = 13.6 Hz, CHH), 7.09 (d, 1H, J = 8.2 Hz, CH), 7.14 (s, 1H CH), 7.24 (m, 1H, 
CH), 7.69-7.72 (3H, 3xCH), 7.81-7.83 (2H, 2xCH), 8.31 (bs, 1H, NH). 13C-NMR: (CDCl3, 
100MHz) d = 18.4 (CH3), 29.9 (CH), 44.5 (CH2), 112.12 (CH), 118.24 (C), 118.5 (CH), 122.0 
(CH), 122.2 (CH), 123.1 (2xCH), 125.0 (C), 128.0 (C), 131.8 (C), 133.9 (2xCH), 134.5 
(2xC), 168.6 (2xC). IR: n~  [cm-1] = 3383 (m), 2964 (w), 2360 (w), 1765 (s), 1705 (vs), 1466 
(s), 1429 (s), 1398 (vs), 1032 (s), 717 (s). HRMS found M+, 338.0802, C19H15N2O2Cl requires 
M+, 338.0822. Elementary analysis found C 66.90%, H 4.35%, N 8.10%, C19H15N2O2Cl 
requires C 67.36%, H 4.46%, N 8.27%. 
2-[2-(5-Bromo-1H-indol-3-yl)-propyl]-isoindole-1,3-dione (215g). The general procedure 
was followed with 2-(2-methylallyl)isoindoline-1,3-dione (0.79 g, 3.9 mmol), 
N-benzhydrylidene-N'-(4-bromo-phenyl)-hydrazine (1.38 g, 3.9 mmol), [Rh(cod)Cl]2 (19 mg, 
1 mol%) and PTSA (0.74 g, 3.9 mmol) to give 2-[2-(5-bromo-1H-indol-3-yl)-propyl]-
isoindole-1,3-dione (0.74 g, 50 %). 1H-NMR: (CDCl3, 400MHz) d = 1.36 (d, 3H, J = 6.9 Hz, 
CH3), 3.58 (m, 1H, CH), 3.79 (dd, 1H, J = 8.7 Hz, J = 13.8 Hz, CHH), 3.94 (dd, 1H, 
J = 6.2 Hz, J = 13.8 Hz, CHH), 7.08-7.16 (3H, 3xCH), 7.65-7.81 (5H, 5xCH), 8.27 (s, 1H, 
NH). 13C-NMR: (CDCl3, 100MHz) d = 18.4 (CH3), 29.8 (CH), 44.5 (CH2), 112.6 (CH), 112.6 
(C), 118.2 (C), 121.6 (CH), 121.8 (CH), 123.1 (2xCH), 124.8 (CH), 128.6 (C), 131.8 (C), 
133.9 (2xCH), 134.8 (2xC), 168.5 (2xC). IR: n~  [cm-1] = 3377 (s), 1770 (s), 1716 (vs), 1466 
(s), 1433 (s), 1398 (vs), 1354 (s), 1034 (s), 795 (s), 715 (vs). HRMS found M+, 382.0280, 
C19H15BrN2O2 requires M, 382.0317. Elementary analysis found C 59.75%, H 3.95%, 
N 7.35%, C19H15BrN2O2 requires C 59.55%, H 3.95%, N 7.31%. 
2-[2-(7-Methyl-1H-indol-3-yl)-propyl]-isoindole-1,3-dione (215h). The general procedure 
was followed with 2-(2-methylallyl)isoindoline-1,3-dione (0.95 g, 4.7 mmol), N-
benzhydrylidene-N'-o-tolyl-hydrazine (1.35 g, 4.7 mmol), [Rh(cod)Cl]2 (23 mg, 1 mol%) and 
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PTSA (0.90 g, 4.7 mmol) to give 2-[2-(7-Methyl-1H-indol-3-yl)-propyl]-isoindole-1,3-dione 
(0.72 g, 48 %). 1H-NMR: (CDCl3, 400MHz) d = 1.38 (d, 3H, J = 7.0 Hz, CH3), 2.45 (s, 3H, 
CH3), 3.68 (m, 1H, CH), 3.81 (dd, 1H, J = 8.9 Hz, J = 13.7 Hz, CHH), 4.05 (dd, 1H, 
J = 6.4 Hz, J = 13.7 Hz, CHH), 6.96-7.11 (3H, 3xCH), 7.66-7.82 (5H, 5xCH), 8.07 (bs, 1H, 
NH). 13C-NMR: (CDCl3, 100MHz) d = 16.5 (CH3), 18.5 (CH3), 30.2 (CH), 44.5 (CH2), 116.9 
(CH), 118.9 (C), 119.6 (CH), 120.2 (CH), 120.3 (C), 122.5 (CH), 123.1 (2xCH), 126.3 (C), 
132.0 (C), 133.8 (2xCH), 135.8 (2xC), 168.6 (2xC). IR: n~  [cm-1] = 3402 (s), 1770 (s), 1716 
(vs), 1466 (s), 1458 (s), 1433 (s), 1398 (vs), 1034 (s), 714 (vs). HRMS found M+, 318.1395, 
C20H18N2O2 require M+, 318.1368. Elementary analysis found C 75.30%, H 5.80%, N 8.20%, 
C20H18N2O2 requires C 75.45%, H 5.70%, N 8.80%. 
2-[2-(7-Chloro-1H-indol-3-yl)-propyl]-isoindole-1,3-dione (215i). The general procedure 
was followed with 2-(2-methylallyl)isoindoline-1,3-dione (0.93 g, 4.6 mmol), 
N-benzhydrylidene-N'-(2-chloro-phenyl)-hydrazine (1.41 g, 4.6 mmol), [Rh(cod)Cl]2 (23 mg, 
1 mol%) and PTSA (0.87 g, 4.6 mmol) to give 2-[2-(7-chloro-1H-indol-3-yl)-propyl]-
isoindole-1,3-dione (0.21 g, 42 %). 1H-NMR: (CDCl3, 400MHz) d = 1.38 (d, 3H, J = 7.0 Hz, 
CH3), 3.63 (m, 1H, CH), 3.80 (dd, 1H, J = 8.8 Hz , J = 13.8 Hz, CHH), 4.00 (dd, 1H, 
J = 6.5 Hz, J = 13.8 Hz, CHH), 7.00 (dd, 1H, J = 7.8 Hz, CH), 7.15 (s, 1H CH), 7.65-7.70 
(4H, 4xCH), 7.78-7.82 (2H, 2xCH), 8.38 (bs, 1H, NH). 13C-NMR: (CDCl3, 100MHz) d = 18.4 
(CH3), 30.2 (CH), 44.4 (CH2), 116.5 (C), 117.8 (CH), 119.5 (C), 120.1 (CH), 121.3 (2xCH), 
123.1 (2xCH), 128.3 (C), 131.9 (2xC), 133.5 (C), 133.9 (2xCH), 168.6 (2xC). 
IR: n~  [cm-1] = 3381(m), 1765 (m), 1705 (vs), 1398 (m), 1032 (m), 893 (m), 717 (m). HRMS 
found M+, 338.0844, C19H15ClN2O2 requires M, 338.0822. Elementary analysis found 
C 67.43%, H 4.07%, N 8.10%, C19H15ClN2O2 requires C 67.36%, H 4.46%, N 8.27%. 
10.3.5 GENERAL PROCEDURE FOR THE TANDEM HYDROFORMYLATION / FISCHER 
IINDOLE SYNTHESIS WITH SUBSEQUENT ADDITION OF ACID 
2-[2-(5-Methoxy-1H-indol-3-yl)-propyl]-isoindole-1,3-dione (215j). A typical procedure 
is described. 2-(2-Methylallyl)isoindoline-1,3-dione (301 mg, 1.50 mmol), a-Boc-1-(4-
methoxyphenyl)hydrazine (356 mg, 1.50 mmol) and Rh(acac)(CO)2 (1.16 mg , 0.03 mol%) 
were dissolved in anhydrous THF (2.71 g, 10 wt% olefin), filled in an autoclave and 
pressurized with 10bar H2 and 50bar CO. After stirring for 3 days at 120°C the mixture was 
poured into H2SO4 (15 ml, 4 wt% in THF) and the resulting mixture was stirred for additional 
2h under reflux. NH3 (10 ml, 30 wt% in water) was added and the mixture was extracted 3 
times with EtOAc. The solvent was evaporated and the residue was chromatographed 
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(EtOAc, cyclohexane, silica) to give 2-[2-(5-Methoxy-1H-indol-3-yl)-propyl]-isoindole-1,3-
dione (462 mg, 95%). 1H-NMR: (CDCl3, 500 MHz) d = 1.38 (d, 3H, J = 7.0 Hz, CH3); 3.60 
(m, 1H, J = 7.0 Hz, CH); 3.78 (dd, 1H, J = 9.0 Hz, J = 13.6 Hz, CHH); 3.85 (s, 3H, CH3); 
4.01 (dd, 1H, J = 6.2 Hz, J = 13.6 Hz, CHH); 6.79 (d, 1H, J = 8.7 Hz, CH); 7.07 (s, 1H, CH); 
7.19 (d, 1H, J = 8.7 Hz, CH); 7.27 (s, 1H, CH); 7.66 (d, 2H, J = 5.4 Hz, 2xCH); 7.78 (d, 2H, 
J = 5.4 Hz, 2xCH); 8.26 (s, 1H, NH). 13C-NMR: (CDCl3, 125MHz) d = 18.2 (CH3); 30.0 
(CH); 44.5 (CH2); 55.7 (CH3); 100.6 (CH); 111.9 (CH); 112.3 (CH); 118.1 (C); 121.3 (CH); 
123.0 (2xCH); 127.2 (C); 131.3 (C); 131.9 (2xC); 133.8 (2xCH); 153.8 (C); 168.6 (2xC). IR: 
n~  [cm-1] = 3399 (m); 1770 (m); 1700 (vs); 1484 (s); 1428 (m); 1398 (s); 1376 (m); 1216 (s); 
1157 (m); 1037 (s); 713 (s). HRMS found [M]+ 334.1299, C20H18N2O3 requires [M]+ 
334.1318. Elementary analysis found C 71.64%, H 5.38%, N 8.11%, C20H18N2O3 requires 
C 71.84%, H 5.43%, N 8.38%. 
N-Ethyl-N-[2-(1H-indol-3-yl)-propyl]-4-methyl-benzenesulfonamide (215k). The 
general procedure was followed with N-ethyl-4-methyl-N-(2-methyl-allyl)-
benzenesulfonamide (0.71 g, 2.8 mmol), phenylhydrazine (0.30 g, 2.8 mmol) and 
Rh(acac)(CO)2 (2.2 mg, 0.3 mol%) to give N-ethyl-N-[2-(1H-indol-3-yl)-propyl]-4-methyl-
benzenesulfonamide (0.94 g, 94 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.11 (t, 3H, J = 7.3 Hz, 
CH3); 1.50 (d, 3H, J = 6.5 Hz, CH3); 2.43 (s, 3H, CH3); 3.29 (q, 2H, J = 7.3 Hz, CH2); 3.40-
3.47 (3H, CH2, CH); 7.07 (s, 1H, CH); 7.15 (dd, 1H, J = 7.0 Hz, J = 8.1 Hz, CH); 7.22 (dd, 
1H, J = 7.0 Hz, J = 8.1 Hz, CH); 7.28 (d, 2H, J = 8.0 Hz, 2xCH); 7.40 (d, 1H, J = 8.1 Hz, 
CH); 7.68 (d, 1H, J = 8.1 Hz, CH); 7.72 (d, 2H, J = 8.0 Hz, 2xCH); 8.46 (bs, 1H, NH). 
13C-NMR: (CDCl3, 125 MHz) d = 13.6 (CH3); 18.2 (CH3); 21.3 (CH3); 30.2 (CH); 43.3 
(CH2); 54.0 (CH2); 111.3 (CH); 118.2 (C); 118.6 (CH); 119.0 (CH); 121.0 (CH); 121.7 (CH); 
126.4 (C); 127.0 (2xCH); 129.5 (2xCH); 136.3 (C); 136.9 (C); 142.9 (C). IR: n~  [cm-1] = 3398 
(s); 2972 (s); 2931 (s); 1599 (s); 1456 (s); 1329 (s); 1153 (m); 741 (m). HRMS found [M]+ 
356.1584, C20H24N2O2S requires [M]+ 356.1558. 
N-Ethyl-N-[2-(1H-indol-3-yl)-propyl]-benzamide (215l). The general procedure was 
followed with N-ethyl-4-methyl-N-(2-methyl-allyl)-benzamide (0.66 g, 3.3 mmol), 
phenylhydrazine (0.35 g, 3.3 mmol) and Rh(acac)(CO)2 (2.5 mg, 0.3 mol%) to give N-ethyl-
N-[2-(1H-indol-3-yl)-propyl]-benzamide (0.82 g, 85 %). 1H-NMR: (C2D2Cl4, 400 MHz, 
80°C) d = 1.06-1.20 (3H, CH3); 1.43 (d, 3H, J = 6.5 Hz, CH3); 3.30-3.79 (5H, 2xCH2, CH); 
7.00 (s, 1H, CH); 7.10 (dd, 1H, J = 7.5 Hz, J = 7.3 Hz, CH); 7.20 (t, 1H, J = 8.0 Hz, 
J = 7.0 Hz,); 7.27-7.29 (2H, 2xCH); 7.35-7.53 (5H, 5xCH); 8.21 (bs, 1H, NH). 13C-NMR: 
EXPERIMENTAL SECTION 
- 133 - 
(CDCl3, 100 MHz) d = 13.5, 12.5 (CH3); 18.8, 17.8 (CH3); 28.9, 30.4 (CH); 44.0, 39.9 (CH2); 
50.6, 54.7 (CH2); 111.3, 114.9 (CH); 118.4, 117.1 (C); 118.7, 118.3 (CH); 120.8, 121.0 (CH); 
121.3 (CH); 126.1, 126.5 (2xCH); 126.8 (C); 128.2, 128.7 (2xCH); 128.9, 129.0 (CH); 136.3 
(C); 137.1, 136.9 (C); 171.9 (C). IR: n~  [cm-1] = 3188 (s); 2972 (s); 2931 (s); 1633 (s); 1456 
(s); 1381 (s); 1105 (m); 739 (s).  
N-Ethyl-N-[2-(1H-indol-3-yl)-propyl]-acetamide (215m). The general procedure was 
followed with N-ethyl-4-methyl-N-(2-methyl-allyl)-acetamide (0.58 g, 4.1 mmol), 
phenylhydrazine (0.44 g, 4.1 mmol) and Rh(acac)(CO)2 (3.2 mg, 0.3 mol%) to give N-ethyl-
N-[2-(1H-indol-3-yl)-propyl]-acetamide (0.61 g, 61 %). 1H-NMR: (CDCl3, 500 MHz) 
d = 1.01, 1.10 (t, 3H, J = 7.1 Hz, CH3); 1.33, 1.41 (d, 3H, J = 6.9 Hz, CH3); 2.06, 1.95 (s, 3H, 
CH3); 2.97-3.12 (2H, CH2); 3.36-3.55 (2H, CH2); 3.73 (m, 1H, CH); 6.98, 6.95 (s, 1H, CH); 
7.08, 7.03 (d, 1H, J = 8.0 Hz, CH); 7.15, 7.11 (d, 1H, J = 8.0 Hz, CH); 7.32, 7.34 (d, 1H, 
J = 8.0 Hz, CH); 7.66, 7.57 (d, 1H, J = 8.0 Hz, CH); 8.81, 9.01 (bs, 1H, NH). 13C-NMR: 
(CDCl3, 125 MHz) d = 13.5, 12.5 (CH3); 18.6, 18.1 (CH3); 21.4, 21.6 (CH3); 29.2, 30.9 (CH); 
43.7, 40.7 (CH2); 51.9, 54.7 (CH2); 111.2, 111.5 (CH); 118.8, 118.5 (CH); 119.0, 117.7 (C); 
119.1, 119.4 (CH); 121.0, 120.6 (CH); 121.5, 121.7 (CH); 126.9, 126.2 (C); 136.5, 136.3 (C); 
170.6, 170.5 (C). IR: n~  [cm-1] = 3271 (s); 2970 (s); 2931 (s); 1631 (s); 1458 (s); 1379 (s); 
1033 (m); 742 (s). HRMS found [M+H]+ 245.1682, C15H20N2O requires [M+H]+ 245.1654. 
Ethyl-[2-(1H-indol-3-yl)-propyl]-carbamic acid ethyl ester (215n). The general 
procedure was followed with ethyl-(2-methyl-allyl)-carbamic acid ethyl ester (0.62 g, 
3.6 mmol), phenylhydrazine (0.39 g, 3.6 mmol) and Rh(acac)(CO)2 (2.8 mg, 0.3 mol%) to 
give ethyl-[2-(1H-indol-3-yl)-propyl]-carbamic acid ethyl ester (0.58 g, 58 %).1H-NMR: 
(CDCl3, 400 MHz) d = 1.03-1.13 (3H, CH3); 1.28 (t, 3H, J = 7.1 Hz, CH3); 1.39 (bs, 3H, 
CH3); 3.23-3.72 (5H, 2xCH2, CH); 4.15-4.20 (2H, CH2); 7.01, 6.98 (s, 1H, CH); 7.12 (dd, 1H, 
J = 7.3 Hz, J = 7.3 Hz, CH); 7.19 (dd, 1H, J = 7.3 Hz, J = 7.7 Hz, CH); 7.35 (d, 1H, 
J = 7.7 Hz, CH); 7.69 (bs, 1H, CH); 8.38 (bs, 1H, NH). 13C-NMR: (CDCl3, 100 MHz) 
d = 12.9, 13.4 (CH3); 14.6 (CH3); 18.4, 18.1 (CH3); 29.9, 30.7 (CH); 42.3, 42.8 (CH2); 52.9, 
53.5 (CH2); 61.0 (CH2); 110.6 (C); 111.3, 111.2 (CH); 119.0 (2xCH); 119.2 (C); 120.6 (CH); 
121.8 (CH); 136.5 (C); 154.7 (C). IR: n~  [cm-1] = 3315 (vs); 2973 (s); 2886 (s); 1683 (vs); 
1484 (s); 1380 (m); 1172 (s); 1074 (m); 771 (m). HRMS found [M]+ 274.1652, C16H22N2O2 
requires [M]+ 274.1682. 
Ethyl 4-(5-bromo-1H-indol-3-yl)piperidine-1-carboxylate (218). The general procedure 
was followed with ethyl 4-methylenepiperidine-1-carboxylate (1.75 g, 10.3 mmol), 
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4-bromo-phenylhydrazine (1.93 g, 10.3 mmol) and Rh(acac)(CO)2 (11 mg, 0.3 mol%) to give 
ethyl 4-(5-bromo-1H-indol-3-yl)piperidine-1-carboxylate (1.93 g, 39 %).1H-NMR: (CDCl3, 
500 MHz) d = 1.29 (t, 3H, J = 7.2 Hz, CH3); 1.63 (q, 2H, J = 11.7 Hz, CH2); 2.00 (d, 2H, 
J = 13.7 Hz, CH2); 2.92 (t, 3H, J = 11.7 Hz, CH2); 4.17 (q, 2H, J = 7.2 Hz, CH2); 4.28 (bs, 
2H, CH2); 6.92 (s, 1H, CH); 7.20 (d, 1H, J = 8.5 Hz, CH); 7.25 (d, 1H, J = 8.5 Hz, CH); 7.73 
(s, 1H, CH); 8.56 (s, 1H, NH). 13C-NMR: (CDCl3, 100 MHz) d = 14.7 (CH3); 32.6 (2xCH2); 
33.4 (CH); 44.4 (2xCH2); 61.3 (CH2); 112.3 (C); 112.7 (CH); 120.2 (C); 121.0 (CH); 121.4 
(CH); 124.6 (CH); 128.2 (C); 135.0 (C); 155.6 (C). 
Ethyl 4-(5-bromo-1-(4-fluorophenyl)-1H-indol-3-yl)piperidine-1-carboxylate (219). CuI 
(5.35 mg, 5 mol%), N,N’-dimethyl-ethylen-diamine (20.2 mg, 20 mol%), K3PO4*7H2O 
(399 mg, 1.18 mmol) 4-fluoro-iodo-benzene (150 mg, 0.67 mmol) and 125 (197 mg, 
0.56 mmol) were dissolved in toluene (1M). After stirring for 24h at 110°C the mixture was 
poured into EtOAc and filtered through a pad of silica. The solvent was removed to give ethyl 
4-(5-bromo-1-(4-fluorophenyl)-1H-indol-3-yl)piperidine-1-carboxylate (250 mg, 100 %) 
without further purification. 1H-NMR: (CDCl3, 500 MHz) d = 1.28 (t, 3H, J = 7.2 Hz, CH3); 
1.67 (q, 2H, J = 9.7 Hz, CH2); 2.04 (d, 2H, J = 13.7 Hz, CH2); 2.97 (q, 3H, J = 12.0 Hz, CH2, 
CH); 4.16 (q, 2H, J = 7.2 Hz, CH2); 4.30 (bs, 2H, CH2); 7.03 (s, 1H, CH); 7.17 (dd, 2H, 
J = 8.6Hz, J = 9.0 Hz, 2xCH); 7.27 (bs, 2H, 2xCH); 7.37 (dd, 2H, J = 8.6, J = 9.0 Hz, 2xCH); 
7.78 (s, 1H, CH). 13C-NMR: (CDCl3, 125 MHz) d = 14.6 (CH3); 32.5 (2xCH2); 33.3 (CH); 
44.3 (2xCH2); 61.1 (CH2); 111.8 (CH); 113.01 (C); 116.4 (d, 2C, J = 23 Hz, 2xCH); 121.3 
(C); 124.8 (CH); 125.3 (CH); 125.9 (d, 2C, J = 10 Hz, 2xCH); 129.3 (C); 135.1 (d, 1C, 
J = 36 Hz, C); 155.5 (C); 161.0 (d, 1C, J = 248 Hz, C). IR: n~  [cm-1] = 2929 (m); 2850 (m); 
1693 (vs); 1511 (vs); 1457 (vs); 1442 (s); 1382 (m); 1213 (vs); 1120 (s); 840 (s); 788 (s). 
HRMS found [M]+ 444.0864, C22H22BrFN2O2 requires [M]+ 444.0849. 
10.3.6 GENERAL PROCEDURE FOR THE REGIOSELECTIVE TANDEM 
HYDROFORMYLATION / FISCHER INDOLE SYNTHESIS 
Methyl 4-(1H-indol-3-yl)butanoate (226). A typical procedure is described. Methyl pent-
4-enoate (263 mg, 2.30 mmol), phenylhydrazine (249 mg, 2.30 mmol), Rh(acac)(CO)2 
(1.78 mg , 0.3 mol%) and XANTPHOS (40.0 mg, 3 mol%) were dissolved in anhydrous THF 
(2.36 g, 10 wt% olefin), filled in an autoclave and pressurized with 10bar H2 and 10bar CO. 
After stirring for 3 days at 70°C the mixture was poured into H2SO4 (15 ml, 4 wt% in THF) 
and the resulting mixture was stirred for additional 2h under reflux. NH3 (10 ml, 30 wt% in 
water) was added and the mixture was extracted 3 times with EtOAc. The solvent was 
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evaporated and the residue was chromatographed (EtOAc/cyclohexane, silica) to give methyl 
4-(1H-indol-3-yl)butanoate (455 mg, 91%). Analytical data fits with literature104. 
N-[2-(1H-Indol-3-yl)-ethyl]-4-methyl-benzenesulfonamide (227a). The general procedure 
was followed with N-allyl-4-methyl-benzenesulfonamide (336 mg, 1.59 mmol), 
phenylhydrazine (172 mg, 1.59 mmol), Rh(acac)(CO)2 (1.23 mg, 0.30 mol%) and 
XANTPHOS (28 mg, 3 mol%) to give N-[2-(1H-Indol-3-yl)-ethyl]-4-methyl-
benzenesulfonamide (295 mg, 59 %). Analytical data fits with literature105. 
2-[2-(1H-Indol-3-yl)-ethyl]-isoindole-1,3-dione (227b). The general procedure was 
followed with 2-allyl-isoindole-1,3-dione (322 mg, 1.72 mmol), phenylhydrazine (186 mg, 
1.72 mmol), Rh(acac)(CO)2 (0.13 mg, 0.30 mol%) and XANTPHOS (29.9 mg, 3 mol%) to 
give 2-[2-(1H-indol-3-yl)-ethyl]-isoindole-1,3-dione (255 mg, 51 %). Analytical data was 
obtained from the mixture of n/iso-isomers. n-regioisomer: 1H-NMR: (CDCl3, 500 MHz) 
d = 3.17 (dd, 2H, J = 7.5 Hz, J = 8.1 Hz, CH2); 4.02 (dd, 2H, J = 7.5 Hz, J = 8.1 Hz, CH2); 
7.08 (s, 1H, CH); 7.13 (dd, 1H, J = 7.3 Hz, J = 8.1 Hz, CH); 7.19 (dd, 1H, J = 7.3 Hz, 
J = 8.1 Hz, CH); 7.34 (d, 1H, J = 8.1 Hz, CH); 7.50 (d, 1H, J = 7.0 Hz, CH); 7.75 (d, 1H, 
J = 7.3 Hz, CH); 7.66 (d, 2H, J = 5.5 Hz, 2xCH); 8.11 (s, 1H, NH). 13C-NMR: (CDCl3, 
125 MHz) d = 24.4 (CH2); 38.5 (CH2); 111.1 (CH); 112.9 (C); 118.8 (CH); 119.4 (CH); 122.0 
(CH); 123.1 (2xCH); 127.3 (2xC); 132.4 (C); 133.6 (2xCH); 136.2 (2xC); 168.3 (2xC). 
Characteristic data for the iso-regioisomer (structure confirmed with 1D-NOESY): 1H-NMR: 
(CDCl3, 500 MHz) d = 2.44 (s, 3H, CH3); 4.97 (s, 2H, CH2); 7.07 (dd, 1H, J = 7.0 Hz, 
J = 7.0 Hz, CH); 7.15 (dd, 1H, J = 7.0 Hz, J = 7.0 Hz, CH); 7.28 (d, 1H, J = 7.0 Hz, CH); 
7.50 (d, 1H, J = 7.0 Hz, CH); 7.66 (d, 2H, J = 5.5 Hz, 2xCH); 7.8 (d, 2H, J = 5.5 Hz, 2xCH); 
8.56 (s, 1H, NH). 13C-NMR: (CDCl3, 100 MHz) d = 8.3 (CH3); 32.6 (CH2); 110.1 (C); 110.8 
(CH); 119.0 (CH); 119.2 (CH); 122.5 (CH); 123.4 (2xCH); 128.2 (C); 128.9 (C); 131.9 (2xC); 
134.1 (2xCH); 135.6 (C); 168.4 (2xC). HRMS found [M]+ 290.1068, C18H14N2O2 requires 
[M]+ 290.1055. 
2-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-isoindole-1,3-dione (227c). The general procedure 
was followed with 2-allyl-isoindole-1,3-dione (292 mg, 1.56 mmol), a-Boc-
1-(4-methoxyphenyl) hydrazine (372 mg, 1.56 mmol), Rh(acac)(CO)2 (0.12 mg, 0.30 mol%) 
                                               
104 Perregaard, J.; Moltzen, E.K.; Meier, E.; Sanchez, C.; J. Med. Chem. 1995, 38, 1998-2008. 
105 Onistschenko, A.; Stamm, H.; Chem. Ber. 1989, 122, 2397-2398. 
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and XANTPHOS (27.1 mg, 3 mol%) to give 2-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-
isoindole-1,3-dione (400 mg, 80 %). Analytical data fits with literature106. 
N-Ethyl-N-[2-(1H-indol-3-yl)-ethyl]-4-methyl-benzenesulfonamide (227d). The general 
procedure was followed with N-allyl-N-ethyl-4-methyl-benzenesulfonamide (349 mg, 
1.46 mmol), phenylhydrazine (158 mg, 1.46 mmol), Rh(acac)(CO)2 (1.13 mg, 0.30 mol%) 
and XANTPHOS (25 mg, 3 mol%) to give N-ethyl-N-[2-(1H-indol-3-yl)-ethyl]-4-methyl-
benzenesulfonamide (405 mg, 81 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.14 (t, 3H, 
J = 7.2 Hz, CH3); 2.38 (s, 3H, CH3); 3.03 (dd, 2H, J = 7.7 Hz, J = 8.3 Hz, CH2); 3.29 (q, 2H, 
J = 7.2 Hz, CH2); 3.41 (dd, 2H, J = 7.7 Hz, J = 8.3 Hz, CH2); 7.01 (s, 1H, CH); 7.10 (dd, 1H, 
J = 7.5 Hz, J = 8.0 Hz, CH); 7.16 (dd, 1H, J = 7.5 Hz, J = 8.2 Hz, CH); 7.24 (d, 2H, 
J = 8.2 Hz, 2xCH); 7.35 (d, 1H, J = 8.2 Hz, CH); 7.57 (d, 1H, J = 8.0 Hz, CH); 7.69 (d, 2H, 
J = 8.2 Hz, 2xCH); 8.41 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 14.8 (CH3); 21.3 
(CH3); 25.4 (CH2); 43.0 (CH2); 48.1 (CH2); 111.3 (CH); 112.1 (C); 118.3 (CH); 119.1 (CH); 
121.7 (CH); 122.2 (CH); 127.0 (2xCH); 129.5 (2xCH); 129.6 (C); 136.9 (C); 142.9 (C). IR: 
n~  [cm-1] = 3399 (s); 2954 (s); 2923 (vs); 2856 (s); 1455 (vs); 1332 (s); 1153 (s). 
HRMS found [M]+ 342.1415, C19H22N2O2S requires [M]+ 342.1402. 
N-Ethyl-N-[2-(1H-indol-3-yl)-ethyl]-acetamide (227e). The general procedure was 
followed with N-allyl-N-ethyl-4-acetamide (276 mg, 2.17 mmol), phenylhydrazine (235 mg, 
2.17 mmol), Rh(acac)(CO)2 (1.68 mg, 0.30 mol%) and XANTPHOS (18.8 mg, 3 mol%) to 
give N-ethyl-N-[2-(1H-indol-3-yl)-ethyl]-acetamide (295 mg, 59 %). Analytical data fits with 
literature107. 
N-Ethyl-N-[3-(1H-indol-3-yl)-propyl]-4-methyl-benzenesulfonamide (227f). The general 
procedure was followed with N-but-3-enyl-N-ethyl-4-methyl-benzenesulfonamide (355 mg, 
1.40 mmol), phenylhydrazine (152 mg, 1.40 mmol), Rh(acac)(CO)2 (1.09 mg, 0.30 mol%) 
and XANTPHOS (12.2 mg, 3 mol%) to give N-ethyl-N-[3-(1H-indol-3-yl)-propyl]-4-methyl-
benzenesulfonamide (290 mg, 58 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.09 (t, 3H, 
J = 7.2 Hz, CH3); 1.94 (m, 2H, J = 7.5 Hz, CH2); 2.39 (s, 3H, CH3); 2.76 (t, 2H, J = 7.5 Hz, 
CH2); 3.20-3.24 (4H, 2xCH2); 7.00 (s, 1H, CH); 7.10 (dd, 1H, J = 7.5 Hz, J = 7.5 Hz, CH); 
7.18 (dd, 1H, J = 7.2 Hz, J = 8.0 Hz, CH); 7.23 (d, 2H, J = 8.1 Hz, 2xCH); 7.35 (d, 1H, 
J = 8.0 Hz, CH); 7.53 (d, 1H, J = 8.0 Hz, CH); 7.65 (d, 2H, J = 8.1 Hz, 2xCH); 8.14 (s, 1H, 
                                               
106 Petrunin, I. A.; Vinograd, L. Kh.; Przhiyalgovskaya, N. M.; Suvorov, N. N.; Chem. Heterocycl. Compd. 1987, 
8, 839-842.  
107 Povalyaeva, O. S.; Kurkovskaya, L. N.; Vigdorchik, M. M.; Suvorov, N. N.; J. Org. Chem. USSR 1987, 6, 
1171-1179. 
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NH). 13C-NMR: (CDCl3, 125 MHz) d = 14.0 (CH3); 21.4 (CH3); 22.1 (CH2); 28.7 (CH2); 42.6 
(CH2); 47.2 (CH2); 111.1 (CH); 115.1 (C); 118.6 (CH); 119.0 (CH); 121.5 (CH); 121.8 (CH); 
127.0 (2xCH); 127.3 (C); 129.5 (2xCH); 136.3 (C); 137.0 (C); 142.9 (C). IR: n~  [cm-1] = 3403 
(s); 2935 (s); 1455 (vs); 1336 (vs); 1305 (vs); 1184 (s); 1155 (vs); 1089 (vs); 742 (vs); 715 
(s); 551 (s). HRMS found [M]+ 356.1569, C20H24N2O2S requires [M]+ 356.1558. 
Ethyl-[2-(1H-indol-3-yl)-ethyl]-carbamic acid ethyl ester (227g) The general procedure 
was followed with allyl-ethyl-carbamic acid ethyl ester (302 mg, 1.92 mmol), 
phenylhydrazine (208 mg, 1.92 mmol), Rh(acac)(CO)2 (1.49 mg, 0.30 mol%) and 
XANTPHOS (33.3 mg, 3 mol%) to give ethyl-[2-(1H-indol-3-yl)-ethyl]-carbamic acid ethyl 
ester (255 mg, 51 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.12 (bs, 3H, CH3); 1.27 (bs, 3H, 
CH3); 3.01 (bs, 2H, CH2); 3.32, 3.27 (2bs, 2H, CH2); 3.53 (bs, 2H, CH2); 4.14, 4.16 (2bs, 2H, 
CH2); 6.99 (s, 1H, CH); 7.13 (dd, 1H, J = 7.2 Hz, J = 7.2 Hz, CH); 7.19 (dd, 1H, J = 7.7 Hz, 
J = 7.2 Hz, CH); 7.35 (d, 1H, J = 7.7 Hz, CH); 7.65 (bs, 1H, CH); 8.27 (s, 1H, NH). 
13C-NMR: (CDCl3, 125 MHz) d = 13.4, 13.9 (CH3); 14.7 (CH3); 24.9, 24.3 (CH2); 26.9 
(CH2); 42.3 (CH2); 47.3, 48.1 (CH2); 61.0 (CH3); 111.1 (CH); 113.2 (C); 118.7 (CH); 119.2 
(CH); 121.9 (2xCH); 127.4 (C); 136.3 (C); 156.3 (C). IR: n~  [cm-1] = 3318 (vs); 2977 (vs); 
1697 (vs); 1486 (vs); 1280 (vs); 1193 (vs); 1095 (s); 1012 (s); 742 (s). HRMS found [M]+ 
260.1490, C15H20N2O2 requires [M]+ 260.1525. 
N-Ethyl-N-[2-(1H-indol-3-yl)-ethyl]-benzamide (227h). The general procedure was 
followed with N-allyl-N-ethyl-benzamide (324 mg, 1.71 mmol), phenylhydrazine (185 mg, 
1.71 mmol), Rh(acac)(CO)2 (1.32 mg, 0.30 mol%) and XANTPHOS (29.7 mg, 3 mol%) to 
give N-ethyl-N-[2-(1H-indol-3-yl)-ethyl]-benzamide (160 mg, 32 ). 1H-NMR: (CDCl3, 
500 MHz) d = 1.27 (bs, 3H, CH3); 2.94, 3.19 (2xbs, 2H, CH2); 3.20, 3.51 (2xbs, 2H, CH2); 
3.67, 3.81 (2bs, 2H, CH2); 6.83-7.78 (10H, 10xCH); 8.24 (s, 1H, NH). 13C-NMR: (CDCl3, 
125 MHz) d = 25.0, 23.4 (CH2); 44.3, 39.9 (CH2); 45.6, 49.3 (CH2); 111.2 (CH); 118.8 (CH); 
119.3 (CH); 126.3 (2xCH); 126.3 (2xCH); 128.4 (2xCH); 129.1, 129.0 (CH); 137.1, 136.2 
(C). IR: n~  [cm-1] = 3181 (s); 2929 (s); 1606 (vs); 1596 (vs); 1467 (m); 1455 (s); 1319 (m); 
748 (s). HRMS found [M]+ 292.1539, C19H20N2O requires [M]+ 292.1575. 
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10.4 EXPERIMENTS IN CHAPTER 3 
10.4.1 SYNTHESIS OF AMINOOLEFINES 
N,N-Diethyl-1-phenylprop-2-en-1-amine (301g). NaH (431 mg, 10.7 mmol) was 
suspended in dry Et2O (60 ml). A solution of cinnamyl alcohol (14.5 g, 107 mmol) in dry 
Et2O (20 ml) was added dropwise followed by 2,2,2 trichloroacetonitrile (15.6 g, 107 mmol) 
at -10°C. The solvent was removed and the residue was taken up in MeOH/pentane (200 ml, 
0.25wt% MeOH in pentane). The mixture was filtered through a pad of alumina and the 
solvent was removed to give cinnamyl 2,2,2-trichloroacetimidate (30.0 g, 100 %), which was 
used for the next step without purification. Cinnamyl 2,2,2-trichloroacetimidate (30.0 g, 
107 mmol) in xylene (500 ml) was stirred over night under reflux. The solvent was removed 
to give 2,2,2-trichloro-N-(1-phenylallyl)acetamide (30.0 g, 100 %) without the need for 
purification. 2,2,2-Trichloro-N-(1-phenylallyl)acetamide (30.0 g, 107 mmol) in EtOH 
(100 ml) and NaOH solution (6M, 150 ml) was stirred for 40h at ambient temperature. The 
mixture was extracted with Et2O. The solvent was removed and the residue was taken up in 
HCl-saturated Et2O (100 ml). Filtration gave 1-phenylprop-2-en-1-amine hydrochloride 
(11.6 g, 64 %), which was not purified for the next step. 1-Phenylprop-2-en-1-amine 
hydrochloride (1.02 g, 6.0 mmol), EtBr (6.44 g, 60 mmol), 18-crown[6] (85 mg, 5 mol%) and 
K2CO3 (2.08 g, 15 mmol) in dry CH3CN (30 ml) were stirred for 12h under reflux. The 
mixture was filtered through a pad of alumina and the solvent was removed to give N,N-
diethyl-1-phenylprop-2-en-1-amine (1.0 g, 89 %) without further purification. 1H-NMR: 
(CDCl3, 500 MHz) d = 1.00 (t, 6H, J = 7.1 Hz, 2xCH3); 2.54-2.63 (4H, 2xCH2); 4.15 (d, 1H, 
J = 8.7 Hz, CH); 5.15 (d, 1H, J = 10.2 Hz, CHH); 5.20 (d, 1H, J = 17.2 Hz, CHH); 5.97 (ddt, 
1H, J = 8.0 Hz, J = 10.2 Hz, J = 17.2 Hz, CH); 7.25 (d, 1H, J = 7.2 Hz, CH); 7.32 (dd, 2H, 
J = 7.2 Hz, J = 7.5 Hz, 2xCH); 7.40 (d, 2H, J = 7.4 Hz, 2xCH). 13C-NMR: (CDCl3, 125 MHz) 
d = 11.6 (2xCH3); 42.9 (2xCH2); 69.4 (CH); 116.0 (CH2); 126.7 (CH); 127.8 (2xCH); 128.2 
(2xCH); 139.5 (CH); 143.1 (C). IR: n~  [cm-1] = 2969 (s); 2871 (m); 2815 (m); 1450 (s); 1382 
(m); 1110 (s); 997 (m); 919 (s); 755 (m); 732 (s); 700 (s). 
rac-1-(1-Phenylallyl)piperidine (rac-301h). Cinnamyl ethyl carbonate (2.56 g, 
12.4 mmol), piperidine (7.68 g, 37.3 mmol), [Ir(cod)Cl]2 (167 mg, 2 mol%) and P(OPh)3 
(290 mg, 8 mol%) in dry EtOH (25 ml) were stirred for 2h under reflux. The solvent was 
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evaporated and the residue was chromatographed (silica, 2.5 vol% EtOAc in cyclohexane) to 
give rac-1-(1-phenylallyl)piperidine (2.02 g, 81 %). Analytical data fits with literature108. 
(-)-1-(1-Phenylallyl)piperidine ((-)-301h). Cinnamyl ethyl carbonate (2.56 g, 12.4 mmol), 
piperidine (7.68 g, 37.3 mmol), [Ir(cod)Cl]2 (167 mg, 2 mol%) and O,O'-(R)-(1,1'-dinaphthyl-
2,2'-diyl)-N,N'-di-(R,R)-1-phenylethylphosphoramidite (134 mg, 2 mol%) in dry THF (12 ml) 
were stirred over night at ambient temperature. The solvent was evaporated and the residue 
was chromatographed (silica, 2.5 vol% EtOAc in cyclohexane) to give (-)-1-(1-
phenylallyl)piperidine (2.38 g, 95 %, 96 %ee109). Analytical data fits with literature108. 
(+)-1-(1-Phenylallyl)piperidine ((-)-301h). Cinnamyl ethyl carbonate (2.56 g, 12.4 mmol), 
piperidine (7.68 g, 37.3 mmol), [Ir(cod)Cl]2 (167 mg, 2 mol%) and O,O'-(S)-(1,1'-dinaphthyl-
2,2'-diyl)-N,N'-di-(S,S)-1-phenylethylphosphoramidite (134 mg, 2 mol%) in dry THF (12 ml) 
were stirred over night at ambient temperature. The solvent was evaporated and the residue 
was chromatographed (silica, 2.5 vol% EtOAc in cyclohexane) to give (+)-1-(1-
phenylallyl)piperidine (2.38 g, 95 %, 96 %ee109). Analytical data fits with literature108. 
1-Cinnamylpiperidine (301i). Piperdine (7.91 g, 93 mmol), NEt3 (10.3 g, 102 mmol) and 
DMAP (567 mg, 5 mol%) were dissolved in dry THF (100 ml). To this solution 
cinnamylchloride (15.5 g, 93 mmol) was added dropwise at 0°C and the resulting mixture was 
stirred for 3h at ambient temperatures. The precipitate was removed by filtration and the 
solvent was evaporated to give (E)-3-phenyl-1-(piperidin-1-yl)prop-2-en-1-one (18.9 g, 94 %) 
which is used for the next step without purification. LiAlH4 (1.74 g, 46 mmol) was suspended 
in dry Et2O (100 ml) and (E)-3-phenyl-1-(piperidin-1-yl)prop-2-en-1-one (18.0 g, 84 mmol) 
in dry Et2O (50 ml) was added carefully. After stirring overnight at ambient temperatures the 
mixture was quenched with cool water until gas formation was not witnessed anymore. The 
precipitate was separated by filtration and the solvent was evaporated. The residue was 
purified by chromatography (silica, cyclohexane, EtOAc, NEt3) to give 1-cinnamylpiperidine 
(6.55 g, 39%). Analytical data fits with literature110. 
1-(3-Phenylbut-3-enyl)piperidine (301j). Acetophenone (27.6 g, 230 mmol), piperidine 
(19.6 g, 230 mmol) and paraformaldehyde (35.2 g, 391 mmol) in dry EtOH (50 ml) were 
stirred for 1h under reflux. Hydrochloric acid (0.5 ml) was added and the mixture was filtered. 
The filtrate was concentrated and the product was colleted by filtration. The crude product 
was recrystallized from EtOH to give 1-phenyl-3-(piperidin-1-yl)propan-1-one (15.9 g, 
                                               
108 Ohmura, T.; Hartwig, J.F.; J. Am. Chem. Soc. 2002, 124, 15164-15165. 
109 Determined by HPLC with a Daicel Chiracel OJ 
110 Katritzky, A.R.; Yao, J.; Qi, M.; J. Org. Chem. 1998, 63, 5232-5234. 
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32 %). Methyl triphenyl phosphonium bromide (28.6 g, 80.2 mmol) was suspended in dry 
THF (300 ml). At 0°C n-butyllithium solution (2.5M in hexane, 32 ml) was added and the 
mixture was stirred for 1h at ambient temperature. 1-Phenyl-3-(piperidin-1-yl)propan-1-one 
(15.8 g, 72.9 mmol) was added and the mixture was stirred for an additional hour. The solvent 
was evaporated and the crude product was distilled (75°C, 2·10-2 mbar) to give 1-(3-
phenylbut-3-enyl)piperidine (8.61 g, 55 %). 1H-NMR: (CDCl3, 400 MHz) d = 1.41 (bs, 2H, 
CH2); 1.55-1.60 (4H, 2xCH2); 2.40-2.44 (6H, 3xCH2); 2.71 (dd, 2H, J = 8.0 Hz, J = 8.0 Hz, 
CH2); 5.07 (s, 1H, CHH); 5.29 (s, 1H, CHH); 7.24 (dd, 1H, J = 7.2 Hz, J = 7.2 Hz, CH); 7.30 
(dd, 2H, J = 7.2 Hz, J = 7.7 Hz, 2xCH); 7.40 (d, 2H, J = 7.7 Hz, 2xCH). 13C-NMR: (CDCl3, 
100 MHz) d = 24.4 (CH2); 26.0 (2xCH2); 32.9 (CH2); 54.6 (2xCH2); 58.7 (CH2); 112.9 (CH2); 
126.0 (2xCH); 127.3 (CH); 128.2 (2xCH); 141.0 (C); 146.8 (C). IR: n~  [cm-1] = 2933 (vs); 
2852 (s); 2798 (s); 1442 (s); 1155 (s); 1122 (s); 892 (s); 775 (s); 703 (s); 412 (vs); 404 (vs). 
HRMS found [M+H]+ 216.1776, C15H21N2 requires [M+H]+, 216.1752. Elementary analysis 
found C 83.13%, H 9.88%, N 6.20%, C15H21N2 requires C 83.67%, H 9.83%, N 6.50%. 
N,N-Diethyl-3-methyl-1-phenylbut-3-en-1-amine (301k). A solution of benzaldehyde 
(79.7 g, 750 mmol) in Et2O (250 ml) was added to a solution of EtNH2 (33.8 g, 750 mmol) in 
Et2O (250 ml) at 0°C. MgSO4 (50 g) was added and the mixture was stirred for 1h at ambient 
temperature followed by filtration. The solvent was removed and the residue was distilled 
(86°C, 10 mbar) to give N-benzylideneethanamine (78.8 g, 79 %). At 0°C a solution of 
methallylic chloride (10.8 g, 119 mmol) and N-benzylideneethanamine (10.6 g, 79 mmol) in 
dry THF (50 ml) was added to a suspension of zinc dust (10.4 g, 158 mmol) in dry THF 
(100 ml). The mixture was stirred for 4h at ambient temperature and was then filtered through 
a sintered glass filter. Saturated ammonium hydrochloride solution was added to the filtrate 
and the pH was adjusted to 10 with NaOH solution. The mixture was extracted with EtOAc 
and the solvent was removed to give N-ethyl-3-methyl-1-phenylbut-3-en-1-amine (15.0 g, 
100 %). A suspension of N-ethyl-3-methyl-1-phenylbut-3-en-1-amine (4.4 g, 23 mmol), EtBr 
(3.8 g, 35 mmol) and K2CO3 (4.8 g, 35 mmol) in dry CH3CN (25 ml) was stirred for 12h 
under reflux. The mixture was filtered through a pad of alumina. The solvent was removed 
and the residue was chromatographed (silica, EtOAc, cyclohexane, NEt3) to give N,N-diethyl-
3-methyl-1-phenylbut-3-en-1-amine (3.84 g, 77 %). 1H-NMR: (CDCl3, 400 MHz) d = 1.06 (t, 
6H, J = 7.1 Hz, 2xCH3); 1.70 (s, 3H, CH3); 2.33-2.73 (6H, 3xCH2); 3.94 (dd, 1H, J = 5.8 Hz, 
J = 5.8 Hz, CH); 4.63 (s, 1H, CHH); 4.71 (s, 1H, CHH); 7.24-7.34 (5H, 5xCH). 13C-NMR: 
(CDCl3, 100 MHz) d = 13.0 (2xCH3); 22.5 (CH3); 40.5 (CH2); 43.0 (2xCH2); 62.2 (CH); 
112.3 (CH2); 126.6 (CH); 127.6 (2xCH); 128.5 (2xCH); 140.8 (C); 143.3 (C). IR: n~  [cm-1] = 
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3025 (m); 2967 (vs); 2813 (s); 1646 (m); 1492 (m); 1373 (s); 1295 (m); 1201 (m); 1029 (m); 
887 (s); 700 (vs) Elementary analysis found C 82.20%, H 10.68%, N 6.10%, C15H23N 
requires C 82.89%, H 10.67%, N 6.44%. 
N,N-Diethyl-1-phenylbut-3-en-1-amine (301l). A solution of benzaldehyde (79.7 g, 
750 mmol) in Et2O (250 ml) was added to a solution of EtNH2 (33.8 g, 750 mmol) in Et2O 
(250 ml) at 0°C. MgSO4 (50 g) was added and the mixture was stirred for 1h at ambient 
temperature. The mixture was filtered, the solvent was removed and the residue was distilled 
(86°C, 10 mbar) to give N-benzylideneethanamine (78.8 g, 79 %). At 0°C a solution of allylic 
bromide (15.5 g, 128 mmol) and N-benzylideneethanamine (11.4 g, 85.6 mmol) in dry THF 
(50 ml) is added to a suspension of zinc dust (10.4 g, 158 mmol) in dry THF (100 ml). The 
mixture was stirred for 4h at ambient temperature and was then filtered through a sintered 
glass filter. Saturated NH4Cl solution was added to the filtrate and the pH was adjusted to 10 
with NaOH. The mixture was extracted with EtOAc and the solvent was removed to give 
N-ethyl-1-phenylbut-3-en-1-amine (15.0 g, 100 %) without further purification. A suspension 
of N-ethyl-1-phenylbut-3-en-1-amine (5.0 g, 29 mmol), EtBr (4.6 g, 43 mmol) and K2CO3 
(5.9 g, 43 mmol) in dry CH3CN (25 ml) was stirred for 12h under reflux. The mixture was 
filtered through a pad of alumina and the solvent was removed to give N,N-diethyl-1-
phenylbut-3-en-1-amine (4.38 g, 76 %) without further purification. 1H-NMR: (CDCl3, 
400 MHz) d = 1.02 (t, 6H, J = 7.1 Hz, 2xCH3); 2.37-2.70 (6H, 3xCH2); 3.72 (dd, 1H, 
J = 5.7 Hz, J = 5.7 Hz, CH); 4.92 (d, 1H, J = 10.3 Hz, CHH); 4.99 (d, 1H, J = 17.1 Hz, CHH); 
5.66 (ddt, 1H, J = 7.0 Hz, J = 10.3 Hz, J = 17.1 Hz, CH); 7.22-7.32 (5H, 5xCH). 13C-NMR: 
(CDCl3, 100 MHz) d = 12.5 (2xCH3); 37.0 (CH2); 42.9 (2xCH2); 64.3 (CH); 115.9 (CH2); 
126.6 (CH); 127.8 (2xCH); 128.5 (2xCH); 126.4 (CH); 141.2 (C). IR: n~  [cm-1] = 2969 (s); 
2813 (m); 1639 (w); 1452 (m); 1382 (m); 1199 (m); 995 (w); 765 (w). Elementary analysis 
found C 82.53%, H 10.87%, N 6.84%, C14H21N requires C 82.70%, H 10.41%, N 6.89%.  
1-Methyl-4-methylene-piperidine (301m). NaH (11.9 g, 297 mmol) is suspended in dry 
DMSO (100 ml) and is stirred for 45 min at 75 °C. The solution is cooled to 0°C. To this 
mixture a solution of methyl-triphenyl-phosphonium bromide (106 g, 297 mmol) in dry 
DMSO (200 ml) is added and is stirred for 10min at ambient temperature. 1-Methyl-piperidin-
4-one (30.5 g, 270 mmol) was added and the mixture was stirred for 30 min at ambient 
temperature. The product was distilled directly from the reaction mixture (bp: 
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75 °C/100 mbar) to obtain 1-methyl-4-methylene-piperidine (25.3 g, 84%). Analytical data 
fits with literature111. 
10.4.2 TANDEM HYDROFORMYLATION / HYDRAZONE FORMATION 
Dimethyl-[4-(phenyl-hydrazono)-butyl]-amine (303a). In a typical procedure 
N,N-dimethylprop-2-en-1-amine (679 mg, 7.97 mmol), phenylhydrazine (862 mg, 
7.97 mmol), Rh(acac)(CO)2 (6.2 mg, 0.3 mol%) and XANTPHOS (69 mg, 0.15 mol%) in 
anhydrous THF (6.1 g, 10 wt% olefin) were filled in an autoclave. The autoclave was 
pressurized with 10bar H2 and 10bar CO. After stirring for 68 hours (The reaction is stirred 
magnetically. With a stirrer that mixes gas phase and liquid phase intensively, the reaction 
time can be reduced by far to our experience) at 70°C the solvent was removed to give 
dimethyl-[4-(phenyl-hydrazono)-butyl]-amine (1.64 g, 100 %) without further purification. 
Analytical data was obtained from an inseparable mixture of E/Z isomers. 1H-NMR: (CDCl3, 
400 MHz) d = 1.69-1.72 (2H, CH2); 2.22 (s, 3H, CH3); 2.28-2.33 (4H, 2xCH2); 6.52-6.81 
(1H, CH); 6.97-7.03 (3H, 3xCH); 7.20-7.23 (2H, 2xCH). Major isomer: 13C-NMR: (CDCl3, 
100 MHz) d = 23.6 (CH2); 29.8 (CH2); 44.8 (2xCH3); 56.4 (CH2); 112.2 (2xCH); 118.8 
(CH2); 128.8 (2xCH); 140.6 (CH); 146.1 (C). Minor isomer: 13C-NMR: (CDCl3, 100 MHz) 
d = 23.6 (CH2); 24.8 (CH2); 45.3 (2xCH3); 58.9 (CH2); 112.2 (2xCH); 119.0 (CH2); 128.8 
(2xCH); 140.1 (CH); 145.3 (C). IR: n~  [cm-1] = 2943 (vs), 2779 (s), 1603 (vs), 1496 (vs), 
1259 (vs), 1115 (s), 750 (vs), 694 (vs). HRMS found M+ 205.1580, C12H19N3 requires M+, 
205.1579. Elementary analysis found C 69.67%, H 9.14%, N 19.72%, C12H19N3 requires 
C 70.20%, H 9.33%, N 20.47%. 
N-Phenyl-N'-(4-piperidin-1-yl-butylidene)-hydrazine (303b). The general procedure for 
the tandem hydroformylation / hydrazone formation was followed with 1-allyl-piperidine 
(823 mg, 6.57 mmol), phenylhydrazine (710 mg, 6.57 mmol), Rh(acac)(CO)2 (5 mg, 
0.3 mol%) and XANTPHOS (57 mg, 0.15 mol%) to give N-phenyl-N'-(4-piperidin-1-yl-
butylidene)-hydrazine (1.57 g, 97 %) without further purification. Analytical data was 
obtained from the inseparable mixture of E/Z isomers. 1H-NMR: (CDCl3, 500 MHz) d = 1.09-
1.16 (2H, CH2); 1.45-1.74(7H, 3xCH2, CH); 2.28-2.36 (7H, 3xCH2, CH); 6.52-7.36 (7H, 
6xCH, NH). Major isomer: 13C-NMR: (CDCl3, 100 MHz) d = 22.9 (CH2); 24.0 (CH2); 24.2 
(CH2); 25.7 (2xCH2); 54.3 (2xCH2); 58.5 (CH2); 112.2 (2xCH); 119.0 (CH); 128.9 (2xCH); 
140.7 (CH); 145.3 (C). Minor isomer: 13C-NMR: (CDCl3, 125 MHz) d = 23.4 (CH2); 24.2 
(CH2); 24.8 (CH2); 25.6 (2xCH2); 54.0 (2xCH2); 56.7 (CH2); 112.6 (2xCH); 119.3 (CH); 
                                               
111 Della, E.W.; Smith, P.A.; J. Org. Chem. 1999, 64, 1798-1806. 
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128.9 (2xCH); 140.6 (CH); 145.4 (C). IR: n~  [cm-1] = 2935 (vs), 2779 (s), 1601 (vs), 1496 
(vs), 1257 (vs), 1115 (s), 748 (vs), 694 (vs). HRMS found [M+H]+ 246.1987, C15H25N3 
requires [M+H]+, 246.1970.  
N-(4-Methoxy-phenyl)-N'-(4-piperidin-1-yl-butylidene)-hydrazine (303c). The general 
procedure for the tandem hydroformylation / hydrazone formation was followed with 1-allyl-
piperidine (485 mg, 3.87 mmol), 4-methoxy-phenylhydrazine (538 mg, 3.87 mmol), 
Rh(acac)(CO)2 (3 mg, 0.3 mol%) and XANTPHOS (34 mg, 0.15 mol%) to give N-(4-
Methoxy-phenyl)-N'-(4-piperidin-1-yl-butylidene)-hydrazine (989 mg, 93 %) without further 
purification. Analytical data was obtained from the inseparable mixture of E/Z isomers. Major 
isomer: 1H-NMR: (CDCl3, 500 MHz) d = 1.43 (bs, 2H, CH2); 1.55-1.60 (4H, 2xCH2); 1.71-
1.76 (2H, CH2); 2.25-2.38 (8H, 4xCH2); 3.74 (s, 3H, CH3); 6.79 (d, 2H, J = 9.0 Hz, 2xCH); 
6.91 (d, 2H, J = 9.0 Hz, 2xCH); 7.04 (t, 1H, J = 5.2 Hz, CH); 8.10 (bs, 1H, NH). Minor 
isomer: 1H-NMR: (CDCl3, 500 MHz) d = 1.43 (bs, 2H, CH2); 1.55-1.60 (4H, 2xCH2); 1.71-
1.76 (2H, CH2); 2.25-2.38 (8H, 4xCH2); 3.75 (s, 3H, CH3); 6.48 (t, 1H, J = 6.0 Hz, CH); 6.81 
(d, 2H, J = 9.0 Hz, 2xCH); 6.99 (d, 2H, J = 9.0 Hz, 2xCH); 8.10 (bs, 1H, NH). Major isomer: 
13C-NMR: (CDCl3, 100 MHz) d = 23.2 (CH2); 24.4 (CH2); 25.9 (2xCH2); 30.3 (CH2); 54.6 
(2xCH2); 55.7 (CH3); 58.8 (CH2); 114.0 (2xCH); 114.7 (2xCH); 139.6 (C); 140.7 (CH); 153.5 
(C). Minor isomer: 13C-NMR: (CDCl3, 125 MHz) d = 23.7 (CH2); 24.3 (CH2); 25.8 (2xCH2); 
30.3 (CH2); 54.3 (2xCH2); 55.7 (CH3); 57.2 (CH2); 114.2 (2xCH); 114.6 (2xCH); 140.0 (C); 
140.1 (CH); 153.5 (C). IR: n~  [cm-1] = 3307 (s), 2935 (vs), 2767 (s), 1514 (vs), 1234 (vs), 
1115 (s), 823 (vs). HRMS found M+ 275.1994 C16H25N3O requires M+, 275.1998.  
4-[N'-(4-Dimethylamino-butylidene)-hydrazino]-benzonitrile (303d). The general 
procedure for the tandem hydroformylation / hydrazone formation was followed with 
N,N-dimethylprop-2-en-1-amine (399 mg, 4.69 mmol), 4-cyano-phenylhydrazine (624 mg, 
4.69 mmol), Rh(acac)(CO)2 (3.6 mg, 0.3 mol%) and XANTPHOS (41 mg, 0.15 mol%) to 
give 4-[N'-(4-dimethylamino-butylidene)-hydrazino]-benzonitrile (973 mg, 90 %) without 
further purification. Analytical data was obtained from the inseparable mixture of E/Z 
isomers. Major isomer: 1H-NMR: (CDCl3, 500 MHz) d = 1.69-1.78 (2H, CH2); 2.21-2.39 
(10H, CH3, 2xCH2); 6.64 (t, 1H, J = 6.9 Hz, CH); 6.97 (d, 2H, J = 8.7 Hz, 2xCH); 7.45 (d, 
2H, J = 8.7 Hz, 2xCH); 10.5 (bs, 1H, NH). Minor isomer: 1H-NMR: (CDCl3, 500 MHz) 
d = 1.69-1.78 (2H, CH2); 2.21-2.39 (10H, CH3, 2xCH2); 6.97 (d, 2H, J = 8.7 Hz, 2xCH); 7.16 
(t, 1H, J = 5.2 Hz, CH); 7.45 (d, 2H, J = 8.7 Hz, 2xCH); 7.80 (bs, 1H, NH). Major isomer: 
13C-NMR: (CDCl3, 125 MHz) d = 23.5 (CH2); 30.0 (CH2); 44.8 (2xCH3); 56.0 (CH2); 100.4 
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(C); 112.2 (2xCH); 120.4 (C); 133.6 (2xCH); 143.3 (CH); 149.7 (C). Minor isomer: 
13C-NMR: (CDCl3, 125 MHz) d = 24.1 (CH2); 24.8 (CH2); 45.4 (2xCH3); 59.0 (CH2); 101.1 
(C); 112.1 (2xCH); 120.1 (C); 133.5 (2xCH); 143.6 (CH); 148.4 (C). IR: n~  [cm-1] = 3284 (s), 
2945 (vs), 2820 (s), 2218 (vs), 1612 (s), 1533 (vs), 1271 (vs), 1167 (s), 833 (vs). HRMS 
found M+ 230.1558 C13H18N4 requires M+, 230.1531.  
N-(4-Nitro-phenyl)-N'-(4-piperidin-1-yl-butylidene)-hydrazine (303e). The general 
procedure for the tandem hydroformylation / hydrazone formation was followed with 1-allyl-
piperidine (458 mg, 3.66 mmol), 4-nitro-phenylhydrazine (560 mg, 3.66 mmol), 
Rh(acac)(CO)2 (2.8 mg, 0.3 mol%) and XANTPHOS (32 mg, 0.15 mol%) to give N-(4-nitro-
phenyl)-N'-(4-piperidin-1-yl-butylidene)-hydrazine (845 mg, 80 %) without further 
purification. Analytical data was obtained from the inseparable mixture of E/Z isomers. Major 
isomer: 1H-NMR: (CDCl3, 500 MHz) d = 1.37-1.44 (2H, CH2); 1.53-1.58 (4H, 2xCH2); 1.71-
1.80 (2H, CH2); 2.24-2.38 (8H, 4xCH2); 7.04 (d, 2H, J = 9.5 Hz, 2xCH); 7.20 (t, 1H, 
J = 5.2 Hz, CH); 8.09 (d, 2H, J = 9.5 Hz, 2xCH); 9.75 (bs, 1H, NH). Minor isomer: 1H-NMR: 
(CDCl3, 500 MHz) d = 1.48-1.52 (2H, CH2); 1.60-1.64 (4H, 2xCH2); 1.71-1.80 (2H, CH2); 
2.24-2.38 (8H, 4xCH2); 6.70 (t, 1H, J = 6.7 Hz, CH); 6.95 (d, 2H, J = 9.4 Hz, 2xCH); 7.98 
(bs, 1H, NH); 8.11 (d, 2H, J = 9.4 Hz, 2xCH). Major isomer: 13C-NMR: (CDCl3, 100 MHz) 
d = 24.0 (CH2); 24.4 (2xCH2); 26.0 (2xCH2); 30.3 (CH2); 54.0 (CH2); 58.7 (CH2); 111.6 
(2xCH); 126.2 (2xCH); 136.9 (C); 145.1 (CH); 151.1 (C). Minor isomer: 13C-NMR: (CDCl3, 
125 MHz) d = 24.0 (CH2); 24.3 (2xCH2); 25.6 (2xCH2); 30.3 (CH2); 54.6 (CH2); 56.1 (CH2); 
111.1 (2xCH); 126.0 (2xCH); 136.9 (C); 145.4 (CH); 150.1 (C). IR: n~  [cm-1] = 3294 (s), 
2935 (vs), 2802 (s), 1604 (s), 1504 (vs), 1274 (vs), 1109 (s), 841 (vs). HRMS found [M+H]+ 
291.1790 C15H22N4O2 requires M+, 291.1821. 
10.4.3 FIRST GENERATION PROTOCOL OF TANDEM HYDROFORMYLATION / FISCHER 
INDOLE SYNTHESIS 
[2-(1H-Indol-3-yl)-ethyl]-dimethyl-amine (304a). In a typical procedure 
N,N-dimethylprop-2-en-1-amine (679 mg, 7.97 mmol), phenylhydrazine (862 mg, 
7.97 mmol), Rh(acac)(CO)2 (6 mg , 0.3 mol%) and XANTPHOS (69 mg, 1.5 mol%) in 
anhydrous THF (6.1 g, 10 wt% olefin) were filled in an autoclave. The autoclave was 
pressurized with 10bar H2 and 10bar CO. After stirring for 3 days (The reaction is stirred 
magnetically. With a stirrer that mixes gas phase and liquid phase intensively, the reaction 
time can be reduced by far to our experience) at 70°C the solvent was evaporated and the 
residue was taken up in H2SO4 (30 ml, 4 wt% in water). After stirring the mixture for 2h 
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under reflux NH3 (10 ml, 30 wt% in water) was added and the mixture was extracted with 
EtOAc. The solvent was evaporated to give [2-(1H-indol-3-yl)-ethyl]-dimethyl-amine (1.5 g, 
100%) without further purification. Analytical data fits with literature112. 
3-(2-Piperidin-1-yl-ethyl)-1H-indole (304b). The first generation protocol was followed 
with 1-allyl-piperidine (823 mg, 6.57 mmol), phenylhydrazine (710 mg, 6.57 mmol), 
Rh(acac)(CO)2 (5 mg, 0.3 mol%) and XANTPHOS (57 mg, 3 mol%) to give 3-(2-piperidin-1-
yl-ethyl)-1H-indole (1.45 g, 97 %) without further purification. Analytical data fits with 
literature113.  
3-[2-(4-Phenyl-piperazin-1-yl)-ethyl]-1H-indole hydrochloride (304c). The first 
generation protocol was followed with 1-allyl-4-phenyl-piperazine (994 mg, 4.91 mmol), 
phenylhydrazine (531 mg, 4.91 mmol), Rh(acac)(CO)2 (3.8 mg, 0.3 mol%) and XANTPHOS 
(42.6 mg, 3 mol%). The crude product was taken up in dry THF (10 ml) and HCl (20 ml, 
saturated in Et2O) was added dropwise. The precipitate was collected by filtration giving 3-[2-
(4-phenyl-piperazin-1-yl)-ethyl]-1H-indole hydrochloride (1.44 g, 96 %). 1H-NMR: (DMSO-
d6, 500 MHz) d = 3.20-3.22 (8H, 4xCH2); 3.66-3.68 (2H, CH2); 3.81-3.84 (2H, CH2); 6.86 
(dd, 1H, J = 7.5 Hz, J = 7.5 Hz, CH); 7.00-7.03 (3H, 3xCH); 7.09 (dd, 1H, J = 7.5 Hz, 
J = 7.5 Hz, CH); 7.23-7.26 (4H, 3xCH, NH); 7.36 (d, 1H, J = 7.5 Hz, CH); 7.66 (d, 1H, 
J = 7.5 Hz, CH); 11.03 (s, 1H, NH); 11.48 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) 
d = 19.5 (CH2); 45.5 (2xCH2); 50.5 (2xCH2); 55.5 (CH2); 109.2 (C); 111.6 (CH); 114.5 (CH); 
116.06 (2xCH); 118.5 (CH); 120.1 (CH); 121.3 (CH); 123.2 (CH); 126.7 (C); 129.2 (2xCH); 
136.3 (C); 149.6 (C). IR: n~  [cm-1] = 3415 (s); 3216 (s); 2427 (s); 1596 (s); 1494 (s); 1457 
(vs); 1436 (s); 754 (vs); 692 (s). HRMS found [M]+ 305.1868 C20H23N3 requires M+, 
305.1892. 
Ethyl 4-(2-(1H-indol-3-yl)ethyl)piperazine-1-carboxylate (304d). The first generation 
protocol was followed with 4-allyl-piperazine-1-carboxylic acid ethyl ester (329 mg, 
1.66 mmol), Phenylhydrazine (179 mg, 1.66 mmol), Rh(acac)(CO)2 (1.3 mg, 0.3 mol%) and 
XANTPHOS (14.4 mg, 3 mol%). The crude product was purified by chromatography (silica, 
EtOAc, cyclohexane, NEt3) to give Ethyl 4-(2-(1H-indol-3-yl)ethyl)piperazine-1-carboxylate 
(468 mg, 94 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.27 (t, 3H, J = 7.0 Hz, CH3); 2.52 (bs, 4H, 
2xCH2); 2.71 (t, 2H, J = 8.0 Hz, CH2); 2.97 (t, 2H, J = 8.0 Hz, CH2); 3.54 (bs, 4H, 2xCH2); 
4.15 (q, 2H, J = 7.0 Hz, CH2); 7.00 (s, 1H, CH); 7.11 (dd, 1H, J = 7.1 Hz, J = 7.7 Hz, CH); 
                                               
112 Grina, J.A.; Ratcliff, M.R.; Stermitz, F.R.; J. Org. Chem. 1982, 47, 2648-2651. 
113 Lounasmaa, M.; Jokela, R.; Tetrahedron 1989, 45, 3975-3992. 
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7.18 (dd, 1H, J = 7.1 Hz, J = 8.0 Hz, CH); 7.33 (d, 1H, J = 8.0 Hz, CH); 7.60 (d, 1H, 
J = 7.7 Hz, CH); 8.34 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 14.6 (CH3); 22.7 (CH2); 
43.6 (2xCH2); 52.8 (2zCH2); 59.1 (CH2); 61.3 (CH2); 111.1 (CH); 113.9 (C); 118.6 (CH); 
119.1 (CH); 121.5 (CH); 121.8 (CH); 127.4 (C); 136.2 (C); 155.5 (C). IR: n~  [cm-1] = 3268 
(w); 2979 (m); 2809 (m); 2485 (w); 1714 (s); 1481 (m); 767 (w). HRMS found [M+H]+ 
302.1847 C17H23N3O2 requires [M+H]+, 302.1869. 
3-(3-(piperidin-1-yl)propyl)-1H-indole (304e). The first generation protocol was followed 
with 1-(but-3-enyl)piperidine (574 mg, 4.13 mmol), phenylhydrazine (446 mg, 4.13 mmol), 
Rh(acac)(CO)2 (3.2 mg, 0.3 mol%) and XANTPHOS (35.8 mg, 3 mol%) to give 3-(3-
(piperidin-1-yl)propyl)-1H-indole (908 mg, 91 %) without further purification. 1H-NMR: 
(CDCl3, 400 MHz) d = 1.42 (bs, 2H, CH2); 1.56-16.2 (4H, 2xCH2); 1.89-1.97 (2H, CH2); 
2.39-2.43 (bs, 6H, 3xCH2); 2.75 (t, 2H, J = 7.6 Hz, CH2); 6.92 (s, 1H, CH); 7.08 (dd, 1H, 
J = 7.0 Hz, J = 7.8 Hz, CH); 7.16 (dd, 1H, J = 7.0 Hz, J = 8.1 Hz, CH); 7.31 (d, 1H, 
J = 8.1 Hz, CH); 7.59 (d, 1H, J = 7.8 Hz, CH); 8.37 (bs, 1H, NH). 13C-NMR: (CDCl3, 
125 MHz) d = 23.1 (CH2); 24.4 (CH2); 25.9 (2xCH2); 27.3 (CH2); 54.9 (2xCH2); 59.3 (CH2); 
111.0 (CH); 116.3 (C); 118.9 (CH); 121.1 (CH); 121.7 (CH); 127.5 (C); 136.3 (C). IR: n~  
[cm-1] = 3218 (s); 2944 (vs); 2937 (vs); 2805 (s); 1455 (s); 1106 (vs); 781 (s); 732 (vs). 
HRMS found [M]+ 242.1784 C16H22N2 requires M+, 242.1783. 
Ethyl 4-(3-(1H-indol-3-yl)propyl)piperazine-1-carboxylate (304f). The first generation 
protocol was followed with ethyl 4-(but-3-enyl)piperazine-1-carboxylate (337 mg, 
1.59 mmol), phenylhydrazine (172 mg, 1.59 mmol), Rh(acac)(CO)2 (1.2 mg, 0.3 mol%) and 
XANTPHOS (13.8 mg, 3 mol%) to give ethyl 4-(3-(1H-indol-3-yl)propyl)piperazine-1-
carboxylate (455 mg, 91 %) without further purification. 1H-NMR: (CDCl3, 500 MHz) 
d = 1.27 (t, 3H, J = 7.0 Hz, CH3); 1.88-1.94 (2H, CH2); 2.40-2.45 (6H, 3xCH2); 2.78 (t, 2H, 
J = 7.5 Hz, CH2); 3.51 (bs, 4H, 2xCH2); 4.16 (q, 2H, J = 7.0 Hz, CH2); 6.93 (s, 1H, CH); 7.10 
(dd, 1H, J = 7.2 Hz, J = 7.5 Hz, CH); 7.17 (dd, 1H, J = 7.5 Hz, J = 8.0 Hz, CH); 7.31 (d, 1H, 
J = 8.0 Hz, CH); 7.60 (d, 1H, J = 7.2 Hz, CH); 8.61 (bs, 1H, NH). 13C-NMR: (CDCl3, 
125 MHz) d = 16.2 (CH3); 24.4 (CH2); 28.7 (CH2); 45.2 (2xCH2); 54.4 (2xCH2); 59.8 (CH2); 
62.8 (CH2); 112.7 (CH); 117.4 (C); 120.4 (2xCH); 122.8 (CH); 123.2 (CH); 129.0 (C); 137.9 
(C); 157.1 (C). IR: n~  [cm-1] = 3324 (s); 2935 (s); 2809 (s); 1700 (vs); 1434 (vs); 1243 (vs); 
1128 (vs); 740 (vs). HRMS found [M]+ 315.1970 C18H25N3O2 requires M+, 315.1947. 
N,N-diethyl-2-(1H-indol-3-yl)-1-phenylethanamine (304g). The first generation protocol 
was followed with N,N-diethyl-1-phenylprop-2-en-1-amine (250 mg, 1.32 mmol), 
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phenylhydrazine (142 mg, 1.32 mmol), Rh(acac)(CO)2 (0.34 mg, 1 mol%) and XANTPHOS 
(38 mg, 5 mol%). The crude product was purified by chromatography (silica, EtOAc, 
cyclohexane, NEt3) to give N,N-diethyl-2-(1H-indol-3-yl)-1-phenylethanamine (327 mg, 
85 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.06-1.11 (6H, 2xCH3); 2.50-2.55 (2H, CH2); 2.78-
2.84 (2H, CH2); 3.18 (d, 1H, J = 9.9 Hz, CHH); 3.46 (d, 1H, J = 14.5 Hz, CHH); 4.10 (dd, 
1H, J = 9.9 Hz, J = 14.5 Hz, CH); 6.56 (s, 1H, CH); 7.10-7.28 (8H, 8xCH); 7.61 (d, 1H, 
J = 7.7 Hz, CH); 7.99 (bs, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 12.8 (2xCH3); 28.3 
(CH2); 43.4 (2xCH2); 64.8 (CH); 110.9 (CH); 113.7 (C); 118.6 (CH); 118.9 (CH); 121.5 
(CH); 122.5 (CH); 126.5 (CH); 127.6 (2xCH); 127.8 (C); 128.8 (2xCH); 135.9 (C); 141.9 (C). 
IR: n~  [cm-1] = 3419 (m); 2967 (s); 1492 (m); 1455 (s); 740 (s); 700 (s). HRMS found 
[M+H]+ 293.1986 C20H25N2 requires [M+H]+, 293.1939. 
3-(2-Phenyl-2-(piperidin-1-yl)ethyl)-1H-indole ((rac)-304h). The first generation protocol 
was followed with rac-1-(1-phenylallyl)piperidine (661 mg, 3.3 mmol), phenylhydrazine 
(355 mg, 3.3 mmol), Rh(acac)(CO)2 (8.5 mg, 1 mol%) and XANTPHOS (95 mg, 5 mol%). 
The crude product was purified by chromatography (silica, EtOAc, cyclohexane, NEt3) to 
give 3-(2-phenyl-2-(piperidin-1-yl)ethyl)-1H-indole (540 mg, 54 %). 1H-NMR: (CDCl3, 
500 MHz) d = 1.44 (bs, 2H, CH2); 1.65 (bs, 4H, 2xCH2); 2.57 (bs, 4H, 2xCH2); 3.26 (d, 1H, 
J = 9.7 Hz, CHH); 3.54 (d, 1H, J = 4.5 Hz, CHH); 3.80 (dd, 1H, J = 4.5 Hz, J = 9.7 Hz, CH); 
6.59 (s, 1H, CH); 7.13 (dd, 1H, J = 7.2 Hz, J = 7.7 Hz, CH); 7.18 (dd, 1H, J = 7.2 Hz, 
J = 7.7 Hz, CH); 7.24-7.30 (6H, 6xCH); 7.63 (d, 1H, J = 7.7 Hz, CH); 8.17 (s, 1H, NH). 
13C-NMR: (CDCl3, 125 MHz) d = 26.2 (CH2); 27.9 (2xCH2); 29.8 (CH2); 53.0 (2xCH2); 72.4 
(CH); 112.5 (CH); 115.0 (C); 120.2 (CH); 120.4 (CH); 123.0 (CH); 124.1 (CH); 128.3 (CH); 
129.2 (2xCH); 129.3 (C); 130.5 (2xCH); 137.4 (C); 141.9 (C). IR: n~  [cm-1] = 3426 (s); 2929 
(s); 2852 (s); 2798 (s); 1602 (s); 1492 (s); 1469 (s); 1454 (s); 1093 (s); 1068 (m); 1033 (m); 
910 (s); 738 (s). HRMS found [M+H]+ 305.2037 C21H25N2 requires [M+H]+, 305.2056. 
3-((+)-2-Phenyl-2-(piperidin-1-yl)ethyl)-1H-indole ((+)-304h). The title compound was 
obtained with 95 %ee109. 1H-NMR: (CDCl3, 500 MHz) d = 1.44 (bs, 2H, CH2); 1.65 (bs, 4H, 
2xCH2); 2.57 (bs, 4H, 2xCH2); 3.26 (d, 1H, J = 9.7 Hz, CHH); 3.54 (d, 1H, J = 4.5 Hz, CHH); 
3.80 (dd, 1H, J = 4.5 Hz, J = 9.7 Hz, CH); 6.59 (s, 1H, CH); 7.13 (dd, 1H, J = 7.2 Hz, 
J = 7.7 Hz, CH); 7.18 (dd, 1H, J = 7.2 Hz, J = 7.7 Hz, CH); 7.24-7.30 (6H, 6xCH); 7.63 (d, 
1H, J = 7.7 Hz, CH); 8.17 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 26.2 (CH2); 27.9 
(2xCH2); 29.8 (CH2); 53.0 (2xCH2); 72.4 (CH); 112.5 (CH); 115.0 (C); 120.2 (CH); 120.4 
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(CH); 123.0 (CH); 124.1 (CH); 128.3 (CH); 129.2 (2xCH); 129.3 (C); 130.5 (2xCH); 137.4 
(C); 141.9 (C). [a] = +59.6° (c=1.00, CH2Cl2). 
3-((-)-2-Phenyl-2-(piperidin-1-yl)ethyl)-1H-indole ((-)-304h). The title compound was 
obtained with 95 %ee109. 1H-NMR: (CDCl3, 500 MHz) d = 1.44 (bs, 2H, CH2); 1.65 (bs, 4H, 
2xCH2); 2.57 (bs, 4H, 2xCH2); 3.26 (d, 1H, J = 9.7 Hz, CHH); 3.54 (d, 1H, J = 4.5 Hz, CHH); 
3.80 (dd, 1H, J = 4.5 Hz, J = 9.7 Hz, CH); 6.59 (s, 1H, CH); 7.13 (dd, 1H, J = 7.2 Hz, 
J = 7.7 Hz, CH); 7.18 (dd, 1H, J = 7.2 Hz, J = 7.7 Hz, CH); 7.24-7.30 (6H, 6xCH); 7.63 (d, 
1H, J = 7.7 Hz, CH); 8.17 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 26.2 (CH2); 27.9 
(2xCH2); 29.8 (CH2); 53.0 (2xCH2); 72.4 (CH); 112.5 (CH); 115.0 (C); 120.2 (CH); 120.4 
(CH); 123.0 (CH); 124.1 (CH); 128.3 (CH); 129.2 (2xCH); 129.3 (C); 130.5 (2xCH); 137.4 
(C); 141.9 (C).  
2-phenyl-3-(2-(piperidin-1-yl)ethyl)-1H-indole (304i). The first generation protocol was 
followed with 1-cinnamylpiperdine (313 mg, 1.56 mmol), phenylhydrazine (168 mg, 
1.56 mmol), Rh(acac)(CO)2 (2 mg, 0.5 mol%) and BIPHEPHOS (122 mg, 10 mol%). The 
crude product was purified by chromatography (silica, cyclohexane, EtOAc, NEt3) to give 
2-phenyl-3-(2-(piperidin-1-yl)ethyl)-1H-indole (300 mg, 60%).1H-NMR: (CDCl3, 500 MHz) 
d = 1.46 (bs, 2H, CH2); 1.63 (bs, 4H, 2xCH2); 2.52 (bs, 4H, 2xCH2); 2.68 (t, 2H, J = 8.5 Hz, 
CH2); 3.12 (t, 2H, J = 8.5 Hz, CH2); 7.14 (dd, 1H, J = 7.1 Hz, J = 7.0 Hz, CH); 7.20 (dd, 1H, 
J = 7.1 Hz, J = 7.7 Hz, CH); 7.34-7.37 (2H, 2xCH); 7.44 (dd, 2H, J = 8.0 Hz, J = 8.0 Hz, 
2xCH); 7.56 (d, 2H, J = 8.0 Hz, 2xCH); 7.65 (d, 1H, J = 8.0 Hz, CH); 8.31 (s, 1H, NH). 13C-
NMR: (CDCl3, 125 MHz) d = 22.1 (CH2); 24.4 (CH2); 25.9 (2xCH2); 54.6 (2xCH2); 60.0 
(CH2); 110.8 (CH); 111.2 (C); 119.1 (CH); 119.5 (CH); 122.2 (CH); 127.5 (CH); 127.9 
(2xCH); 128.8 (2xCH); 129.2 (C); 133.2 (C); 134.7 (C); 135.9 (C). Substitution pattern on 
indole ring confirmed by 1D-NOESY and gCOSY. IR: n~  [cm-1] = 3405 (m) 2931 (s), 1602 
(s), 1456 (s), 1261 (s), 1101 (s), 739 (vs), 696 (vs). HRMS found [M+H]+ 305.1991 C21H27N2 
requires [M+H]+, 305.1974. 
3-(1-Phenyl-3-(piperidin-1-yl)propyl)-1H-indole (304j). The first generation protocol was 
followed with 1-(3-phenylbut-3-enyl)piperidine (676 mg, 3.14 mmol), phenylhydrazine 
(340 mg, 3.14 mg) and Rh(acac)(CO)2 (8.1 mg, 1 mol%). The crude product was purified by 
chromatography (silica, EtOAc, cyclohexane, NEt3) to give 3-(1-phenyl-3-(piperidin-1-
yl)propyl)-1H-indole (414 mg, 41 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.45 (s, 2H, CH2); 
1.60 (s, 4H, 2xCH2); 2.21-2.45 (8H, 4xCH2); 4.22 (t, 1H, J = 7.1 Hz, CH); 7.01 (dd, 1H, 
J = 7.2 Hz, J = 8.0 Hz, CH); 7.03 (s, 1H, CH); 7.13 (d, 1H, J = 8.2 Hz, CH); 7.17 (d, 1H, 
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J = 8.2 Hz, CH); 7.25 (dd, 2H, J = 7.2 Hz, J = 7.5 Hz, 2xCH); 7.30-7.32 (3H, 3xCH); 7.46 (d, 
1H, J = 8.0 Hz, CH); 8.38 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 24.5 (CH2); 26.0 
(2xCH2); 33.3 (CH2); 41.0 (CH); 54.7 (2xCH2); 57.9 (CH2); 111.0 (CH); 119.1 (CH); 119.4 
(CH); 120.1 (C); 121.0 (CH); 121.8 (CH); 125.9 (CH); 127.0 (C); 127.8 (2xCH); 128.2 
(2xCH); 136.5 (C); 145.3 (C). IR: n~  [cm-1] = 3399 (s); 2952 (m); 1666 (s); 1650 (s); 1529 
(vs); 1471 (s); 1274 (s); 1095 (s); 835 (m); 804 (s). HRMS found [M+H]+ 318.2097 C22H25N2 
requires [M+H]+, 318.2098. 
N,N-Diethyl-3-(1H-indol-3-yl)-1-phenylbutan-1-amine (304k). The first generation 
protocol was followed with N,N-diethyl-3-methyl-1-phenylbut-3-en-1-amine (678 mg, 
3.12 mmol), Phenylhydrazine (337 mg, 3.12 mmol) and Rh(acac)(CO)2 (8 mg, 1 mol%). The 
crude product was purified by chromatography (silica, EtOAc, cyclohexane, NEt3) to give 
N,N-diethyl-3-(1H-indol-3-yl)-1-phenylbutan-1-amine (511 mg, 51 %). Analytical data was 
obtained from the inseparable mixture of diastereomers: 1H-NMR: (CDCl3, 500 MHz) 
d = 1.03, 1.10 (t, 6H, J = 7.0 Hz, 2xCH3); 1.41, 1.45 (d, 3H, J = 6.8 Hz, CH3); 2.07-2.25 (1H, 
CH); 2.33-2.43, 2.69-2.80 (4H, 2xCH2); 2.54-2.61, 2.96-3.05 (2H, CH2); 3.77, 3.93 (dd, 1H, 
J = 5.8 Hz, J = 9.0 Hz, CH); 6.91 (s, 1H, CH); 7.12-7.64 (9H, 9xCH); 8.36, 8.44 (bs, 1H, 
NH). 13C-NMR: (CDCl3, 125 MHz) d = 12.8, 12.9 (2xCH3); 20.6, 22.5 (CH3); 27.5, 27.9 
(CH); 40.0, 40.7 (CH2); 43.0, 43.2 (2xCH2); 61.8, 62.3 (CH); 111.0, 111.1 (CH); 118.6 (CH); 
119.2, 119.3 (CH); 119.9, 120.3 (CH); 121.4 (CH); 122.6 (C); 126.5 (C); 126.6, 126.8 (CH); 
127.7, 127.8 (2xCH); 128.7, 128.9 (2xCH); 136.3, 136.4 (C); 140.8, 141.0 (C). IR: n~  [cm-1] 
= 3419 (s); 2058 (m); 2965 (s); 1670 (m); 1600 (m); 1492 (s); 1455 (s); 1226 (m); 908 (s); 
736 (vs). HRMS found [M]+ 320.2277 C22H28N2 requires [M]+, 320.2253. 
N,N-Diethyl-3-(1H-indol-3-yl)-1-phenylpropan-1-amine (304l). The first generation 
protocol was followed with N,N-diethyl-1-phenylbut-3-en-1-amine (332 mg, 1.63 mmol), 
phenylhydrazine (176 mg, 1.63 mmol), Rh(acac)(CO)2 (1.3 mg, 0.3 mol%) and XANTPHOS 
(14 mg, 1.5 mol%). The crude product was purified by chromatography (silica, EtOAc, 
cyclohexane, NEt3) to give N,N-diethyl-3-(1H-indol-3-yl)-1-phenylpropan-1-amine (403 mg, 
81 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.06 (t, 6H, J = 7.0 Hz, 2xCH3); 2.15-2.23 (1H, 
CHH); 2.38-2.45 (3H, CH2,CHH); 2.59-2.68 (1H, CHH); 2.71-2.77 (3H, CH2, CHH); 3.81 
(dd, 1H, J = 8.5 Hz, J = 8.7 Hz, CH); 6.92 (s, 1H, CH); 7.12 (dd, 1H, J = 7.0 Hz, J = 7.7 Hz, 
CH); 7.21 (dd, 1H, J = 7.0 Hz, J = 8.0 Hz, CH); 7.31-7.40 (6H, 6xCH); 7.56 (d, 1H, 
J = 7.7 Hz, CH); 8.08 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 12.8 (2xCH3); 22.4 
(CH2); 33.2 (CH2); 43.2 (2xCH2); 64.3 (CH); 111.0 (CH); 116.6 (C); 118.9 (2xCH); 121.0 
EXPERIMENTAL SECTION 
 
- 150 - 
(CH); 121.7 (CH); 126.8 (CH); 127.5 (C); 127.9 (2xCH); 128.7 (2xCH); 136.3 (C); 141.4 (C). 
IR: n~  [cm-1] = 3419 (s); 2967 (vs); 2929 (s); 2869 (s); 1455 (vs); 740 (vs); 701 (s). HRMS 
found [M]+ 306.2128 C21H26N2 requires [M]+, 306.2098. 
3-(1-Methylpiperidin-4-yl)-1H-indole (304m). The first generation protocol was followed 
with 1-methyl-4-methylene-piperidine (519 mg, 4.67 mmol), phenylhydrazine (505 mg, 
4.67 mmol) and Rh(acac)(CO)2 (3.6 mg, 0.3 mol%) to give 3-(1-methylpiperidin-4-yl)-1H-
indole (781 mg, 78 %) without further purification. 1H-NMR: (CDCl3, 400 MHz) d = 1.86 (dt, 
2H, J = 11.8 Hz, J = 12.7 Hz, CH2); 2.05-2.06 (2H, CH2); 2.15 (t, 2H, J = 11.8 Hz, CH2); 2.36 
(s, 3H, CH3); 2.82 (t, 1H, J = 11.8 Hz, CH); 3.00 (d, 2H, J = 11.8 Hz, CH2); 6.91 (s, 1H, CH); 
7.09 (dd, 1H, J = 6.8 Hz, J = 7.0 Hz, CH); 7.17 (dd, 1H, J = 7.0 Hz, J = 8.0 Hz, CH); 7.32 (d, 
1H, J = 8.0 Hz, CH); 7.65 (d, 1H, J = 8.0 Hz, CH); 8.72 (s, 1H, NH). 13C-NMR: (CDCl3, 
100 MHz) d = 32.8 (CH); 32.9 (2xCH2); 46.5 (CH3); 56.3 (2xCH2); 111.2 (CH); 118.8 (CH); 
119.0 (CH); 119.8 (CH); 120.9 (C); 121.7 (CH); 126.5 (C); 136.4 (C). IR: n~  [cm-1] = 3147 
(m); 2935 (s); 2921 (s); 2844 (m); 2782 (s); 1457 (s); 1276 (s); 1222 (m); 1110 (m); 989 (s); 
732 (vs). HRMS found [M]+ 214.1490 C14H18N2 requires [M]+, 214.1470. 
5-Fluoro-3-(1-methylpiperidin-4-yl)-1H-indole (304n). The first generation protocol was 
followed with 1-methyl-4-methylene-piperidine (479 mg, 4.3 mmol), 4-fluoro 
phenylhydrazine (543 mg, 4.3 mmol) and Rh(acac)(CO)2 (3.3 mg, 0.3 mol%) to give 5-
fluoro-3-(1-methylpiperidin-4-yl)-1H-indole (653 mg, 65 %) without further purification.1H-
NMR: (CDCl3, 500 MHz) d = 1.80 (dt, 2H, J = 12.3 Hz, J = 13.1 Hz, CH2); 2.02 (d, 2H, 
J = 12.1 Hz, CH2); 2.13 (t, 2H, J = 12.1 Hz, CH2); 2.34 (s, 3H, CH3); 2.73 (t, 1H, J = 12.1 Hz, 
CH); 2.98 (d, 2H, J = 11.5 Hz, CH2); 6.90 (dd, 1H, J = 9.0 Hz, J = 9.0 Hz, CH); 6.98 (s, 1H, 
CH); 7.23-7.27 (2H, 2xCH); 8.60 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 32.7 (CH); 
32.8 (2xCH2); 46.4 (CH3); 56.2 (2xCH2); 103.8 (d, 1C, JC-F = 23 Hz, CH); 110.1 (d, 1C, JC-
F = 26 Hz, CH); 111.7 (CH); 121.2 (C); 121.6 (CH); 132.9 (C); 157.4 (d, 1C, JC-F = 234 Hz, 
C). IR: n~  [cm-1] = 3102 (s); 3045 (s); 2942 (vs); 2929 (vs); 2884 (s); 2794 (vs); 1465 (vs); 
1274 (s); 1170 (vs); 939 (vs); 790 (s); 757 (s). HRMS found [M]+ 232.1405 C14H17FN2 
requires [M]+, 232.1375. 
5-Chloro-3-(1-methylpiperidin-4-yl)-1H-indole (304o). The first generation protocol was 
followed with 1-methyl-4-methylene-piperidine (643 mg, 5.78 mmol), 4-chloro-
phenylhydrazine (825 mg, 5.78 mmol) and Rh(acac)(CO)2 (4.7 mg, 0.3 mol%) to give 5-
chloro-3-(1-methylpiperidin-4-yl)-1H-indole (1.21 g, 85 %) without further purification. 1H-
NMR: (CDCl3, 500 MHz) d = 1.85 (dt, 2H, J = 12.1 Hz, J = 12.7 Hz, CH2); 2.10 (d, 2H, 
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J = 12.7 Hz, CH2); 2.14 (t, 2H, J = 11.7 Hz, CH2); 2.37 (s, 3H, CH3); 2.77 (t, 1H, J = 12.1 Hz, 
CH); 3.00 (d, 2H, J = 11.7 Hz, CH2); 7.00 (s, 1H, CH); 7.16 (d, 1H, J = 8.5 Hz, CH); 7.28 (d, 
1H, J = 8.5 Hz, CH); 7.63 (s, 1H, CH); 8.27 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) 
d = 32.8 (CH); 33.0 (2xCH2); 46.5 (CH3); 56.3 (2xCH2); 112.1 (C); 112.1 (CH); 118.6 (CH); 
121.1 (CH); 122.1 (C); 122.1 (CH); 124.8 (C); 125.5 (C); 127.8 (C). IR: n~  [cm-1] = 3087 (s); 
2964 (s); 2917 (vs); 2771 (s); 1494 (s); 1378 (m); 1274 (s); 1122 (s); 1064 (s); 790 (s); 732 
(vs). HRMS found [M]+ 248.1059 C14H17ClN2 requires [M]+, 248.1080. 
5-Bromo-3-(1-methylpiperidin-4-yl)-1H-indole (304p). The first generation protocol was 
followed with 1-methyl-4-methylene-piperidine (569 mg, 5.12 mmol), 4-bromo-
phenylhydrazine (957 mg, 5.12 mmol) and Rh(acac)(CO)2 (4 mg, 0.3 mol%) to give 5-bromo-
3-(1-methylpiperidin-4-yl)-1H-indole (1.50 g, 100 %) without further purification. 1H-NMR: 
(CDCl3, 400 MHz) d = 1.82 (dt, 2H, J = 12.1 Hz, J = 12.6 Hz, CH2); 1.98-2.02 (2H, 2xCH2); 
2.12 (t, 2H, J = 12.1 Hz, CH2); 2.34 (s, 3H, CH3); 2.73 (t, 1H, J = 12.1 Hz, CH); 2.97 (d, 2H, 
J = 11.6 Hz, CH2); 6.92 (s, 1H, CH); 7.18-7.21 (2H, 2xCH); 7.74 (s, 1H, CH); 8.64 (s, 1H, 
NH). 13C-NMR: (CDCl3, 100 MHz) d = 31.7 (CH); 31.9 (2xCH2); 45.4 (CH3); 55.3 (2xCH2); 
111.2 (C); 11.7 (CH); 119.8 (C); 120.1 (CH); 120.6 (CH); 123.5 (CH); 127.4 (C); 134.0 (C). 
IR: n~  [cm-1] = 2938 (vs); 2786 (vs); 1452 (vs); 1276 (s); 1128 (s); 796 (s); 769 (s). HRMS 
found [M]+ 292.0547 C14H17BrN2 requires [M]+, 292.0575. 
5-Methyl-3-(1-methylpiperidin-4-yl)-1H-indole (304q). The first generation protocol was 
followed with 1-methyl-4-methylene-piperidine (487 mg, 4.38 mmol), 4-methyl-
phenylhydrazine (535 mg, 4.38 mmol) and Rh(acac)(CO)2 (3.4 mg, 0.3 mol%) to give 5-
methyl-3-(1-methylpiperidin-4-yl)-1H-indole (656 mg, 66 %) without further purification. 1H-
NMR: (CDCl3, 400 MHz) d = 1.87 (dt, 2H, J = 11.8 Hz, J = 12.5 Hz, CH2); 2.03 (d, 2H, 
J = 12.5 Hz, CH2); 2.15 (t, 2H, J = 11.8 Hz, CH2); 2.35 (s, 3H, CH3); 2.45 (s, 3H, CH3); 2.78 
(t, 1H, J = 11.8 Hz, CH); 3.00 (d, 2H, J = 11.8 Hz, CH2); 6.89 (s, 1H, CH); 6.99 (d, 1H, 
J = 8.3 Hz, CH); 7.22 (d, 1H, J = 8.3 Hz, CH); 7.43 (s, 1H, CH); 8.26 (s, 1H, NH). 13C-NMR: 
(CDCl3, 100 MHz) d = 21.5 (CH3); 32.9 (2xCH2); 37.2 (CH); 46.5 (CH3); 56.4 (2xCH2); 
110.9 (CH); 118.7 (CH); 119.9 (CH); 120.5 (C); 123.4 (CH); 126.8 (C); 128.1 (C); 134.7 (C). 
IR: n~  [cm-1] = 2937 (vs); 2690 (s); 1467 (s); 1376 (s); 1274 (s); 1124 (s); 792 (vs); 630 (s). 
HRMS found [M]+ 228.1626 C15H20N2 requires [M]+, 228.1627. 
5-Methoxy-3-(1-methylpiperidin-4-yl)-1H-indole (304r). The first generation protocol 
was followed with 1-methyl-4-methylene-piperidine (455 mg, 4.09 mmol), 4-methoxy-
phenylhydrazine (565 mg, 4.09 mmol) and Rh(acac)(CO)2 (3.2 mg, 0.3 mol%) to give 3-(1-
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methylpiperidin-4-yl)-1H-indole (845 mg, 85 %) without further purification. 1H-NMR: 
(CDCl3, 400 MHz) d = 1.84 (dt, 2H, J = 12.1 Hz, J = 12.8 Hz, CH2); 2.02 (d, 2H, J = 12.1 Hz, 
CH2); 2.14 (t, 2H, J = 12.1 Hz, CH2); 2.34 (s, 3H, CH3); 2.75 (t, 1H, J = 12.1 Hz, CH); 2.99 
(d, 2H, J = 11.5 Hz, CH2); 3.84 (s, 3H, CH3); 6.84 (d, 1H, J = 8.8 Hz, CH); 6.91 (s, 1H, CH); 
7.05 (s, 1H, CH); 7.21 (d, 1H, J = 8.8 Hz, CH); 8.34 (s, 1H, NH). 13C-NMR: (CDCl3, 
100 MHz) d = 32.8 (2xCH2); 37.3 (CH); 46.4 (CH3); 56.0 (CH3); 56.3 (2xCH2); 101.0 (CH); 
111.9 (2xCH); 120.6 (CH); 120.7 (C); 126.9 (C); 131.6 (C). IR: n~  [cm-1] = 3141 (s); 2935 
(vs); 2830 (vs); 1511 (vs); 1448 (vs); 1276 (vs); 1213 (s); 1056 (s); 792 (s). HRMS found 
[M+H]+ 245.1672 C15H21N2O requires [M+H]+, 245.1654. 
10.4.4 SECOND GENERATION PROTOCOL FOR THE TANDEM HYDROFORMYLATION / 
FISCHER INDOLE SYNTHESIS IN WATER 
3-(1-Methylpiperidin-4-yl)-1H-indole (304m). In a typical experiment 1-methyl-4-
methylenepiperidine (259 mg, 2.33 mmol), phenylhydrazine (252 mg, 2.33 mmol), 
Rh(acac)(CO)2 (1.8 mg , 0.3 mol%) and TPPTS (20 mg, 1.5 mol%) in H2SO4 (9.3 g, 4 wt% in 
water, 2.5 wt% olefin) were filled in an autoclave. The autoclave was pressurized with 10bar 
H2 and 50bar CO. After stirring for 3 days (The reaction is stirred magnetically. With a stirrer 
that mixes gas phase and liquid phase intensively, the reaction time can be reduced by far to 
our experience) at 100°C NH3 (10 ml, 30 wt% in water) was added and the mixture was 
extracted with EtOAc. The solvent was evaporated to give 3-(1-methylpiperidin-4-yl)-1H-
indole (400 mg, 80%) without further purification.  
5-Fluoro-3-(1-methylpiperidin-4-yl)-1H-indole (304n). The second generation protocol 
was followed with 1-methyl-4-methylene-piperidine (239 mg, 2.15 mmol), 4-fluoro 
phenylhydrazine hydrochloride (350 mg, 2.15 mmol), Rh(acac)(CO)2 (1.7 mg, 0.3 mol%) and 
TPPTS (18 mg, 1.5 mol%) to give 5-fluoro-3-(1-methylpiperidin-4-yl)-1H-indole (477 mg, 
95 %) without further purification. 
5-Chloro-3-(1-methylpiperidin-4-yl)-1H-indole (304o). The second generation protocol 
was followed with 1-methyl-4-methylene-piperidine (223 mg, 2.01 mmol), 4-chloro-
phenylhydrazine hydrochloride (360 mg, 2.01 mmol), Rh(acac)(CO)2 (1.6 mg, 0.3 mol%) and 
TPPTS (17 mg, 1.5 mol%) to give 5-chloro-3-(1-methylpiperidin-4-yl)-1H-indole (500 mg, 
100 %) without further purification.  
5-Bromo-3-(1-methylpiperidin-4-yl)-1H-indole (304p). The second generation protocol 
was followed with 1-methyl-4-methylene-piperidine (190 mg, 1.71 mmol), 4-bromo-
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phenylhydrazine hydrochloride (381 mg, 1.71 mmol), Rh(acac)(CO)2 (1.3 mg, 0.3 mol%) and 
TPPTS (14.5 mg, 1.5 mol%) to give 5-bromo-3-(1-methylpiperidin-4-yl)-1H-indole (479 g, 
96 %) without further purification.  
7-Chloro-3-(1-methylpiperidin-4-yl)-1H-indole (304s). The second generation protocol 
was followed with 1-methyl-4-methylene-piperidine (223 mg, 2.01 mmol), 2-chloro-
phenylhydrazine hydrochloride (360 mg, 2.01 mmol), Rh(acac)(CO)2 (1.5 mg, 0.3 mol%) and 
TPPTS (17 mg, 1.5 mol%) to give 7-chloro-3-(1-methylpiperidin-4-yl)-1H-indole (480 g, 
96 %) without further purification. 1H-NMR: (CDCl3, 500 MHz) d = 1.87 (dt, 2H, 
J = 12.2 Hz, J = 12.7 Hz, CH2); 2.05 (d, 2H, J = 12.7 Hz, CH2); 2.14 (t, 2H, J = 11.7 Hz, 
CH2); 2.36 (s, 3H, CH3); 2.79 (t, 1H, J = 11.7 Hz, CH); 3.00 (d, 2H, J = 11.7 Hz, CH2); 6.99 
(s, 1H, CH); 7.02 (dd, 1H, J = 7.7 Hz, J = 8.0 Hz, CH); 7.17 (d, 1H, J = 7.7 Hz, CH); 7.54 (d, 
1H, J = 8.0 Hz, CH); 8.68 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 32.9 (2xCH2); 33.0 
(CH); 46.5 (CH3); 56.3 (2xCH2); 116.7 (C); 117.7 (CH); 119.7 (CH); 120.5 (CH); 121.1 
(CH); 122.3 (C); 128.2 (C); 133.6 (C). IR: n~  [cm-1] = 3045 (s); 2942 (s); 2848 (s); 2794 (vs); 
2742 (s); 1 469 (m); 1444 (s); 1199 (s); 1116 (s); 775 (s). HRMS found [M]+ 248.1088 
C14H17ClN2O requires [M]+, 248.1080. 
Ethyl 4-(2-(1H-indol-3-yl)ethyl)piperazine-1-carboxylate (304d). The second generation 
protocol was followed with 4-allyl-piperazine-1-carboxylic acid ethyl ester (638 mg, 
3.2 mmol), phenylhydrazine (174 mg, 1.6 mmol), Rh(acac)(CO)2 (1.3 mg, 0.3 mol%) and 
SULFOXANTPHOS (36 mg, 3 mol%). The crude product was purified by chromatography 
(silica, EtOAc, cyclohexane, NEt3) to give ethyl 4-(2-(1H-indol-3-yl)ethyl)piperazine-1-
carboxylate (485 mg, 100 %). 
3-(3-(Piperidin-1-yl)propyl)-1H-indole (304e). The second generation protocol was 
followed with 1-(but-3-enyl)piperidine (574 mg, 4.13 mmol), phenylhydrazine (223 mg, 
2.06 mmol), Rh(acac)(CO)2 (1.6 mg, 0.3 mol%) and SULFOXANTPHOS (46 mg, 3 mol%). 
The crude product was purified by chromatography (silica, EtOAc, cyclohexane, NEt3) to 
give 3-(3-(piperidin-1-yl)propyl)-1H-indole (249 mg, 50 %). 
N,N-Diethyl-3-(1H-indol-3-yl)-1-phenylpropan-1-amine (304l). The second generation 
protocol was followed with N,N-diethyl-1-phenylbut-3-en-1-amine (664 mg, 3.26 mmol), 
phenylhydrazine (176 mg, 1.63 mmol), Rh(acac)(CO)2 (1.3 mg, 0.3 mol%) and 
SULFOXANTPHOS (36 mg, 3 mol%). The crude product was purified by chromatography 
(silica, EtOAc, cyclohexane, NEt3) to give N,N-diethyl-3-(1H-indol-3-yl)-1-phenylpropan-1-
amine (500 mg, 100 %). 
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10.4.5 SYNTHESIS OF LY 349 950 & 334 370 
N-[4-(4-Fluoro-benzoylamino)-phenyl]-hydrazinecarboxylic acid tert-butyl ester 
(302i). At 0°C 4-fluorobenzoyl chloride (7.0 g, 44 mmol) was added dropwise to solution of 
4-iodo-anilin (9.6 g, 44 mmol), DMAP (270 mg, 5 mol%) and NEt3 (4.9 g, 48 mmol) in dry 
THF (100 ml). The mixture was stirred for 1h at ambient temperature. The precipitate was 
filtered off and the solvent was removed to give 4-fluoro-N-(4-iodo-phenyl)-benzamide 
(14.8 g, 99 %), which was subjected to the next step without purification. A suspension of 4-
Fluoro-N-(4-iodo-phenyl)-benzamide (7.4 g, 22 mmol), hydrazinecarboxylic acid tert-butyl 
ester (3.4 g, 26 mmol), CuI (207 mg, 5 mol%), 1,10-phenantroline (391 mg, 10 mol%) and 
Cs2CO3 (9.9 g, 30 mmol) in dry DMF (21 ml) was stirred for 68h at 80°C. The mixture was 
poured into EtOAc (100 ml) and the solids were separated by filtration through a pad of silica. 
The solvent was removed and the residue was purified by chromatography (silica, 
cyclohexane, CH2Cl2, NEt3) to give N-[4-(4-fluoro-benzoylamino)-phenyl]-
hydrazinecarboxylic acid tert-butyl ester (5.7 g, 78 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.47 
(s, 9H, 3xCH3); 4.40 (s, 2H, NH2); 7.04 (dd, 2H, J = 8.5 Hz, J = 8.5 Hz, 2xCH); 7.38 (d, 2H, 
J = 8.7 Hz, 2xCH); 7.54 (d, 2H, J = 8.7 Hz, 2xCH); 7.82 (dd, 2H, J = 8.5 Hz, J = 8.5 Hz, 
2xCH); 8.32 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 28.3 (3xCH3); 81.8 (C); 115.5 (d, 
2C, JC-F = 21 Hz, 2xCH); 120.3 (2xCH); 123.9 (2xCH); 129.5 (d, 2C, JC-F = 8 Hz, 2xCH); 
131.0 (d, 1C, JC-F = 4 Hz, C); 134.5 (C); 139.6 (C); 155.1 (C); 164.7 (d, 1C, JC-F = 253 Hz, 
C); 164.8 (C). IR: n~  [cm-1] = 3367 (s); 2981 (s); 2931 (s); 1691 (s); 1592 (vs); 1525 (vs); 
1413 (vs); 1311 (vs); 1232 (vs); 1149 (vs); 1039 (vs); 836 (vs); 759 (vs). HRMS found [M]+ 
345.1484, C18H20FN3O3 requires [M]+, 345.1489. Elementary analysis found C 62.16%, 
H 5.80%, N 12.03 C18H20FN3O3 requires C 62.20%, H 5.84%, N 12.17.  
N-[3-(2-Dimethylamino-ethyl)-1H-indol-5-yl]-4-fluoro-benzamide (LY 349 950). The 
first generation protocol is followed with N,N-Dimethylprop-2-en-1-amine (262 mg, 
3.1 mmol), N-[4-(4-Fluoro-benzoylamino)-phenyl]-hydrazinecarboxylic acid tert-butyl ester 
(1.06 g, 3.1 mmol), Rh(acac)(CO)2 (8 mg, 1 mol%) and XANTPHOS (89 mg, 5 mol%). The 
crude product is purified by chromatography (silica, CH2Cl2, cyclohexane, NEt3) to give N-
[3-(2-Dimethylamino-ethyl)-1H-indol-5-yl]-4-fluoro-benzamide (440 mg, 44 %). 1H-NMR: 
(CDCl3, 500 MHz) d = 2.30 (s, 6H, 2xCH3); 2.62 (t, 2H, J = 8.0 Hz, CH2); 2.87 (t, 2H, 
J = 8.0 Hz, CH2); 6.94 (s, 1H, CH); 7.11 (dd, 2H, J = 8.7 Hz, J = 8.2 Hz, 2xCH); 7.20 (d, 1H, 
J = 8.7 Hz, CH); 7.26 (s, 1H, CH); 7.81 (s, 1H, CH); 7.90 (bs, 2H, 2xCH); 8.13 (s, 1H, NH); 
8.59 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 23.4 (CH2); 45.3 (2xCH3); 60.0 (CH2); 
114.0 (CH); 111.6 (CH); 114.2 (C); 115.6 (d, 2C, JC-F = 21 Hz, 2xCH); 116.9 (CH); 122.8 
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(CH); 127.6 (C); 129.4 (d, 2C, JC-F = 8 Hz, 2xCH); 129.7 (C); 131.4 (C); 134.0 (C); 163.7 
(C); 165.3 (d, 1C, JC-F = 251 Hz, C). IR: n~  [cm-1] = 3291 (s); 2942 (m); 2823 (m); 1644 (vs); 
1602 (vs); 1540 (s); 1481 (vs); 1330 (m); 1232 (s); 1159 (s); 850 (s); 796 (m). HRMS found 
[M+H]+ 326.1689 C19H20FN3O requires [M+H]+, 326.1709.  
4-Fluoro-N-[3-(1-methyl-piperidin-4-yl)-1H-indol-5-yl]-benzamide (LY 334 370). The 
second generation protocol is followed with 1-Methyl-4-methylene-piperidine (158 mg, 
1.42 mmol), N-[4-(4-Fluoro-benzoylamino)-phenyl]-hydrazinecarboxylic acid tert-butyl ester 
(491 mg, 1.42 mmol), Rh(acac)(CO)2 (3.7 mg, 1 mol%) and TPPTS (40 mg, 5 mol%) to give 
4-Fluoro-N-[3-(1-methyl-piperidin-4-yl)-1H-indol-5-yl]-benzamide (474 mg, 95 %). 1H-
NMR: (CDCl3, 500 MHz) d = 1.68 (q, 2H, J = 11.8 Hz, 2xCH2); 1.86 (d, 2H, J = 11.2 Hz, 
CH2); 1.96 (t, 2H, J = 11.7 Hz, CH2); 2.23 (s, 3H, CH3); 2.60 (t, 1H, J = 11.0 Hz, CH); 2.82 
(d, 2H, J = 9.7 Hz, CH2); 6.71 (s, 1H, CH); 6.98 (bs, 2H, 2xCH); 7.11 (d, 1H, J = 8.3 Hz, 
CH); 7.18 (d, 1H, J = 8.3 Hz, CH); 7.84 (bs, 2H, 2xCH); 7.88 (s, 1H, CH); 8.61 (bs, 1H, NH); 
9.27 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 32.4 (CH); 32.5 (2xCH2); 46.1 (CH3); 
56.0 (2xCH2); 111.5 (CH); 112.2 (CH); 115.4 (d, 2C, JC-F = 21 Hz, 2xCH2); 116.8 (CH); 
120.6 (C); 121.1 (CH); 126.6 (C); 129.3 (C); 129.4 (d, 2C, JC-F = 8 Hz, 2xCH); 131.2 (C); 
134.2 (C); 164.5 (d, 1C, J = 251 Hz, CC); 165.3 (C). IR: n~  [cm-1] = 3291 (s); 2933 (s); 2850 
(m); 1646 (vs); 1602 (s); 1540 (s); 1481 (vs); 1328 (m); 1232 (s); 1159 (s); 850 (s); 796 (m). 
HRMS found [M]+ 351.1729 C21H22FN3O requires [M]+, 351.1711. 
10.4.6 SYNTHESIS OF L 775 606 
1-But-3-enyl-4-[2-(3-fluoro-phenyl)-ethyl]-piperazine (301n). (3-Fluoro-phenyl)-acetic 
acid (10.0 g, 64.9 mmol) in dry THF (150 ml) was dropped to a suspension of LiAlH4 (4.92 g, 
130 mmol) in dry THF (150 ml) at 0°C. The mixture was stirred for 3h under reflux. At 0°C 
KOH (2.28 g) in water (9 ml) was added dropwise. The resulting suspension was stirred for 
15min under reflux. The precipitate was filtered off, washed with THF (50 ml) and dried over 
MgSO4. The solvent was removed to give 2-(3-fluoro-phenyl)-ethanol (8.97 g, 99 %) without 
further purification. At 0°C Br2 (13.9 g, 86.9 mmol) was added dropwise to a solution of 
triphenyl-phosphane (22.8 g, 86.9 mmol) and imidazole (5.91 g, 86.9 mmol) in dry CH2Cl2 
(60 ml) followed by 2-(3-fluoro-phenyl)-ethanol (8.70 g, 62.0 mmol) in dry CH2Cl2 (20 ml). 
The mixture was stirred for 1h at ambient temperature and was washed consecutively with 
saturated NaS2O3 solution (10 ml) and saturated NaCl solution (10 ml). The organic layer 
was dried over MgSO4 and the solvent was removed. The residue was filtered through a pad 
of silica (cyclohexane / Et2O 5:1) and the solvent was removed to give 1-(2-bromo-ethyl)-3-
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fluoro-benzene (11.3 g, 89 %) without the need for further purification. 1-(2-Bromo-ethyl)-3-
fluoro-benzene (4.71 g, 23.2 mmol) was added dropwise to a refluxing suspension of 
piperazine-1-carboxylic acid ethyl ester (4.41 g, 27.8 mmol) and K2CO3 (4.89 g, 35.4 mmol) 
in dry CH3CN (10 ml). The mixture was stirred for 12h under reflux and was then filtrated 
through a pad of alumina. The solvent was removed to give 4-[2-(3-fluoro-phenyl)-ethyl]-
piperazine-1-carboxylic acid ethyl ester (5.53 g, 85 %), which was subjected to the next step 
without purification. 4-[2-(3-Fluoro-phenyl)-ethyl]-piperazine-1-carboxylic acid ethyl ester 
(5.20 g, 18.5 mmol) in NaOH (20 wt% in water, 50 ml) and EtOH (50 ml was stirred for 12h 
under reflux. The mixture was extracted with EtOAc (3x100 ml). The organic layer was dried 
over MgSO4 and the solvent was removed to give 1-[2-(3-fluoro-phenyl)-ethyl]-piperazine 
(3.80 g, 99 %) without purification. 4-Bromo-but-1-ene (0.9 g, 6.9 mmol) was added 
dropwise to a refluxing suspension of 1-[2-(3-fluoro-phenyl)-ethyl]-piperazine (1.2 g, 
5.7 mmol) and K2CO3 (1.2 g, 8.6 mmol) in dry CH3CN (10 ml). The mixture was stirred for 
12h under reflux and was then filtrated through a pad of alumina. The solvent was removed to 
give 1-but-3-enyl-4-[2-(3-fluoro-phenyl)-ethyl]-piperazine (1.49 g, 99 %). without further 
purification 1H-NMR: (CDCl3, 500 MHz) d = 2.21-2.25 (2H, CH2); 2.40 (dd, 2H, J = 7.2 Hz, 
J = 8.5 Hz, CH2); 2.52 (bs, 8H, 4xCH2); 2.56 (dd, 2H, J = 7.6 Hz, J = 8.7 Hz, CH2); 2.76 (dd, 
2H, J = 7.6 Hz, J = 8.7 Hz, CH2); 4.97 (d, 1H, J = 10.2 Hz, CHH); 5.03 (d, 1H, J = 17.2 Hz, 
CHH); 5.77 (ddt, 1H, J = 6.8 Hz, J = 10.2 Hz, J = 17.2 Hz, CH); 6.83-6.89 (2H, 2xCH); 6.93 
(d, 1H, J = 7.5 Hz, CH); 7.19 (dd, 1H, J = 7.5 Hz, J = 7.5 Hz, CH). 13C-NMR: (CDCl3, 
125 MHz) d = 31.3 (CH2); 33.3 (CH2); 53.0 (4xCH2); 57.9 (CH2); 60.0 (CH2); 112.8 (d, 1C, 
JC-F = 21 Hz, CH); 115.4 (d, 1C, JC-F = 21 Hz, CH); 115.6 (CH2); 124.3 (d, 1C, JC-F = 4 Hz, 
CH); 129.7 (d, 1C, JC-F = 8 Hz, CH); 136.4 (CH); 142.8 (d, 1C, JC-F = 8 Hz, C); 162.8 (d, 1C, 
JC-F = 246 Hz, C). IR: n~  [cm-1] = 2938 (s); 2807 (s); 1616 (m); 1589 (s); 1488 (s); 1461 (s); 
1251 (s); 1159 (s); 1010 (m); 912 (m); 781 (m). 
N-(4-[1,2,4]Triazol-4-yl-phenyl)-hydrazinecarboxylic acid tert-butyl ester (302j). At 
0°C NEt3 (14.0 g, 139 mmol) followed by TMS-Cl (31.9 g, 294 mmol) were added dropwise 
to a suspension of 4-iodo-anilin (4.31 g, 19.6 mmol) and sym-diformylhydrazine (4.35 g, 
49.4 mmol) in dry pyridine (200 ml). The mixture was stirred for 12h under reflux. The 
solvent was removed and the residue was taken up in water (200 ml). The precipitate was 
filtered off and dried in vacuo to give pure 4-(4-iodo-phenyl)-4H-[1,2,4]triazole (3.70 g, 
70 %). A suspension of 4-(4-iodo-phenyl)-4H-[1,2,4]triazole (4.50 g, 16.6 mmol), 
hydrazinecarboxylic acid tert-butyl ester (2.76 g, 20.9 mmol), CuI (35.0 mg, 1 mol%), 9,10-
phenantroline (313 mg, 10 mol%) and Cs2CO3 (7.92 g, 24.3 mmol) in dry DMF (18 ml) was 
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stirred for 68h at 80°C. Then the mixture was poured into EtOAc (100 ml) and the solids were 
separated by filtration through a pad of silica. The solvent was removed and the residue was 
purified by chromatography (silica, cyclohexane, CH2Cl2, NEt3) to give N-(4-[1,2,4]triazol-4-
yl-phenyl)-hydrazinecarboxylic acid tert-butyl ester (2.29 g, 48 %). 1H-NMR: (CDCl3, 
500 MHz) d = 1.51 (s, 9H, 3xCH3); 4.43 (s, 2H, NH2); 7.28 (d, 2H, J = 8.8 Hz, 2xCH); 7.71 
(d, 2H, J = 8.8 Hz, 2xCH); 8.41 (s, 2H, 2xCH). 13C-NMR: (CDCl3, 125 MHz) d = 28.2 
(3xCH3); 82.7 (C); 122.0 (2xCH); 123.9 (2xCH); 129.4 (C); 130.2 (2xCH); 143.8 (C); 154.5 
(C). IR: n~  [cm-1] = 3324 (s); 3108 (s); 2985 (s); 1693 (vs); 1612 (s); 1525 (vs); 1369 (vs); 
1288 (vs); 1157 (vs); 836 (vs). HRMS found [M+H]+ 276.1470, C13H17N5O2 requires 
[M+H]+, 276.1460. Elementary analysis found C 56.36%, H 6.27%, N 25.31 C13H17N5O2 
requires C 56.71%, H 6.22%, N 25.44%. 
3-(3-{4-[2-(3-Fluoro-phenyl)-ethyl]-piperazin-1-yl}-propyl)-5-[1,2,4]triazol-4-yl-1H-
indole (L 775 606). The first generation protocol is followed with 1-But-3-enyl-4-[2-(3-
fluoro-phenyl)-ethyl]-piperazine (455 mg, 1.7 mmol), N-(4-[1,2,4]Triazol-4-yl-phenyl)-
hydrazinecarboxylic acid tert-butyl ester (477 mg, 1.7 mmol), Rh(acac)(CO)2 (4.5 mg, 
1 mol%) and XANTPHOS (50 mg, 5 mol%). The crude product is purified by 
chromatography (silica, CH2Cl2, EtOH, NEt3) to give 3-(3-{4-[2-(3-Fluoro-phenyl)-ethyl]-
piperazin-1-yl}-propyl)-5-[1,2,4]triazol-4-yl-1H-indole (382 mg, 51 %). 1H-NMR: (CDCl3, 
500 MHz) d = 1.27 (t, 2H, J = 7.2 Hz, CH2); 1.41 (t, 2H, J = 7.2 Hz, CH2); 1.89 (p, 2H, 
J = 7.5 Hz, CH2); 2.44 (t, 2H, J = 7.5 Hz, CH2); 2.55-2.58 (4H, 2xCH2); 2.74-2.78 (6H, 
3xCH2); 6.84 (d, 1H, J = 8.5 Hz, CH); 6.88 (d, 1H, J = 8.5 Hz, CH); 6.94 (d, 1H, J = 7.5 Hz, 
CH); 7.05 (d, 1H, J = 8.5 Hz, CH); 7.14 (s, 1H, CH); 7.19 (d, 1H, J = 7.5 Hz, CH); 7.47 (d, 
1H, J = 8.5 Hz, CH); 7.52 (s, 1H, CH); 8.44 (s, 2H, 2xCH); 9.51 (s, 1H, NH ).13C-NMR: 
(CDCl3, 125 MHz) d = 22.6 (CH2); 27.0 (CH2); 33.0 (CH2); 52.8 (2xCH2); 53.0 (2xCH2); 58.0 
(CH2); 59.7 (CH2); 112.6 (CH); 112.6 (d, 1C, JC-F = 21 Hz, CH); 113.2 (CH); 115.4 (d, 1C, 
JC-F = 19 Hz, CH); 116.4 (C); 116.5 (CH); 124.3 (CH); 125.8 (C); 127.9 (C); 128.1 (d, 1C, 
JC-F = 11 Hz, CH); 129.7 (d, 1C, JC-F = 8 Hz, CH); 136.1 (C); 142.5 (2xCH); 142.8 (d, 1C, 
JC-F = 6 Hz, C); 162.6 (d, 1C, JC-F = 246 Hz, C). IR: n~  [cm-1] = 3126 (s); 2940 (vs); 2811 
(vs); 2773 (s); 1616 (s); 1587 (vs); 1488 (vs); 1448 (vs); 1267 (s); 1249 (vs); 1157 (s); 1139 
(vs); 1093 (vs); 784 (s); 730 (vs). 
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10.5 EXPERIMENTS IN CHAPTER 4 
10.5.1 SYNTHESIS OF 401B 
Ethyl 4-(1H-indol-3-yl)piperidine-1-carboxylate (414a). The general procedure for the 
tandem hydroformylation / Fischer indole synthesis with subsequent addition of acid (see 
10.3.5) was followed with ethyl 4-methylenepiperidine-1-carboxylate (621 mg, 3.67 mmol), 
phenylhydrazine (397 mg, 3.67 mmol), Rh(acac)(CO)2 (2.84 mg , 0.3 mol%), 10bar H2 and 
50bar CO in anhydrous THF (5.59 g, 10 wt% olefin) (3d, 120°C). The crude product was 
purified by flash chromatography on silica to give ethyl 4-(1H-indol-3-yl)piperidine-1-
carboxylate (557 mg, 56%). 1H-NMR: (CDCl3, 500 MHz) d = 1.36 (t, 3H, J = 7.1 Hz, CH3); 
1.73 (q, 2H, J = 11.1 Hz, CH2); 2.09 (d, 2H, J = 15.2 Hz, CH2); 3.00-3.07 (3H, CH, CH2); 
4.26 (q, 2H, J = 7.1 Hz, CH2); 4.37 (bs, 2H, CH2); 6.92 (s, 1H, CH); 7.17 (dd, 1H, J = 7.0 Hz, 
J = 8.0 Hz, CH); 7.25 (dd, 1H, J = 7.0 Hz, J = 8.2 Hz, CH); 7.38 (d, 1H, J = 8.2 Hz, CH); 
7.69 (d, 1H, J = 8.0 Hz, CH); 8.64 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 14.6 (CH3); 
32.5 (2xCH2); 33.4 (CH); 44.4 (2xCH2); 61.2 (CH2); 111.2 (CH); 118.7 (CH); 118.8 (CH); 
119.8 (CH); 120.2 (C); 121.6 (CH); 126.2 (C); 136.3 (C); 155.6 (C). 
3-(piperidin-4-yl)-1H-indole (415a). Ethyl 4-(1H-indol-3-yl)piperidine-1-carboxylate 
(400 mg, 1.47 mmol) in EtOH (10 ml) and NaOH (20 wt%, 10 g) was stirred under reflux 
over night. After extraction of the product with EtOAc the solvent was evaporated to give 
3-(piperidin-4-yl)-1H-indole (282 mg, 96 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.26 (bs, 1H, 
CH); 1.55 (bs, 2H, CH2); 1.85 (bs, 2H, CH2); 2.64 (bs, 2H, CH2); 3.00 (bs, 2H, CH2); 7.00-
7.03 (3H, 3xCH); 7.31 (bs, 1H, CH); 7.53 (bs, 1H, CH); 10.76 (bs, 1H, NH). 13C-NMR: 
(dmso-d6, 125 MHz) d = 32.8 (CH); 33.8 (2xCH2); 46.6 (2xCH2); 111.4 (CH); 118.0 (CH); 
118.6 (CH); 120.4 (CH); 120.8 (CH); 126.2 (C); 136.4 (C). (C) not observed.  
N-(4-(4-(1H-indol-3-yl)piperidin-1-yl)butyl)benzamide (401b). 3-(piperidin-4-yl)-1H-
indole (129 mg, 0.80 mmol), N-allyl benzamide (129 mg, 0.80 mmol), [Rh(cod)2]BF4 
(3.24 mg , 1 mol%) and XANTPHOS (46.2 mg, 10 mol%) were dissolved in a mixture of 
anhydrous toluene and anhydrous MeOH (2.45 g, 5 wt% olefin), filled in an autoclave and 
pressurized with 50bar H2 and 10bar CO. After stirring for 3d at 125°C the solvent was 
evaporated and the residue was purified by chromatography (silica, cyclohexane, CH2Cl2, 
NEt3) to give N-(4-(4-(1H-indol-3-yl)piperidin-1-yl)butyl)benzamide (170 mg, 57 %). 1H-
NMR: (CDCl3, 500 MHz) d = 1.52-1.54 (4H, 2xCH2); 1.64 (q, 2H, J = 12.3 Hz, CH2); 1.87 
(d, 2H, J = 12.8 Hz, CH2); 1.96 (t, 2H, J = 11.8 Hz, CH2); 2.29 (t, 2H, J = 6.8 Hz, CH2); 2.67 
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(t, 1H, J = 11.8 Hz, CH); 2.90 (d, 2H, J = 11.5 Hz, CH2); 3.09 (2d, 1H, J = 5.8 Hz, J = 5.8 Hz, 
NH); 3.31 (dt, 2H, J = 6.5 Hz, J = 5.8 Hz, CH2); 6.78 (s, 1H, CH); 6.90 (dd, 1H, J = 7.0 Hz, 
J = 6.8 Hz, CH); 6.99 (dd, 1H, J = 8.0 Hz, J = 7.0 Hz, CH); 7.21 (d, 1H, J = 8.0 Hz, CH); 
7.24-7.27 (1H, CH); 7.28 (s, 1H, CH); 7.31 (d, 1H, J = 7.3 Hz, CH); 7.45 (d, 1H, J = 8.0 Hz, 
CH); 7.66-7.68 (2H, 2xCH); 9.28 (s, 1H, NH). 13C-NMR: (CDCl3, 100 MHz) d = 24.3 (CH2); 
27.2 (CH2); 32.6 (2xCH2); 33.2 (CH); 39.5 (CH2); 54.0 (2xCH2); 58.1 (CH2); 111.1 (CH); 
118.2 (CH); 118.5 (CH); 119.7 (CH); 120.2 (C); 121.0 (CH); 126.2 (C); 126.8 (2xCH); 128.0 
(2xCH); 130.7 (CH); 134.7 (C); 136.2 (C); 167.4 (C). IR: n~  [cm-1] = 3268 (m); 2927 (m); 
2856 (m); 1637 (s); 1540 (m); 1452 (m); 1376 (m); 1309 (m). HRMS found [M]+ 375.2319, 
C24H29N3O requires 375.2328. 
10.5.2 SYNTHESIS OF 402 
Ethyl 4-(5-fluoro-1H-indol-3-yl)piperidine-1-carboxylate (414b). The general procedure 
for the tandem hydroformylation / Fischer indole synthesis with subsequent addition of acid 
(see 10.3.5) was followed with ethyl 4-methylenepiperidine-1-carboxylate (816 mg, 
4.82 mmol), N-(4-fluoro-phenyl)-hydrazine carboxylic acid tert-butyl ester (1.09 g, 
4.82 mmol), Rh(acac)(CO)2 (12.4 mg , 1 mol%), 10bar H2 and 50bar CO in anhydrous THF 
(7.34 g, 10 wt% olefin).The crude product was purified by flash chromatography on silica to 
give ethyl 4-(5-fluoro-1H-indol-3-yl)piperidine-1-carboxylate (538 mg, 38%). 1H-NMR: 
(CDCl3, 500 MHz) d = 1.29 (t, 3H, J = 7.1 Hz, CH3); 1.64-1.66 (2H, CH2); 2.03 (d, 2H, 
J = 13.2 Hz, CH2); 2.91-2.95 (3H, CH, CH2); 4.17 (q, 2H, J = 7.1 Hz, CH2); 4.28 (bs, 1H, 
CH); 6.94 (dd, 1H, J = 9.0 Hz, J = 9.0 Hz, CH); 6.99 (s, 1H, CH); 7.27 (s, 1H, CH); 7.28 (d, 
1H, J = 9.0 Hz, CH); 8.22 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 14.7 (CH3); 32.6 
(2xCH2); 33.6 (CH); 44.4 (2xCH2); 61.3 (CH2); 103.8 (d, 1C, JC-F = 23 Hz, CH); 110.3 (d, 
1C, JC-F = 27 Hz, CH); 111.8 (d, 1C, JC-F = 10 Hz, CH); 120.9 (d, 1C, JC-F = 4 Hz, C); 121.5 
(CH); 126.7 (d, 1C, JC-F = 10 Hz, C); 132.9 (C); 155.7 (C); 157.5 (d, 1C, JC-F = 234 Hz, C). 
5-fluoro-3-(piperidin-4-yl)-1H-indole (415b). Ethyl 4-(5-fluoro-1H-indol-3-yl)piperidine-
1-carboxylate (537 mg, 1.85 mmol) in EtOH (10 ml) and NaOH (20 wt%, 10 g) was stirred 
under reflux over night. After extraction of the product with EtOAc the solvent was 
evaporated to give 5-fluoro-3-(piperidin-4-yl)-1H-indole (404 mg, 100 %). 1H-NMR: (CDCl3, 
500 MHz) d = 1.52 (q, 2H, J = 12.0 Hz, CH2); 1.80 (d, 2H, J = 12.0 Hz, CH2); 2.60 (t, 2H, 
J = 12.0 Hz, CH2); 2.75 (t, 1H, J = 11.7 Hz, CH); 2.97 (d, 2H, J = 11.7 Hz, CH2); 3.32 (bs, 
1H, NH); 6.84 (dd, 1H, J = 9.0 Hz, J = 9.2 Hz, CH); 7.09 (s, 1H, CH); 7.25-7.28 (2H, 2xCH); 
10.87 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 33.5 (CH); 33.5 (2xCH2); 46.4 
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(2xCH2); 103.2 (d, 1C, JC-F = 23 Hz, CH); 108.8 (d, 1C, JC-F = 27 Hz, CH); 112.2 (d, 1C, 
J = 10 Hz, CH); 120.6 (C); 122.7 (CH); 126.3 (d, 1C, JC-F = 10 Hz, C); 133.1 (C); 156.4 (d, 
1C, J = 230 Hz, C). 
1-allyl-3,4-dihydroquinolin-2(1H)-one (412c). NaH (1.61 g, 40 mmol, 60 wt% in mineral 
oil) was suspended in anhydrous THF (25 ml). 3,4-dihydroquinolin-2(1H)-one (1.03 g, 
6.98 mmol) was added followed by allylic bromide (16.6 g, 137 mmol). After stirring the 
mixture over night at ambient temperature H2O (25 ml) was added and the mixture was 
extracted with EtOAc. The solvent was evaporated to give 1-allyl-3,4-dihydroquinolin-2(1H)-
one (1.14 g, 87 %). 1H-NMR: (CDCl3, 400 MHz) d = 2.67 (dd, 2H, J = 7.9 Hz, J = 9.3 Hz, 
CH2); 2.91 (dd, 2H, J = 7.9 Hz, J = 9.3 Hz, CH2); 4.55 (d, 2H, J = 4.9 Hz, CH2); 5.14 (d, 1H, 
J = 17.8 Hz, CHH); 5.17 (d, 1H, J = 11.3 Hz, CHH); 5.88 (ddt, 1H, J = 4.9 Hz, J = 11.3 Hz, 
J = 17.8 Hz, CH); 6.98 (d, 2H, J = 7.8 Hz, 2xCH); 7.15 (d, 1H, J = 7.8 Hz, CH); 7.20 (dd, 1H, 
J = 6.0 Hz, J = 6.8 Hz, CH). 13C-NMR: (CDCl3, 100 MHz) d = 25.4 (CH2); 31.7 (CH2); 45.0 
(CH2); 115.3 (CH); 116.2 (CH2); 122.7 (CH); 126.2 (C); 127.3 (CH); 127.7 (CH); 132.6 
(CH); 139.8 (C); 169.9 (C). IR: n~  [cm-1] = 3081 (w); 2927 (w); 2246 (w); 1681 (vs); 1602 
(s); 1461 (s); 1376 (vs); 1186 (s); 756 (s). HRMS found [M]+ 187.1027, C12H13NO requires 
187.1057. 
1-(4-(4-(5-fluoro-1H-indol-3-yl)piperidin-1-yl)butyl)-3,4-dihydroquinolin-2(1H)-one 
(402). 5-Fluoro-3-(piperidin-4-yl)-1H-indole (156 mg, 0.72 mmol), 1-allyl-3,4-
dihydroquinolin-2(1H)-one (134 mg, 0.72 mmol), [Rh(cod)2]BF4 (2.90 mg , 1 mol%) and 
XANTPHOS (41.4 mg, 10 mol%) were dissolved in a mixture of anhydrous toluene and 
anhydrous MeOH (2.54 g, 5 wt% olefin), filled in an autoclave and pressurized with 50bar H2 
and 10bar CO. After stirring for 3d at 125°C the solvent was evaporated and the residue was 
purified by chromatography (silica, cyclohexane, CH2Cl2, NEt3) to give 1-(4-(4-(5-fluoro-1H-
indol-3-yl)piperidin-1-yl)butyl)-3,4-dihydroquinolin-2(1H)-one (147 mg, 49 %). 1H-NMR: 
(CDCl3, 500 MHz) d = 1.63-1.70 (4H, CH2); 1.80 (q, 2H, J = 11.7 Hz, CH2); 2.01 (d, 2H, 
J = 12.5 Hz, CH2); 2.14 (t, 2H, J = 11.0 Hz, CH2); 2.46 (t, 2H, J = 6.8 Hz, CH2); 2.63 (t, 2H, 
J = 7.2 Hz, CH2); 2.75 (t, 1H, J = 11.7 Hz, CH2); 2.87 (t, 2H, J = 7.2 Hz, CH2); 3.05 (d, 2H, 
J = 11.0 Hz, CH2); 3.97 (t, 2H, J = 7.0 Hz, CH2); 6.87 (dd, 1H, J = 8.7 Hz, J = 7.5 Hz, CH); 
6.98 (bs, 2H, 2xCH); 7.06 (d, 1H, J = 8.2 Hz, CH); 7.14 (d, 1H, J = 8.2 Hz, CH); 7.22-7.25 
(3H, 3xCH); 8.97 (s, 1H, NH). 13C-NMR: (CDCl3, 100 MHz) d = 23.9 (CH2); 25.0 (CH2); 
25.5 (CH2); 31.8 (CH2); 32.6 (2xCH2); 33.3 (CH); 47.2 (CH2); 54.1 (2xCH2); 58.2 (CH2); 
103.6 (d, 1C, JC-F = 24 Hz, CH); 109.8 (d, 1C, JC-F = 26 Hz, CH); 111.8 (d, 1C, JC-F = 10 Hz, 
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CH); 114.9 (CH); 120.9 (C); 121.7 (CH); 122.7 (CH); 126.7 (d, 1C, JC-F = 10 Hz, C); 127.4 
(CH); 127.9 (CH); 132.9 (C); 139.4 (C); 157.3 (d, 1C, JC-F = 234 Hz, C); 170.2 (C). 
IR: n~  [cm-1] = 3467 (w); 3052 (s); 2985 (s); 2942 (s); 2304 (m); 1664 (s); 1602 (s); 1461 (s); 
1384 (s); 1265 (vs). HRMS found [M+H]+ 420.2440, C26H30FN3O requires 420.2429. 
10.5.3 SYNTHESIS OF 403 
3-(1-(3,3-diphenylpropyl)piperidin-4-yl)-1H-indole (403). 3-(Piperidin-4-yl)-1H-indole 
(254 mg, 1.27 mmol), diphenylethene (343 mg, 1.90 mmol), [Rh(cod)Cl]2 (31.2 mg , 5 mol%) 
and tributyl phosphane (38.5 mg, 15 mol%) were dissolved in anhydrous dioxane (3.08 g, 
10 wt% olefin), filled in an autoclave and pressurized with 10bar H2 and 90bar CO. After 
stirring for 3d at 130°C the solvent was evaporated and the residue was purified by 
chromatography (silica, cyclohexane, CH2Cl2, NEt3) to give 3-(1-(3,3-diphenylpropyl) 
piperidin-4-yl)-1H-indole (283 mg, 57 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.91 (q, 2H, 
J = 11.9 Hz, CH2); 2.12 (d, 2H, J = 12.5 Hz, CH2); 2.19 (t, 2H, J = 11.5 Hz, CH2); 2.38-2.44 
(4H, 2xCH2); 2.90 (t, 1H, J = 11.9 Hz, CH); 3.11 (d, 2H, J = 11.0 Hz, CH2); 4.07 (t, 1H, 
J = 6.7 Hz, CH); 6.94 (s, 1H, CH); 7.17 (dd, 1H, J = 7.5 Hz, J = 7.5 Hz, CH); 7.23-7.26 (1H, 
CH); 7.33-7.36 (11H, 11xCH); 7.72 (d, 1H, J = 8.0 Hz, CH); 8.69 (s, 1H, NH). 13C-NMR: 
(CDCl3, 125 MHz) d = 32.8 (CH2); 32.9 (2xCH2); 33.4 (CH); 49.3 (CH); 54.4 (2xCH2); 57.4 
(CH2); 111.2 (CH); 118.7 (CH); 118.9 (CH); 119.7 (CH); 121.0 (C); 121.5 (CH); 126.0 
(2xCH); 126.5 (C); 127.5 (4xCH); 128.3 (4xCH); 136.3 (C); 144.8 (3xC). IR: n~  [cm-
1] = 3424 (m); 3058 (m); 3025 (m); 2929 (vs); 2769 (m); 1598 (m); 1492 (s); 1450 (vs); 1128 
(s); 765 (s). HRMS found [M]+ 394.2425, C28H30N2 requires [M]+ 394.2441. 
10.5.4 SYNTHESIS OF 404 
Ethyl 4-(5-methoxy-1H-indol-3-yl)piperidine-1-carboxylate (414c). The general 
procedure for the tandem hydroformylation / Fischer indole synthesis with subsequent 
addition of acid (see 10.3.5) was followed with ethyl 4-methylenepiperidine-1-carboxylate 
(2.795 g, 16.5 mmol), 1-(4-methoxyphenyl)hydrazine (2.285 g, 16.5 mmol), Rh(acac)(CO)2 
(42.9 mg , 1 mol%), 10bar H2 and 50bar CO in anhydrous THF (22.38 g, 10 wt% olefin)The 
crude product was purified by flash chromatography on silica to give ethyl 4-(5-methoxy-1H-
indol-3-yl)piperidine-1-carboxylate (3.475 mg, 70%). 1H-NMR: (CDCl3, 500 MHz) d = 1.29 
(t, 3H, J = 7.1 Hz, CH3); 1.66 (d, 2H, J = 11.0 Hz, CH2); 2.05 (d, 2H, J = 12.2 Hz, CH2); 2.96 
(t, 2H, J = 11.7 Hz, CH2); 3.88 (s, 3H, CH3); 4.18 (q, 2H, J = 7.1 Hz, CH2); 4.30 (bs, 2H, 
CH2); 6.87 (d, 1H, J = 8.7 Hz, CH); 6.92 (s, 1H, CH); 7.06 (s, 1H, CH); 7.25 (d, 1H, 
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J = 8.7 Hz, CH); 8.20 (s, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 14.7 (CH3); 32.6 
(2xCH2); 33.5 (CH); 44.5 (2xCH2); 56.0 (CH3); 61.2 (CH2); 101.0 (CH); 111.9 (2xCH); 120.3 
(C); 120.6 (CH); 126.7 (C); 131.6 (C); 153.7 (C); 155.7 (C). 
5-Methoxy-3-(piperidin-4-yl)-1H-indole (415c). Ethyl 4-(5-methoxy-1H-indol-
3-yl)piperidine-1-carboxylate (3.41 g, 11.3 mmol) in EtOH (50 ml) and NaOH (20 wt%, 50 g) 
is stirred under reflux over night. After extraction of the product with EtOAc the solvent was 
evaporated to give 5-methoxy-3-(piperidin-4-yl)-1H-indole (2.6 g, 100 %). 1H-NMR: (dmso-
d6, x00 MHz) d = 1.90 (d, 2H, J = 11.8 Hz, CH2); 2.80 (t, 2H, J = 10.8 Hz, CH2); 3.14 (d, 2H, 
J = 12.1 Hz, CH2); 3.71 (s, 3H, CH3); 4.50 (bs, 4H, CH, CH2, NH); 6.66 (d, 1H, J = 8.6 Hz, 
CH); 6.99 (s, 1H, CH); 7.03 (s, 1H, CH); 7.19 (d, 1H, J = 8.6 Hz, CH); 10.7 (s, 1H, NH). 
13C-NMR: (dmso-d6, 100 MHz) d = 31.0 (3xCH2); 32.3 (CH); 44.7 (2xCH2); 55.6 (CH3); 
100.7 (CH); 111.1 (CH); 112.2 (CH); 118.9 (C); 121.5 (CH); 126.4 (C); 131.7 (C); 152.9 (C). 
Ethyl 4-(2-(4-(5-methoxy-1H-indol-3-yl)piperidin-1-yl)ethyl)piperidine-1-carboxylate 
(416). Ethyl 4-methylenepiperidine-1-carboxylate (1.76 g, 10.4 mmol), 5-methoxy-
3-(piperidin-4-yl)-1H-indole (2.40 g, 10.4 mmol) and [Rh(cod)Cl]2 (51.3 mg , 1 mol%) were 
dissolved in a mixture of anhydrous toluene and anhydrous MeOH (33.4 g, 10 wt% olefin), 
filled in an autoclave and pressurized with 10bar H2 and 50bar CO. After stirring for 3d at 
120°C the solvent was evaporated and the residue wais purified by flash chromatography on 
silica to give ethyl 4-(2-(4-(5-methoxy-1H-indol-3-yl)piperidin-1-yl)ethyl)piperidine-
1-carboxylate (2.38 mg, 55%). 1H-NMR: (CDCl3, 500 MHz) d = 1.13 (q, 2H, J = 12.6 Hz, 
CH2); 1.25 (t, 3H, J = 7.0 Hz, CH3); 1.39-1.52 (3H, CH2, CH); 1.66 (d, 2H, J = 12.3 Hz, 
CH2); 1.80 (q, 2H, J = 12.1 Hz, CH2); 2.03 (d, 2H, J = 11.0 Hz, CH2); 2.11 (t, 2H, 
J = 11.8 Hz, CH2); 2.35 (t, 1H, J = 11.5 Hz, CH); 2.42 (t, 2H, J = 7.5 Hz, CH2); 2.68-281 (4H, 
2xCH2); 3.06 (d, 2H, J = 11.5 Hz, CH2); 3.82 (s, 3H, CH3); 4.12 (q, 2H, J = 7.0 Hz, CH2); 
6.81 (d, 1H, J = 8.8 Hz, CH); 6.88 (s, 1H, CH); 7.04 (s, 1H, CH); 7.18 (d, 1H, CH); 8.87 (s, 
1H, NH). 13C-NMR: (CDCl3, 100 MHz) d = 14.5 (CH3); 32.0 (CH2); 32.8 (2xCH2); 33.4 
(CH); 33.5 (CH2); 33.5 (CH2); 34.4 (CH); 43.8 (CH2); 49.3 (CH2); 54.4 (2xCH2); 55.8 (CH3); 
56.4 (CH2); 61.0 (CH2); 100.8 (CH); 111.5 (CH); 111.8 (CH); 120.5 (C); 120.6 (CH); 126.7 
(C); 131.5 (C); 153.3 (C); 155.4 (C). 
5-Methoxy-3-(1-(2-(piperidin-4-yl)ethyl)piperidin-4-yl)-1H-indole (417). Ethyl-
4-(2-(4-(5-methoxy-1H-indol-3-yl)piperidin-1-yl)ethyl)piperidine-1-carboxylate (2.39 g, 
5.77 mmol) in EtOH (25 ml) and NaOH (20 wt%, 25 g) was stirred under reflux over night. 
After extraction of the product with EtOAc the solvent was evaporated to give 5-methoxy-3-
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(1-(2-(piperidin-4-yl)ethyl)piperidin-4-yl)-1H-indole (1.93 g, 98 %). 1H-NMR: (CDCl3, 
500 MHz) d = 1.41-1.49 (4H, 2xCH2); 1.76-1.81 (3H, CH2, CH); 2.01-2.12 (4H, 2xCH2); 
2.39-2.43 (2H, CH2); 2.70 (t, 2H, J = 12 Hz, CH2); 2.77 (q, 2H, J = 8 Hz, CH2); 2.86-2.89 
(1H, CH); 3.00-3.08 (2H, CH2); 3.24-3.27 (2H, CH2); 3.83 (s, 3H, CH3); 6.43 (bs, 1H, NH); 
6.81 (d, 1H, J = 8.5 Hz, CH); 6.91 (s, 1H, CH); 7.04 (s, 1H, CH); 7.21 (d, 1H, J = 8.5 Hz, 
CH); 8.47 (bs, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 30.6 (2xCH2); 32.6 (CH2); 32.8 
(2xCH2); 33.4 (CH); 33.5 (CH); 44.9 (2xCH2); 54.4 (2xCH2); 56.0 (CH3); 56.2 (CH2); 101.2 
(CH); 111.9 (2xCH); 120.6 (CH); 126.9 (C); 131.6 (C); 153.5 (C). 
(E)-3-(3,4-dichlorophenyl)-1-(4-(2-(4-(5-methoxy-1H-indol-3-yl)piperidin-1-
yl)ethyl)piperidin-1-yl)prop-2-en-1-one (404). 3,4-dichlorocinnamyl acid (576 mg, 
2.65 mmol) and DMAP (16 mg, 5 mol%) were dissolved in anhydrous THF (5 ml). A 
solution of DCC (603 mg, 2.92 mmol) and 5-methoxy-3-(1-(2-(piperidin-4-yl)ethyl)piperidin-
4-yl)-1H-indole (907 mg, 2.65 mmol) in anhydrous THF (5 ml) was added at 0°C. After 
stirring the mixture over night at ambient temperature the solvent was evaporated and the 
residue was purified by chromatography to give (E)-3-(3,4-dichlorophenyl)-
1-(4-(2-(4-(5-methoxy-1H-indol-3-yl)piperidin-1-yl)ethyl)piperidin-1-yl)prop-2-en-1-one 
(890 mg, 62 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.18-1.21 (2H, CH2); 1.52 (q, 2H, 
J = 7.5 Hz, CH2); 1.55 (bs, 1H, CH); 1.80 (d, 2H, J = 9.7 Hz, CH2); 2.03 (d, 2H, J = 12.0 Hz, 
CH2); 2.11 (t, 2H, J = 11.3 Hz, CH2); 2.42 (t, 2H, J = 7.3 Hz, CH2); 2.67 (t, 1H, J = 11.5 Hz, 
CHH); 2.76 (q, 2H, J = 11.8 Hz, CH2); 3.04 (d, 2H, J = 10.7 Hz, CH2); 3.09 (t, 1H, 
J = 12.0 Hz, CHH); 3.84 (s, 3H, CH3); 4.04 (d, 1H, J = 12.0 Hz, CHH); 4.66 (d, 1H, 
J = 11.7 Hz, CHH); 6.82 (d, 1H, J = 8.7 Hz, CH); 6.87 (d, 1H, J = 15.5 Hz, CH); 6.93 (s, 1H, 
CH); 7.05 (s, 1H, CH); 7.22 (d, 1H, J = 8.7 Hz, CH); 7.29 (d, 1H, J = 8.2 Hz, CH); 7.40 (d, 
1H, J = 8.2 Hz, CH); 7.50 (d, 1H, J = 15.5 Hz, CH); 7.57 (s, 1H, CH); 8.56 (bs, 1H, NH). 
13C-NMR: (CDCl3, 100 MHz) d = 31.9 (CH2); 32.8 (2xCH2); 33.1 (CH); 33.4 (2xCH2); 34.7 
(CH); 42.3 (CH2); 46.2 (CH2); 54.5 (2xCH2); 56.0 (CH3); 56.4 (CH2); 101.1 (CH); 111.7 
(CH); 111.9 (CH); 119.5 (CH); 120.7 (CH); 126.9 (CH); 128.9 (CH); 130.6 (CH); 131.6 (C); 
132.9 (C); 133.1 (C); 135.4 (C); 139.6 (CH); 153.5 (C); 164.6 (C). IR: n~  [cm-1] = 3424 (s); 
2929 (s); 2850 (m); 1646 (vs); 1598 (s); 1473 (vs); 1448 (s); 1209 (s); 1029 (m); 977 (m). 
HRMS found [M]+ 539.2108, C30H35Cl2N3O2 requires 539.2109. 
10.6 EXPERIMENTS IN CHAPTER 5 
3-(2-(diphenylmethylene)hydrazinyl)benzoic acid (502). 3-Hydrazino-benzoic acid 
(4.47 g, 23.7 mmol) and benzophenone (4.32 g, 23.7 mmol) were dissolved in H2O/EtOH 
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(140 ml, 9:5) and stirred at 80°C. Upon completion of the reaction the mixture was cooled and 
the precipitate was collected by filtration to give 3-(2-(diphenylmethylene)hydrazinyl)benzoic 
acid (4.08 g, 54 %). 1H-NMR: (dmso-d6, 500 MHz) d = 7.26-7.37 (7H, 7xCH2); 7.45 (d, 2H, 
J = 7.2 Hz, 2xCH2); 7.53 (dd, 2H, J = 7.4 Hz, J = 9.7 Hz, 2xCH2); 7.58 (dd, 2H, J = 7.4 Hz, 
J = 7.2 Hz, 2xCH2); 7.86 (s, 1H, CH); 9.17 (s, 1H, NH); 12.8 (bs, 1H, OH). 13C-NMR: 
(dmso-d6, 125 MHz) d = 114.1, 114.0 (CH); 117.1, 117.0 (CH); 120.1 (CH); 126.1 (2xCH); 
127.9 (CH); 128.3 (2xCH); 129.1 (4xCH); 129.5 (2xCH); 131.4 (C); 133.1 (C); 138.7 (C); 
143.9 (C); 145.7 (C); 167.7 (C). Elementary analysis found C 76.10%, H 4.90%, 
N 8.60%, C20H16N2O2 requires C 75.93%, H 5.10%, N 8.85%. 
3-(2-(diphenylmethylene)hydrazinyl)-N-ethyl-N-(2-methylallyl)benzamide (503). 
N-Ethyl-2-methylprop-2-en-1-amine (2.12 g, 21 mmol), DMAP (522 mg, 5 mol%) and 
3-(2-(diphenylmethylene)hydrazinyl)benzoic acid (6.77 g, 21 mmol) were dissolved in 
anhydrous CH2Cl2 (20 ml). DCC (4.85 g, 23.5 mmol) in anhydrous CH2Cl2 (10 ml) was 
added at 0°C and the mixture was stirred for 20 h at ambient temperature. The solvent was 
evaporated and the residue was taken up in Et2O. After filtration the solvent was evaporated 
and the residue was chromatographed (silica, cyclohexane, EtOAc) to give 
3-(2-(diphenylmethylene)hydrazinyl)-N-ethyl-N-(2-methylallyl)benzamide (6.54 g, 76 %). 
1H-NMR: (CDCl3, 500 MHz) d = 1.25, 1.13 (2bs, 3H, CH3); 1.67, 1.83 (2bs, 3H, CH3); 3.56, 
3.32 (2bs, 2H, CH2); 3.84, 4.18 (2s, 2H, CH2); 4.93-5.01 (2H, CH2); 6.90-7.17 (3H, 3xCH); 
7.26-7.38 (6H, 6xCH); 7.55-7.64 (6H, 6xCH). 13C-NMR: (CDCl3, 100 MHz) d = 12.0 (CH3); 
20.0 (CH3); 39.6, 42.6 (CH2); 54.2, 48.8 (CH2); 111.1 (CH); 112.2 (CH2); 113.7 (CH); 117.7 
(CH); 126.5 (2xCH); 128.1 (2xCH); 129.0 (3xCH); 129.1 (CH); 129.7 (3xCH); 132.5 (C); 
138.1 (C); 171.7 (C). Elementary analysis found C 77.10%, H 6.80%, N 10.00%, C26H27N3O 
requires C 78.65%, H 6.85%, N 10.57%.  
3-(2-(diphenylmethylene)hydrazinyl)-N-ethyl-N-(3-formyl-2-methylpropyl)benzamide 
(504). 3-(2-(Diphenylmethylene)hydrazinyl)-N-ethyl-N-(2-methylallyl)benzamide (930 mg, 
2.34 mmol) and [Rh(cod)Cl]2 (12 mg, 1 mol%) were dissolved in anhydrous THF (92 g, 
1 wt% olefin), filled in an autoclave and pressurized with 10bar H2 and 50bar CO. After 
stirring for 7 h at 120°C the solvent was removed and the residue was purified by 
chromatography (silica, cyclohexane, EtOAc) to give 3-(2-(diphenylmethylene)hydrazinyl)-
N-ethyl-N-(3-formyl-2-methylpropyl)benzamide (834 mg, 83 %). 1H-NMR: (CDCl3, 
400 MHz) d = 1.04 (bs, 3H, CH3); 1.17 (bs, 3H, CH3); 2.25-2.33 (2H, CH2); 2.45-3.48 (2H, 
CH2); 3.32-3.48 (4H, 2xCH2); 6.83 (d, 1H, J = 10 Hz, CH); 7.10 (s, 1H, CH); 7.14 (bs, 1H, 
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CH); 7.28-7.40 (6H, 6xCH); 7.56-7.65 (5H, 5xCH); 9.80 (s, 1H, CH). 13C-NMR: (CDCl3, 
100 MHz) d = 13.8, 12.0 (CH3); 18.1, 20.9 (CH3); 26.6 (CH3); 36.2 (CH2); 44.0 (CH2); 49.2 
(CH2); 110.8 (CH); 113.6 (CH); 117.4 (CH); 126.5 (2xCH); 128.2 (2xCH); 129.0 (3xCH); 
129.3 (CH); 129.7 (3xCH); 132.5 (C); 137.8 (C); 138.0 (C); 144.7 (C); 176.3 (C); 202.1 (CH). 
Hex-5-enyl 3-(2-(diphenylmethylene)hydrazinyl)benzoate (507a). 5-Hexenol (251 mg, 
2.51 mmol), DMAP (15 mg, 5 mol%) and 3-(2-(diphenylmethylene)hydrazinyl)benzoic acid 
(794 mg, 2.51 mmol) were dissolved in anhydrous CH2Cl2 (4 ml). DCC (570 mg, 2.76 mmol) 
in anhydrous CH2Cl2 (1 ml) was added at 0°C and the mixture was stirred for 20 h at ambient 
temperature. The solvent was evaporated and the residue was taken up in Et2O. After filtration 
the solvent was evaporated and the residue was chromatographed (silica, cyclohexane, 
EtOAc) to give hex-5-enyl 3-(2-(diphenylmethylene)hydrazinyl)benzoate (795 mg, 80 %). 
1H-NMR: (CDCl3, 500 MHz) d = 1.56 (p, 2H, J = 7.5 Hz, CH2); 1.78 (p, 2H, J = 6.5 Hz, 
CH2); 2.13 (q, 2H, J = 7.1 Hz, CH2); 4.31 (t, 2H, J = 6.5 Hz, CH2); 4.98 (d, 1H, J = 10.2 Hz, 
CHH); 5.04 (d, 1H, J = 17.2 Hz, CHH); 5.82 (ddt, 1H, J = 6.5 Hz, J = 10.2 Hz, J = 17.2 Hz, 
CH); 7.30-7.82 (5H, 14xCH, NH). 13C-NMR: (CDCl3, 100 MHz) d = 25.2 (CH2); 28.1 (CH2); 
33.3 (CH2); 64.8 (CH2); 113.8 (CH); 114.8 (CH2); 117.1 (CH); 120.9 (CH); 126.5 (2xCH); 
128.2 (4xCH); 129.0 (CH); 129.2 (CH); 129.3 (CH); 129.7 (CH); 130.0 (2xCH); 132.4 (CH); 
132.5 (C); 137.5 (C); 138.0 (C); 144.7 (C); 166.7 (C). HRMS found M+ 398.1963, 
C26H26N2O2 requires M+, 398.1932.  
Undec-10-enyl 3-(2-(diphenylmethylene)hydrazinyl)benzoate (507b). 11-Undecenol 
(2.73 g, 16.0 mmol), DMAP (98 mg, 5 mol%) and 3-(2-(diphenylmethylene)hydrazinyl) 
benzoic acid (5.06 g, 16.0 mmol) were dissolved in anhydrous CH2Cl2 (20 ml). DCC (3.63 g, 
17.6 mmol) in anhydrous CH2Cl2 (10 ml) was added at 0°C. The mixture was stirred for 20 h 
ambient temperature. The solvent was evaporated and the residue was taken up in Et2O. After 
filtration the solvent was evaporated and the residue was chromatographed (silica, 
cyclohexane, EtOAc) to give undec-10-enyl 3-(2-(diphenylmethylene)hydrazinyl)benzoate 
(7.49 g, 100 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.29-1-46 (12H, 6xCH2); 1.75-1.80 (2H, 
CH2); 2.05 (q, 2H, J = 7.0 Hz, CH2); 4.31 (t, 2H, J = 6.7 Hz, CH2); 4.95 (d, 1H, J = 11.2 Hz, 
CHH); 5.02 (d, 1H, J = 17.2 Hz, CHH); 5.82 (ddt, 1H, J = 6.7 Hz, J = 11.2 Hz, J = 17.2 Hz, 
CH); 7.30-7.83 (15H, 15xCH, NH). 13C-NMR: (CDCl3, 100 MHz) d = 25.9 (CH2); 28.7 
(CH2); 28.8 (CH2); 29.0 (CH2); 29.2 (CH2); 29.3 (CH2); 29.4 (CH2); 33.7 (CH2); 65.0 (CH2); 
113.8 (CH); 114.1 (CH2); 117.0 (CH); 120.9 (CH); 126.5 (2xCH); 128.1 (4xCH); 128.9 (CH); 
129.2 (CH); 129.3 (CH); 129.7 (CH); 130.0 (CH); 131.3 (C); 132.5 (C); 138.0 (C); 144.7 (C); 
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144.9 (C); 166.7 (C). IR: n~  [cm-1] = 3332 (s); 3060 (s); 2937 (vs); 2854 (vs); 2123 (vs); 1722 
(vs); 1606 (vs); 1590 (vs); 1444 (vs); 1294 (s); 1226 (vs); 1105 (s); 754 (vs). HRMS found 
M+ 468.2757, C31H36N2O2 requires M+, 468.2737. Elementary analysis found C 79.10%, 
H 7.80%, N 5.50%, C31H36N2O2 requires C 79.45%, H 7.74%, N 5.98%.  
6-formylhexyl 3-(2-(diphenylmethylene)hydrazinyl)benzoate (508a). Hex-5-enyl 
3-(2-(diphenylmethylene)hydrazinyl)benzoate (735 mg, 1.84 mol), Rh(acac)(CO)2 (5 mg, 
1 mol%) and BIPHEPHOS (145 mg, 10 mol%) were dissolved in anhydrous THF (5.87 g, 
10 wt% olefin), filled in an autoclave and pressurized with 10bar H2 and 10bar CO. After 
stirring for 5 h at 60°C the solvent was removed and the residue was purified by 
chromatography (silica, cyclohexane, EtOAc) to give 6-formylhexyl 
3-(2-(diphenylmethylene)hydrazinyl)benzoate (252 mg, 32 %) as an inseparable mixture of 
n/iso-aldehyde, which was analyzed with NMR. 1H-NMR: (CDCl3, 400 MHz) d = 1.42-1.82 
(8H, 4xCH2); 2.42 (t, 2H, J = 7.0 Hz, CH2); 4.31 (q, 2H, J = 6.5 Hz, CH2); 7.30-7.81 (15H, 
14xCH, NH); 9.73 (t, 1H, J = 1.8 Hz, CH). 13C-NMR: (CDCl3, 100 MHz) d = 21.8 (CH2); 
28.4 (CH2); 28.7 (CH2); 43.7 (CH2); 64.8 (CH2); 113.8 (CH); 117.1 (CH); 120.9 (CH); 126.5 
(2xCH); 128.1 (2xCH); 128.2 (CH); 129.0 (2xCH); 129.2 (CH); 129.3 (CH); 129.7 (CH); 
131.1 (C); 132.3 (CH); 132.5 (C); 138.0 (C); 144.7 (C); 166.8 (C); 202.6 (CH). Characteristic 
data for the iso-regioisomer: 1H-NMR: (CDCl3, 400 MHz) d = 1.11 (d, 3H, J = 7.0 Hz, CH3); 
2.36 (m, 1H, J = 7.0 Hz, CH); 9.60 (d, 1H, J = 1.8 Hz, CH). 13C-NMR: (CDCl3, 100 MHz) 
d = 13.3 (CH3); 25.8 (CH2); 28.6 (CH2); 29.9 (CH2); 46.1 (CH); 204.8 (CH).  
11-formylundecyl 3-(2-(diphenylmethylene)hydrazinyl)benzoate (508b). Undec-10-enyl 
3-(2-(diphenylmethylene)hydrazinyl)benzoate (7.52 g, 16.0 mol), Rh(acac)(CO)2 (4 mg, 
0.1 mol%) and BIPHEPHOS (63 mg, 1 mol%) were dissolved in anhydrous THF (150 g), 
filled in an autoclave and pressurized with 10bar H2 and 10bar CO. After stirring for 20 h at 
40°C the solvent was removed and the residue was purified by chromatography (silica, 
cyclohexane, EtOAc) to give 11-formylundecyl 3-(2-(diphenylmethylene)hydrazinyl) 
benzoate (6.92 g, 87 %) as an inseparable mixture of n/iso-aldehyde, which was analyzed by 
NMR. 1H-NMR: (CDCl3, 400 MHz) d = 1.26-1.91 (18H, 9xCH2); 2.37 (t, 2H, J = 7.3 Hz, 
CH2); 4.27 (t, 2H, J = 6.8 Hz, CH2); 7.24-7.78 (15H, 14xCH, NH); 9.70 (t, 1H, J = 1.8 Hz, 
CH). 13C-NMR: (CDCl3, 100 MHz) d = 21.9 (CH2); 28.6 (CH2); 29.1 (CH2); 29.2 (CH2); 29.2 
(CH2); 29.3 (CH2); 29.3 (CH2); 29.4 (CH2); 30.3 (CH2); 43.7 (CH2); 64.9 (CH2); 113.7 (CH); 
117.0 (CH); 120.8 (CH); 126.4 (2xCH); 128.1 (3xCH); 128.1 (CH); 128.9 (3xCH); 129.1 
(CH); 129.2 (CH); 129.6 (3xCH); 129.9 (CH); 131.2 (C); 132.3 (CH); 132.4 (C); 137.9 (C); 
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144.6 (C); 144.9 (C); 166.6 (C); 202.7 (CH). Characteristic data for the iso-regioisomer: 
1H-NMR: (CDCl3, 400 MHz) d = 1.05 (d, 3H, J = 7.0 Hz, CH3); 2.28 (m, 1H, J = 7.0 Hz, 
CH); 9.57 (d, 1H, J = 2.0 Hz, CH). 13C-NMR: (CDCl3, 100 MHz) d = 13.2 (CH3); 34.8 (CH2); 
46.1 (CH); 205.2 (CH). 
3-(2-(dodecylidene-12-ol)-hydrazinyl)benzoic acid (510). 12-Hydroxydodecanal (2.99 g, 
14.9 mmol) and 3-hydrazino benzoic acid (1.63 g, 14.9 mmol) were stirred in anhydrous THF 
(50 ml) for 1h at 60°C follows by filtration through a sintered glass filter. The solvent was 
evaporated to give 3-(2-(dodecylidene-12-ol)-hydrazinyl)benzoic acid (4.83 g, 97 %). 
1H-NMR: (CDCl3, 400 MHz) d = 1.23 (bs, 16H, 8xCH2); 1.48-1.54 (4H, 2xCH2); 3.60 (t, 2H, 
J = 6.6 Hz, CH2); 6.51-7.61 (8H, 5xCH, 2xOH, NH). 13C-NMR: (CDCl3, 100 MHz) d = 25.5 
(CH2); 26.9 (CH2); 29.1 (CH2); 29.3 (2xCH2); 29.4 (2xCH2); 29.5 (CH2); 32.0 (CH2); 32.5 
(CH2); 62.8 (CH2); 113.7 (CH); 117.3 (CH); 120.8 (CH); 129.2 (CH); 130.5 (C); 142.5 (CH); 
142.6 (C); 171.0 (C). IR: n~  [cm-1] = 3297 (s); 2927 (vs); 2854 (vs); 2624 (m); 1693 (vs); 
1606 (vs); 1490 (m); 1463 (s); 1303 (s); 1108 (s); 1054 (s); 885 (s). HRMS found M+ 
334.2267, C19H30N2O3 requires M+, 334.2278. Elementary analysis found C 67.51%, 
H 9.54%, N 8.72%, C19H30N2O3 requires C 68.23%, H 9.04%, N 8.38%.  
11-iodoundec-1-ene (513). Triphenyl phosphane (32.7 g, 125 mmol) and imidazole (8.50 g, 
125 mmol) were dissolved in anhydrous CH2Cl2 (250 ml). At 0°C iodine (31.7 mmol, 
125 mmol) was added in portions. 11-Undecenol (15.2 g, 89 mmol) was added and the 
mixture was stirred for 1 h. The mixture was washed with Na2S2O3 (100 ml, saturated in H2O) 
and the solvent was evaporated. The residue was taken up in pentane (200 ml) and was 
filtered followed by evaporation of the solvent to give 11-iodoundec-1-ene (24.6 g, 98 %). 
1H-NMR: (CDCl3, 500 MHz) d = 1.27 (bs, 8H, 4xCH2); 1.36 (bs, 4H, 2xCH2); 1.80 (p, 2H, 
J = 7.2 Hz, CH2); 2.02 (q, 2H, J = 7.0 Hz, CH2); 3.16 (t, 2H, J = 7.0 Hz, CH2); 4.91 (d, 1H, 
J = 10.2 Hz, CHH); 4.96 (d, 1H, J = 17.2 Hz, CHH); 5.78 (ddt, 1H, J = 6.7 Hz, J = 10.2 Hz, 
J = 17.2 Hz, CH). 13C-NMR: (CDCl3, 125 MHz) d = 7.1 (CH2); 28.5 (CH2); 28.8 (CH2); 29.0 
(CH2); 29.3 (2xCH2); 30.4 (CH2); 33.5 (CH2); 33.7 (CH2); 114.1 (CH2); 139.1 (CH). 
1-iodo-3-(undec-10-enyloxy)benzene (514). 3-Iodo-phenol (1.86 g, 8.46 mmol), 
11-iodoundec-1-ene (2.26 g, 8.06 mmol), K2CO3 (1.23 g, 8.86 mmol) and 18-crown[6] 
(213 mg, 10 mol%) were stirred in anhydrous THF (25 ml) for 20h under reflux. The solvent 
was evaporated and the residue was taken up in H2O and CH2Cl2. The organic layer was 
washed with NaOH (1N in H2O). The solvent was evaporated to give 1-iodo-3-(undec-
10-enyloxy)benzene (2.75 g, 92 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.33-1.48 (12H, 
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6xCH2); 1.78 (p, 2H, J = 7.2 Hz, CH2); 2.08 (q, 2H, J = 6.7 Hz, CH2); 3.91 (t, 2H, J = 6.5 Hz, 
CH2); 4.97 (d, 1H, J = 10.2 Hz, CHH); 5.03 (d, 1H, J = 17.2 Hz, CHH); 5.84 (ddt, 1H, 
J = 6.7 Hz, J = 10.2 Hz, J = 17.2 Hz, CH); 6.86 (d, 1H, J = 8.2 Hz, CH); 6.98 (dd, 1H, 
J = 8.2 Hz, J = 8.2 Hz, CH); 7.26-7.28 (2H, 2xCH). 13C-NMR: (CDCl3, 100 MHz) d = 25.9 
(CH2); 28.8 (CH2); 29.0 (CH2); 29.1 (CH2); 29.2 (CH2); 29.3 (CH2); 29.4 (CH2); 33.7 (CH2); 
70.5 (CH2); 94.3 (C); 114.0 (CH); 114.1 (CH2); 123.5 (CH); 129.4 (CH); 130.5 (CH); 138.9 
(CH); 159.6 (C). 
1-(3-(undec-10-enyloxy)phenyl)hydrazine carboxylic acid tert-butyl ester (515). 1-iodo-
3-(undec-10-enyloxy)benzene (2.19 g, 58.8 mmol), hydrazine carboxylic acid tert-butyl ester 
(1.05 g, 7.97 mmol), CuI (63 mg, 5 mol%), 1,10-phenantroline (239 mg, 10 mol%) and 
Cs2CO3 (3.03 g, 9.3 mmol) were stirred in dry DMF (7 ml) for 21 h at 80°C. Then the mixture 
was poured into EtOAc (30 ml) and was filtered through a pad of silica. The solvent was 
removed and the residue was purified by chromatography (silica, cyclohexane, CH2Cl2, NEt3) 
to give 1-(3-(undec-10-enyloxy)phenyl)hydrazine carboxylic acid tert-butyl ester (1.51 g, 
68 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.29-1.35 (12H, 6xCH2); 1.50 (s, 9H, 3xCH3); 1.75 
(p, 2H, J = 7.0 Hz, CH2); 2.03 (q, 2H, J = 7.0 Hz, CH2); 3.92 (t, 2H, J = 6.5 Hz, CH2); 4.41 (s, 
2H, NH2); 4.92 (d, 1H, J = 10.2 Hz, CHH); 4.98 (d, 1H, J = 17.1 Hz, CHH); 5.79 (ddt, 1H, 
J = 7.0 Hz, J = 10.2 Hz, J = 17.1 Hz, CH); 6.64 (d, 1H, J = 8.3 Hz, CH); 7.03-7.05 (2H, 
2xCH); 7.16 (dd, 1H, J = 7.5 Hz, J = 7.8 Hz, CH). 13C-NMR: (CDCl3, 125 MHz) d = 25.9 
(CH2); 28.2 (3xCH3); 28.8 (CH2); 29.0 (CH2); 29.2 (CH2); 29.3 (CH2); 29.3 (CH2); 29.4 
(CH2); 33.7 (CH2); 67.9 (CH2); 81.6 (C); 109-7 (CH); 110.7 (CH); 114.0 (CH2); 115.4 (CH); 
128.5 (CH); 139.1 (CH); 144.1 (C); 155.0 (C); 159.0 (C). IR: n~  [cm-1] = 3338 (w); 3075 (w); 
2975 (s); 2927 (vs); 2854 (s); 1698 (vs); 1602 (vs); 1367 (vs); 1336 (vs); 1280 (s); 1255 (s); 
1220 (s); 1164 (vs). HRMS found M+ 376.2749, C22H36N2O3 requires M+, 376.2772. 
Elementary analysis found C 70.70%, H 9.60%, N 7.37%, C22H36N2O3 requires C 70.18%, 
H 9.64%, N 7.44%. 
Preperation of 517. 1-(3-(undec-10-enyloxy)phenyl)hydrazinecarboxylic acid tert-butyl 
ester (300 mg, 0.80 mmol), Rh(acac)(CO)2 (8.43 mg, 4 mol%) and XANTPHOS (64 mg, 
20 mol%) in anhydrous THF were filled in an autoclave, pressurized with 10bar CO and 
10bar H2 and were stirred for 68h at 100°C. The solvent was removed and the residue was 
purified by flash chromatography (silica, CH2Cl2, i-PrOH) to give 415 (310 mg, 100 %). 415 
(301 mg, 0.74 mmol) was dissolved in H2SO4 (150 g, 4 wt% in THF) and was stirred for 2h 
under reflux. After addition of NH3 the mixture was extracted with EtOAc, the solvent was 
remove and the residue was purified by prepHPLC to give the title compound (41 mg, 20 %) 
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as a mixture of n/iso-regioisomers. Major isomer: 1H-NMR: (CDCl3, 500 MHz) d = 0.46-1.27 
(10H, 5xCH2); 1.45-1.53 (4H, 2xCH2); 1.66-1.92 (2H, CH2); 2.57 (dt, 1H, J = 3.7 Hz, 
J = 14.3 Hz, CHH); 2.99 (dt, 1H, J = 5.0 Hz, J = 14.3 Hz, CHH); 4.19-4.30 (2H, CH2); 6.87 
(s, 1H, CH); 6.92 (d, 1H, J = 8.7 Hz, CH); 6.99 (s, 1H, CH); 7.55 (d, 1H, J = 8.7 Hz, CH); 
7.74 (bs, 1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 25.3 (4xCH2); 26.7 (2xCH2); 27.4 
(2xCH2); 28.9 (2xCH2); 71.2 (2xCH2); 103.0 (CH); 112.9 (CH); 120.7 (CH); 121.4 (CH). 
Minor isomer: 1H-NMR: (CDCl3, 500 MHz) d = 0.17 (bs, 1H, CHH); 0.55 (bs, 1H,CHH); 
0.66-0.72 (4H, 2xCH2); 1.02-1.72 (11H, CH3, 4xCH2); 2.46 (dt, 1H, J = 5.0 Hz, J = 19.0 Hz, 
CHH); 2.98 (dt, 1H, J = 5.0 Hz, J = 14.2 Hz, CHH); 3.79 (dt, 12H, J = 8.7 Hz, J = 11.5 Hz, 
CHH); 4.28 (dt, 1H, J = 11.5 Hz, J = 11.7 Hz, CHH); 6.80 (d, 1H, J = 8.5 Hz, CH); 7.03 (s, 
1H, CH); 7.36 (d, 1H, J = 8.5 Hz, CH); 7.58 (bs, 1H, NH). ESI/MS: 277 [M+H]+. 
1-(4-(4-Iodophenoxy)butoxy)-4-iodobenzene (529a). 4-Iodophenol (4.41 g, 20.0 mmol), 
1,4-dibromobutane (1.97 g, 9.11 mmol), K2CO3 (3.15 g, 22.8 mmol) and 18-crown[6] 
(243 mg, 10 mol%) were stirred in anhydrous THF (100 ml) under reflux for 20h. The solvent 
was evaporated and the residue was taken up in H2O (100 ml) and CH2Cl2 (100 ml). The 
organic layer was washed with NaOH (1N in H2O) and the solvent was evaporated to give 
1-(4-(4-iodophenoxy)butoxy)-4-iodobenzene (4.35 g, 97 %). 1H-NMR: (CDCl3, 500 MHz) 
d = 1.94 (t, 4H, J = 5.5 Hz, 2xCH2); 3.98 (t, 4H, J = 5.5 Hz, 2xCH2); 6.66 (d, 4H, J = 9.0 Hz, 
4xCH); 7.53 (d, 4H, J = 9.0 Hz, 4xCH). 13C-NMR: (CDCl3, 125 MHz) d = 25.8 (2xCH2); 67.5 
(2xCH2); 82.6 (2xC); 116.9 (4xCH); 138.2 (4xCH); 158.8 (2xC). HRMS found M+ 493.9266, 
C16H16I2O2 requires M+, 493.9292.  
1-(10-(4-Iodophenoxy)decyloxy)-4-iodobenzene (529b). 4-Iodophenol (3.77 g, 
17.1 mmol), 1,10-dibromodecane (2.33 g, 7.78 mmol), K2CO3 (2.69 g, 19.5 mmol) and 
18-crown[6] (212 mg, 10 mol%) were stirred in anhydrous THF (100 ml) under reflux for 
20 h. The solvent was evaporated and the residue was taken up in H2O (100 ml) and CH2Cl2 
(100 ml). The organic layer was washed with NaOH (1N in H2O) and the solvent was 
evaporated to give 1-(10-(4-iodophenoxy)decyloxy)-4-iodobenzene (3.90 g, 87 %). 1H-NMR: 
(CDCl3, 500 MHz) d = 1.31-1.35 (8H, 4xCH2); 1.42-1.44 (4H, 2xCH2); 1.75 (dt, 4H, 
J = 6.7 Hz, J = 8.0 Hz, 2xCH2); 3.90 (t, 4H, J = 6.7 Hz, 2xCH2); 6.66 (d, 4H, J = 9.0 Hz, 
4xCH); 7.53 (d, 4H, J = 9.0 Hz, 4xCH). 13C-NMR: (CDCl3, 125 MHz) d = 25.9 (2xCH2); 29.1 
(2xCH2); 29.3 (2xCH2); 29.4 (2xCH2); 68.1 (2xCH2); 82.4 (2xC); 116.9 (4xCH); 138.1 
(4xCH); 159.0 (2xC). 
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4-(4-(4-(Hydrazinecarboxylic acid tert-butyl ester)phenoxy)butoxy) benzenhydrazine 
carboxylic acid tert-butyl ester (530a). 1-(4-(4-Iodophenoxy)butoxy)-4-iodobenzene 
(2.95 g, 5.97 mmol), hydrazine carboxylic acid tert-butyl ester (1.89 g, 14.3 mmol), CuI 
(23 mg, 2 mol%), 1,10-phenantroline (238 mg, 22 mol%) and Cs2CO3 (5.45 g, 16.7 mmol) 
were stirred in dry DMF (6 ml) for 21 h at 80°C. Then the mixture was poured into EtOAc 
(30 ml) and was filtered through a pad of silica. The solvent was removed and the residue was 
purified by chromatography (silica, cyclohexane, CH2Cl2, NEt3) to give 
4-(4-(4-(hydrazinecarboxylic acid tert-butyl ester) phenoxy) butoxy) benzenhydrazine 
carboxylic acid tert-butyl ester (2.52 g, 84 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.47 (s, 18H, 
6xCH3); 1.95 (t, 4H, J = 5.2 Hz, 2xCH2); 4.00 (bs, 4H, 2xCH2); 4.43 (bs, 4H, 2xNH2); 6.83 
(d, 4H, J = 8.7 Hz, 4xCH); 7.28 (d, 4H, J = 8.7 Hz, 4xCH). 13C-NMR: (CDCl3, 125 MHz) 
d = 25.9 (2xCH2); 28.3 (6xCH3); 67.6 (2xCH2); 81.3 (2xC); 114.0 (4xCH); 125.2 (4xCH); 
136.3 (2xC); 156.2 (2xC). Elementary analysis found C 62.32%, H 7.50%, 
N 10.88%, C26H38N4O6 requires C 62.13%, H 7.62%, N 11.15%. 
4-(4-(4-(Hydrazinecarboxylic acid tert-butyl ester) phenoxy) decoxy) benzenhydrazine 
carboxylic acid tert-butyl ester (530b). 1-(10-(4-Iodophenoxy)decyloxy)-4-iodobenzene 
(3.69 g, 6.39 mmol), hydrazine carboxylic acid tert-butyl ester (2.03 g, 15.3 mmol), CuI 
(150 mg, 12.5 mol%), 1,10-phenantroline (238 mg, 25 mol%) and Cs2CO3 (5.83 g, 
17.9 mmol) were stirred in dry DMF (6 ml) for 21 h at 80°C. Then the mixture was poured 
into EtOAc (30 ml) and was filtered through a pad of silica. The solvent was removed and the 
residue was purified by chromatography (silica, cyclohexane, CH2Cl2, NEt3) to give 4-(4-(4-
(hydrazine carboxylic acid tert-butyl ester) phenoxy) decoxy) benzenhydrazine carboxylic 
acid tert-butyl ester (2.90 g, 77 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.32 (bs, 8H, 4xCH2); 
1.42-1.46 (4H, 2xCH2); 1.46 (s, 18H, 6xCH3); 1.75 (dt, 4H, J = 7.2 Hz, J = 7.7 Hz, 2xCH2); 
3.92 (t, 4H, J = 6.5 Hz, 2xCH2); 4.38 (bs, 4H, 2xNH2); 6.81 (d, 4H, J = 9.0 Hz, 4xCH); 7.27 
(d, 4H, J = 9.0 Hz, 4xCH). 13C-NMR: (CDCl3, 125 MHz) d = 25.9 (2xCH2); 28.3 (6xCH3); 
29.2 (2xCH2); 29.3 (2xCH2); 29.4 (2xCH2); 68.1 (2xCH2); 81.2 (2xC); 114.0 (4xCH); 125.2 
(4xCH); 136.1 (2xC); 156.4 (2xC). Elementary analysis found C 65.50%, H 8.77%, 
N 9.50%, C32H50N4O6 requires C 65.50%, H 8.59%, N 9.55%. 
4-Methylenepiperidine (532). Ethyl 4-methylenepiperidine-1-carboxylate (14.8 g, 
87.5 mmol) was stirred in glycol (75 ml) and NaOH (50 wt% in H2O, 80 g) under reflux over 
night. The product was extracted with Et2O and the organic layer was washed with H2O. The 
solvent was removed and the residue was distilled to give 4-methylenepiperidine (3.78 g, 
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44 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.75 (bs, 1H, NH); 2.04 (dd, 4H, J = 7.2 Hz, 
J = 7.7 Hz, 2xCH2); 2.71 (dd, 4H, J = 7.2 Hz, J = 7.7 Hz, 2xCH2); 4.51 (s, 2H, CH2). 
1,2-Bis(4-methylenepiperidin-1-yl)ethane-1,2-dione (533). 4-Methylenepiperidine 
(2.10 g, 21.2 mmol), NEt3 (1.19 g, 11.1 mmol) and DMAP (65 mg, 5 mol%) were dissolved 
in anhydrous THF (25 ml) and oxalylchloride (1.28 g, 10.1 mmol) was added dropwise at 
0°C. The mixture was stirred for 1h at ambient temperature. The precipitate was removed by 
filtration and the solvent was evaporated to give 1,2-bis(4-methylenepiperidin-1-yl)ethane-
1,2-dione (1.70 g, 68 %). 1H-NMR: (CDCl3, 500 MHz) d = 2.27 (dd, 4H, J = 5.8 Hz, 
J = 6.0 Hz, 2xCH2); 3.39 (dd, 2H, J = 5.8 Hz, J = 6.0 Hz, CH2); 3.63 (dd, 2H, J = 5.8 Hz, 
J = 6.0 Hz, CH2); 4.82 (d, 2H, J = 4.3 Hz, CH2). 13C-NMR: (CDCl3, 125 MHz) d = 33.9 
(2xCH2); 34.9 (2xCH2); 42.4 (2xCH2); 47.6 (2xCH2); 110.6 (2xCH2); 143.6 (2xC); 163.4 
(2xC). IR: n~  [cm-1] = 3461 (w); 3076 (s); 2937 (vs); 1617 (vs); 1498 (vs); 1440 (vs); 1274 
(vs); 1180 (s); 1070 (vs); 985 (vs); 889 (vs). Elementary analysis found C 66.91%, H 8.40%, 
N 11.17%, C14H20N2O2 requires C 67.71%, H 8.12%, N 11.28%. 
Preparation of 534a. 1,2-Bis(4-methylenepiperidin-1-yl)ethane-1,2-dione (160 mg, 
0.65 mmol), 4-(4-(4-(hydrazinecarboxylic acid tert-butyl ester) phenoxy) butoxy) 
benzenhydrazine carboxylic acid tert-butyl ester (324 mg, 0.65 mmol) and Rh(acac)(CO)2 
(6.6 mg, 4 mol%) were dissolved in anhydrous THF (129 ml), filled in an autoclave and 
pressurized with 50bar CO and 10bar H2. The mixture was stirred at 110°C for 20h. The 
solvent was removed and the residue was purified by flash chromatography (silica, 
CH2Cl2/EtOH 9:1) to give 433a (425 mg, 85 %). 1H-NMR: (CDCl3, 400 MHz) d = 1.17 (bs, 
4H, 2xCH2); 1.37 (s, 18H, 9xCH3); 1.69 (bs, 4H, 2xCH2); 1.72 (bs, 2H, 2xCH); 1.90-1.99 
(4H, 2xCH2); 2.23 (bs, 4H, 2xCH2); 2.61 (bs, 2H, CH2); 3.00 (bs, 2H, 2xCH2); 3.50 (bs, 2H, 
CH2); 4.05 (bs, 4H, 2xCH2); 4.40 (bs, 2H, 2xCH2); 6.84 (bs, 2H, 2xCH); 6.95 (s, 8H, 8xCH). 
13C-NMR: (CDCl3, 100 MHz) d = 26.9 (2xCH2); 29.1 (6xCH3); 32.3 (2xCH2); 33.2 (2xCH2); 
35.3 (2xCH); 40.0 (2xCH2); 41.8 (2xCH2); 47.2 (2xCH2); 68.9 (2xCH2); 82.1 (2xC); 116.4 
(4xCH); 130.8 (2xC); 130.9 (4xCH); 145.0 (2xCH); 153.7 (2xC); 159.6 (2xC); 164.1 (2xC). 
ESI/MS: 797 [M+Na]+; 775 [M+H]+; 719 [M-tert.-Bu+H]+; 697 [M-Boc+Na]+; 597 
[M-2Boc+Na]+; 575 [M-2Boc+H]+. 
Preparation of 534b. 1,2-Bis(4-methylenepiperidin-1-yl)ethane-1,2-dione (145 mg, 
0.58 mmol), 4-(4-(4-(hydrazine carboxylic acid tert-butyl ester) phenoxy) decoxy) 
benzenhydrazine carboxylic acid tert-butyl ester (341 mg, 0.58 mmol) and Rh(acac)(CO)2 
(6 mg, 4 mol%) were dissolved in anhydrous THF (116 ml), filled in an autoclave and 
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pressurized with 50bar CO and 10bar H2. The mixture was stirred at 110°C for 20h. The 
solvent was removed and the residue was purified by flash chromatography (silica, 
CH2Cl2/EtOH 9:1) to give 534b (407 mg, 81 %). 1H-NMR: (CDCl3, 500 MHz) d = 0.64-1.11 
(46H, 14xCH2, 6xCH3); 1.55 (bs, 2H, 2xCH); 1.90-2.01 (2H, CH2); 2.28-2.42 (2H, CH2); 2.84 
(bs, 2H, CH2); 3.26 (t, 4H, J = 6.4 Hz, 2xCH2); 3.73 (bs, 2H, CH2); 5.88 (bs, 2H, 2xCH); 6.25 
(s, 8H, 8xCH. 13C-NMR: (CDCl3, 125 MHz) d = 29.1 (4xCH2); 31.3 (6xCH3); 32.3 (4xCH2); 
32.5 (4xCH2); 34.4 (CH2); 35.4 (CH2); 40.3 (2xCH); 44.0 (2xCH2); 49.3 (2xCH2); 71.4 
(2xCH2); 84.2 (2xC); 118.6 (4xCH); 132.5 (2xC); 133.0 (4xCH); 147.2 (2xCH); 155.9 (2xC); 
161.9 (2xC); 166.2 (2xC). ESI/MS: 881 [M+Na]+; 659 [M-2Boc+H]+. 
10.7 EXPERIMENTS IN CHAPTER 6 
Preparation of 604. 2,2'-Bis(allyloxy)-1,1'-binaphthyl (205 mg, 0.56 mmol), 4-(4-(4-
(hydrazinecarboxylic acid tert-butyl ester) phenoxy) butoxy) benzenhydrazine carboxylic acid 
tert-butyl ester (281 mg, 0.56 mmol), Rh(acac)(CO)2 (5.9 mg, 4 mol%) and XANTPHOS 
(65 mg, 20 mol%) were dissolved in anhydrous THF (112 ml), filled in an autoclave and 
pressurized with 10bar CO and 10bar H2. The mixture was stirred at 100°C for 20h. The 
solvent was removed and the residue was purified by flash chromatography (silica, 
CH2Cl2/EtOH 9:1) to give 604 (483 mg, 97 %). 1H-NMR: (CDCl3, 500 MHz) d = 1.35-1.91 
(30H, 6xCH2, 6xCH3); 3.88-3.95 (8H, 4xCH2); 6.32 (t, 2H, J = 5.2 Hz, 2xCH); 6.90 (s, 8H, 
8xCH); 7.05 (d, 2H, J = 8.5 Hz, 2xCH); 7.10 (dd, 2H, J = 6.5 Hz, J = 8.5 Hz, 2xCH); 7.24 
(dd, 2H, J = 6.5 Hz, J = 8.0 Hz, 2xCH); 7.33 (d, 2H, J = 9.2 Hz, 2xCH); 7.79 (d, 2H, 
J = 8.0 Hz, 2xCH); 7.87 (d, 2H, J = 9.2 Hz, 2xCH). 13C-NMR: (CDCl3, 125 MHz) d = 26.2 
(2xCH2); 28.2 (6xCH3); 28.7 (2xCH2); 29.2 (2xCH2); 68.2 (2xCH2); 68.9 (2xCH2); 115.3 
(4xCH); 115.9 (2xCH); 120.2 (2xC); 123.5 (2xCH); 125.3 (2xCH); 126.0 (2xCH); 127.7 
(2xCH); 129.1 (2xCH); 129.2 (2xC); 129.6 (2xC); 130.1 (4xCH); 133.6 (2xC); 145.8 (2xCH); 
153.0 (2xC); 154.1 (2xC); 158.8 (2xC). 
10.8 EXPERIMENTS IN CHAPTER 7 
2-(diphenylphosphino)-N-(2-methyl-1-phenylallyl)benzamide (702). LiAlH4 (4.67 g, 
123 mmol) was suspended in dry THF (100 ml). A solution of (E)-2-methyl-3-phenylacrylic 
acid (24.9 g, 154 mmol) in dry THF (50 ml) was added dropwise and the resulting mixture 
was stirred over night at ambient temperatures. At 0°C water was added carefully, until 
hydrogen production stops. The slurry was dissolved by subsequent addition ofH2SO4 and the 
solution was extracted with EtOAc to give (E)-2-methyl-3-phenylprop-2-en-1-ol (22.7 g, 
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100 %) without further purification. NaH (314 mg, 10 mol%) was suspended in dry Et2O 
(60 ml) and (E)-2-methyl-3-phenylprop-2-en-1-ol (11.7 g, 78.6 mmol) in dry Et2O (20 ml) 
was added within 10 min. At -10°C trichloroacetonitrile (11.4 g, 78.6 mmol) was added 
dropwise and the resulting mixture was stirred for 15 min at 0°C. The solvent was removed 
and the residue was dissolved in pentane (200 ml with 0.5 ml MeOH). The solution was 
decanted from the remaining solid and the solvent was evaporated to give (E)-2-methyl-3-
phenylallyl 2,2,2-trichloroacetimidate (19.6 g, 85 %) without further purification. A solution 
of (E)-2-methyl-3-phenylallyl 2,2,2-trichloroacetimidate (16.5 g, 56.6 mmol) in xylene 
(500 ml) was stirred over night under reflux. The solvent was removed to give 2,2,2-trichloro-
N-(2-methyl-1-phenylallyl)acetamide (16.5 g, 100 %) without further purification. A solution 
of 2,2,2-trichloro-N-(2-methyl-1-phenylallyl)acetamide in EtOH (100 ml) and NaOH (150 ml, 
8N in H2O) was stirred at ambient temperatures for 40 h. The mixture was extracted and the 
solution was saturated with HCl-gas. The precipitate was collected by filtration to give 2-
methyl-1-phenylprop-2-en-1-amine hydrochloride (5.25 g, 55 ). A solution of 2-methyl-1-
phenylprop-2-en-1-amine (422 mg, 2.3 mmol) and DCC (521 mg, 2.53 mmol) in anhydrous 
CH2Cl2 (2 ml) was added to a solution of 2-(diphenylphosphino)benzoic acid (703 mg, 
2.3 mmol) and DMAP (14 mg, 5 mol%) in CH2Cl2 (2 ml). After stirring over night at ambient 
temperatures the solvent was evaporated and the residue was taken up in Et2O. The solvent 
was removed in vacuo after filtration through a sintered glass filter and the residue was 
purified by chromatography (silica, cyclohexane, EtOAc) to give 2-(diphenylphosphino)-N-
(2-methyl-1-phenylallyl)benzamide (450 mg, 45%). 1H-NMR: (CDCl3, 500 MHz) d = 1.65 (s, 
3H, CH3); 4.99 (s, 1H, CHH); 5.07 (s, 1H, CHH); 5.59 (d, 1H, J = 7.5 Hz, CH); 6.51 (bs, 1H, 
NH); 7.00 (bs, 1H, CH); 7.19-7.40 (17H, 17xCH); 7.70 (bs, 1H, CH). 13C-NMR: (CDCl3, 
125 MHz) d = 20.2 (CH3); 59.2 (CH); 111.9 (CH2); 127.3 (4xCH); 128.5 (9xCH); 130.1 
(1xCH); 133.6 (4xCH); 134.2 (CH); 135.4 (C); 136.7 (2xC); 139.6 (2xC); 141.6 (C); 143.6 
(2xC); 167.8 (C). 31P-NMR (CDCl3, 80Hz) d = -10.02 (s, 1P, PAr3). 
HRMS found [M]+ 436.1847, C29H26NOP requires [M+H]+ 436.1864. 
(E)-2-methyl-3-phenylprop-2-en-1-ol (710). (E)-Ethyl 2-methyl-3-phenylallyl carbonate 
(952 mg, 4.32 mmol), hexylamine (1.31 g, 12.97 mmol), P(OPh)3 (101 mg, 8 mol%) and 
[Ir(cod)Cl]2 (58 mmol, 2 mol%) in dry EtOH (10 ml) were stirred for 2 h under reflux. The 
solvent was removed in vacuo and the residue was purified by chromatography (silica, 
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2.5 vol% EtOAc in cyclohexane) to give (E)-2-methyl-3-phenylprop-2-en-1-ol (555 mg, 
56 %). Analytical data fits with the literature114. 
1-(cyclohexenylmethyl)piperidine (717). Cyclohexenylmethyl ethyl carbonate (205 mg, 
1.1 mmol), piperidine (285 mg, 3.4 mmol), P(OPh)3 (26 mg, 8 mol%) and [Ir(cod)Cl]2 
(15 mmol, 2 mol%) in dry EtOH (2 ml) were stirred for 2 h under reflux. The solvent was 
removed in vacuo to give 1-(cyclohexenylmethyl)piperidine (100 %*, 40 % conversion).1H-
NMR: (CDCl3, 500 MHz) d = 1.40-1.62 (18H, 9xCH2); 2.83 (s, 2H, CH2); 5.56 (s, 1H, 
CH).13C-NMR: (CDCl3, 125 MHz) d = 22.2 (2xCH2); 22.7 (CH2); 24.1 (CH2); 25.0 (CH2); 
25.1 (CH2); 27.4 (CH2); 54.2 (2xCH2); 66.2 (CH2); 129.2 (CH); 132.3 (C). 
N-hexyl-2-methylenecyclohexanamine (719). Ethyl 2-methylenecyclohexyl carbonate 
(1.47 g, 7.7 mmol), hexylamine (2.33 g, 23.0 mmol), P(OPh)3 (180 mg, 8 mol%) and 
[Ir(cod)Cl]2 (103 mmol, 2 mol%) in dry EtOH (15 ml) were stirred for 24 h under reflux. The 
solvent was removed and the residue was purified by chromatography (silica, 2.5 vol% 
EtOAc in cyclohexane) to give N-hexyl-2-methylenecyclohexanamine (1.14 g, 73 %, 80 % 
conversion).1H-NMR: (CDCl3, 500 MHz) d = 0.81 (bs, 3H, CH3); 1.15-1.92 (16H, 8xCH2); 
2.20 (bs, 1H, CH); 2.46-2.49 (2H, CH2); 4.65 (s, 2H, CH2). 13C-NMR: (CDCl3, 125 MHz) 
d = 13.9 (CH3); 22.5 (CH2); 23.4 (CH2); 27.0 (CH2); 28.3 (CH2); 30.2 (CH2); 31.7 (CH2); 33.4 
(CH2); 34.7 (CH2); 47.4 (CH2); 60.6 (CH); 105.7 (CH2); 150.8 (C). 
2-methylenecyclohexyl 2-(diphenylphosphino)benzoate (724). A solution of 2-
methylenecyclohexanol (161 mg, 1.4 mmol) and DCC (323 mg, 1.6 mmol) in anhydrous 
CH2Cl2 (2 ml) was added to a solution of 2-(diphenylphosphino)benzoic acid (436 mg, 
1.4 mmol) and DMAP (9 mg, 5 mol%) in CH2Cl2 (4 ml). After stirring over night at ambient 
temperatures the solvent was evaporated and the residue was taken up in Et2O. The solvent 
was removed in vacuo after filtration through a sintered glass filter and the residue was 
purified by chromatography (silica, cyclohexane, EtOAc) to give 2-methylenecyclohexyl 2-
(diphenylphosphino)benzoate (570 mg, 100%). 1H-NMR: (CDCl3, 500 MHz) d = 1.47-2.41 
(8H, 4xCH2); 4.75 (s, 1H, CHH); 4.84 (s, 1H, CHH); 5.34-5.40 (1H, CH); 6.91-6.97 (1H, 
CH); 7.26-7.42 (12H, 12CH); 8-09-8.16 (1H, CH). 13C-NMR: (CDCl3, 125 MHz) d = 23.3 
(CH2); 27.4 (CH2); 33.2 (CH2); 33.5 (CH2); 75.2 (CH); 107.6 (CH2); 128.2 (CH); 128.4-128.5 
(6xCH); 130.5 (CH); 131.8 (CH); 133.8 (2xCH); 134.0 (CH); 134.3 (CH); 138.1 (2xC); 140.5 
(C); 146.3 (2xC); 165.7 (C). 31P-NMR (CDCl3, 80Hz) d = -3.93 (s, 1P, PAr3). 
                                               
114 Lee, D.-Y.; Moon, C.W.; Jun, C.-H.; J. Org. Chem. 2002, 67, 3945-3948. 
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(1,2-trans)-2-(2-oxoethyl)cyclohexyl 2-(diphenylphosphino)benzoate (725). A solution of 
2-methylenecyclohexyl 2-(diphenylphosphino)benzoate (27 mg, 0.07 mmol) and 
Rh(acac)(CO)2 (0.4 mg, 3 mol%) in dry benzene (350 mg) was filled in autoclave, was 
pressurized with CO (30 bar) and H2 (30 bar) and was stirred for 68 h at 40°C. The solvent 
was evaporated and the residue was analyzed by NMR. 1H-NMR: (CDCl3, 500 MHz) 
d = 1.55-2.10 (10H, 5xCH2); 2.42 (bs, 1H, CH); 4.65 (bs, 1H, CH); 6.90 (s, 1H, CH); 7.26-
7.68 (12H, 12xCH); 8.02 (s, 1H, CH); 9.57 (s, 1H, CH). 31P-NMR (CDCl3, 80Hz) d = -3.73 
(s, 1P, PAr3). 
(1,2-trans)-2-(5-methoxy-1H-indol-3-yl)cyclohexyl 2-(diphenylphosphino)benzoate 
(727). A solution of 2-methylenecyclohexyl 2-(diphenylphosphino)benzoate (308 mg, 
0.77 mmol), tert-butyl 1-(4-methoxyphenyl)hydrazinecarboxylate (183 mg, 0.77 mmol), 
Rh(acac)(CO)2 (6 mg, 3 mol%) in dry THF (3.8 g) was filled in autoclave, was pressurized 
with CO (30 bar) and H2 (30 bar) and was stirred for 68 h at 40°C. The solvent was 
evaporated and the residue was taken up in H2SO4 (4 wt% in dry THF, 15 ml) and was stirred 
for 2 h under reflux. Ammonia (30 wt% in H2O, 5 ml) was added and the mixture was 
extracted with EtOAc. The solvent was removed and the 219 mg of the residue was purified 
by chromatography (silica, cyclohexane, EtOAc) to give (1,2-trans)-2-(5-methoxy-1H-indol-
3-yl)cyclohexyl 2-(diphenylphosphino)benzoate (44 %, 105 mg) as the only diastereomer. 1H-
NMR: (CDCl3, 500 MHz) d = 1.59-2.17 (8H, 8xCH2); 3.07 (dt, 1H, J = 4.0 Hz115, J = 10.8 Hz, 
CH); 3.84 (s, 3H, CH3); 5.16 (dt, 1H, J = 4.0 Hz115, J = 9.3 Hz, CH); 6.84 (s, 3H, 3xCH); 7.11 
(s, 1H, CH); 7.16-7.31 (11H, 11xCH); 7.53-7.59 (2H, 2xCH); 7.73 (bs, 1H, CH); 7.87 (bs, 
1H, NH). 13C-NMR: (CDCl3, 125 MHz) d = 24.6 (CH2); 25.7 (CH2); 32.0 (CH2); 33.2 (CH2); 
39.8 (CH); 55.9 (CH3); 77.4 (CH); 101.2 (CH); 111.7 (CH); 111.8 (CH); 117.9 (C); 121.1 
(CH); 127.7 (C); 127.9 (CH); 128.3 (5xCH); 128.4 (CH); 130.3 (CH); 131.2 (C); 131.4 (CH); 
133.8 (2xCH); 133.9 (2xCH); 134.0 (CH); 134.9 (C); 138.2 (2xC); 140.0 (C); 153.7 (C); 
166.5 (C). 31P-NMR (CDCl3, 80Hz) d = -4.16 (s, 1P, PAr3). 
10.9 EXPERIMENTS IN CHAPTER 8 
10.9.1 HYDROFORMYLATION ON POLYMER SUPPORT 
Polymer supported synthesis of 12-oxododecanoic acid (819) on PS Wang resin. 
Wangresin (500 mg, 1.1 mmol/g) undecenoic acid (304 mg, 1.65 mmol), DIPCDI (208 mg, 
                                               
115 Coupling constant is characteristic for the trans-diastereomer. See Garden, S.J.; Silva, R.B. ; Pinto, A.C.; 
Tetrahedron 2002, 58, 8399–8412 for coupling constants of the cis- and the trans-isomer of 3-(2-
hydroxycyclohexyl)-indole. 
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1.65 mmol), DMAP (10 mg, 5 mol%) and DMF (3 ml) were placed in a syringe and were 
shaken for 24h at ambient temperatures. The solvent was removed and the resin was washed 
consecutively with DMF, (5x), CH2Cl2 (5x), DMF (5x), CH2Cl2 (5x), Et2O (5x), MeOH (5x) 
and Et2O (5x). The resin was dried in vacuo. This resin (52 mg, 1.00 mmol/g), Rh(acac)(CO)2 
(3 mg, 11 µmol) and dry THF (80 ml) were placed in a PARR autoclave. The vessel was 
pressurized with CO (10 bar) and H2 (10 bar) and the mixture was stirred carefully for 20h at 
80°C. The resin was collected by filtration and was washed consecutively with THF 
(3x10 ml), THF/pentane (1:1, 3x10 ml) and pentane (3x10 ml) followed by drying in vacuo. 
This aldehyde resin (30 mg, 0.97 mmol/g) was shaken with TFA/CH2Cl2 (1:1, 3x10ml) for 
20min at ambient temperature. The organic solutions were collected and the solvent and TFA 
were removed in vacuo to give 12-oxododecanoic acid (3.53 mg, 87%). 1H-NMR: (CDCl3, 
500 MHz) d = 0.85-1.27 (16H, 8xCH2); 1.61 (bs, 2H, CH2); 2.33 (bs, 2H, CH2); 9.74 (bs, 1H, 
CH). 
Polymer supported synthesis of 5-(4-(4-(2-oxoethyl)piperidin-1-ylsulfonyl) phenyl) 
pentanoic acid (822) on PS Wang resin. Resin 820 (30.6 mg, 0.87 mmol/g), Rh (acac)(CO)2 
(13.0 mg, 52 µmol) and dry THF (80 ml) were placed in a PARR autoclave. The vessel was 
pressurized with CO (50 bar) and H2 (10 bar) and the mixture was stirred carefully for 20h at 
80°C. The resin was collected by filtration and was washed consecutively with THF 
(3x10 ml), THF/pentane (1:1, 3x10 ml) and pentane (3x10 ml) followed by drying in vacuo. 
This aldehyde resin (31.4 mg, 0.85 mmol/g) was shaken with TFA/CH2Cl2 (1:1, 3x10ml) for 
20min at ambient temperature. The organic solutions were collected and the solvent and TFA 
were removed in vacuo to give 5-(4-(4-(2-oxoethyl)piperidin-1-ylsulfonyl) phenyl) pentanoic 
acid (9.8 mg, 100%). 1H-NMR: (CDCl3, 500 MHz) d = 1.67 (bs, 7H, 3xCH2, CH); 2.26 (t, 
2H, J = 11.6 Hz, CH2); 2.36 (s, 4H, 2xCH2); 2.69 (s, 2H, CH2); 3.12 (s, 2H, CH2); 3.75 (d, 
1H, J = 10.8 Hz, CH2); 7.31 (d, 2H, J = 7.6 Hz, 2xCH); 7.62 (d, 2H, J = 7.6 Hz, 2xCH); 9.70 
(s, 1H, CH); 11.57 (bs, 1H, OH). 
10.9.2 TANDEM HYDROFORMYLATION / HYDRAZONE FORMATION ON POLYMER 
SUPPORT. 
Polymer supported synthesis of (E)-tert-butyl 2-(2-(1-(4-(5-methoxy-5-oxopentyl) 
phenylsulfonyl) piperidin-4-yl) ethylidene)-1-(4-methoxyphenyl) hydrazinecarboxylate 
(825) on PS HMBA resin. Resin 823 (30 mg, 0.73 mmol/g (theory)), Rh(acac)(CO)2 
(0.87 mg, 20 mol%), tert-butyl 1-(4-methoxyphenyl)hydrazinecarboxylate (52 mg, 219µmol) 
and dry THF (2 ml) in a conical glass vial were placed in a BERGHOF autoclave. The vessel 
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was pressurized with CO (50 bar) and H2 (10 bar) and the mixture was magnetically stirred 
for 44h at 80°C. The resin was collected by filtration and was washed consecutively with THF 
(3x10 ml), THF/MeOH (1:1, 3x10 ml) and MeOH (3x10 ml) followed by drying in vacuo. 
The hydrazone resin (35.5 mg, 0.62 mmol/g) was stirred in dioxane/DIPEA/MeOH (5:4:1, 
3ml) for 12h at 80°C. The resin was filtered and washed with THF (3x10 ml), THF/MeOH 
(1:1, 3x10 ml) and MeOH (3x10 ml). The solvent was removed in vacuo to give (E)-tert-butyl 
2-(2-(1-(4-(5-methoxy-5-oxopentyl) phenylsulfonyl) piperidin-4-yl) ethylidene)-1-(4-
methoxyphenyl) hydrazinecarboxylate (3 mg, 23%). 1H-NMR: (CDCl3, 500 MHz) d = 1.32-
1.52 (9H, 4xCH2, CH); 1.40 (s, 9H, 3xCH3) 2.19 (t, 2H, J = 6.0 Hz, CH2); 2.33 (bs, 2H, CH2); 
2.69 (bs, 2H, CH2); 2.92-3.07 (2H, CH2); 3.66 (s, 3H, CH3); 3.68 (bs, 2H, CH2); 3.82 (s, 3H, 
CH3); 6.55 (t, 1H, J = 5.5 Hz, CH); 6.93 (s, 4H, 4xCH); 7.30 (d, 2H, J = 8.4 Hz, 2xCH); 7.62 
(d, 2H, J = 8.4 Hz, 2xCH). ESI/MS: 624 [M+Na]+. 
10.9.3 TANDEM HYDROFORMYLATION / FISCHER INDOLIZATION ON POLYMER 
SUPPORT 
Polymer supported synthesis of N-ethyl-2-(5-methoxy-1H-indol-3-yl)propan-1-amine 
(833) on PS sulfonylchloride resin. Resin 803 (51 mg, 1.37 mmol/g), Rh(acac)(CO)2 
(3.58 mg, 20 mol%), tert-butyl 1-(4-methoxyphenyl)hydrazinecarboxylate (165 mg, 
694µmol) and dry THF (2 ml) in a conical glass vial were placed in a BERGHOF autoclave. 
The vessel was pressurized with CO (50 bar) and H2 (10 bar) and the mixture was 
magnetically stirred for 44h at 80°C. The resin was collected by filtration and was washed 
consecutively with THF (3x10 ml), THF/MeOH (1:1, 3x10 ml) and MeOH (3x10 ml) 
followed by drying in vacuo. The hydrazone resin (68 mg, 1.02 mmol/g), BF3*Et2O (99 mg, 
694 µmol) and molecular sieves (4Ǻ) were stirred in dry CH2Cl2/AcOH (1:1, 2 ml) for 17h at 
65°C. The resin was filtered, washed with CH2Cl2 (3x10 ml), CH2Cl2/MeOH (1:1, 3x10 ml) 
and MeOH (3x10 ml) and dried in vacuo to give indole resin (57 mg, 1.16 mmol/g). This 
resin (57 mg, 1.16 mmol/g) and Li-biphenylide in THF (694µmol) were stirred in dry THF 
(2ml) for 2h at 0°C. The mixture was quenched with water (100µl) and the resin was 
separated by filtration. The resin was washed with THF/H2O (1:1, 2x2ml) and THF/HCl (2N 
in water, 1:1, 2x2ml). THF was removed in vacuo and the residue was taken up in EtOAc. 
The organic layers were separated and were washed with HCl (1N in water, 1x). The collected 
aqueous layers were washed with EtOAc (2x) and the pH was adjusted to pH=11. The 
aqueous layer was extracted with EtOAc (3x). The solvent was removed to give N-ethyl-2-(5-
methoxy-1H-indol-3-yl)propan-1-amine (3 mg, 20%). ESI/MS: 232 [M+H]+. 
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Polymer supported synthesis of N-ethyl-2-(1H-indol-3-yl)propan-1-amine (830) on PS 
sulfonylchloride resin. Resin 803 (51 mg, 1.37 mmol/g), Rh(acac)(CO)2 (3.62 mg, 
20 mol%), 1-(diphenylmethylene)-2-phenylhydrazine (190 mg, 700µmol), PTSA (66 mg, 
350µmol) and dry THF (2 ml) in a conical glass vial were placed in a BERGHOF autoclave. 
The vessel was pressurized with CO (50 bar) and H2 (10 bar) and the mixture was 
magnetically stirred for 44h at 80°C. The resin was collected by filtration and was washed 
consecutively with THF (3x10 ml), THF/MeOH (1:1, 3x10 ml) and MeOH (3x10 ml) 
followed by drying in vacuo. This resin (58mg, 1.20 mmol/g) and Li-biphenylide (in THF, 
696µmol) were stirred in dry THF (2ml) for 2h at 0°C. The mixture was quenched with water 
(100µl) and the resin was separated by filtration. The resin was washed with THF/H2O (1:1, 
2x2ml) and THF/HCl (2N in water, 1:1, 2x2ml). THF was removed in vacuo and the residue 
was taken up in EtOAc. The organic layers were separated and were washed with HCl (1N in 
water, 1x). The collected aqueous layers were washed with EtOAc (2x) and the pH was 
adjusted to pH=11. The aqueous layer was extracted with EtOAc (3x). The solvent was 
removed to give N-ethyl-2-(5-methoxy-1H-indol-3-yl)propan-1-amine (3 mg, 21%). 
1H-NMR: (CDCl3, 500 MHz) d = 1.20 (t, 3H, J = 7.2 Hz, CH3); 1.47 (d, 3H, J = 7.0 Hz, 
CH3); 2.92 (bs, 2H, CH2); 3.14 (dd, 1H, J = 9.0 Hz, J = 10.6 Hz, CHH); 3.27 (dd, 1H, 
J = 8.5 Hz, J = 10.6 Hz, CHH); 3.41 (m, 1H, J = 7.0 Hz, CH); 5.20 (bs, 1H, NH); 7.05 (dd, 
1H, J = 7.6 Hz, J = 7.7 Hz, CH); 7.14 (dd, 1H, J = 7.6 Hz, J = 8.0 Hz, CH); 7.18 (s, 1H, CH); 
7.39 (d, 1H, J = 7.7 Hz, CH); 7.64 (d, 1H, J = 8.0 Hz, CH). NH not detected. ESI/MS: 203 
[M+H]+. 
  
ZUSAMMENFASSUNG 
In dieser Arbeit wurde gezeigt, dass die Tandem Hydroformylierung / FISCHER 
Indolsynthese ein geeignetes Werkzeug für die diversitätsorientierte Synthese biologisch 
relevanter Tryptamine und ihrer Homologe ist. Bei dieser neuen Tandemreaktion wird die 
Hydroformylierung von Aminoolefinen in Gegenwart aromatischer Hydrazine und von 
BRØNSTEDT-Säuren durchgeführt und man erhält Tryptamine in einem Schritt (Abbildung 1).  
Abbildung 1: Prinzip der Tandem Hydroformylierung / 
Fischer Indolsynthese. 
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Im Gegensatz zum klassischen Protokoll, entfällt eine vorherige Synthese des benötigten 
Aldehyds, gefolgt von dessen Umsetzung zu einem als Acetal, Aminal, Bisulfitaddukt oder 
Enolether geschützten Aldehyd. Stattdessen werden Olefine in situ in Aldehyde umgewandelt, 
als Hydrazone abgefangen und sofort zu Tryptaminen indolisiert. Daher wird die simple 
Umformung funktioneller Gruppen durch kettenaufbauende Schritte in einem 
Einschrittverfahren ersetzt, das Zeit und Ressourcen einspart. Dieser Zugangsweg ist eine 
attraktive Alternative für bestehende Produktionsprozesse, da mit der Verwendung von 
Olefinen als alternative Rohstoffbasis, der Verfahrenspatentschutz umgangen werden könnte.  
Ausgehend von geeigneten Aminen können Aminoolefine mit verschiedenen Methoden 
hergestellt werden, die als Stand der Technik zu bezeichnen sind (z.B. Substitution, 
Allylierung, WITTIG-Olefinierung, BARBIER-Reaktion, Carbomagnesierung, etc.). Dabei 
können alle biologisch wichtigen Valenzen, wie die Kettenlänge der Seitenkette und das 
Substitutionsmuster dieser Seitenkette, berücksichtigt werden und die daraus resultierenden 
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Aminoolefine lassen sich der Tandem Hydroformylierung / FISCHER Indolsynthese als 
verlässliches Werkzeug für die Synthese von Tryptaminen zuführen (Abbildung 2). 
 
Dabei sind in Abhängigkeit vom Typ des verwendeten Olefins unterschiedliche 
Reaktionsbedingungen entwickelt worden. Unpolare Olefine, insbesondere geschützte 
primäre und sekundäre Aminoolefine benötigen ein unpolares Reaktionsmedium. Hier hat 
sich die Verwendung von Schwefelsäure in THF als am besten geeignetes System 
herausgestellt. Die höchste Selektivität kann beobachtet werden, durch BUCHWALD-
HARTWIG-Aminierung gewinnbare Benzyhydryliden geschützte aromatische Hydrazine 
eingesetzt werden. Aber auch andere Hydrazinquellen, wie ungeschützte Hydrazine und 
a-Boc-geschützte Hydrazine, geben zufrieden stellende Ausbeuten (Abbildung 3).  
 
Tryptamine 
Homotryptamine 
Abbildung 2: Kombination moderner Synthesemethoden für Aminoolefin emit der Tandem 
Hydroformylierung / Fischer Indolsynthese als diversitätsorientierterZugang zu Tryptaminen. 
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Abbildung 3: Tandem Hydroformylierung / Fischer Indolsynthese unpolarer Olefine. 
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Im Fall polarer Aminoolefine, wie z.B. tertiäre Aminoolefine, die ein sehr polares 
Reaktionsmedium benötigen, wird wässrige Schwefelsäure verwendet. Eine hohe Löslichkeit 
des Hydroformylierungskatalysators kann durch den Zusatz sulfonierter Phosphanliganden, 
wie trisulfoniertes Triphenylphosphan (TPPTS) oder disulfoniertes XANTPHOS 
(sulfoXANTPHOS) erreicht werden, wobei letzterer hohe n-Selektivitäten bei der 
regioselektiven Hydroformylierung gibt. Kommerziell erhältliche Hydrazin-Hydrochloride 
können genauso eingesetzt werden, wie a-Boc geschützte Hydrazine. Insbesondere bei der 
Synthese von Wirkstoffen zur Migränebehandlung haben sich letztere als besonders geeignet 
erwiesen (Abbildung 4). 
Abbildung 4: Tandem Hydroformylierung / Fischer Indolsynthese polarer Olefine. 
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Sogar stereochemische Aspekte können berücksichtigt werden. Entweder kann das 
einzusetzende Aminoolefin bereits stereochemische Information in sich tragen, oder es 
werden prochirale Olefine eingesetzt, die ein neues Stereozentrum während der 
Tandemreaktion bilden. 
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Abbildung 5: Verwendung chiraler Allylamine unter Erhalt der 
Absolutkonfiguration. 
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Werden chirale Allylamine verwendet, so wird keine Epimerisierung durch 
Doppelbindungsverschiebung beobachtet und die Absolutkonfiguration bleibt erhalten 
(Abbildung 5). 
Werden jedoch disubstituierte, terminale Olefine eingesetzt, so kann die 
Relativkonfiguration des Stereozentrums in b-Position bezüglich des Aldehyds kontrolliert 
werden, indem BREIT’s Protokoll zur substratgesteuerten Hydroformylierung auf diese neue 
Tandemreaktion übertragen wurdet (Abbildung 6).  
Abbildung 6: Diastereoselektive Tandem Hydroformylierung / Fischer 
Indolsynthese. 
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Selbst Probleme mit der Regioselektivität der klassischen FISCHER Indolsynthese 
meta-substituierter aromatischer Hydrazine lassen sich durch die erste erfolgreiche 
intramolekulare FISCHER Indolsynthese überwinden. Hierbei wird ausschließlich das 
6-substituierte Indole erhalten (Abbildung 7).  
Abbildung 7: Regioselektive Tandem Hydroformylierung / Fischer 
Indolsynthese. 
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Primäre und sekundäre Tryptamine und ihre Homologe, die durch Tandem 
Hydroformylierung / Fischer Indolsynthese gewonnen worden sind, sind geeignete Substrate 
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für eine Hydroaminomethylierung. Diese Rhodium katalysierte Tandemreaktion, bestehend 
aus Hydroformylierung und reduktiver Aminierung, erlaubt eine zusätzliche 
Funktionalisierung des Tryptaminstickstoffes und somit die Synthese komplexerer Wirkstoffe 
zu erhalten. Die Kombination dieser beiden Tandemreaktionen stellt einen ungewöhnlichen 
schnellen und effizienten Zugang zu 3-Piperidylindolwirkstoffen dar (Abbildung 8).  
Abbildung 8: Kombination von Tandem Hydroformylierung / Fischer Indolsynthese und 
Hydroaminomethylierung in einer effizienten Synthese hoch-funktionalisierter Tryptamine.  
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Die automatisierte kombinatorische Synthese an der festen Phase ist eine 
Schlüsseltechnologie für die Entwicklung neuer Wirkstoffe. Durch die Übertragung der 
Tandem Hydroformylierung / FISCHER Indolsynthese von Lösung an die feste Phase unter 
Verwendung von Polystyrolsulfonylchlorid-Harz kann diese Tandemreaktion ein attraktives 
Werkzeug für die kombinatorische und diversitätsorientierte Synthese von Indolbibliotheken 
sein (Abbildung 9). 
Abbildung 9: Tandem Hydroformylierung / Fischer Indolsynthese an 
der festen Phase. 
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Wird die Hydroformylierung in Anwesenheit aromatischer Hydrazine aber ohne Säure 
durchgeführt, so können Arylhydrazone in meist quantitativer Ausbeute erhalten werden. 
Folgereaktionen wie Hydrierung können nicht beobachtet werden. Substituenten, die 
katalytisch hydriert werden könnten, bleiben genauso erhalten, wie die 
Hydrazondoppelbindung. Diese erhöhte Stabilität der Arylhydrazone gegenüber katalytischer 
Hydrierung steht im klaren Gegensatz zum Verhalten von Aminoaldehyden und 
Alkylhydrazonen, die beide unter Hydroformylierungsbedingungen zum Alkohol bzw. zum 
Hydrazine hydriert werden können. Zusammenfassend kann die Hydrazongruppe als 
produktive Schutzgruppe für Aldehyde interpretiert werden, solange diese Schutzgruppe, wie 
bei der FISCHER Indolsynthese, Teil des Produktes ist. Die Tandem 
Hydroformylierung / Hydrazonbildung kann genutzt werden um makrocyclische 
Bishydrazone in außergewöhnlich hohen Ausbeuten zu gewinnen (Abbildung 10). 
Abbildung 10: Synthese makrocyclischer Bishydrazone unter 
Hydroformylierungsbedingungen. 
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Abbildung 11: Metallscreening auf das Quenchen der Fluoreszenzaktivität makrocyclischer 
Bishydrazone. 
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Obwohl diese Makrozyklen nicht selektiv indolisieren, repräsentieren sie eine neue 
Substratklasse, die eine unerwartete Selektivität bzgl. einiger Metalle beim Quenchen ihrer 
Fluoreszenzaktivität zeigen. Neben starken Wechselwirkungen mit Vanadium(II) und 
Chrom(III) scheinen die Wechselwirkungen mit Eisen(III)salzen die interessantsten für 
Anwendungen in der Diagnostik oder der Schadstoffanalyse zu sein. (Abbildung 11). 
 
